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This research focuses on the current legal protection for agricultural 
biotechnological inventions in Europe and the U.S. It has been a subject of 
debate whether plants and agricultural biotechnological inventions which 
includes plants, transgenic plants and plant varieties, can be the subject of 
patent protection, in addition to or as an alternative to the protection 
afforded by plant variety rights. Biotechnological patents have been 
criticized for granting an excessive scope of protection to proprietors, 
whereas plant variety rights have been slighted for not providing enough 
protection. Hence, this research is built on a few main themes, namely; the 
discussion of IP protection for agricultural biotechnological inventions as 
currently in practice in Europe and the U.S., as well as the deliberation on 
the current system as practised in Malaysia. The research also discusses 
the issue of the interface between the patent regime and plant variety 
rights over agricultural biotechnological inventions as there are possible 
overlaps between the two systems, notwithstanding the exclusivity of 
protection of plant varieties under the PVR system. 
 
The research looks at the prospect for Malaysia as a developing country to 
enhance its current IP framework and legislation in order to develop its 
agricultural biotechnology industry. Hence, it focuses on whether there is a 
single system as a model of IP regime to be adopted by Malaysia in order 
to provide the best IP protection for its agricultural biotechnology industry. 
The comparative approach is inevitable, in referring to the European model 
and the American model as a guide. The relevant factors such as the 
different setting, society and economic strength are given due 
consideration in coming up with the proposal to amend the current 
ii 
 
intellectual property law and legal system in Malaysia. At the end, the 
thesis puts forward a model for Malaysia to further develop its system. 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
	,1%$2!*!!%#

I owe a great many thanks to a great many people who helped and 
supported me during the writing of this thesis. First and foremost, my 
utmost gratitude to my supervisors, Prof. Paul Torremans and Prof. Dr. Ida 
Madieha Abd Ghani Azmi, whose sincerity and encouragement I will never 
forget. Prof. Paul Torremans, my principal supervisor, has been guiding me 
during all phases of this research. I am also indebted to my co-supervisor, 
Prof. Dr. Ida Madieha Abdul Ghani Azmi for the valuable guidance and 
constant advice. She has been my inspiration as I hurdle all the obstacles 
in the completion this research work particularly during semi-structured 
interviews and data collection for chapters on Malaysian biotechnology.  
  
Thanks and appreciation to the helpful people at various research 
institutions in Malaysia (MARDI, FRIM, MPOB, MRB, MCB) for their support 
and co-operation during the interview sessions. Particular thanks are due 
to officials at Biotech Corp, MyIPO, MOSTI and DOA for the assistance in 
data collection relating to patents and plant breeders’ rights in Malaysia. I 
would also thank my faculty members, both in the University of 
Nottingham and International Islamic University Malaysia, for their support 
and encouragement throughout the study. 
 
An honourable mention goes to my beloved parents and family for their 
care, support and strength along the way. I would like to express a sense 
of gratitude to my husband, Mr. Rohisham Mamat for his unending love, 
support, understanding and patience throughout my study. Last but not 
least, my deepest thanks and regards to my beloved late father, Mr Ismail 
Awang Besar, who supported me in any respect and built a strong 
foundation on me. Indeed, he has a place of honour, deep within my heart. 
iv 
 
	""'!&#$%%	,'$%(
CBD   Convention of Biodiversity 
DNA  Deoxyribonucleic Acid 
DOA  Department of Agriculture 
DUS  Distinct Uniform and Stable 
EPC  European Patent Convention 
EPO  European Patent Office 
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FRIM  Forest Research Institute of Malaysia 
MARDI  Malaysian Agricultural Research and Development Institute  
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MyIPO  Malaysian Intellectual Property Office 
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UPA  Utility Patent Act 
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WTO  World Trade Organization 
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Biotechnology is not a new science. It is based on very old traditions used 
since the beginning of the civilized world to improve products of the land such 
as agricultural products and animal farming.1 The origin of biotechnology can 
be traced back to prehistoric times, when microorganisms were already used 
for processes like fermentation. Beer brewing, cheese making and production 
of sour milk are some of the common examples which are often included in 
describing what is called biotechnology.  
 
The term ‘biotechnology’ generally refers to the use of biological processes, as 
through the exploitation and manipulation of living organisms or biological 
systems, in the development or manufacture of a product or in the 
technological solution to a problem. As such, biotechnology is a general 
category that has applications in pharmacology, medicine, agriculture, and 
many other fields. In relation to genetic engineering, the techniques have 
been used to manipulate the deoxyribonucleic acid (DNA) of bacteria and 
other organisms to manufacture biological products such as drugs. Plants and 
foods with desired qualities such as prolonged shelf life or increased resistance 
to diseases and pests have been created through genetic engineering; that is, 
by inserting DNA from other organisms.2 
                                                 
1 GREAVES, ROSA, 1991. Biotechnological Inventions. ! / GREAVES, Rosa, ed. #" 
%""!	Chur,Switzerland : Worldwide Information Inc. p. 5. 
2 R. W. Old and S. B. Primrose, 1994. Principles of Gene Manipulation ; J. E. Smith, Biotechnology 
1996. ""[online], Available at : 
<URL:http://www.answers.com/topic/biotechnology?cat=health>[Accessed 04 December 2007] 
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In the context of the modern biotechnological revolution, plant genetic 
resources have become a significant source for plant breeding, crop 
development and enhancement.3 Undoubtedly, like most technology, 
biotechnology can be used for good or ill, but in the field of agriculture, it has 
the prospect of giving enormous benefits in the quality and yield of foods and 
the range over which they can be grown.4 The advent of genetic engineering 
has permitted the expeditious introduction of a wide range of desirable traits 
into plants. These include: pest control traits such as insect and virus 
resistance as well as herbicide tolerance; post-harvest traits such as delayed 
ripening of spoilage prone fruits; male and/or seed sterility for hybrid 
systems; and output traits such as plant colour and vitamin enrichment.5 
Despite the fact that some people have been opposing and viewing 
biotechnology with caution, the remaining section of the public is attracted to 
the benefits of biotechnology for food, for example as evidenced by the 
demand for ,$	 tomatoes, that is a new variety of tomatoes which 
remain ripe far longer than normal tomatoes before they rot after their 
introduction in the United States.6  
 
Biotechnology has taken the development of new plants and seeds into the 
fast lane.7 The world is experiencing a ‘breakthrough in agricultural technology 
that may soon enable us to harvest crops from deserts, farm tomatoes in sea 
                                                 
3 The work of Brush, S. (see BLAKENEY, Michael, 2001, Intellectual Property And Agriculture : The 
Issue Of Biotechnology. ! /MCMAHON, Joseph A., e. 01" /((-
2London : Cameron May Ltd. p. 350.  
4
 NOTT, Robin, 1995. The Biotech Directive: Does Europe Need a New Draft?. !#3 12, pp. 
563-567, at p. 563. 
5 The work of Linder (see BLAKENEY, Michael, 2001, Intellectual Property And Agriculture : The 
Issue Of Biotechnology. ! /MCMAHON, Joseph A., e. 01" /((-
2London : Cameron May Ltd. p. 350)  
6 NOTT, Robin, "  Note 4. 
7 0 "	  27 September 1986, at 82. (see CHRISTIE, Andrew, 1989. Patents for Plant 
Innovation. !#3 11, pp. 394-408) 
3 
 
water, grow super potatoes in many new localities, and enjoy entirely new 
crops such as . We can now isolate and manipulate the genes that 
constitute the hereditary materials of each species’ genetic makeup.’8 These 
recent developments in biotechnology have increased the need to protect 
inventions and regulate commercial exploitation.  
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The most important mechanisms for legally protecting agricultural 
biotechnological inventions are patents and plant variety rights. It has been a 
subject of debate and a matter of dispute whether plants and agricultural 
biotechnological inventions can be the subject of patent protection, in addition 
to or as an alternative to the protection afforded by plant variety rights. 
Biotechnological patents have been criticized for granting an excessive scope 
of protection to proprietors, whereas plant variety rights have been slighted 
for not providing enough protection.9 This issue is one of many questions in 
patent law to which no single global answer could be given, owing to the 
differences of law from one country to another.10  
 
The possibility of patent protection for plants and animals was first mooted at 
about the beginning of the 20th century. However it was a long time before 
this view was accepted by legislatures, courts and Patent Offices.11 This is due 
to the belief that living organisms and cells were non-patentable products of 
nature. Hence, under the rationale that naturally occurring organisms were not 
                                                 
8 The work of Norman (see MARIN, Patricia L.C., 2002, # #" + # "
3	"	/ #	   	 		   %		 New York : Kluwer Law 
International. p. 4) 
9
 The work of Roberts and Royon (see FUNDER, Joshua V., 1999. Rethinking Patents for Plant 
Innovation. !#3 11, 551-574 at p. 567.) 
10 CRESPI, R.S., 2004. European Union. !/ ERBISCH, Frederick H., ed. !" #
3	"%"Cambridge: CABI Publishing. p. 261. 
11 NOTT, Robin, 1992. Patent Protection for Plants and Animals. !#3 3, pp. 79-86 at p. 79. 
4 
 
new, the assumption was that patents could not be granted. In such a case, it 
was perceived that the grant of a patent would remove from the public domain 
something ‘which nature has produced and which nature has intended to be 
equally for the use of all men’.12  
 
The issue of the patenting of life-forms was finally given a judicial answer in 
the landmark decision of the United States Supreme Court in 1980 in 

13It was held that a bacterial strain into which a plasmid from 
another strain had been inserted constituted patentable subject-matter. The 
Court distinguished the products of nature from man-made inventions and 
held that statutory subject-matter included ‘anything under the sun made by 
man’ and that genetically engineered micro-organisms were not precluded 
from constituting patentable subject-matter merely because they were living 
cells. Although this clearly spelled out liberal approach, not many countries 
have followed up by clear permissive legislation. In fact, there are only a few 
specific exclusions in those jurisdictions, hence vagueness reins.14  
 
Undeniably, intellectual property rights (IPRs) offer a temporary monopoly for 
the commercial exploitation of an invention and innovation, thus creating an 
incentive for further research and development. As patents primarily serve an 
economic function, the basic belief governing the system is the conviction that 
the protection provides an incentive for people to innovate and invest. Hence 
the possibility of recouping the high investment in genetic engineering and 
plant development industry can effectively be guaranteed through adequate 
                                                 
12 WESTERLUND, Li, 2002. %"#	/4""		5
#6- The Hague : Kluwer Law International. p. 1. 
13 206 USPQ 193 (1980). 
14 NOTT, Robin; 	 Note 11, p. 80. 
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legal protection. This justification, though controversial, is equally legitimate 
from a public policy perspective. Nevertheless, the economic justification for 
patent is not always uncontroversial, as many IPRs, which include patent laws, 
have been asserted of going too far in protecting those who produce 
innovations at the expense of those who use them. Historically, and even 
today, the way patents have been justified in different countries has depended 
on the level of industrial development.15 The use of IPRs in plant breeding 
especially in developing and least developed countries have raised issues on 
food security, smallholders’ access to technology and the possible 
monopolization of genetic resources.16 
 
Another related concern in developed countries is pertaining to the changes in 
the structure and composition of the plant breeding and seed industry, in 
particular the increasing involvement of large companies. The increasing role 
of the private sector in fundamental research has triggered the issue of the 
appropriate scope and system of protection for results of such research.17 For 
example, Monsanto’s decision to co-operate with plant breeders in the 
development of new plant varieties through the combination of traditional 
plant-breeding methods with its genetic resources aroused the question of the 
extent to which IPRs should be used to protect the results of genetic 
research.18 
 
0 0 3$"
'!*!
                                                 
15 DUTFIELD, Graham, 2003. !" # 3	   6+ "" !		 
0-	Hampshire : Ashgate Publishing Limited. p. 2. 
16 BONADIO, Enrico, 2007. Crop Breeding and Intellectual Property in the Global Village. !#3 
5, pp. 167-171. 
17 HEITZ, Andre, 1988. Intellectual Property in New Plant Varieties and Biotechnological 
Inventions. !#3 10, pp. 297-301. 
18 LLEWELYN, Margaret, 2000. The Patentability of Biological Material: Continuing Contradiction 
and Confusion. !#3 5, pp. 191-197. 
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As far as the global intellectual property regime is concerned, the most 
significant IPR treaties in the context of plants and biotechnological inventions 
are the Agreement on Trade-Related Aspects of Intellectual Property Rights 
(henceforward the TRIPS Agreement or TRIPS), and the Convention of the 
International Union for the Protection of New Varieties of Plants (The UPOV 
Convention). The former, which is administered by the Geneva-based World 
Trade Organization (WTO), is so important because it is the first and the only 
international treaty which seeks to establish enforceable universal minimum 
standards of protection for all the major intellectual property rights. The latter, 
which is administered by another intergovernmental organization, the 
International Union for the Protection of New Varieties of Plants (UPOV), is 
significant because it deals specifically with plant varieties.19 These two 
treaties, together with regional treaties such as the European Patent 
Convention (EPC) and the European Directive on the Legal Protection of 
Biotechnological Inventions20 (henceforward EU Directive 98/44) will be 
discussed in greater detail in Chapter 2 of this thesis. 
                                                 
19 DUTFIELD, Graham, 2000. !" # 3	  0  %	 London: 
Earthscan Publications Ltd., p. 8. 
20 Directive 98/44/EC of the European Parliament and the Council of 6 July 1998 on the legal 
protection of biotechnological inventions. 
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This thesis is concerned with the issues surrounding the legal protection of 
agricultural biotechnological inventions. As far as inventions in agricultural 
biotechnology are concerned, they may be related to any of three types: 
methods, genes, or varieties. ‘Methods’ are techniques used in breeding or 
genetic manipulation. ‘Genes’ refer to biological information which mainly 
consists of isolated genes or proteins but also includes unicellular 
microorganisms such as bacteria, whereas ‘varieties’ generally refer to a 
specific hybrid of plant. This thesis will focus on the issues of legal protection 
for ‘plant varieties’ as they have attracted much debate and discussion on that 
particular area. 
 
Among the primary questions that will be the central themes are the current 
legal protections available in European countries (EU) in particular in the 
United Kingdom (UK) for agricultural biotechnological inventions. The thesis 
will also scrutinize the various ways the laws relating to intellectual property 
rights have been interpreted in dealing with the issues of protecting the 
biotechnological inventions relating to plants and plant varieties in the UK. 
Besides, the thesis seeks to examine the advantages and disadvantages of the 
patent regime in comparison to plant variety rights in order to evaluate 
whether there is an interface problem as has been asserted by the 
protagonists of patents and plant variety rights.  
 
Most importantly, the thesis is aimed at answering the main question for the 
whole research, that is to propose the best way to protect agricultural 
biotechnological inventions in Malaysia, taking into account the relevant 
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factors such as the much slower development of biotechnological inventions 
relating to plants compared to the development in the UK, the different nature 
of farming activities, economic strength, and so forth. In other words, it is 
vital to ascertain the extent and ways the intellectual property laws in the UK 
relating to agricultural biotechnological inventions that would be relevant and 
significant to shape and improve the current laws in Malaysia. 
 
0 4!#$$$*(
The methodology that will be applied to the whole research is a mixture of 
black-letter approach and qualitative approach. The black-letter or doctrinal 
approach is inevitable in order to analyze the international treaties such as 
TRIPS and the International Convention for the Protection of New Varieties of 
Plants (UPOV), regional treaties under the EU such as the European Patent 
Convention (EPC) and EU Directive 98/44, national laws such as the UK 
Patents Act 1977, the UK Plant Varieties Act 1997, the US Plant Patent Act 
1930, the US Plant Variety Protection Act 1970 (as amended in 1994), the US 
Patent Act 1952, the Malaysian Patent Act 1983, the Malaysian Protection of 
New Plant Varieties Act 2004 and so forth, as well as a number of decided 
cases on the issue of agricultural biotechnology. The doctrinal approach is 
appropriate and proves to be the best way to produce legal analysis of the 
relevant treaties, conventions, statutes, and case-law which form an important 
part of this thesis.  
 
On top of that, the qualitative approach also forms a significant component of 
the thesis. The empirical study will be in the form of a semi-structured 
interview and meetings that will be conducted at various agencies, bodies and 
research institutes in Malaysia which are involved in agricultural biotechnology 
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industry. At this juncture, it is worth noting that “semi-structured interview” 
refers to a flexible method of interview, in which it allows new questions to be 
brought up during the interview as a result of what the interviewee says. This 
is opposed to a structured interview which is more formalized and has limited 
set of questions. As far as the research is concerned, the interviewees which 
have been selected, in fact, representing a large component of the agricultural 
biotechnology industry, and would be directly affected by whatever laws which 
are enacted and implemented in Malaysia. This empirical aspect of the 
research is vital because it would demonstrate the views as to the 
appropriateness and effectiveness of the systems available to the researchers 
and plant breeders in agricultural biotechnology. Besides, it seeks to explore 
the existing impediments, issues and problems encountered by the industry 
players especially in the area of research and development of the agricultural 
biotechnology sector. The study is justified to eventually meet the changing 
needs of those engaged in research and development of the agro-
biotechnology that ultimately would further boost the growth of the industry in 
Malaysia.  
 
0 3 +&$%$),-#!'
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The first Chapter is an introduction which highlights the current debate and 
issues surrounding the legal protection of agricultural biotechnological 
inventions, in parallel to the advent in biotechnology relating to plants. The 
chapter describes the methodology applied for the whole study which consists 
of doctrinal and empirical research. It also seeks to define and clarify the legal 
terminologies which are used throughout this thesis. The definition and 
interpretation is vital in the sense that there have been much confusion and 
10 
 
uncertainties over their intended or applicable meaning. Among the 
terminologies or phrases that will be dealt with in detail are the concept of 
agriculture, the meaning of the word “invention” as opposed to discovery in 
relation to patent law, definitions of biological process, microorganism, plant, 
plant breeders, plant variety, seeds, transgenic plant and so forth. The various 
ways of interpreting the above terminologies is apparently one of the main 
reasons for different approaches for awarding patents in various jurisdictions 
like the UK, the U.S. and developing countries which include Malaysia. 
 
<=-#!'.  
This chapter looks at the international and European background in relation to 
legal protection of agricultural biotechnology. In particular this chapter 
concentrates on the laws relating to plant and animal varieties as provided 
under UPOV. Breeders’ rights under UPOV will be analyzed from explanatory 
theoretical basis relative to the development that has taken place right from 
its inception in 1961 until the revision in 1972, 1978 and 1991. It is 
interesting to note that most, if not all, plant variety rights around the world 
are generally based on the UPOV Convention. The scope of protection and the 
issue of ‘double protection’ will be given special emphasis as they form the 
essence of the provisions. This thesis further brings into focus the scenario of 
European patent regime under the two relevant sources of patent law in 
Europe namely the EPC and EU Directive 98/44. The EPC plays an important 
role as it forms the basis of national laws within Europe leading to the current 
situation whereby plant varieties are, for the most part, considered non-
patentable subject-matter protected only under a specialized plant breeders’ 
rights form of protection. Most of the debates revolve around Article 53(b) of 
the EPC which excludes plant and animal varieties and essentially biological 
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processes from patentability, even though it restores patentability to 
microbiological process and the products thereof. The issue will be specifically 
analyzed as it is an exclusion from the general possibility of patenting 
technological inventions and only concerns the biotechnological field. 
 
Chapter 2 will also discuss the role of the Directive 98/44 which was adopted 
by the European Parliament and the Council of the EU in harmonizing the 
national laws of EU Member States relating to the protection of 
biotechnological inventions. The Directive, being an EU instrument, was not 
directly applicable to the EPC, although it is apparent that the European Patent 
Office (EPO) has adopted its main provisions as regard plant patenting. The 
Directive 98/44 in fact was not free from controversy after its entry into force, 
to the extent that it was even challenged for annulment by some of its 
Member States. The question whether the Directive is consistent with the 
international obligations of the Member States will also be considered in this 
chapter. 
 
For the purpose of this study, the UK being one of the member states of EU 
will be taken as a case study, representing the legal scenario and application 
of patent regime and plant variety rights in relation to agricultural 
biotechnology in Europe. The reason lies on the fact that Malaysia’s patent 
laws and practice are very similar to those of EPC and the UK. In other words, 
the Malaysian Patent Act 1983 has traces of similarity with the UK Patents Act 
1977. It is pertinent to note at this juncture that Malaysia is lacking case law 
in the area of patents in particular and intellectual property in laws in general, 
hence the UK cases as well as cases decided by the EPO are highly influential 
and beneficial in interpreting Malaysian provisions. The practice of the EPO and 
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the examination guidelines are equally useful in the sense that the EPO and 
WIPO have been helping the Malaysian intellectual property office (MyIPO) in 
training and formulating the examination guidelines. Besides, as a developing 
country, there is always a need for Malaysia to base its law and legal system 
on the much more developed legal systems. In this regard, the current UK 
intellectual property law would be taken as a model law subject to Malaysian 
variations wherever appropriate. The U.S. system of protecting plant related 
inventions is also relevant to provide a comparative approach of the legal 
scenario, taking into consideration the differences in terms of economic 
strength, the pace of biotechnological industry, the nature of farming activities 
and so forth. 
 
Chapter 2 will also focus on TRIPS which was concluded along with and 
forming part of the Agreement of WTO. It is significant for setting the 
standards for IPRs far above those existing under other international treaties 
and conventions on intellectual property, which are mainly administered by 
the World Intellectual Property Organization (WIPO). The negotiation history 
which has paved the way to TRIPS will also be dealt with, with special 
emphasis on Article 27 of the TRIPS Agreement. It is important to note that 
TRIPS has been perceived by the developing countries as a new way of 
domination by developed countries over them. This controversy will also be 
considered and examined in this chapter.  
 
The issue of the interface between patent and plant variety rights over 
agricultural biotechnological inventions is another important part of Chapter 2. 
The analysis as to where possible overlaps between the two systems may exist 
is scrutinized from the aspects of differences and similarities of these two 
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regimes. It is important to note that the issue is relevant notwithstanding the 
exclusivity of protection of plant varieties under the PVR system, as the 
European legal framework is far from drawing a clear demarcation line 
between the systems of protection. 21 The last part of Chapter 2 is an analysis 
and review of some of the selected case law which have been decided on the 
issue of patentability of plants and agricultural biotechnology. Among the 
cases that will be examined in detail are $77 6'" !"78, 
# " 		24 and (	.25 These cases are given paramount 
consideration in the sense that they are the landmark cases which delineate 
the approach adopted by EPO interpreting the Article 53(b) EPC on the 
exclusions of plant varieties from patentability. 
 
<=-#!'4  
This chapter looks at the United States’ approach in protecting agricultural 
biotechnological inventions. The fact that the U.S. has never excluded 
biological material and plant varieties from the scope of patentable subject 
matter will serve as a comparative approach for the purpose of this thesis, 
other than the EU’s approach as elaborated in Chapter 2. It is interesting to 
note that the U.S. adopts a unique three-tiered system approach which never 
                                                 
21 MOUFANG, Rainer, 2003. The Interface Between Patents and Plant Variety Rights in Europe. 
Paper presented at .!#9$5#9)	!"#3	#%" 
9"7:7;;8 [online], Available at : 
<URL:http://www.upov.int/en/documents/Symposium2003/wipo_upov_sym_06.pdf>[Accessed 
06 
 December 2007] 
22 $<#  (Case T-49/83) [1984] OJ EPO 112. Also available at: < 
http://legal.european-patent-office.org/dg3/biblio/t830049ep1.htm> [Accessed 09 September 
2008] 
23 6'< #	 (Case T-320/87) [1990] OJ EPO 71. Also available at: 
<http://legal.european-patent-office.org/dg3/biblio/t870320ep1.htm> [Accessed 10 September 
2008] 
24 # " 		< 		 	 =9	  "> 08?@<A8
[1995] EPOR 357; OJ EPO 545. EPO 545. Also available at: <http://legal.european-patent-
office.org/dg3/biblio/t930356ep1.htm> [Accessed 11 September 2008] 
25 (	<0	"#(Case G01/98) [2000] EPOR 303; [1999] EPOR 123. Available at: < 
http://legal.european-patent-office.org/dg3/pdf/g980001ep1.pdf> [Accessed 25 September 2008] 
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places any restriction on the potential use of any regime of protection. This in 
effect dispenses with any potential overlap between different regimes of 
protection for plant varieties. In the U.S., plant varieties can be protected 
under a specific plant patent or under a system of utility patents or under the 
Plant Variety Protection.26 This approach which differs from many other parts 
of the world in protecting newly developed plant varieties is perceived to 
contribute to the booming agribusiness industry in the U.S. Because of the 
influence of U.S. intellectual property law and cases on the most parts of the 
world, whether directly or indirectly, the three-tiered system approach in 
protecting agricultural biotechnology including some leading cases and recent 
development will be considered in detail in this chapter. 
 
<&=-#!'3  
This chapter in turn looks at the legal scenario of IPRs for biotechnological 
invention in Malaysia. The primary pieces of legislation are the Patent Act 
1983 and the Protection of New Plant Varieties Act 2004. The relevant 
provisions from these two statutes will be discussed, notwithstanding the fact 
that the latter is relatively new and yet to be tested in any case law. Another 
important component of Chapter 4 is the insights of the latest development of 
agricultural biotechnology in Malaysia which include the current government’s 
policy in actively promoting biotechnology research and development with the 
aim to attract investment for the industry as well as to enhance the local 
biotechnology. This is evident from the fact that the government has launched 
its Bio-Valley Project in 2003 and has produced the National Biotechnology 
                                                 
26 TORREMANS, Paul, 2001. Plant Varieties And The TRIPs Agreement : Time For A Revision?. !/
MCMAHON, Joseph A., e. 01"/((-2London : Cameron 
May Ltd. p. 96. 
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Policy in 2005, supported with a huge allocation of fund under Ninth Malaysia 
Plan (2006-2010) for the development of biotechnology in Malaysia.  
 
<&=-#!'8  
The empirical part of this thesis which is incorporated in Chapter 5 consists of 
studies on related bodies, agencies and companies in Malaysia which have 
direct involvement with agricultural biotechnology. These include Malaysian 
Biotechnology Corporation (BiotechCorp), Plant Varieties Office at the 
Department of Agriculture (DOA), Intellectual Property Corporation of Malaysia 
(MyIPO), Malaysian Agricultural Research and Development Institute (MARDI), 
Forest Research Institute of  Malaysia (FRIM), Malaysian Rubber Board (MRB), 
Malaysian Cocoa Board (MCB), and Malaysian Palm Oil Board (MPOB). The 
report and analysis of the data, information and statistics obtained from the 
study in the form of semi-structured interviews are incorporated in this 
chapter. The main focus of the study is to examine the current practice of the 
agricultural biotechnology industry and to address the issues such as; whether 
the plant related invention is adequately protected under the intellectual 
property laws in Malaysia and to what extent there is a need of an improved 
legal system in Malaysia. The general headings under which the information 
obtained from the study are aimed to cover the plant breeding activities, type 
of intellectual property used, general levels of use, awareness and satisfaction 
with the protection, research and development activities, the ideal legislation27 
and current issues relevant to the study. This study is aimed as an indicator of 
the general view held across the agricultural biotechnology industry in 
Malaysia. 
                                                 
27 A similar study has been carried out in EU. Refer  LLEWELYN, Margaret and ADCOCK, Mike, 
2006. #!"#Oxford : Hart Publishing. p. 440. 
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This Chapter incorporates a comprehensive and detailed discussion in a form 
of proposal, which is geared towards a better intellectual property laws in 
Malaysia. The proposal is based on the assessment of the study in Chapter 4 
and 5 as well as the essence of current practice in the UK and the U.S. in 
Chapter 2 and Chapter 3 respectively. It is vital to have a balanced approach 
by weighing pros and cons in order to create an enabling environment in 
Malaysia. The ultimate aim of this thesis is to propose a law and a viable 
system which best suits the need of agricultural biotechnology scenario in 
Malaysia. The answer could lie in the middle-ground approach which is the 
harmonization of patents and plant variety rights. Whatever the outcome is, 
justification and policy consideration would be given paramount consideration 
in parallel to the practicality and the viability of the legal protection for the 
agricultural biotechnological inventions in Malaysia. 
 
<&=-#!':
The final Chapter is a concluding chapter which reiterates and summarizes all 
the six preceding chapters of the whole thesis, with an emphasis on the thesis 
outcome. Most importantly, it highlights the contribution and fruit of the 
research which has been dedicated throughout the whole duration of the 
study, with the main aim of enhancing the current IP legal system in Malaysia, 
towards global harmonization ultimately. 
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At first glance, the topic of the research would appear to be straightforward 
and not at all complicated. The complexity arises in relation to some of the 
terminology and concepts which have no universal definition, yet will be 
utilized throughout the writing of this thesis. Hence, it is essential to provide 
at the very outset a sufficiently clear literal and legal definition to the 
terminology wherever possible. The following terminology will be addressed in 
turn. 
 
(i) Agriculture 
(ii) Biological process, microbiological process 
(iii) Genetic engineering 
(iv) Invention (as opposed to discovery) 
(v) Patent 
(vi) Utility models for innovation 
(vii) Plant, plant variety, crops, seed 
(vii) Plant variety rights, plant breeders’ rights, farmers’ rights 
(viii)	protection
 
It is worth mentioning at this juncture that the definition and interpretation for 
the above terminology would be discussed and enunciated in reference to 
relevant statutes, treaties, directives, case law, legal dictionaries, 
encyclopedias and common usage in the legal fraternity. The interpretation 
from a scientific point of view will also be given due consideration as the topic 
of this research is to some extent closely related to the advances in science 
and technology, in particular biotechnology.  
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Most of the dictionaries28 and encyclopedias29 basically define the term 
‘agriculture’ as the art and science of cultivating the soil, growing and 
harvesting crops, and raising livestock. In the context of modern agriculture, 
the era of mechanized agriculture began with the invention of such farm 
machines as the reaper, the cultivator, the thresher, and the combine. 
Harvesting operations have been mechanized for almost every plant product 
grown. Breeding programs have developed highly specialized animal, plant, 
and poultry varieties, thus increasing production efficiency. The development 
of genetic engineering has given rise to genetically modified transgenic crops 
and, to a lesser degree, livestock that possesses a gene from an unrelated 
species that confers a desired quality.30 
 
In short, the phrase ‘agricultural biotechnological inventions’ in this thesis 
refers to all forms of invention and development relating to plant life. This, of 
course, includes the creation of new plants, such as plant genetic material, 
transgenic plants as wells as the techniques or process for creating new plants 
and such material. As the focus of the research is on plants and crops, it would 
not cover animals or animal varieties, notwithstanding the fact that livestock 
forms part of the general definition of agriculture. This is justifiable from the 
context that most of the debates on this area revolve around the adequacy 
and efficiency of the legal protection over plants and the related inventions. 

                                                 
28 GARNER, Brian A., Ed., 2004. %"&	6-
" 8th ed. United States : Thomson West. p. 
75. 
29
 Refer %" "	 ""   "" ""  "-$
""+""0"1.. Available at : <URL : 
 http://www.answers.com/topic/agriculture?cat=technology> [Accessed 08 January 2008] 
30 ANON., 2003. 0"""". 6th ed. Columbia : Columbia University 
Press. 
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It is essential to distinguish the meaning and interpretation of these two 
scientific terms literally and legally. The issue of the interpretation of these 
two terms initially stems from the provisions of Article 27(3)(b) of the TRIPS 
Agreement and Article 53(b) EPC which spell out the exclusions from 
patentability on certain living organisms.  
 
Article 27(3)(b) TRIPS Agreement says that: ‘Members may also exclude from 
patentability: plants and animals other than micro-organisms, and essentially 
biological processes for the production of plants or animals other than non-
biological and microbiological processes...’  
 
Article 53(b) EPC states that: ‘European patents shall not be granted in 
respect of: plant or animal varieties or essentially biological processes for the 
production of plants or animals; this provision does not apply to 
microbiological processes or the products thereof.’ 
 
Similar exclusions from patentability have been adopted in various national 
statutes,   Section 76A (Schedule A2) of the UK Patents Act 1977 and 
Section 13(1)(b) of  the Malaysian Patents Act 1983. Apparently, Article 53(b) 
EPC and Article 4(1) of the EU Directive 98/44 incorporate similar exclusions 
on patentability for biological processes.  
 
Literally, biological process refers to a process relating to biology or life.31 
Hence, a process for the production of plants or animals is ‘essentially 
biological’ if it consists entirely of natural phenomena such as crossing or 
                                                 
31
 GARNER, Brian A., 	 Note 28. p. 178. 
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selection.32 The term ‘microbiological process’ is succinctly defined by Article 2 
EU Directive 98/44 and the UK Patents Act (Schedule A2) to mean any process 
involving or performed upon or resulting in microbiological material. The same 
definition is found in the Rule 23b(6) of the Implementing Rules EPC. 
 
It is important to distinguish between these two terms and concepts, as the 
former would result in the exclusion from patentability, while the latter is 
legally patentable under the various legislations as enunciated above. As the 
value of a patent is in the protection it confers, this issue is very fundamental 
in this field. One of the examples in which the term ‘microbiological process’ 
was expounded is the case of # " 		33 It was held that 
microorganisms could be patentable, being the products of microbiological 
processes, and were defined as ‘generally unicellular organisms with 
dimensions beneath the limits of visions which can be propagated and 
manipulated in a laboratory’ which did include viruses and plasmids.34 
Nevertheless, the above case of #"		 has been overtaken by 
another landmark case, (	, which will be discussed in detail in Chapter 
2. 
 
Although a number of decisions35 by the EPO Technical Board have addressed 
the exceptions to patentability in the context of genetically engineered life 
forms, there is no clear demarcation line yet between what is to be considered 
a patentable ‘microbiological’ process and a non-patentable ‘essentially 
biological’ process. Further, since there are no binding definitions to show a 
                                                 
32 Article 2 (2) EU Directive 98/44; Section 76A (Schedule A2.11) UK Patents Act 1977. 
33
 , Note 6. 
34 SCHERTENLEIB, Denis, 2004.  The Patentability and Protection of Living Organisms in the 
European Union. !#3  5, pp. 203-213, at p. 203. 
35 For example, Plant Genetic Systems/Glutamine Synthesis Inhibitors (Case G-3/95)[1996] OJ 
EPO 169; (Case T-356/93)[1995] EPOR 357. 
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clear-cut distinction between these two terms in the EPC, the potential for 
differing interpretations and applications persists among the various member 
nations' courts.36 It is interesting to note that there have been related issues 
which have attracted considerable debate and discussion on this point, 
, where is the exact point of demarcation between a plant cell regarded in 
patent law as a micro-organism and therefore patentable, and a plant cell 
which may be excluded from protection?37 On a more theoretical level, it has 
become clear that there is no clear scientific line between biology and micro-
biology, rendering the whole meaning of the distinction between non-
patentable biological processes and their patentable microbiological 
counterparts opaque and difficult to operate.38 
 
In addition, on the issue of patenting microbiological processes involving 
transgenic plants and plant varieties specifically, rule 23c of the EPC 
(Implementing Regulations) clearly states that the product of a microbiological 
process shall not be patentable if it is a plant or animal variety.  
 
The fact that the language of Article 53(b) EPC is open to various 
interpretations has made the EPO at times struggle both internally to agree 
what the exclusion covers and externally to convince others that its approach 
is the correct one. For example in the case of # " 		,39 the 
distinction drawn by the Technical Board between essentially biological and 
microbiological was unclear and did not pinpoint when a process would be said 
                                                 
36
 LICATA, Jane Massey, # %" !	  0  # 9++". 
Available at : <URL : http://www.licataandtyrrell.com/epopat.htm> [Accessed 09 January 2008]  
37 LLEWELYN, Margaret and ADCOCK, Mike, 	 Note 27. p. 293. 
38 CORNISH, W. and LLEWELYN, D., 2007!"#/#	  0	
3 6th ed.London : Sweet & Maxwell. p. 231. 
39 , note 24.  
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to be no longer essentially biological.40 A recent interlocutory decision of a 
Technical Board of Appeal in the case of #%	""6(T 83/05)41 
of the European Patent Office has been referred to the Enlarged Board of 
Appeal in order to define the boundaries for the exclusion from patentability 
established in Article 53(b) EPC. In this case, the Enlarged Board of Appeal is 
to decide whether or not the relevant method falls within the Article 53(b) 
exclusion. Among the questions which have been put to the Enlarged Board of 
Appeal is to decide on the relevant criteria for distinguishing non-
microbiological plant production processes excluded from patent protection 
under Article 53(b) EPC from the non-excluded ones. As at November 2010, 
this Enlarged Board of Appeal Decision was still pending under the reference 
number G 2/07.42 
 
The apparent interface between the EPC and the EU Directive 98/44 in terms 
of their respective approach over patentability of transgenic plants will be 
dealt with in detail in the next chapter.  
 
To sum up, as far as this thesis is concerned, based on the above discussion, 
the working definition for the following terms is: 
• “biological process” is all processes which consist entirely of natural 
phenomena for the production of plants such as crossing and selection;  
•  “microbiological process” refers the relevant processes involving or 
performed upon or resulting in microbiological material (as expressly 
provided in the EU Directive 98/44 and the UK Patents Act 1977).  
                                                 
40 LLEWELYN, Margaret and ADCOCK, Mike, "  p. 290-303. 
41 #%	""6#"	6 T 0083/05 – 
3.3.04 (Interlocutory decision of 22 May 2007). 
42 Mc Donald, Chris, 2007. #9"		%"#"			,##" 
Available at: <URL: http://www.withersrogers.co.uk/content/view/134/45/> [Accessed 19 
February 2008] 
23 
 
 
 
<=!%!#,!%*%!!'%*
Genetic engineering refers to a method of creating new life-forms and organic 
matter by gene-splicing and other techniques.43 The U.S. Supreme Court in 
the landmark case 
  44 has evidently ruled that those 
creations are patentable. Genetic engineering is usually done independently of 
the natural reproductive process. The result is a so-called genetically modified 
organism (GMO). To date, a substantial effort in genetic engineering has been 
focused on agriculture. Proponents of genetic engineering claim that it has 
numerous benefits, including the production of food-bearing plants that are 
resistant to extreme weather and adverse climates, insect infestations, 
disease, molds, and fungi.45 
 
In relation to biotechnology, genetic engineering falls under the wide umbrella 
of biotechnology. This is due to the fact that biotechnology is a generic term 
which is used to cover a very broad field of study, which ranges from the 
many tools and techniques that are commonplace today in agriculture and 
food production, to the latest technologies, including gene manipulation, gene 
transfer, DNA typing and the cloning of mammals. With the rapidity of 
changes occurring in the sector, the terminology is constantly evolving, and 
yesterday's buzzword is today's jargon, and might be tomorrow's mainstream 
                                                 
43
 GARNER, Brian A., 	 Note 28. p. 707. 
44  Note 13. 
45
 Refer <URL:http://whatis.techtarget.com/definition/0,,sid9_gci1110323,00.html> [Accessed 10 
January 2008] 
24 
 
term. The evolution of terminology has occurred so rapidly that it has been 
very difficult to remain abreast of its current usages.46  
To recapitulate, the term genetic engineering refers to methods and processes 
to investigate the isolation, change and transfer of genetic material. 
 
<&=%&!%#$%<$--$!#$,$&!'(=
Black’s Law Dictionary defines invention in the context of patents as a 
patentable device or process created through independent effort and 
characterized by an extraordinary degree of skill or ingenuity.47 As far as the 
patent law is concerned, for an invention to be patentable, it must meet 
specific criteria and, in addition, not be explicitly excluded from patentability. 
As a matter of fact, only few countries have in their respective patent laws set 
forth a positive definition of the subject matter considered to be an invention 
under the legal concept.48 The Malaysian patent law is an exception in this 
respect, stating that: ‘An invention means an idea of an inventor which 
permits in practice the solution to a specific problem in the field of 
technology.’49 The definition is very general and broad, which may cover 
inventions in the field of biotechnology. 
 
The TRIPS Agreement provides no definition of an invention yet mandates that 
patent protection is equally extended to all technologies, including 
biotechnological inventions.50 The EU Directive 98/44 stipulates the elaborated 
                                                 
46 Glossary of biotechnology and genetic engineering, 1999. 	 


 ,"9'+5(	=,9>[online] Available at: 
<URL:http://www.fao.org/sd/RTdirect/RTre0036.htm> [Accessed 10 January 2008] 
47
 GARNER, Brian A., 	 Note 28. p. 843. 
48 WESTERLUND, Li, 	Note 12. p. 24. 
49 Section 12(1) Malaysian Patent Act 1983. 
50 Article 27 paragraph 1 TRIPS Agreement provides that: ‘Subject to the provisions of paragraphs 
2 and 3, patents shall be available for any inventions, whether products or processes, in all fields 
of technology, provided that they are new, involve an inventive step and are capable of industrial 
application…’ 
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characteristics of a patentable invention. Article 3(1) says that: ‘For the 
purpose of this Directive, inventions which are new, which involve an inventive 
step and which are susceptible of industrial application shall be patentable 
even if they concern a product consisting of or containing biological material or 
a process by means of which biological material is produced, processed or 
used.’ The difficulty of outlining a positive, precise legal definition of the 
invention concept explains why most patent laws do no include one.51 
 
The principle is that patents cannot be granted for discoveries, as clearly spelt 
out in all patent laws, while at the same time biotechnological inventions 
consisting of gene sequences are patentable. For biological phenomena which 
to a certain extent ‘exist in nature’, the invention concept has somewhat been 
extended in order to accommodate these types of inventions like gene 
sequences, cell lines and the like.52 The key distinction is well-known in many 
patent systems: discovery is the unearthing of causes, properties or 
phenomena already existing in nature; invention is the application of such 
knowledge to the satisfaction of social needs.53 
 
One of the most frequently debated issues relating to the concept of 
patentable invention is whether inventions using plant material or transgenic 
plants are eligible for patent protection. The issue has attracted considerable 
debates and concerns specifically in Europe. This is attributed to the practice 
of the European Patent Office (EPO) which grants patent protection for 
inventions relating to processes and genetic materials used to create 
transgenic plants, but does not allow product claims to transgenic plants. The 
                                                 
51 WESTERLUND, Li, 	Note 12, p. 25. 
52 ! p.24. 
53 CORNISH, W. and LLEWELYN, D., 	, note 38. pp. 215-216. 
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EPO considers modification of a plant’s genetic material equivalent to creating 
new plant variety, and the EPC expressly prohibits patenting plant varieties.54 
The EPC classifies plant varieties as non-patentable subject matter, even when 
the transgenic plants would otherwise satisfy the criteria for patentability, 
namely: novelty, inventive step and industrial utility. Although transgenic 
plants can be claimed using product-by-process claims, most applicants would 
prefer the stronger protection afforded by product claims to transgenic 
plants.55 This issue will again be examined in greater detail in the next 
chapter.  
 
In short, for the purpose of this thesis, the term ‘agricultural biotechnological 
inventions’ denotes all plant related inventions which may cover transgenic 
plants, as well as new plant varieties. 
  
<&=
#!%#
Basically, patent is the governmental grant of a right, privilege, or authority.56 
In essence it is the grant of a monopoly to an inventor who has used his skill 
to invent something new. The monopoly is not absolute; patents are only 
granted for a limited period and are accompanied by public disclosure enabling 
others in the field to consider and perhaps subsequently improve on it. Patent 
has been the longest standing, best known and, arguably, economically most 
valuable form of protection of rights by the law of intellectual property.57 
                                                 
54 Article 53 (b) EPC. 
55 PERDUE, Donna O., 1999. The Changing Landscape for Patenting Transgenic Plants in Europe. 
3!#(-	, 6. [online] Available at:  
<http://www.law.washington.edu/Casrip/Newsletter/Vol6/newsv6i1Perdue.html> [Accessed 10 
January 2008] 
56
 GARNER, Brian A., 	 Note 28. p. 1156. 
57 TORREMANS, Paul, 2005.   0	 !" # 6- 4th ed. Oxford : 
Oxford University Press. p. 37. 
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Patent is generally granted over an invention if the invention is new, involves 
an inventive step and is capable of industrial application.58 
 
As far as the international dimension is concerned, cries have been long heard 
clamouring for greater levels of harmonization in domestic patent law between 
trading nations. The idea of the establishment of a global patent system has 
raised the problem of whether worldwide patent law is ever likely to be 
feasible, given the different levels of development, innovatory capacity and 
legal systems found around the world. The culmination of harmonization of 
substantive patent law at the international level eventually took place when 
the TRIPS Agreement was signed, and the WTO being set up as a world trade 
organization whose competence includes aspects of intellectual property.59 
 
The TRIPS Agreement imposes for the first time substantive minimum 
standards in patent law with which all WTO Member States have to comply. 
TRIPS defines the concept of patentable subject-matter broadly, on the basis 
that patent should be made available for any inventions in any field of 
technology, as long as the invention is new, involves an inventive step and is 
capable of industrial application.60 
 
As far as the development in Europe is concerned, the search for a common 
European concept of the patent led to the signing in Munich in 1973 of the EPC 
which establishes the EPO which has, since 1978, offered to applicants a 
European Patent in effect. This is achieved by signatory states agreeing to 
                                                 
58
 Section 1(1) UK Patents Act 1977; Section 11 Malaysian Patents Act 1983; Article 27(1) TRIPS 
Agreement. 
59
 TORREMANS, Paul, 	  Note 57. pp. 41-43. 
60 Article 27-34 TRIPS Agreement. 
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harmonize their own patent law with the definition in the EPC – hence the 
1977 Patents Act in the UK – and the EPO then awarding patents in all 
Member States where the applicant has sought to acquire patent protection.61 
In the year 2000, the EPC has been revised with the aims amongst other 
things, to integrate in the EPC new developments in international law, 
especially those of the TRIPS Agreement and of the Patent Law Treaty. The 
European patent laws system will be dealt with in the next chapter.  
 
Since the U.S. intellectual property laws on agricultural biotechnological 
inventions are also part of the discussion in this thesis (Chapter 3), it is 
pertinent to note that the U.S. has three types of patent in relation to patent 
law, that is a ‘design patent’, a ‘utility patent’ and a ‘plant patent’. The 
difference between a design patent and a utility patent is that a design patent 
protects the ornamental design, configuration, improved decorative 
appearance, or shape of an invention. This patent is appropriate when the 
basic product already exists in the marketplace and is not being improved 
upon in function but only in style. For example, designer eyeglass frames and 
the original Coca-Cola bottles, would have all been protected with design 
patents. A U.S. design patent lasts for 14 years. 62 
 
A utility patent protects any new invention or functional improvements on 
existing inventions.63 This can be to a product, machine, a process, or even 
composition of matter. For example, going from LED technology to OLED 
would call for a new utility patent. In this case the material of the light 
emitting diodes has gone from the synthetic material used in LEDs to organic 
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 TORREMANS, Paul, "., p. 44. 
62 Refer <http://www.uspto.gov/patents/index.jsp> 
63 ! 
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material in OLEDs. Other examples would be a better carburetter, a new type 
of self-fastening baby’s diaper or a new recipe. The life of a US utility patent 
lasts 20 years from the date of filing.  
 
Plant patents may be granted to anyone who invents or discovers and 
asexually reproduces any distinct and new variety of plant.64 It expires 20 
years from the filing date of the patent application. The discussion on the U.S. 
utility patent and plant patent is dealt with in a considerable detail in Chapter 
3. 
 
To recapitulate, the term patent in this thesis denotes a bundle of exclusive 
rights granted by a state to a patentee for a fixed period of time in exchange 
for a disclosure of an invention. 
 
<&=##($!)$'%%$&#$%
A utility model is an intellectual property right to protect inventions. This right 
is available in a number of national jurisdictions, which include Malaysia. It is 
very similar to the patent, but usually has a shorter term (often 6 or 10 
years)65 and less stringent patentability requirements. The rights conferred by 
utility model laws are very similar to those granted by patent laws, but are 
more suited, but not restricted to, to what may be considered as ‘incremental 
inventions’. A utility model right can be obtained for example, for electronic 
circuits, machines, chemical products, foodstuffs, pharmaceutical products and 
so forth. Terms such as ‘petty patent’, ‘innovation patent’, ‘minor patent’, and 
                                                 
64 ! 
65 In Malaysia, the term of protection for a utility innovation is 10 years; refer Section 35(1) 
Malaysian Patents Act 1983. 
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‘small patent’ may also be considered to fall within the definition of ‘utility 
model’. 
 
As far as the term of ‘utility model’ is concerned, there is no standard 
provision by WIPO for utility innovation. In Malaysia, a lesser extent invention 
can qualify as a utility innovation. It is an exclusive right granted for a ‘minor’ 
invention which does not required to satisfy the test of inventiveness as 
required of a patent. Hence, a utility innovation can be applied as long as it is 
new and industrially applicable. Under the Malaysian Patents Act 1983, ‘utility 
innovation’ refers to any innovation which creates a new product or process, 
or any new improvement of a known product or process, which is capable of 
industrial application, and includes an invention.66 As far as the rights and 
procedures are concerned, a utility innovation is subjected to a substantive 
examination as a patent application.67  
 
It is noteworthy that the UK, in contrast to Malaysian patent system, does not 
presently have a utility model system. In 2001 the European Commission 
started a consultation on the possibility of a Community utility model with the 
aim of harmonizing the existing utility model systems.  Nevertheless, progress 
has not been reported. In 2005, the European Commission announced that it 
would withdraw its proposal for a (harmonizing) Directive on utility models.68 
                                                 
66 Section 17 Malaysian Patents Act 1983. 
67 Section 17A(1)&(2) Malaysian Patents Act 1983. 
68 The proposal was finally withdrawn on March 17, 2006, [2006] OJ C 64/3 of March 17, 2006. 
Refer : <http://eur-
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Therefore, a harmonization of the national utility model systems is not on the 
European Union’s agenda anymore.69 
 
As a matter of fact, the road ahead for utility model protection seems to be a 
difficult one. This can be seen from the confusion which is rampant within the 
UK. There is no apparent consensus as to either the need for utility model 
protection nor its scope if adopted. The prevailing impression is one of 
uncertainty, and possible confusion, over the role utility model protection 
would play.70

In short, the term ‘utility innovation’ in this thesis refers to the right granted 
to an invention which satisfies the requirements of novelty and industrial 
application. 
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Generally, plant is a living organism of the kind exemplified by trees, shrubs, 
herbs, grasses, ferns, and mosses, typically growing in a permanent site, 
absorbing water and inorganic substances through its roots, and synthesizing 
nutrients in its leaves by photosynthesis using the green pigment 
chlorophyll.71 Scientifically, the term ‘plant’ refers to any organism in the 
kingdom , consisting of multicellular, eukaryotic life form with six 
fundamental characteristics: photosynthesis as the almost exclusive mode of 
                                                 
69 KONIGER, Karsten, Registration without Examination: The Utility Model – A Useful Model?, 
Available at: 
<http://www.springer.com/cda/content/document/cda_downloaddocument/9783540887423-
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70 LLEWELYN, Margaret, 1995. Proposals for the Introduction of a Community Utility Model 
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nutrition, essentially unlimited growth at meristems, cells that contain 
cellulose in their walls and are therefore somewhat rigid, the absence of 
organs of movement, the absence of sensory and nervous systems, and life 
histories that show alternation of generations.72 In the context of patent laws, 
other than ‘plant’, another term which is very closely related to it is ‘plant 
variety’. Plant variety is defined by some dictionaries73 to basically mean a 
population of plants that differ consistently from the typical form of the 
species, occurring naturally in a geographical area. Scientifically, plant variety 
is a plant belonging to a taxonomic subdivision of a species consisting of 
naturally occurring or selectively bred populations or individuals that differ 
from the remainder of the species in certain minor characteristics.74
 
From the legal point of view, the definition of the term plant variety is 
provided in a number of laws, notably the legislation on plant variety 
protection. This is different for the term ‘plant’, as there are not many laws 
which enunciate its specific definition, except for Section 2 of the Malaysian 
Plant Variety Protection Act 2004. In this 2004 Act, plant is clearly interpreted 
to mean ‘any living organism in the plant kingdom but excludes any micro-
organism.’  The lack of definition for the term plant could be attributed to the 
fact that it is a common, general term in nature. In contrast, there is a vast 
definition for the term ‘plant variety’ which to some extent reflects the 
significance of the development in agricultural biotechnology.  
 
                                                 
72ANON., 2006%""	"" Encyclopædia Britannica Inc., [online] Available 
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Article 1(vi) of the 1991 UPOV Act defines a plant variety as ‘any plant 
grouping within a single botanical taxon of the lowest known rank, which 
grouping, irrespective of whether the conditions for the grant of a plant variety 
right are fully met, can be: 
(a) defined by the expression of the characteristics that results from a given 
genotype or combination of genotypes, 
(b) distinguished from any other plant grouping by the expression of at least 
one of the said characteristics, and 
(c) considered as a unit with regard to its suitability for being propagated 
unchanged.’ 
 
The above definition mirrors the definition provided by Article 5 of Regulation 
(EC) No 2100/94 (for the purpose of Article 2 EU Directive 98/44 on the 
concept of ‘plant variety) as well as Rule 23b(4) of the Implementing Rules 
EPC. The National legislation has also adopted the same definition namely the 
UK Plant Varieties Act 1997 and Malaysian Plant Variety Protection Act 2004. 
However, the fact that apparently, specific terms with specific definitions have 
been used does not necessarily indicate that those terms have an agreed 
meaning and interpretation. The above criteria of plant varieties are in fact not 
entirely precise and may give rise to difficulties of interpretation.  
 
It is worth noting at this juncture that the TRIPS Agreement does not provide 
any definition as to what is a plant variety, with the impression that this is a 
recognized concept with a single meaning common to both science and law.75 
There is in fact no universal definition of what is a plant or a plant variety, and 
this is exemplified by the continuing discussions over , whether fungi 
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are plants or micro-organisms, and whether one single stable gene within a 
grouping of plants is sufficient to warrant those plants being considered as a 
variety for a plant variety right purposes. 76 The distinction of ‘plant’ and ‘plant 
variety’ is very crucial from the legal point of view, as the former is generally 
patentable provided all the conditions are fulfilled under the patent law, 
whereas the latter is excluded from patentability, but is protected under UPOV 
or any 	 	 system. This has been the legal position and practice in 
Europe, under Article 53(b) EPC. An extensive discussion on the European 
patent laws and the latest legal development will be dealt with in the next 
chapter. 
 
The question of what constitutes a plant variety can be seen in a number of 
cases which came under the scrutiny of the EPO. For example, in the case of 
# " 		 77 the Technical Board of Appeal EPO considered the 
definition of plant variety. The Board referred to earlier cases of   CD 
and 6'CA cases and confirmed the definitions used in both, namely; a 
variety is a ‘multiplicity of plants which are largely the same in their 
characteristics and remain the same within specific tolerances after every 
propagation or every propagation cycle.’80 
 
Some other related terms to plant are ‘crop’ and ‘seed’. Crop is a general term 
which refers to a plant that is cultivated for the purpose of harvesting its seed, 
roots, leaves, or other parts that are useful to human.81 Hence, in agriculture, 
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78 , Note 22. 
79 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80 [1995] EPOR 357 at para 21. 
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a plant or plant product that can be grown and harvested extensively for profit 
or subsistence is called crop.82 In this sense, the term ‘crop’ is utilized in more 
specific context like the production of plant for the purpose of harvesting and 
cultivating.83  
 
The other term, ‘seed’ is literally defined as the grains or ripened ovules of 
plants used for sowing.84 Propagation of plants by seed and technological use 
of seed and seed products are among the most important activities of modern 
society. In the context of seed industry, the term denotes activities in 
breeding, developing, growing and commercializing seed.85 As far as this 
thesis is concerned, it would also cover the biotechnological inventions in 
relation to seed, as ‘seed’ itself falls under the wide coverage of plants and 
agriculture. 
 
In conclusion, for the purpose of this thesis, the working definition for the 
abovementioned terms is as follows: 
• “Plant” refers to any living organism in the plant kingdom but excludes 
any micro-organism. 
• “Plant variety” denotes a taxonomic subcategory of a species within 
the plant kingdom that has its own distinct recognizable characteristics 
irrespective of whether it is eligible for a grant of plant breeders’ rights 
or not. 
                                                 
82 ANON., 2006. %""	"" [online] Encyclopædia Britannica Inc., Available 
at: <URL:http://www.answers.com/topic/crop> [Accessed 16 January 2008] 
83 Refer 
"	9  Available at : 
 <URL:http://dictionary.cambridge.org/define.asp?key=18433&dict=CALD> [Accessed 16 January 
2008] 
84
 Refer $.	 9, Available at <URL:http://www.m-w.com/dictionary/seed> 
[Accessed 16 January 2008]; the similar definition can be found in other dictionaries and 
encyclopedias, refer "  
"	  %" "	 ""  
"", 	 Note 2. 
85 International Seed Federation, Refer <URL:http://www.worldseed.org/en- 
us/international_seed/home.html> [Accessed 16 January 2008] 
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• “Crop” means a plant grown and harvested extensively for profit or 
subsistence. 
• “Seed” refers to the vegetative propagating material for the 
reproduction of a plant. 
 
<&=
%#&'!#('*#-%#"'!!!'5'*#)'!'5'*#
Plant variety rights (PVR) which are also known as plant breeders' rights (PBR) 
are fundamentally a bundle of rights granted to the breeder of a new variety 
of plant. PVR may subsist on varieties of all plant genera and species.86 
‘Breeder’ is legally defined as the person who bred, or discovered and 
developed, a variety, the person who is the employer of the aforementioned 
person or who has commissioned the latter’s work, where the laws of the 
relevant Contracting Party so provide, or the successor in title of the first or 
second aforementioned person, as the case may be.87 For the purpose of this 
thesis, the terms PVR will be used. 
 
This legal protection of plant varieties was initially established in the late 
1950s in a number of countries and eventually regulated at the international 
level of the ‘International Union for the Protection of New Varieties of Plants’ 
(the UPOV88 Convention of 1961). The main motivation for devising the special 
PVR system was that the long-established patent system, intended for the 
protection of technical inventions was for various reasons not considered 
suitable for protecting new plant varieties obtained by traditional methods.89 
In this sense, the PVR regime was designed to give the traditional plant 
                                                 
86 Section 1(2) UK Plant Varieties Act 1997. 
87 Article 1(iv) UPOV 1991. 
88 The French language acronym for the International Union for the Protection of New Varieties of 
Plant. 
89 The Chartered Institute of Patent Attorneys (CIPA), Intellectual Property Protection for New 
Plants, Available at <URL:http://www.cipa.org.uk> [Accessed 06 December 2007] 
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breeders an increased incentive to develop new varieties while respecting their 
traditions of exchanging material.90 The system was set up by plant breeders 
for plant breeders hence it forms one of the unique facets of PVR.91 
 
The scope of the breeder’s right is spelt out in Article 14(1)(a) of the UPOV 
1991. The Article says that: ‘Subject to Articles 15 and 16, the following acts 
in respect of the propagating material of the protected variety shall require the 
authorization of the breeder: 
(i) production or reproduction (multiplication), 
(ii) conditioning for the purpose of propagation, 
(iii) offering for sale, 
(iv) selling or other marketing, 
(v) exporting, 
(vi) importing, 
(vii) stocking for any of the purposes mentioned in (i) to (vi), above. 
 
The above provision is incorporated in the UK Plant Varieties Act 1997 (Section 
6(1)), as well as the Malaysian Protection of New Plant Varieties Act 2004 
(Section 30(1)). Another important aspect of PVR is the conditions for the 
grant of the rights. In order to qualify for protection, a variety must be new, 
distinct, uniform and stable92 (DUS characteristics). The elaboration of these 
conditions will be done in the next chapter. 
 
                                                 
90 BARTON, John H., 2004. Acquiring Protection for Improved Germplasm and Inbred Lines. !/
ERBISCH, Frederick H., ed. !"#3	"%"Cambridge: 
CABI Publishing. p. 25. 
91 LLEWELYN, Margaret, and COOK, Trevor, 1998. # ) 3	/  9
!!"#!	 EA, EAAD. London : The 
Intellectual Property Institute. 
92 Article 5(1) UPOV 1991, Section 4 (2) UK Plant Varieties Right 1997, Section 14(1) Malaysian 
Protection Of New Plant Varieties Act 2004. 
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Another term which is also relevant in the context of PVR is ‘farmers’ rights.’ 
The term ‘farmer’ is legally defined as any person who - 
(a) cultivates crops by cultivating the land himself; 
(b) cultivates crops by directly supervising the cultivation of land through any 
other person; or 
(c) conserves and preserves, severally or jointly, with any person any 
traditional variety of crops or adds value to the traditional variety through the 
selection and identification of their useful properties.93 The issue of farmers’ 
rights arises in a quest to counterbalance the stronger property rights 
recognized for formal breeders of commercial plant varieties.94 The concept of 
farmers’ rights was formally introduced by the Food and Agricultural 
Organization (FAO) commission through a special resolution annexed to the 
original FAO International Undertaking of 1983. The FAO Conference 
Resolution 5/89 describes farmers’ rights as: 
‘…[R]ights arising from the past, present and future contributions of farmers in 
conserving, improving and making available plant genetic resources, 
particularly those in centers of origin/diversity. These rights are vested in the 
international community, as trustee for present and future generations of 
farmers, for the purpose of ensuring full benefits to farmers, and supporting 
the continuation of their contributions.’95 
 
                                                 
93 Section 2 Malaysian Protection Of New Plant Varieties Act 2004. 
94 PATEL, Kirit K., 2004. Farmers’ Rights Over Plant Genetic Resources in the South: Challenges 
and Opportunities. !/ ERBISCH, Frederick H., ed. !" # 3	  "
%"Cambridge: CABI Publishing. p. 96. 
95 !  ANDERSEN, Regine, 2006. Realising Farmers’ Rights under the International Treaty on 
Plant Genetic Resources for Food and Agriculture, Summary of Findings from the Farmers’ Rights 
Project (Phase 1). ,(!3EE<7;;@, Lysaker, Norway: The Fridtjof Nansen Institute. Available 
at:  
<http://www.alphagalileo.org/nontextfiles/FR_core_findings.PDF> [Accessed 18 January 2008]. 
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In relation to the PVR, the above description of farmers’ rights are perceived 
as very general in nature, whereas a much more specific definition and 
interpretation would be necessary to ascertain the scope of the rights. As far 
as UPOV 1991 is concerned, the farmers’ rights can indirectly be inferred from 
Article 15(2) by way of optional exception. It states that: …. 
‘….each Contracting Party may, within reasonable limits and subject to the 
safeguarding of the legitimate interests of the breeder, restrict the breeder’s 
right in relation to any variety in order to permit farmers to use for 
propagating purposes, on their own holdings, the product of the harvest which 
they have obtained by planting, on their own holdings, the protected variety or 
a variety…’ 
 
It follows from the above provision that the countries which have acceded to 
UPOV 1991 are given the option to recognize farmers’ rights in relation to their 
customary practice in farming activities. These may include the right to access 
improved plant varieties and use farm-saved seed of commercial varieties for 
planting and exchange, the right to grow, improve and market local varieties 
and their products, the right to be compensated for the use of local varieties in 
the development of new commercial products by outsiders, as well as the right 
to participate in decision making processes related to acquisition, 
improvement and use of plant genetic resources for food and agriculture.96 
 
In relation to PVR, farmers who play the role as breeders are also given the 
equal rights which are provided for breeders of plant varieties under the 
Malaysian Protection of New Plant Varieties Act 2004. Section 13(1) of the 
2004 Act says that: 
                                                 
96 PATEL, Kirit K., 	  Note 94. 
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‘An application for the registration of a new plant variety and grant of a 
breeder’s right under section 12 shall only be made by- 
=>a breeder; 
=>the employer of the breeder; 
=">the successor in title of the breeder; 
=>a farmer or group of farmers, local community or indigenous people who 
have carried out the functions of a breeder; 
=>any government or statutory body which has carried out the functions of a 
breeder.’ 
 
The issue of farm-saved seed by farmers is also part of discussion on plant 
breeders’ exemptions which are enunciated under Article 15(1) UPOV 1991. 
This exemption is a part of ‘farmers’ privilege’, a concept which is used 
  in the context of the exemption for farmers who used saved seed for a 
further round of producing the harvest.97  The concern has been voiced out by 
many proponents of farmers’ rights as well as developing countries in view of 
the proliferation of monopoly of large companies which indirectly affect 
farmers’ choice in the market in particular and farmers’ rights in general.98 As 
far as this thesis is concerned, the above issue would also be covered in the 
next chapter, when discussing the scope of breeders’ rights under UPOV 1961, 
1971 and 1991. 
 
To recapitulate, 
• “PVR” or “PBR” refers to a bundle of exclusive rights as enunciated in 
UPOV, granted to the breeders of a new variety of plant. 
                                                 
97 MOUFANG, Ranier, 	 Note 21. 
98 !  p. 99. 
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• “Farmers’ rights” signifies the customary rights arising from the 
practice of farmers, , to reuse and exchange seeds from their 
harvests. 
 
<&=	-'$#!,#$% 
‘	& is a Latin phrase which literally means ‘of its own kind; unique.’99 
The term is usually used to refer to the event, situation, action material, 
person, entity or any such things which are clearly ascertainable and are 
unique of its kind. The term 		 appears in the provision of the TRIPS 
Agreement in relation to patentable subject matter under Article 27.  Article 
27(3)(b) states that: 
‘Members may exclude from patentability plants and animals other than 
micro-organisms, and essentially biological processes for the production of 
plants or animals other than non-biological and microbiological processes. 
However, Members shall provide for the protection of plant varieties either by 
patents or by an effective 		system or by any combination thereof…’ 
 
Interestingly, there is no definite system or regime which is specifically 
obligated by TRIPS on member states in relation the phrase ‘effective 	
	 system’. Industrialized nations, in particular those who subscribe to 
UPOV are of the view that the phrase refers to the UPOV-based PVR system, 
on the fact that UPOV is a proven system of protection for plant variety. UPOV 
has also slowly and gradually gained membership from around the world.  
 
                                                 
99 ANON., 2005. 0 9+ 
" + #	Fonline] Oxford: Oxford University Press. 
Available at: <URL:  http://www.answers.com/topic/sui-generis> [Accessed 20 January 2008] 
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It is also worth noting those countries which are not UPOV members have the 
option to replicate or incorporate the provisions of UPOV in their national laws 
without joining this international organization. In this way, they would retain 
the freedom to act in the country's interest and change the law as and when 
required.100 The scope of Article 27(3)(b) TRIPS Agreement will be analyzed in 
the next chapter.  
 
In short, for the purpose of this thesis, the term ‘	 	& system or 
protection simply refers to the UPOV-based PVR system. 
 
 
0 6$%,$%>$%#'"#$%

This thesis contributes in highlighting the ways by which Malaysia as a 
developing country could improve and enhance its existing IP laws on 
agricultural biotechnological inventions. The findings and proposals which are 
substantially incorporated in Chapter 6 could be used as an academic 
reference, especially to those involving with IP laws in Malaysia. The thesis is 
also informative in the sense that it covers the discussion on recent 
developments in EU in general, the UK and the U.S. in relation to laws relating 
to plant biotechnology. The writing ultimately contributes towards global 
harmonization of IP laws, as Malaysia itself is committed to enhance its IP 
regime in order to become part of the global players in the future. 
 
                                                 
100 NIJAR, Gurdial Singh, 6""	"				,[online] Available 
at: <URL: http://www.twnside.org.sg/title/gsn-cn.htm> [Accessed 20 January 2008] 
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Although IPRs fall under the domain of national law and hence vary from 
country to country, industrialized countries in particular have gradually been 
achieving an international harmonization of patent laws as well as their 
expansion in scope. In the 1880s, the first international treaty to regulate IPRs 
at the international level was adopted: the Paris Convention on the Protection 
of Industrial Property (hereinafter the Paris Convention). As this chapter 
focuses on the international intellectual property system, the international 
treaties which include the Paris Convention, the UPOV Convention and the 
TRIPS Agreement will be discussed in considerable detail. In addition, the role 
of WIPO as a specialized agency of the United Nations to promote the 
protection of intellectual property throughout the world will also be covered in 
this chapter.  
 
The other part of Chapter 2 is devoted to examine the position of European 
patent laws, namely the European Patent Convention (EPC) and the EU 
Directive 98/44. Although Europe’s position on patentability is still not very 
clear, this thesis seeks to analyze the relevant provisions of EPC 1973, 1978 
and 2000, as well as the interesting development of law which can be seen in 
the EU Directive 98/44. The Directive signifies an attempt towards European 
harmonization in the area of patent laws.  
 
Chapter 2 also focuses on the important international agreement in the area of 
IPRs namely TRIPS. The negotiation history, the issues and debates on Article 
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27 specifically and its current position will be looked into. Other than TRIPS, 
the Convention on Biological Diversity (CBD), Patent Cooperation Treaty (PCT) 
and Patent Law Treaty (PLT) will also be discussed briefly in this chapter, as 
they represent the effort of harmonization of laws at international level which 
is to some extent relevant to this thesis. 
 
 
. .!
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$%&!%#$%$%#!
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As mentioned in Chapter 1, the two legal rights with which this thesis is mainly 
concerned are patents and plant variety rights (PVR). The origin of both can 
be traced back in the Paris Convention, which created the Paris Union. The 
Paris Convention has played the role as the basic instrument for international 
patent protection. It provides minimal rules of protection, which were 
translated into the national patent legislation. The most significant part is the 
rule of national treatment,101 by which foreign inventors shall be treated in the 
same way as their domestic counterparts and their inventions shall be granted 
the same level of protection. The need for such an international cooperation 
arose in response to the technology and commercial necessities which have 
taken place all over Europe and North America in the nineteenth century. In 
fact, the origins of intellectual property could be linked to the industrial 
revolution in Europe which serves as one of the key elements of the 
technological development.102 The Paris Convention, concluded in 1883, was 
revised at Brussels in 1900, at Washington in 1911, at The Hague in 1925, at 
                                                 
101 Art 2 of the Paris Convention 
102 TORREMANS, Paul, 	  Note 57 p.7. 
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London in 1934, at Lisbon in 1958 and at Stockholm in 1967, and it was 
amended in 1979.103 

. . .!'!!&%#-'$&$%
In relation to agriculture, it is interesting to note that it falls under the broad 
context of the term ‘industrial property’. This is evidenced by Article 1(3) of 
the Convention which states that the term ‘industrial property’ shall be 
understood in the broadest sense and shall apply not only to industry and 
commerce proper, but likewise to agricultural and extractive industries and to 
all manufactured or natural products, for example, wines, grain, tobacco leaf, 
fruit, cattle, minerals, mineral waters, beer, flowers, and flour.  
 
The Paris Convention firmly established the principle that agricultural and 
plant products could be industrial property; however, this did not mean that 
such patents were not sought and obtained prior to the introduction of the 
Convention.104 The language used within the Convention implies that it was 
already possible to protect plant products by one of the rights (including 
patents) covered by the Convention – what the Convention did was to firmly 
establish any such practice as a general principle.105 
 
Other than Article 1(3), the substantive provisions of the Paris Convention 
relevant to this thesis are those which provide for national treatment, rights of 
priority and patent rules. For example, Article 2(1) of the Convention provides 
                                                 
103 +#	+#"+!	#=EDD8> Available at: 
<URL:http://www.wipo.int/treaties/en/ip/paris/summary_paris.html> [Accessed 22 May 2008]. 
104 LLEWELYN, Margaret and ADCOCK, Mike, 	 Note 27. p. 10. Interestingly, the authors of 
this book give certain evidence that patent over uses  of plant material were being granted even 
before the introduction of the Paris Convention, for example British patents were granted in 1637 
to Amye Everard als Ball for a tincture of saffron and roses. 
105 !., p. 11. 
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that ‘nationals of any country of the Union shall, as regard the protection of 
industrial property, enjoy in all the other countries of the Union the 
advantages that their respective laws now grant, or may hereafter grant, to 
nationals; all without prejudice to the rights specially provided for by this 
Convention.’ In this regard, Article 3 further provides: ‘Nationals of countries 
outside the Union who are domiciled or who have real and effective industrial 
or commercial establishments in the territory of one of the countries of the 
Union shall be treated in the same manner as nationals of the countries of the 
Union’. These provisions obligate the countries that are members of the 
Convention to grant nationals of any member country, as well as nationals of 
non-member states who are domiciled or have a real and effective industrial 
or commercial establishment in the member states, the same protection they 
grant to their own nationals. This feature of offering the same treatment to all 
within the jurisdiction irrespective of nationality by each signatory state is 
seen as the culmination of the first round of patent harmonization. 
 
Another important provision is Article 4bis of the Convention, which spells out 
the territoriality feature of patents. It says that ‘patents applied for in the 
various countries of the Union by nationals of countries of the Union shall be 
independent of patents obtained for the same invention in other countries, 
whether members of the Union or not’.106 Hence, it is apparent that a patent is 
not protected internationally, but nationally. By virtue of this Convention, a 
patent claim is required to be filed in each member state where patent 
protection is sought, observing the right to priority. In this sense, the duration 
                                                 
106 Refer paragraph (1) Article 4 bis of the Paris Convention. 
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and scope of protection of each patent is dependant on the domestic 
legislation of each member state.107 
 
. . 4!-!!%##$%
With regard to the implementation of this Convention, it has been 
implemented in the states adhering to the Convention by means of national 
Patents Acts. One hundred and seventy three states now adhere to the Paris 
Convention.108 The Paris Convention clearly manifests that there are different 
national patent laws across the globe without imposing an obligation on 
member states, in particular the developing or less developed countries to 
harmonize their patents laws in accordance to the standards of the domestic 
patents laws of industrialized countries.  
 
. . 3!*%),%,!
Slowly further conventions and revisions extended the scope of cooperation 
and the numbers of countries involved in it, yet it would be inaccurate to see 
the Paris Convention as a harmonizer of substantive law; rather it is best seen 
as a way of facilitating procedural compatibility between the patent systems of 
signatory nations.109 In this regard, the current global scenario is somehow 
different, in particular after the establishment of TRIPS, which has managed to 
impose certain standards of substantive IP laws on member countries.   
 
. 4!$!$)#!?$'%#!!,#
'$-!'#('*%#$%<?
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107 !., para (5). 
108 Figure is correct on 21 June 2010, refer 
<http://www.wipo.int/treaties/en/ShowResults.jsp?treaty_id=2> 
109 TORREMANS, Paul, 	  Note 57 p.42. 
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WIPO is a specialized agency of the United Nations. It is dedicated to 
developing a balanced and accessible international intellectual property (IP) 
system, which rewards creativity, stimulates innovation and contributes to 
economic development while safeguarding the public interest. WIPO was 
established by the WIPO Convention in 1967 with a mandate from its Member 
States to promote the protection of IP throughout the world through 
cooperation among states and in collaboration with other international 
organizations. Its headquarters are in Geneva, Switzerland. WIPO’s 
predecessor is an international organization called the United International 
Bureaus for the Protection of Intellectual Property – best known by its French 
acronym, BIRPI. BIRPI in fact originates from the International Bureaus under 
the Paris Convention and the Berne Convention.110 
 
WIPO plays a significant, diverse role at the international level; that ranges 
from providing a forum for Member States to negotiate international 
intellectual property treaties and standards, to assisting governments in using 
intellectual property as part of their development strategies; from providing 
education and skills training on all levels, to delivering commercial intellectual 
property services to the private sector.111 Currently, WIPO has a total of 184 
Member States.112  
 
. 4 .	%#'#$%$)%#$%#'!#!
In relation to international treaties, WIPO administers a group of treaties 
which set out internationally agreed rights and obligations, and common 
                                                 
110 World Intellectual Property Organization: An Overview. [online]2007 ed., p.6, Available at: 
<URL: http://www.wipo.int /freepublications/en/general/1007/wipo_pub_1007.pdf> [Accessed 11 
June 2008] 
111 !  p.3. 
112 Figure is correct  on November 16, 2010. Refer < http://www.wipo.int/members/en/> 
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standards for protecting IP rights. States which ratify the treaties undertake to 
recognize these rights and to apply the standards within their own territories. 
WIPO actively encourages States to accede to these treaties and to enforce 
their provisions. Widespread accession and consistent enforcement help 
maintain a stable international environment, inspire confidence that IP rights 
will be respected around the world.113 
 
<=
#!%#$@$-!'#$%'!#(<
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As far as international harmonization of patent law is concerned, the role of 
WIPO can be seen significantly in the form of the Washington Patent Co-
operation Treaty 1970 (PCT). It provides a unified procedure for filing patent 
applications to protect inventions in each of its Contracting States.114 This 
means that a single international patent application under the PCT has legal 
effect in all the countries bound by the Treaty. Historically, the PCT was signed 
in Washington in 1970. The Treaty entered into force in 1978 initially with 18 
Contracting States. The first international applications were filed on June 1, 
1978. The Treaty was subsequently amended in 1979, and modified in 1984 
and 2001.115 
 
With regard to the procedures under the rules of the scheme, the applicant 
first of all files a single application. The treatment of that application can be 
subdivided in an international and a national phase. In the international phase 
the starting point is the filing of the application under the PCT rules with the 
national patent office of a Member State or with the international Bureau at 
                                                 
113  Note 103, p. 28. 
114 184 Contracting States as at July 07, 2010, Available at: < 
http://www.wipo.int/members/en/>[Accessed 07 July 2020] 
115 Refer <URL:http://www.wipo.int/pct/en/treaty/about.htm >[Accessed 12 June 2008] 
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WIPO in Geneva. In the application the applicant designates the Member 
States which are of interest to him and in which he would like to obtain a 
patent. In a second stage of the international phase an international search is 
carried out by one of nine selected national patent offices. In a third step the 
International Bureau will publish the publication. In fact, this international 
publication is one of the main advantages of the PCT system, as it provides a 
single and complete source of information for any scientist, rather than the 
pre-existing multiple national patent registers. 
 
In the light of the results of the international search, the applicant has to 
decide whether or not to request that the fourth step of the international 
phase be carried out, which involves an international preliminary examination 
of the application by one of the nine selected patent offices. It is important to 
note that this examination is preliminary and no patent is granted at the end 
of the international phase. It is up to the applicant to decide whether he still 
wishes to pursue the application and move on to the national phase. It is only 
at the end of the national phase that each country involved will accordingly to 
its own rules decide whether or not to grant a national patent.116 
 
Under this scheme, PCT applicants receive valuable information about the 
potential patentability of their inventions and have more time than under the 
traditional patent system to decide in which of the PCT countries to continue 
pursuing patent protection. All in all, the PCT system consolidates and 
streamlines patenting procedures, postponing the significant 
internationalization costs and providing applicants with a sound basis for 
                                                 
116 TORREMANS, Paul, 	  Note 57 pp. 42-43. 
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important decision-making.117 It worth noting at this juncture, the PCT system 
is still nowhere near to the establishment of a global patent system. This is 
attributed to the fact that not all countries participate in the system and most 
importantly, there is no harmonization of substantive patent law. What the 
PCT system provides is only a streamlined application procedure. In this 
regard, another relevant issue to be considered is whether worldwide patent 
law is ever likely to be feasible, taking into account the different levels of 
development, innovatory capacity118 and legal systems around the world.119 
 
The idea of having a ‘world’ patent system remains an important issue, despite 
the debates and arguments on the possibility of having one patent system for 
the whole world. Such an idea of the ‘world’ patent system is depicted in the 
form of one bureau or organization issuing ‘world patents’ which are 
automatically valid in all countries, replacing the current situation where each 
country has its own laws, own patent office and own courts. Interestingly, 
around the turn of this century, WIPO has started putting the pieces into 
places. Three primary building blocks have been identified by WIPO for a new 
world patent system namely a uniform set of procedures, a single international 
search tool and a uniform substantive patent law.120 
 
<=
#!%#2'!#(<
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A uniform set of procedures is the first component which was actually put into 
place in June 2000, when the WIPO member states adopted the Patent Law 
Treaty (PLT). This treaty harmonizes the formalities that patent offices 
                                                 
117   Note 103, p. 35. 
118 For example, in 2006, the top countries of origin for PCT applications were again the U.S., 
Japan and Germany,   Note 103, p. 36. 
119 TORREMANS, Paul, 	  Note 57 p. 43. 
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undertake to administer patent applications. It defines one set of rules on how 
to prepare, file and manage patents in all the countries that sign on. Hence it 
streamlines formal procedures in respect of national and regional patent 
applications and patents, and thus making such procedures more user-
friendly. PLT is open to States which are members of WIPO and/or States 
parties to the Paris Convention. It is also open to certain intergovernmental 
organizations.121 Instruments of ratification or accession must be deposited 
with the Director General of WIPO. The PLT entered into force on April 28, 
2005.122 
 
Specifically, PLT signatories have agreed to a single internationally 
standardized set of formal requirements for national and regional offices, 
standardized forms to be accepted by all offices, filing date requirements, and 
procedures to avoid a loss of the filing date because of a failure to comply with 
formalities, simplified procedures before the patent office, basic principles for 
the implementation of electronic filing, and mechanisms to avoid unintentional 
loss of rights as a result of failure to comply with time limits. In essence, the 
Treaty does not attempt to harmonize substantive patent laws. Instead, the 
approach is more to the administrative side of the patent process. 
 
Once the PLT was adopted in 2000, The WIPO member states agreed to move 
on to harmonization of the basic rules of patenting. This will be achieved 
through the Substantive Patent Law Treaty (SPLT). Hence, discussions on a 
draft Substantive Patent Law Treaty (SPLT) started in May 2001 and focused 
                                                 
121 As of June 13 2010, the PLT had 25 Contracting states, while 59 States and the European 
Patent Organization have signed the treaty, Refer < 
http://www.wipo.int/treaties/en/ShowResults.jsp?lang=en&treaty_id=4> [Accessed 07 July 2010] 
122 WIPO, 2000. 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+  #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. [online] Available at 
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on issues of direct relevance to the grant of patents, in particular: the 
definition of prior art, novelty, inventive step/non-obviousness, industrial 
applicability/utility, the drafting and interpretation of claims and the 
requirement of sufficient disclosure of an invention.123 The WIPO Secretariat 
and Member States (known as the Standing Committee on the law of patents 
or ‘SCP’) agreed that other issues related to substantive patent law 
harmonization, such as first-to-file versus first-to-invent systems, 18 month 
publication of applications and a post-grant opposition system, would be 
considered at a later stage. 
 
During the subsequent SCP meetings, proposals from a number of delegations 
led to the progressive broadening of the contents of the draft. While delegates 
agreed in principle on a number of issues, agreement on other topics proved 
more difficult. In 2006, Member States agreed that the time was not ripe to 
agree on a workplan for the SCP, and so put the SPLT discussions on hold. 
Delegations were divided broadly into those pressing to fast-track a limited 
number of technical issues, and those advocating a broader approach 
including a larger number of issues. Directed by its Member States, WIPO is 
now exploring potential areas of common interest.124 
 
. 4 4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The above development is an indication that the road to a uniform world 
patent system is fraught with dangers and unknown. Indeed the proposed 
setting up of a world patent system would have huge implications. It would 
mean the end of patent policy as a tool for national development strategies. 
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As far as SPLT is concerned, its negotiation is largely a debate between the 
U.S. and Europe. The first draft of the treaty singularly reflected the U.S. 
patent law and the U.S. has made it clear that it is willing to go far as it can to 
secure the adoption of this new law. The Americans’ main negotiable is the 
first-to-invent principle, and the related matter of a grace period. Their big 
non-negotiables appear to be business methods and biotechnology. Meanwhile 
Europe is defending the 		4 of TRIPS, with Japan following its line. The 
developing countries are hardly part of the discussion at all, with a few 
exceptions led by Brazil.125 Clearly, conflict of interest not only exists along 
North-South lines, but also amongst the industrialized countries themselves. 
Not surprisingly, the SPLT has been the most difficult piece of puzzle for 
WIPO.126  
 
As discussed above, although a number of treaties, beginning as far back as 
the Paris Convention in 1883, have created a regime of mutual recognition 
between national patent systems, there has been very little substantive 
harmonization at a global level. To-date, the fact remains that TRIPS was the 
first international treaty to prescribe minimum standards for central issues like 
the subject matter of patent, the term of protection, and the mechanisms of 
enforcement. 
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UPOV was introduced with the main objective of protecting important results 
of agricultural plant breeding which are in the form of crop varieties. Since its 
adoption in 1961 in Paris, it has been one of the most significant 
intergovernmental organizations to provide protection for plant-related 
invention, in particular the new varieties of plant.  
 
Historically, the idea of UPOV could be traced back to discussions in the 1950s. 
These discussions placed the emphasis on protecting the result of agricultural 
plant breeding in view of the opinion that this work should not be treated as 
industrial property protectable by the type of right envisaged by the Paris 
Convention. Interestingly, this view was based on the belief that, whilst the 
Paris Convention established the principle that plant products (in the guise of 
grain, flowers and flour) could be industrial property, the application of the 
principle did not, and should not, extend to the plants which produced these 
products. The reasons behind this view related to the capacity to meet the 
criteria for protection as well as the need to protect the public interest which 
vested in the production of new crop varieties.127 Close readings of the 
academic writers and the courts' decision in Europe, for example in Belgium, 
Germany and the Netherlands show that between 1790 and 1970, several 
arguments were raised to deny plants patent protection. The largest category 
of objections focused on non-compliance with the legal requirements of 
patentability: invention conception, novelty, inventive step, industrial 
applicability and adequate disclosure. For example, a major objection to plant 
patents was that breeders' products lacked industrial applicability.128 
                                                 
127 LLEWELYN, Margaret and ADCOCK, Mike, 	 Note 27, p. 136. 
128 This objection was at the core of a heated dispute surrounding the scope of the term 'industry' 
in Article 1 of the Belgian Patent Act. The similar objection was raised under Dutch legal doctrine 
in Article 3 of the 1910 Dutch Patent Act in respect of the definition of the term 'industry'. Refer 
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In 1950s, as far as the general scenario in Europe and UK is concerned, 
despite the fact that Paris Convention provides for a possibility of protecting 
plant products via patents, there was no political or legal will at that point of 
time to provide patent protection for plant varieties. Hence it was decided that 
a more appropriate response to demands of the plant breeders would be the 
introduction of a new form of right specifically designed to protect animate 
material. The result was the International Convention for the Protection of 
New Plant Varieties (UPOV). It is worth noting that central to the development 
of the UPOV Convention, was the involvement of the plant breeding 
organizations which had come into being during the 1930s and 1940s. The 
International Association of Plant Breeders for the Protection of Plant Varieties 
(ASSINSEL),129 which was founded in 1936, played a central role in promoting 
the need for such rights.130 The most important contribution of the ASSINSEL 
in relation to UPOV is the 1957 ASSINSEL Conference in which twelve 
European countries participated; Austria, Belgium, Denmark, France, the 
Federal republic of Germany, Holland, Italy, Norway, Sweden, Switzerland and 
the UK. Clearly, the Conference is quintessentially a European affair.131  
 
The conference delegates finally decided that, for reasons of perception and 
also because of the scant use made of patent protection where that possibility 
existed, it would be more appropriate to provide a specifically designed 	
	 right. In particular, it was felt that plant material could not meet the 
                                                                                                                                      
VAN OVERWALLE, Geertrui, 1997. 06#"+%"" !	!
5	, Belgium: Leuven University Press. 
129 ASSINSEL is now known as The International Seed Federation (ISF), after its merger with the 
International Seed Trade Federation (FIS) in 2002. Refer <http://www.worldseed.org/en-
us/international_seed/history.html> [Accessed 24 June 2008] 
130  Note 27  p. 143. 
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 Note 27  p. 144. 
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patent law notion of novelty, and plant breeding programs could rarely be 
shown to be inventive. In addition, whilst the results of plant breeding were 
undoubtedly of industrial application, it would not be in the public interest to 
allow plant breeders to have an over-extensive monopoly and it would be 
difficult for plant material to meet the disclosure requirement.132 
 
The 1957 Conference was followed by the second conference in November 
1961, in which the 41 Articles of the Convention were adopted and the UPOV 
came into being. The Convention entered into force in 1968.133 The UPOV 
Convention has been revised three times since 1961, with two substantive 
revisions taking place in 1978 and 1991. It is important to note that all three 
versions remain relevant for a discussion of European provisions. In particular, 
the 1978 and 1991 Acts remain relevant for they both form a reference point 
for determining an ‘effective 		 right’ under Article 27(3)(b) of TRIPS, 
despite the fact that the 1978 Convention is now closed and any countries 
wishing to join UPOV can only do so under the Convention of 1991. At present, 
some states are parties to the 1978 Act while some are parties to the 1991 
Act. Non-member states which wish to join the UPOV regime at present must 
join under the 1991 Act but there is no obligation for existing member states 
to ratify the latest version of the Convention if they do not wish to. 
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As far as the UPOV Convention is concerned, the main purpose of its adoption 
is to ensure that the members of the Union134 acknowledge the achievements 
of breeders of new varieties of plants, by granting to them a property right on 
the basis of a set of clearly defined principles. By virtue of the UPOV, a 
minimum scope of protection is afforded to plant breeders as an incentive for 
the development of new varieties of plants, in order to provide sustainable 
progress in agriculture, horticulture and forestry. A legal protection is very 
essential as breeding new varieties of plants requires a substantial investment 
in terms of skill, labor, material, resources, money and time. The opportunity 
to obtain certain exclusive rights in respect of new varieties provides 
successful plant breeders with a better chance of recovering their costs and 
accumulating the funds necessary for further investment.135 In this regard, it 
is worth noting that the ultimate rationale for the introduction of PVP is that it 
will promote food security because genetic engineering offers humankind an 
important chance to significantly increase yields in coming decades in view of 
the shortage of arable land to produce more food for an expanding population. 
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For plant breeders' rights to be granted, the new variety must meet four 
criteria under the rules established by UPOV. Article 5 of UPOV 1991 provides 
that ‘the breeder's right shall be granted where the variety is:  
(i) new,  
(ii) distinct,  
(iii) uniform and  
                                                 
134 68 members as of October 22, 2009, Refer < 
http://www.upov.int/export/sites/upov/en/about/members/pdf/pub423.pdf> [Accessed 07 July 
2010] 
135   Note 126. 
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(iv) stable.’ 
 
Obviously, the 1991 Convention requires that the varieties are new - new in 
the sense that they have not been previously commercialized or sold prior to 
the UPOV application being submitted (subject to the grace period outlined in 
Article 6(1b)). Besides, the new plant must be distinct from other available 
varieties and display homogeneity. The trait or traits unique to the new variety 
must also be stable so that the plant remains true to type after repeated 
cycles of propagation.136 It is worth noting at this juncture that protection can 
be obtained for a new plant variety how ever it has been obtained, for 
example, through conventional breeding techniques or genetic engineering.  
 
The scope of right is clearly spelt out in Article 14(1)(a) of the UPOV 1991 
which says that: ‘Subject to Articles 15 and 16, the following acts in respect of 
the propagating material of the protected variety shall require the 
authorization of the breeder: 
(i) production or reproduction (multiplication), 
(ii) conditioning for the purpose of propagation, 
(iii) offering for sale, 
(iv) selling or other marketing, 
(v) exporting, 
(vi) importing, 
(vii) stocking for any of the purposes mentioned in (i) to (vi), above.’ 
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Since UPOV is concerned with the plant variety rights, it is of paramount 
important to ascertain the definition of the term ‘plant variety’. Article 2(2) of 
the 1961 UPOV Act clearly defined it as ‘…any cultivar, clone, line, stock or 
hybrid which is capable of cultivation and which satisfies the provisions of sub-
paragraphs (1)(c) and (1)(d) of Article 6.’ Article 6 contained the substantive 
granting provisions: distinctness, uniformity and stability.  
 
However, when the UPOV Convention was revised in 1978, the definition was 
deleted. The reason for this was the belief that there was sufficient consensus 
as to what was a variety to render the provision of variety superfluous. In the 
discussions leading up to the 1991 UPOV Act, it was proposed that a definition 
should be reintroduced. The reason for this was that a definition was seen as 
necessary in order to establish a clear concept between the rights available to 
a breeder for the genetic components of a variety which are potentially 
patentable, and rights which the breeder could claim over a grouping which 
collectively, and in a uniform and stable fashion, comprised the genetic 
components.137  
 
In the 1991 Act, Article 1(iv) states that ‘variety’ means a plant grouping 
within a single botanical taxon of the lowest known rank, which grouping, 
irrespective of whether the conditions for the grant of a breeder’s right are 
fully met, can be: 
- defined by the expression of the characteristics resulting from a given 
genotype or combination of genotypes, 
- distinguished from any other plant grouping by the expression of at least one 
of the said characteristics and 
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- considered as a unit with regard to its suitability for being propagated 
unchanged. 
 
The above definition is apparently comprehensive and very well drafted and 
worded. Nevertheless, as mentioned previously in Chapter 1, the 
reintroduction of a definition into UPOV does not necessarily mean that there 
is now no ambiguity as to what is capable of being protected by a plant variety 
right and what is protectable by a patent. Instead, the reference in Article 1 of 
the 1991 Act to two types of plant variety, those which can meet the granting 
criteria and those which cannot, instills a degree of ambiguity into the 
Convention. For the purpose of plant variety protection, this ambiguity does 
not appear to be significant. However, the fact that the UPOV Convention 
specifically mentions two types of plant variety does bring into question the 
way in which the plant variety rights definition is used for the purpose of 
identifying what is excluded from European patent protection.138  
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Other than the definition of the term ‘variety’, the 1991 Act also includes the 
definition of ‘breeder’. It makes clear that a ‘breeder’ is not only a person who 
bred a variety, but also one who ‘discovered and developed it’. Thus, 
discoveries are formally recognized as protectable under the Convention.139 
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Other than the ambiguity and vagueness surrounding the definition of the 
term ‘plant variety’, the issue of ‘dual protection prohibition’ is one of the 
                                                 
138 !., pp. 161-162. 
139 Under the text of the UPOV 1978 Act, it was possible to interpret that discovered varieties were 
protectable. 
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mostly debated and highlighted in the discussions on UPOV. PVR was at first 
conceived as an alternative to patent rights and it was accepted that the two 
kinds of IPRs should be kept separate. This so-called ‘dual protection 
prohibition’ refers to the prohibition of the grant of a patent over a plant 
variety, which was contained in Article 2(1) of both the 1961 and 1978 UPOV 
Acts. Article 2(1) of 1961 and 1978 UPOV Act says that: ‘Each member State 
of the Union may recognize the right of the breeder provided for in this 
Convention by the grant either of a special title of protection or of a patent. 
Nevertheless, a member State of the Union whose national law admits of 
protection under both these forms ++
	"		"	.’(emphasis added)  
 
Basically, this provision has been taken to mean that dual protection could not 
be sought using both ordinary patent law and a right under the UPOV 
Convention. This interpretation was given additional weight by the specific 
exclusion of plant varieties in the European Patent Convention. Hence, most of 
the criticisms for the plant variety right system in the 1980s revolved around 
the issue of this provision, and this has led to its removal from the text of the 
1991 Act.140 The elimination of this restriction was one of the major targets of 
those looking for a strengthened system of protection.  
 
In spite of the removal of the said provision from the 1991 Act, there remain 
some countries within Europe which are still signatories to the 1961 and 1978 
Acts, and have not brought their national provision into line with the 1991 Act 
as they opt to continue relying on the prohibition. Throughout all the 
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debates141 leading to the 1991 Act, one theme is obvious – to make the plant 
variety right system more attractive to breeders. Hence the decision was to 
bring the rights closer to a patent-type right.  
 
Ironically, some observers contend that the system remains less appealing to 
many developing countries. This observation could be attributed to the fact 
that many developing countries assert that the principles embodied in the 
UPOV Convention are not meant to serve their best interests, since the rights 
of farmers and indigenous communities may be compromised by its 
implementation. Besides, they argue that domestic research capacities in most 
of the developing countries are not internationally competitive, or where most 
farmers have been used to freely using and reproducing varieties elsewhere 
protected, introduction of IPRs that include UPOV system are not only prone to 
be met with substantial opposition by the rural communities, but are also 
unlikely to materialize into substantial pay-offs for either the informal breeding 
sector or the farming communities. That explains why some of the developing 
countries are well into drafting 		 laws on protection of plant varieties 
which clearly move away from UPOV and towards the protection and 
implementation of farmers' rights, community rights and other provisions 
stemming from or related to the internationally binding Convention on 
Biological Diversity.142 
 
                                                 
141 The debates revolved around the changes in the UPOV 1991 which include the virtual 
elimination of both the farmers’ privilege and breeders exemption. Member countries who sign the 
1991 Act 'may' permit varieties for use on their own farms, but it will no longer be an automatic 
right. At the same time, breeders face new restrictions in the free use of genetic material, since 
the holder of a variety may now limit the right of another breeder to develop, produce, sell, stock 
or simply use any variety which is ‘essentially derived’ from a previously protected variety. 
142 Resistance to the UPOV 1991 is discussed in the later part of this Chapter (2.4.9.2). India and 
Nigeria have produced their own versions of 		 PVP system as the alternatives to UPOV to 
ensure better protection for farmers and indigenous communities. 
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Another significant topic for discussions on the UPOV system is the two central 
derogations or limitations to the right. The function of these is to ensure that 
there is a proper balance between protecting the interests of the breeders and 
those of end users. The first limitation allows other breeders the right to use 
protected varieties in commercial breeding programs, while the second 
permits farmers to retain seed from one year to the next without having to 
pay an additional royalty. Both of these have undergone extensive revision in 
the most recent UPOV Act in order to take account of the changes to both the 
nature of plant breeding as well as the end use.143 

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As far as the research or breeder’s exemption is concerned, the UPOV system 
allows breeders to use protected material for research purposes even where 
there is a defined commercial objective to that research. This provision is 
contained in the compulsory exception in the Article 15(1) of the 1991 Act. It 
says that: ‘The breeder’s right shall not extend to 
(i) acts done privately and for non-commercial purposes, 
(ii) acts done for experimental purposes and 
(iii) acts done for the purpose of breeding other varieties,…’ 
These exemptions are in fact a fundamental aspect of the UPOV system as it 
recognizes that real progress in breeding relies on access to the latest 
improvements and new variations. Access is needed to all breeding materials 
in the form of modern varieties to achieve the greatest progress and is only 
possible if protected varieties are available for breeding. In this regard, the 
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breeder's exemption optimizes variety improvement by ensuring that 
germplasm sources remain accessible to all the community of breeders.144 
 
<=%!'#$%$)#!#!'A!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The right to use the protected variety for commercial breeding purposes is 
qualified by the need to show that the resulting variety does not fall within the 
‘essentially derived varieties’ within the provision of Article 14(5) 1991 Act 
which states that the rights granted under Article 14(1)145 shall also apply in 
relation to:  
(i) varieties which are essentially derived from the protected variety, where 
the protected variety is not itself an essentially derived variety, 
(ii) varieties which are not clearly distinguishable in accordance with Article 7 
from the protected variety and 
(iii) varieties whose production requires the repeated use of the protected 
variety.  
 
Interestingly, the introduction of the term ‘essentially derived varieties’ in the 
UPOV Convention 1991 version was seen by many as one of the most 
important enhancements in relation to earlier versions of this Convention. This 
is because, under the 1978 Act, the breeder of any new variety is free to 
exploit that variety commercially irrespective of the genetic distance or 
proximity of the two varieties. In contrast, the 1991 Act curbs the freedom 
                                                 
144 Refer <http://www.wipo.int/sme/en/documents/upov_plant_variety.htm> [Accessed  01 July 
2008] 
145 As mentioned earlier, this spells out the scope of the right which covers the production, 
conditioning, offering for sale, selling, exporting and importing, and stocking a protected variety 
for any of these purposes. 
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and states the right to commercialize may be exercised only if the variety 
concerned is not essentially derived.146  
 
The provision on the essentially derived varieties was indeed intended to 
prevent the exploitation of mutations of protected varieties and varieties that 
had undergone a minor change in relation to the initial variety, for example by 
using biotechnology, without the holder of the initial variety right being able to 
share in the revenues.147 Modern biotechnology means that a breeder can, for 
example, make single gene changes to a plant whilst in effect a clone with 
only a single gene differentiation and yet this is being presented as sufficiently 
different to the unaltered plant to warrant protection.148 
 
With regard to the term ‘essentially derived varieties’, the definition set out in 
Article 14 (5) (b) UPOV Convention 1991 Act reads as follows: 
 ‘a variety shall be deemed to be essentially derived from another variety ('the 
initial variety') when 
(i) it is predominantly derived from the initial variety, or from a variety that is 
itself predominantly derived from the initial variety, while retaining the 
expression of the essential characteristics that result from the genotype or 
combination of genotypes of the initial variety, 
(ii) it is clearly distinguishable from the initial variety and 
(iii) except for the differences which result from the act of derivation, it 
conforms to the initial variety in the expression of the essential characteristics 
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147 KIEWIET, Bart, Essentially derived varieties, 2006. Available at: 
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that result from the genotype or combination of genotypes of the initial 
variety.' 
 
It is clear from the above provisions that the characteristics that the derived 
variety must fulfill are cumulative. In other words, if one of the elements is 
not satisfied then essential derivation is not proved as required by the 
provision. The question of how far an essentially derived variety and the 
original variety have to resemble each other phenotypically is a difficult one to 
answer, since the definition offers scope for various interpretations. 
Establishing whether a variety is an essentially derived variety, based purely 
and simply on a genetic comparison, seems in any case not to be in line with 
the criteria set out in the definition of an essentially derived variety.149 Hence, 
a number of different organizations and individuals have been involved in 
trying to define the parameters for determining if a variety is an essentially 
derived variety or not.  
 
One of the useful interpretations is provided by International Seed Federation 
(ISF)150. ISF notes that even if there are not yet international agreed-upon 
professional rules and usages for assessing essential derivation and for solving 
disputes, the concept has already contributed to avoid infringement, and 
breeders being more careful in their breeding programs. According to the 
principle formulated by ISF, technically, for a variety to be considered as 
essentially derived, it must fulfill three requirements in relation to the initial 
variety while retaining the expression of the essential characteristics of the 
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initial variety; clear distinctness in the sense of the UPOV Convention, 
conformity to the initial variety in the expression of the essential 
characteristics that result from the genotype or combination of genotypes of 
the initial variety, predominant derivation from an initial variety. If one of 
these requirements is not fulfilled, there is no essential derivation. 
 
From the legal aspect, the principle of dependence only exists in favour of a 
non-essentially derived protected variety. This means that the initial variety 
must be a protected one, dependence can only exist from one protected 
variety alone and an essentially derived variety can be directly derived from 
the initial variety or from a variety that is itself predominantly derived from 
the initial variety. It is possible to have a "cascade" of derivation. However, 
each essentially derived variety shall only be dependent on one, the protected 
initial variety. A cascade of dependence shall not exist, the principle having 
been introduced to better protect the breeder of the initial variety and not 
those having made derivations from his work. This principle has mainly been 
introduced to protect more efficiently the initial breeder and not those who 
make derivations from his work.151 
 
<='!'5-'&!*!
Another feature which is seen as a limitation to the UPOV is relating to the 
practice of permitting farmers to retain seed from one harvest to the next for 
the purpose of resowing, which is also known as “farmers’ privilege”. From the 
start of agriculture, farmers have saved seed from their own crops for re-
sowing the following year. In fact that practice was normal and is still essential 
in circumstances where the only seed available to plant a new crop is seed 
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harvested from a prior season on-farm harvest. This practice was recognized 
in the earlier versions of UPOV that is the 1961 and 1978 Acts152, wherein the 
owner or breeder had the right to control commercial propagation and 
marketing, but no other uses. This means that farmers were free to save seed 
for their own use for as long as they wished, and use the harvest without 
restriction. 
 
Nevertheless, this ‘privilege’ as given to farmers had been clouded with 
suspicions by breeders within Europe and the U.S., that farmers were 
retaining larger than necessary amounts of the harvested material in order to 
sow greater area of land. This in effect denies the breeders a further return on 
their research investment.153 Hence, with UPOV 1991, the breeders are given 
expanded rights which affect the farmers' privilege. Farm-saved seed is no 
longer automatically allowed, but only as an optional exception; a government 
may legalize seed saving for the farmer’s own use – and even then the seed 
company has the right to a royalty payment. This is stated in Article 15(2) of 
UPOV 1991 by way of an optional exception, each member of the Union may, 
‘within reasonable limits and subject to the safeguarding of the legitimate 
interests of the breeder, restrict the breeder's right in relation to any variety in 
order to permit farmers to use for propagating purposes, on their own 
holdings, the product of the harvest which they have obtained by planting, on 
their own holdings, the protected variety or other variety covered by Article 
14(5)(a)(i) or (ii)".  
 
                                                 
152 Article 5 of UPOV 1961 and 1978. 
153 LLEWELYN, Margaret and ADCOCK, Mike, 	 Note 27. pp. 190-191. 
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Reiterating the main purpose of plant variety protection which is to encourage 
the development of new varieties of plants, for the benefit of society, the 
Convention requires this optional exemption to be regulated ‘within reasonable 
limits and subject to the safeguarding of the legitimate interests of the 
breeder, ...’. Should this exemption be introduced in a way that failed to 
provide an incentive for breeders to develop new varieties, then society would 
fail to benefit from the system.154 
 
. 3 7
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With regard to the substantial revision to the UPOV Convention in 1991, it was 
done primarily for the reasons of strengthening the protection offered to the 
breeder in certain specific ways, as well as to reflect technological 
developments. More importantly, it also aims to clarify certain provisions in 
the light of the experience of UPOV Member States in operating the 
Convention since 1961.  
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There are a number of important differences between the 1978 and the 1991 
Acts of UPOV with regard to coverage, period, scope and exemptions.  
 
<="!'$)-'$#!,#!&'!#!
One of the notable changes in the 1991 Act is the fact that 1978 Act covers 
plant varieties of nationally defined species or genera, whereas the 1991 Act 
covers plant varieties of all genera and species. This means that under the 
system of the 1978 Convention breeders can discover that their particular 
varieties cannot be protected in a country because the country does not 
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provide protection for the species. The 1991 Convention addressed this 
problem by providing for the eventual protection in all UPOV member States of 
all plant genera and species. In terms of the protection period, the 1991 Act 
has extended it from a minimum of 15 years protection under the 1978 Act to 
a minimum 20 years. 
 
<=B-%$%$)#!!B,&!'*#
Another equally important highlight relates to the expansion of the acts 
subject to the breeder’s authorization in respect of the propagating material of 
the protected variety. They do not only include production, offering for sale 
and marketing, but also reproduction (multiplication), conditioning for the 
purpose of propagation, exporting, importing and stocking for the just 
mentioned purposes. This new provision responds to the industry claims for a 
protection more similar to that conferred under the patent system.155 
 
The other extension to the breeder’s rights under the 1991 Act is the rights 
over the harvested material of the protected variety. The problem arises when 
a variety is taken to a country which does not provide protection for new plant 
varieties and used there to produce an end product, say cut flowers, which is 
exported back to a country where the breeder’s variety is protected. In this 
situation, under the 1978 Convention, the breeder is unable to claim any 
remuneration from the exploitation of his variety. The extension in the 1991 
Convention of the breeder’s right to cover harvested material of a protected 
variety enables the breeder to claim remuneration in the situation.156 
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Whilst there may be some who question the value of the UPOV system even 
they would have to acknowledge that the Convention continues to have 
considerable influence, looking at the growing membership of UPOV as well as 
the fact that the number of rights granted has increased gradually. In fact, 
changes in IPRs in the field of plant varieties are necessary in developing 
countries not only to respond to external demands but also to protect local 
developments. Many developing countries have built extensive breeding 
capabilities, and both public and private entities are increasingly eager to 
ensure protection and reward for their research investment.157 
 
. 3 9 0
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In terms of the practical benefit which has been conferred via plant variety 
protection under the UPOV system, some very clear messages have emerged 
from the UPOV Report which was published in 2005.158 The report, the first of 
its kind since the adoption the UPOV Convention in 1961, includes a study on 
the effects of plant variety protection in five countries, namely, Argentina, 
China, Kenya, Poland and the Republic of Korea. The report highlights the 
many and varied benefits of new plant varieties. Notable among these are the 
economic benefits, such as varieties with improved yields which lead to 
reductions in the price of end-products for consumers, and improved quality 
leading to higher value products with increased marketability. 
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158 UPOV, 2005. 5#9)390 !"9+ #)#". UPOV Publication No. 
353(E) [Executive Summary is available online at < 
http://www.upov.int/en/about/pdf/353_Executive_Summary.pdf> [Accessed 22 July 2008] 
73 
 
It is interesting to note that the study indicates the range of ways in which 
plant variety protection can produce benefits and demonstrates that the 
benefits differ from country to country, reflecting their specific 
circumstances.159 Individual country reports demonstrated increases in the 
overall numbers of varieties developed after the introduction of plant variety 
protection.160 These included, for example, staple crops in the agricultural 
sector, such as barley, maize, rice, soybean, wheat; important horticultural 
crops, such as rose, Chinese cabbage, pear; traditional flowers, such as 
peony, magnolia, camellia in China; forest trees, such as poplar in China; and 
traditional crops, such as ginseng in the Republic of Korea. The reports 
brought out the importance of extending protection to all genera and species 
in a country in order to receive the full benefits of plant variety protection.161 
 
The Impact Study also revealed that the introduction of the UPOV plant variety 
protection system and, in particular, membership of UPOV was accompanied 
by a large number of variety applications by foreign (non-resident) breeders, 
particularly in the ornamental sector. This was seen as enhancement of the 
global competitiveness for producers.  
 
With regard to the domestic breeding, Argentina reported an increase in the 
number of domestic breeding entities, mostly in the private sector, for 
example, in soybean and wheat. The Republic of Korea showed an increase in 
the number of breeders of certain crops, such as rice and rose. Poland 
reported an increase in the number of commercial breeding entities and an 
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160 The outcome of the report forms an important part of the thesis discussion of the need for an 
optimum form of protection. 
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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overall increase in the number of improved varieties produced, despite a 
reduction in state-funded breeding and a decline in the overall number of 
domestic breeding entities. China reported on the stimulation of commercial 
breeding activities in domestic public research institutes and domestic seed 
companies, with an increase in the number of breeders (for example maize 
and wheat in Henan Province) linked to increased numbers of plant variety 
protection applications. The protected varieties generated income for 
breeders, including public research institutions and agricultural universities, 
and encouraged further investment in plant breeding. In short, the study has 
managed to show that an effective plant variety protection could encourage 
the development of new varieties of plants, and it aptly concludes that 
farmers, growers and breeders have access to the best varieties produced by 
breeders throughout UPOV member territories. 
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!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Many developing nations, particularly those in Africa, have resisted ratifying 
the 1991 Act or adopting it as the standard for their plant variety protection 
laws. For example, the foreign ministers of the more than 50-member 
Organization for African Unity (now the African Union) issued a statement at a 
January 1999 meeting calling for a hold on IPR protection for plant varieties 
until an Africa-wide system has been developed that grants greater 
recognition to the cultivation practices of indigenous communities.  
 
However, at a subsequent meeting of the Organisation Africaine  
II !" (OAPIO), patent officials from sixteen francophone 
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African nations recommended that their countries adopt the 1991 Act.162 
Currently, Tunisia, Kenya and South Africa are the only African UPOV member 
states. Developing countries which are members of UPOV include  Albania, 
Argentina, Azerbaijan, Belarus, Bolivia, Brazil, Bulgaria, Chile, China, 
Colombia, Costa Rica, Croatia, Dominican Republic, Ecuador, Georgia, Jordan, 
Kyrgyzstan, Latvia, Lithuania, Mexico, Morocco, Nicaragua, Panama, Paraguay, 
Poland, Romania, Tunisia, Turkey, Ukraine, Trinidad and Tobago Uruguay, 
Uzbekistan and Vietnam.163 Nevertheless, the question whether or not UPOV 
negatively affects agriculture in developing countries is still much debated. 
The oft-cited argument is that UPOV's focus on patents for plant varieties 
hurts farmers, in that it does not allow them to use saved seed or that of 
protected varieties, and hence, it is not surprising that countries with strong 
farmers' rights, such as India, cannot comply to all aspects of UPOV. 
  
All in all, the issue whether the evolved European model164 is necessarily or 
automatically the best system for developing countries which includes 
Malaysia, in the 21st century, remains. Whatever the merits of plant 
intellectual property rights in Europe or other part of the globe, care has to be 
taken when using the European experience as a measure of how countries 
should respond to their TRIPS obligation.165 

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162 HELFER, Laurence R., 2004. !"#3	!#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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3	#"9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163 There is a total of 68 countries which are members of UPOV as of January 15 2011. Refer :< 
http://www.upov.int/en/about/members/pdf/pub423.pdf> 
164
 Other than the UPOV system, The EC Regulation on Community Plant Variety Rights of July 27, 
1994 introduces a community plant variety right. This community plant variety right will not 
replace the existing national plant breeder’s rights, but it will offer – albeit co-existing with 
national regimes – the opportunity to the breeder to get an exclusionary right valid throughout the 
Community, through submission of only one application. 
165 LLEWELYN, Margaret and ADCOCK, Mike, 	 Note 27. pp. 198-199. 
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The Uruguay Round of multilateral trade negotiations held in the framework of 
the General Agreement on Tariffs and Trade (GATT) led to the Agreement 
Establishing the World Trade Organization (WTO Agreement).166 For the first 
time those negotiations included discussions on aspects of IPRs which had an 
effect on international trade. The TRIPS Agreement was finally adopted at 
Marrakesh on April 15, 1994 as Annex 1C of the Final Act Embodying the 
Results of the Uruguay Round of Multilateral Trade Negotiations. The 
Agreement came into force on January 1, 1995.167 The TRIPS Agreement is 
perhaps the most far-reaching international instrument ever subscribed on 
IPRs. It covers all types of IPRs, with the sole exception to breeders’ rights 
(only incidental referred to) and utility models. 
 
The evolution of the TRIPS Agreement could be traced back to the growing 
realization particularly in the U.S., that the counterfeiting of trade marked 
products was having a considerable adverse impact upon trade revenue. The 
initiatives started as early as the late 1970s. The U.S. suggested that GATT 
jurisdiction was to be extended to trade mark counterfeiting. This proposition 
was argued by developing countries led by Brazil and India, on the ground 
that the intellectual property issues were the exclusive territory of WIPO. 
Eventually, after a series of negotiations and discussions, the TRIPS 
Agreement was realized168, as an Annex to the WTO Agreement within the 
                                                 
166 The Uruguay Round negotiations concluded on December 15, 1993. The WTO Agreement was 
adopted on April 15, 1994, in Marrakesh. 
167 Official Journal EC, December 23 1994, L 336, Available at < 
http://europa.eu/scadplus/leg/en/lvb/r11010.htm> [Accessed 21 August 2008] 
168 The Preamble to the TRIPs Agreement commences with a statement of the desire of Members; 
'to reduce distortions and impediments to international trade, and taking into account the need to 
promote effective and adequate protection of intellectual property rights, and to ensure that 
measures and procedures to enforce intellectual property rights do not themselves become 
barriers to legitimate trade..' 
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Uruguay Round.169 The fact that compliance with IP legislation would be linked 
to trade rights was undoubtedly one of the driving forces of the negotiation. 
Before TRIPS was concluded, many efforts failed to achieve what many 
governments, in particular the U.S. and Japan felt was becoming a necessity: 
a binding obligation to eliminate trade in counterfeit and pirated goods. There 
was resistance to the establishment of new norms. Some countries believed 
that no traditional standards were necessary or that they would impede 
legitimate trade. Others held the view that WIPO, not GATT, was the 
appropriate forum for treatment of these issues.170 
 
The TRIPS Agreement establishes minimum universal standards of intellectual 
property protection that should be provided by all WTO member states.171 It 
will supplement with additional obligations of the Paris, Berne, Rome and 
Washington172 Conventions in their respective field.173 Member states are free, 
however, to determine the appropriate method of implementing the provisions 
of the TRIPS Agreement within their own legal system and practice, and may 
implement more extensive protection than required.174 The essential elements 
of standards concerning the availability, scope and use of patent rights are laid 
down in Articles 27-34 TRIPS Agreement. The provisions relating to eligible 
                                                 
169 BLAKENEY, Michael, 1997. 0 3 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London : Sweet & Maxwell. pp. 1-6.  
170 GERVAIS, Daniel, 2003. 003!#/
+			. London : Sweet 
& Maxwell. pp. 1-35. 
171 153  members on 23 July 2008, Refer < 
http://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm> [Accessed 16 November 2010] 
172 The Washington Treaty, adopted in 1989 under the auspices of WIPO, has not entered into 
force. Despite this, the TRIPS Agreement requires the compliance with the Treaty provisions, plus 
a number of additional rules. Refer: http://www.wipo.int/treaties/en/ip/washington/> [Accessed 
03 September 2008] 
173 Refer Article 1(3) TRIPS Agreement. 
174 Article 1(1) provides that: ‘…Members may, but shall not be obliged to, implement in their law 
more extensive protection than is required by this Agreement, provided that such protection does 
not contravene the provisions of this Agreement…’ 
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subject matter, which are of special interest for this thesis, are laid down in 
Article 27 TRIPS Agreement. 
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The general principle with regard to patentable subject matter in Article 27(1) 
TRIPS Agreement defines that patents shall be available for any invention, 
whether products of processes, in all fields of technology, provided that they 
are new, involve an inventive step and are capable of industrial application. 
The Agreement stresses that patents shall be available, and patents rights 
enjoyable without discrimination as to the place of invention, the field of 
technology and whether products are imported or locally produced.175
 
It is worth noting the patent section of the TRIPS Agreement was one of the 
most difficult to negotiate. It involved a number of key North-North as well as 
North-South issues. The negotiations on patentable subject matter in 
particular, represent a microcosm of the GATT treaty negotiations – 
confrontations and compromises between developed countries’ desire to 
provide broad intellectual property protection and developing countries’ 
concern for increasing inaccessibility of modern technology through 
overprotection.176 The result is essentially impressive, in that the scope and 
coverage of the section are comprehensive, and makes TRIPS the most 
important multilateral instrument in this field. The TRIPS Agreement overcame 
the main weakness of the Paris Convention, and instead of relying on domestic 
law, TRIP defined the scope of a patent.177 The TRIPS Agreement adds some 
                                                 
175 Article 27(1) TRIPS Agreement. 
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 BAI, J.Benjamin, 1997. Protecting Plant Varieties under TRIPS and NAFTA: Should Utility 
Patents Be Available for Plants?, 0	!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 32, p. 141. 
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, Note 170, p.220. 
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new standards to those already established by the Paris Convention, such as 
the prohibition of discriminatory treatment of patent rights as regards fields of 
technology (Article 27.1); the establishment of mandatory conditions for 
exclusions from patentability on  public and morality grounds (Article 
27.2); the definition of 'minimum rights' (Article 28), and so forth.   
 
In the field of life sciences, biotechnology and genetic engineering, Article 
27(3)(b) TRIPS Agreement contains exclusionary provisions which are highly 
reminiscent of Article 53(b) EPC. It reads as follows; Article 27(3): Members 
may also exclude from patentability: 
(b) plants and animals other than micro-organisms, and essentially biological 
processes for the production of plants or animals other than non-biological and 
microbiological processes. However, Members shall provide for the protection 
of plant varieties either by patents or by an effective 		 system or by 
any combination thereof. The provisions of this sub-paragraph shall be 
reviewed four years after the entry into force of the Agreement Establishing 
the WTO. 
 
The above provision indicates that the TRIPS Agreement provides for the 
exclusion of plants and animals from patent law, while plant varieties may be 
protected either by patents or by an effective 	 	 system or by a 
combination thereof. In doing so, the TRIPS Agreement seems to take over 
the much disputed EPC distinction between plant or animal 	 and plant or 
animal variety, leaving the first category without any legal protection.178 
Hence, the upshot is that plant and animals, including those that are 
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genetically modified, may be excluded from patenting under Article 27(3)(b). 
This means that, unlike European law and other legislation that followed the 
same approach, this Article refers to ‘plants and animals’ and not to a certain 
classification thereof (‘varieties’, ‘races’ or ‘species’). The distinction is 
important, as the prohibition to patent a ‘variety’ does not prevent in 
European countries the patenting of a plant as such. In the absence of any 
distinction, and in the light also of the second sentence of the same Article 
that introduces an exception for one particular classification (‘plant varieties’), 
the exclusion is to be interpreted in broad terms inclusive of animal and plants 
as such, animal races and animal and plant species.179 
 
Another element of the Article 27(3)(b) TRIPS Agreement is the exclusion of 
‘essentially biological processes’ which is limited by the reference to processes 
‘other than non-biological and microbiological’. The concept of microbiological 
processes as an exception to the exception is present in the European 
legislation. Its aim in the TRIPS context is to limit the exclusion of 
patentability to traditional breeding methods, while preserving the possibility 
to obtain protection, for instance, on developments based on cell manipulation 
or, with the advances in biotechnology, the transfer of genes. According to 
TRIPS Agreement, processes employing microorganisms are patentable, in 
accordance with current practice in most countries.180 
 
All in all, the wording of Article 27(3)(b) of the TRIPS Agreement apparently 
leaves the choice of protection system entirely to the members, which reflect 
on the one hand the broad range of existing systems, ranging from the US 
                                                 
179 CORREA, Carlos M., 1994. The GATT Agreement on Trade-related Aspects of Intellectual 
Property Rights: New Standards for Patent Protection, !#3 8, p. 328. 
180 ! 
81 
 
where plant varieties may be protected by patents of by specific PVP rights or 
even by special plant patent, to the EU countries where PVP is confined to 
specific variety protection systems only. The possibility of excluding plant 
varieties from patent protection under TRIPS and the resistance from many 
developing countries to provide protection in this field resulted in the creation 
of 		 protection according to their own concepts.181 
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A key issue with respect to a 		 system for the protection of plants is 
determining what an effective system constitutes. It is interesting to note that 
the introduction of the 	 	 concept in Article 27(3)(b) reflects two 
broad elements. First, a number of countries in the North and the South 
rejected the compulsory introduction of plant patents. Second, negotiators did 
not manage to agree on one specific alternative to patents. As a result, TRIPS 
gives member states a wide margin of appreciation in determining their 
obligation to introduce plant variety protection.182 In other words, the 	
	 option gives countries the option to develop a law that will not 
undermine the tradition of their farming communities and indigenous people in 
innovating and developing new plant varieties and enhancing biodiversity.  
 
In the intellectual property context, a 	 	 option is usually taken to 
refer to a specially coined IPR outside the traditional categories of IP 
protection. In this regard, UPOV has advanced its system as the principal 
workable example of a 		 plant variety protection system. Hence, it is 
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safe to assume that a UPOV 1991-compatible system would enjoy a 
presumption of the effectiveness required by this Article. Yet, the Article as it 
stands does not mandate UPOV protection and WTO members are thus free to 
develop another type of effective protection.183 
 
In general, developing countries can make a choice amongst the following 
policy options, namely; first, to make provisions for the patent protection of 
plant varieties; second, to join the International Union for the Protection of 
new Varieties of Plants (UPOV) in either of both variants (UPOV 1978 or 
1991); third, to provide for comparable plant variety protection (pvp) without 
formally joining the UPOV Convention; or fourth, to devise a 	 	 
system which is better designed to suit national interests and to take into 
account the protection demands of informal and local communities.184 
 
In fact, the question of the introduction of plant variety protection is one that 
concerns mostly developing countries. Indeed, most developed countries had 
already introduced either plant patents or PVR before the adoption of TRIPS. 
Developing countries that are member of WTO were left with the choice of 
either adopting the existing regime proposed in UPOV or devising their own 
plant variety protection system adapted to their specific situation. In this 
regard, the prominence of the UPOV Convention in the debates concerning 	
	 plant variety protection is in part linked to the fact that the 
interpretation of the concept of ‘effective’ 	 	 system in Article 
27(3)(b) TRIPS remains problematic.  
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The only generally agreed upon interpretation is that UPOV is an effective 	
	 protection regime under TRIPS. This has led some countries such as 
the member states of the African Intellectual Property Organization for 
instance to simply adopt a regime modeled after UPOV-1991 and at the same 
time to commit themselves to join the UPOV Convention.185 Nevertheless, 
space to manoeuvre still exists mainly because there is no formal reference 
made to the UPOV Convention. Furthermore, key elements for the shaping of 
effective 		 systems are either unclear or not defined at all. While the 
TRIPS Agreement could have referenced the UPOV, and made its adoption a 
requirement, this was not done. At the time, one of the reasons for not 
referencing UPOV was specifically that the 1991 version had not been widely 
adopted. 
 
From the perspective of developing countries, the term 'effective' means 'real' 
protection and not the strongest possible protection. Protection should be 
given not only to commercial breeders but, also, to traditional breeders. All 
that a 	 	 law for plant varieties requires is an adherence to the 
minimum provisions of TRIPS, also consistent with obligations of countries 
under other international instruments to which they are parties, such as the 
CBD and its protocols. In fact, it is also suggested by some developed 
countries that what is 'effective' must be adjudged from the view-point of the 
rights-holder of the IPRs. But if traditional breeders are given rights under a 
		 law, then they too are rights-holders. Whether the law is effective 
in protecting their creativity must be assessed from the perspective of their 
interest as well. In these circumstances a 	 	 law that balances the 
                                                 
185 ! 
84 
 
interest of both commercial breeders and traditional breeders can hardly be 
considered ineffective.186 
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Another controversial issue with regard to Article 27(3)(b) TRIPS Agreement is 
the review of its provision. The provision, when it was introduced in 1994, 
provided for its own review within four years by the Council of TRIPS. In fact, 
Article 27(3)(b) is the single provision in the whole TRIPS Agreement subject 
to an early revision. This period is even shorter than the transitional period 
contemplated for developing countries.187 This solution suggests how difficult a 
compromise on biotechnology-related issues has been and need for a deeper 
examination of the matter.188  
 
Back to the review, in December 1998 the Council initiated preliminary work 
on the review of the provision of Article 27(3)(b) of the Agreement concerning 
inventions involving plants and animals, the review of which was due in 1999. 
By February 1999, Members in respect of which this Article was in force were 
invited to provide information on how the matter had been addressed in their 
country and how it was presently treated in their national laws. The 
Secretariat then contacted relevant organizations Food and Agricultural 
Organization (FAO), Convention on Biological Diversity (CBD) and the 
International Union for the Protection of New Varieties of Plants (UPOV) to 
request factual information on their activity in this field. It is worth noting at 
this juncture what the TRIPS Council has done is to require the developing 
countries to answer a three-page questionnaire. This information-gathering is 
to provide the basis for the review. The position of several leading developed 
                                                 
186 NIJAR, Gurdial Singh, 	, Note 100. 
187 Refer Article 65 TRIPS Agreement. 
188 CORREA, Carlos M., 	  Note 179, p. 329. 
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countries is that the review is merely to see how far countries are providing 
for the protection of plant varieties, namely, to monitor the implementation of 
the provision in relation to plant varieties. The EU and the U.S. state clearly 
that the review is thus limited and should not lead to a renegotiation of the 
Article. In particular they state that any attempt by developing countries to 
debate the relationship of TRIPS to other 'aspects such as competition, 
environment, and its impact on health and welfare ...must be resisted...'189 
 
In fact, the discussions concerning the review of Art.27(3)(b) were amongst 
the most controversial discussion in the work of the Council for TRIPS. The 
discussions revealed differences between developed and developing countries 
and touched on major issues on which these two large groups of WTO 
Members may disagree, namely the patenting of life forms and plant 
varieties.190 The discussions revolved around the perceived problems 
embedded in Article 27(3)(b), as highlighted by developing countries, 
; there are no parameters for what a 		 system can amount to, no 
parameters for what is ‘effective’, the view that genes and microbiological 
processes are not inventions and therefore not patentable subject matter, a 
bias ingrained in TRIPS to protect breeders and biotechnologists at the 
expense of farmers and local communities, as well as the perceived conflict 
between TRIPS and the rights and obligations countries previously acquired 
under the CBD.191 
 
                                                 
189 NIJAR, Gurdial Singh, 	, Note 100. 
190 GERVAIS, Daniel, 	, Note 170, p.227. 
191 GRAIN, 2000. ,,3-+03!#7C=8>=>/-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	-	+.09. [online] Available at: <http://www.grain.org/briefing-
files/tripsfeb00.pdf>; Summary of the debate is available at: 
<http://www.wto.org/english/tratop_e/trips_e/art27_3b_background_e.htm>[Accessed 27 
August 2008] 
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The review started, but it did not end. Developing countries made 
recommendations for clarification of TRIPS, but these were not acted upon. 
Finally, the deadline for implementation of Article 27.3(b) in developing 
countries, 1 January 2000, arrived before any conclusions could be drawn 
from the mandated re-examination of the text. In sum, although the review 
has not been a failure, it does not seem to have been very effective.192 
 
The WTO’s Fourth and Fifth Ministerial Conferences in Doha (9 – 14 November 
2001)193 and Cancun (10 – 14 September 2003) respectively, and the World 
Summit on Sustainable Development (WSSD) in Johannesburg (26 August – 5 
September 2002) and the WTO's Sixth Ministerial Conference in Hong Kong in 
2005 additionally failed to modify Article 27(3)(b) in any manner or form. The 
review of TRIPS Article 27.3(b) continues.194 The current state of affairs is not 
unexpected as senior WTO officials privately confirm that whilst the review is 
supposed to cover the substance of the provision, rather than the way in 
which it has been implemented, they are convinced that the review will not be 
able to be concluded successfully until the stage where other provisions of the 
Agreement are also subject to review.195 After all, the EU and the U.S. have 
made it loud and clear that the review is limited and should not lead to a 
renegotiation of the Article.
196
 In short, as mentioned above, a positive 
outcome is not expected in the near future. The status quo may well be the 
most likely outcome, but it is interesting to note that both the African Group 
                                                 
192 ! 
193 Paragraph 19 of the 2001 Doha Declaration has broadened the discussion. It says the TRIPS 
Council should also look at the relationship between the TRIPS Agreement and the UN Convention 
on Biological Diversity, the protection of traditional knowledge and folklore. 
194 Refer 
<http://www.protimos.org/downloads/International%20Treaties/TRIPS/Review%20of%20Article
%2027.3b%20of%20the%20TRIPS%20agreement.pdf> [Accessed 28 August 2008] 
195 TORREMANS, Paul, 	  Note 26, p. 398. 
196 NIJAR, Gurdial Singh, 	, Note 100. 
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which represents the developing countries, as well as the EU, see some scope 
and flexibility to discuss and possibly to protect issues such as traditional 
knowledge, protection of biodiversity and the promotion of farmers’ rights.197 
 
. 8 8-$'#%#'$!$)
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In conclusion, to parts of the business world, TRIPS has provided a means to 
help ensure that investments in research can reap financial rewards, in order 
that their products can be globally marketed under patented protection. In this 
regard, TRIPS means stronger intellectual property protection around the 
world which creates a new space on the global field within and around which 
the protection is further modified. With the partial exception of copyright and 
related rights, TRIPS represented a substantial institutionalization of protection 
at the level of international law. Nevertheless, from the view of most 
developing countries, while the TRIPS agreement serves as an important step 
in harmonizing international intellectual property systems, it currently fails to 
properly balance public and private interests, especially in the gap between 
rich and poor. 
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The preceding discussion in this chapter has deliberated on the two major 
international treaty systems that regulate issues on plant varieties and plant 
breeders’ rights, namely UPOV and TRIPS. As has been highlighted, these two 
treaty systems each contain a comprehensive set of rules for their members 
regarding IPRs over plant varieties. As far as UPOV treaties are concerned, 
they adopt a 		 system of protection especially tailored to the needs 
                                                 
197 TORREMANS, "  pp. 400-401. 
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of plant breeders. The TRIPS Agreement on the other hand requires WTO 
Members to protect new plant varieties using patent rights, a 	 	 
system or some combination thereof. 
 
As TRIPS provides member states with flexibility and because the treaty has 
an uncertain relationship to the UPOV conventions, national governments face 
a wide array of options in choosing the IP regime applicable to plant varieties. 
This section of the thesis seeks to indentify and analyze the issues that arise 
in relation to co-existence of these two major treaties. 
 
Although the UPOV Acts have provided IPR protection for plant varieties for 
more than four decades, their significance has been somehow overshadowed 
by TRIPS, being the first and only IPR treaty that seeks to establish universal, 
minimum standards of protection across the major fields of IP, including 
patents. Although the TRIPS Agreement devotes only minimal attention to 
plant breeders’ rights or PVP and does not even mention the UPOV Acts, its 
adoption has done more to encourage the legal protection of plant varieties 
than any other international agreement, comparing to the UPOV Acts which 
were initially drafted and created to address the needs of European plant 
breeders specifically. 
 
Unlike all prior IP treaties, TRIPS is not a free-standing agreement concerned 
solely with IPRs. Rather, TRIPS is linked to a larger family of trade-related 
agreements, by which industrialized nations secured a commitment from 
developing nations to provide minimum standards of effective legal protection 
to intellectual property products, and in exchange developing nations received 
a commitment from industrialized countries to open their domestic markets to 
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goods and other products manufactured in the developing world.198 The result 
of this global bargain was widespread adherence to all WTO Agreements, 
including the TRIPs Agreement. As of July 2008, 153 states or customs 
territories were obligated to comply with TRIPs by virtue of their membership 
in the WTO.199 As compared to UPOV, as at October 2009, only 68 countries 
are parties to the various UPOV Acts.200 
 
Article 27.3(b) of the TRIPS Agreement contains the only textual provisions 
relating to PVP. Being a global instrument, it is interesting to note that TRIPS’ 
provision on plant varieties do not incorporate any preexisting IP agreements, 
including the 1978 and 1991 UPOV Acts. This omission contrasts sharply with 
other fields of intellectual property, such as patents, copyrights and 
trademarks, for which TRIPs expressly requires WTO Members to comply with 
the standards of protection contained in preexisting IPR agreements, such as 
the Berne Convention for the Protection of Literary and Artistic Works and the 
Paris Convention for the Protection of Industrial Property. As a result of this 
omission, WTO Members are neither required to become members of UPOV 
nor to enact national laws consistent with either UPOV Act in order to comply 
with their obligations under TRIPs. Although the drafting history of TRIPS does 
not explain this markedly different treatment of plant varieties, it seems likely 
that compliance with UPOV was not required because so few WTO Members 
were party to UPOV and those who were could not agree upon which of its two 
most recent Acts should serve as the standard for protection.201 

                                                 
198 HELFER, 	 Note 162, p.34. 
199 Refer <http://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_e.htm> 
200 Refer < http://www.upov.int/en/about/members/pdf/pub423.pdf> 
201 HELFER, 	 Note 162, p.39. 
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In fact, Article 27.3(b) permits WTO Members to protect plant varieties using 
one of three distinct approaches: (1) patent law, (2) an effective 		 
system or (3) a combination of elements from both systems. Thus, unlike 
most other areas of intellectual property protected by TRIPs, Article 27.3(b) 
expressly grants Members significant discretion to choose the manner in which 
they will protect plant varieties and it contemplates that that discretion may 
be exercised differently by different states. 
 
This discretion and the opportunity for divergent outcomes it engenders has 
significant consequences. On the one hand, TRIPS’ failure to incorporate and 
build upon the preexisting UPOV Acts may have a deharmonizing effect, with 
states within the UPOV system enacting one type of plant variety protection 
law and states outside of that system enacting a different kind of law (which 
may or may not resemble each other). This could create significant 
complexities and uncertainties for plant breeders seeking to market protected 
varieties in different jurisdictions. On the other hand, this sanctioned diversity 
of legal approaches allows WTO Members to balance the protection of plant 
breeders’ rights against the other important and competing societal goals.202 
 
With regard to exceptions and limitations, as compared to limitations on plant 
breeders’ rights permitted under the UPOV, the limitations on a patent owner’s 
exclusive rights permitted under the TRIPS Agreement are far narrower. These 
limitations can be divided into exceptions to exclusive rights and compulsory 
licenses, which permit certain uses by third parties but require remuneration 
to the patent owner. 
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Back to the issue on 		 protection for plant varieties under TRIPS, as 
noted above, TRIPS authorizes WTO Members to eschew patent protection for 
plants and plant varieties and adopt instead an ‘effective 		 system’ 
of protection, without defining the term ‘effective 		&. In this regard, 
there is a commentator who asserted that a state adopting national legislation 
in compliance with either the 1978 UPOV Act or the 1991 UPOV Act has 
satisfied its obligations under Article 27.3(b).203 The argument and observation 
could be based on the practice of UPOV Member States which have 
successfully implemented UPOV provisions in their countries respectively. 
 
However, from the perspective of developing countries which do not favour of 
joining UPOV, it can still be argued that the protection required by the two 
UPOV Acts is unnecessary for an ‘effective 	 	 system.’ It is not 
necessary because article 27.3(b) neither requires plant variety protection 
laws to contain the same subject matter, eligibility requirements, exclusive 
rights, terms of protection or other detailed provisions of either of the two 
UPOV Acts., nor TRIPs requires WTO Members to structure their national IPR 
laws in ways that the two UPOV Acts do not. 
 
The above argument is reinforced by the fact that TRIPs’ drafters did not 
intend either UPOV Act to be the exclusive model for 		 protection of 
plant varieties is confirmed by their failure to refer to the Acts anywhere in the 
Agreement. By contrast, where the drafters intended Members to comply with 
                                                 
203 The commentator refers to Danielle Gervais; GERVAIS, D., 1998. 0 03!# /
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standards found in preexisting international IPR treaties, they stated so 
expressly.204  
 
Nevertheless, it could be said that most provisions of the two UPOV Acts are 
fully consistent with an effective 		 system, and countries who chose 
to join UOPV have adopted plant variety protection laws that are consistent 
with one or both UPOV Acts; ‘effective’ in the sense that the UPOV Member 
States have been benefiting from the system and the agricultural 
biotechnology industry in general has grown at a rapid stage. One of the 
evidences is based on the UPOV Impact Study, as discussed earlier.  
 
Having said that, the issue of alternative PVP laws remains as an interesting 
agenda among developing countries. India for instance has designed its own 
‘	 	& system, namely the Protection of Plant Varieties and Farmer’s 
Rights Act 2001. The Act provides a notable counterexample to the trend of 
following UPOV standards. That legislation seeks to implement both breeders’ 
rights and farmers’ rights by recognizing the concept of farmers’ rights and by 
allowing farmers to register the varieties they cultivate. The Act also contains 
benefit sharing provisions that allow individuals and communities to claim 
compensation for their contributions to plant genetic diversity. At this 
juncture, it is noteworthy that Malaysia, being one of the developing countries, 
has enacted the Protection of New Plant Varieties Act 2004, which is pan-
Malaysian in nature, and does incorporate provision on farmers’ right.205 
 
                                                 
204 For example TRIPs, Article 2(1), which incorporates enumerated provisions of the Paris 
Convention for the Protection of Industrial Property. 
205 Malaysia is yet to accede to UPOV, as it needs to amend the 2004 Act to confirm to UPOV’s 
standard and requirements. 
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Despite the above argument, it is submitted that UPOV is currently the only 
‘effective 		& model available in protecting plant varieties. Other ‘	
s’ models which have just been introduced and implemented by some 
countries like India and Malaysia for example, are relatively new and 
specifically tailored to respective countries’ needs and uniqueness. Certain 
flexibilities should be allowed to suit the unique situation and local 
circumstances of each country that wish to accede to UPOV. It is true that 
historically PVR  as introduced by UPOV was meant to provide incentives to 
commercial breeders, but being a dynamic system and to maintain the 
dynamism and relevancy to the seed and agriculture industry in the 
developing countries in particular, UPOV should be able to cater for the 
protection of all levels of breeders which include small farmers. 

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The situation in Europe is slightly complicated in that there are two sources of 
European patent law. These two relevant and significant sources are the 
European Patent Convention (EPC) and the Biotechnology Directive (the 
Directive 98/44) on the legal protection of biotechnological inventions. For the 
purpose of this thesis, the brief history of EPC, its relevant provisions and 
interpretation by European Patent Office (EPO) will be discussed first, followed 
by the discussion on the provisions of the Directive 98/44. 
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All European countries have their own national patent law and most are also 
members of the EPC, the regional patent system which was established in 
1973. The EPC is separate from the European Union (EU), and its membership 
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is different; Switzerland, Liechtenstein, Turkey, Monaco, Iceland, Norway and 
Croatia are members of the EPO but are not members of the EU. The 
Convention is now (as of December 2010) in force in 38 countries.206 The EPC 
is in fact a multilateral treaty providing an autonomous legal system according 
to which European patents207 are granted. Hence, the EPC provides a legal 
framework for the granting of European patents, via a single, harmonized 
procedure before the European Patent Office (EPO). This means that under the 
EPC, a single patent application can cover all, or any selection, of the countries 
that have joined this Convention. The establishment of EPC is significant as it 
aims to reduce the administrative work required for obtaining patent 
protection in a number of its Member States, which would otherwise have to 
be applied for and prosecuted separately in each and every national 
jurisdiction in which the applicant wishes to protect its invention. It is worth 
noting EPC law takes precedence over national laws and these are required to 
be in harmony with it. In this regard, the EPO, which was established in 1974, 
has been playing a vital role as the principal representative of official patent 
opinion throughout Europe. Nevertheless, there is currently no single, centrally 
enforceable, European Union-wide patent. 
 
Historically, the establishment of the EPC could be traced back to the problem 
of filing a separate patent application with different grant procedure in each 
country across the Europe when a patent applicant sought to obtain patent 
protection in Europe in a number of countries. While the EPC does not totally 
                                                 
206 Refer <http://www.epo.org/about-us/epo/member-states.html> [Accessed 01 December 
2010] In addition to the Contracting States, States may also conclude a co-operation agreement 
with the EPO, known as an extension agreement. The state then becomes ‘extension state’, which 
means European patents granted by the EPO may be extended to those countries by the payment 
of additional fees and completion of certain formalities. 
207 The term European patent is used to refer to patents granted under the European Patent 
Convention. 
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overcome the need for translations (since a translation may be required after 
grant to validate a patent in a given EPC Contracting State), it does centralize 
the prosecution in one language and defers the cost of translations until the 
time of grant. 
 
The EPC 1973 was comprehensively revised at a Diplomatic Conference in 
November 2000. The new version of the Convention - abbreviated as ‘EPC 
2000’ is now governing the European patent grant procedure and European 
patents. In fact, this was the first revision of the EPC since 1973 and aimed to 
modernize the European patent law to take account of developments in 
international law, to satisfy the needs of users, to eliminate unnecessary 
requirements and to introduce flexibility into the EPC. Besides, in the last 30 
years, the patent landscape changed significantly and it became apparent that 
there was a real need to overhaul the dated legislation. The EPC 2000 entered 
into force on December 13, 2007.208 Despite the comprehensive revision, the 
EPC 2000 leaves substantive patent law largely unchanged. The main 
amendments are in Article 54(3), concerning the novelty-destroying effect of 
prior European patent applications, and Article 54(5), expressly providing for 
use-limited product protection for a second or further medical use of a known 
substance.209 
 
In relation to PCT, a European patent application may result from the filing of 
an international application under the PCT and the entry into ‘European 
regional phase’. The European patent application is therefore said to be a 
                                                 
208 Refer <http://www.epo.org/patents/law/legal-texts/epc2000/faq.html> [Accessed 15 July 
2008] 
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‘Euro-PCT application’ and the EPO is said to act as a designated or elected 
Office.210 
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As far as EPC substantive patent law is concerned, Article 52 EPC, entitled 
‘Patentable inventions’ is apparently one of the most important articles of the 
Convention. Article 52(1) states: ‘European patents shall be granted for any 
inventions, in all fields of technology, provided that they are new, involve an 
inventive step and are susceptible of industrial application’.  This article 
constitutes the fundamental provision of the EPC which governs the 
patentability of inventions. 
 
However, the EPC provides further indications on what is patentable, by 
introducing exceptions. Article 53 provides that: ‘European patents shall not 
be granted in respect of: 
(a) inventions the commercial exploitation of which would be contrary to 
"ordre public" or morality; such exploitation shall not be deemed to be so 
contrary merely because it is prohibited by law or regulation in some or all of 
the Contracting States; 
(b) plant or animal varieties or essentially biological processes for the 
production of plants or animals; this provision shall not apply to 
microbiological processes or the products thereof; 
(c) methods for treatment of the human or animal body by surgery or therapy 
and diagnostic methods practised on the human or animal body; this provision 
shall not apply to products, in particular substances or compositions, for use in 
any of these methods. 
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For the purpose of this thesis, discussion is focused on Article 53(b) 
specifically, which is pertaining to the patents for plants and plant varieties. In 
essence, Article 53(b) imposes a restriction on the patentability of living 
matter. The provision has been repeated in the patent laws of all the signatory 
countries, for example, it appears in the UK Patents Act 1977 at Schedule A2 
(section 76A) under item 3: ‘The following are not patentable inventions -(f) 
any variety of animal or plant or any essentially biological process for the 
production of animals or plants, not being a micro-biological or other technical 
process or the product of such a process.’ 
 
Historically, living matter had not been considered patentable under two 
distinct lines of thought: first, a legal view that biological material could not 
satisfy the criteria for patentability; and second, a strong ethical objection to 
granting a patent monopoly on any form of life. The exclusions of plant 
varieties from patentability is usually explained or defended on the ground 
that other forms of legal protection are available, namely, plant variety rights. 
Apparently, it might be thought that Article 53(b) would effectively exclude all 
patent applications for plant and animal varieties. Interestingly however, a line 
of cases in the EPO has laid down a very restrictive interpretation of Article 
53(b), with the result that patents covering plants and animals can be 
obtained in many cases.211 The relevant decided cases by EPO will be dealt 
with in a considerable detail in the latter part of this chapter.  
 
Article 53(b) has attracted many views and criticism in terms of its 
interpretation. The provision has been clouded with uncertainties, in particular 
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the extent to which plants and animals can be patented. Since Article 53(b) 
provides an exception to patentability, it must be analyzed carefully. It is 
argued that being an exclusionary provision, it should be given a narrow 
interpretation.212 The two exclusions in the Article 53(b) are; the exclusion of 
plant varieties and the exclusion of essentially biological processes for the 
production of plants. 
 
Hence, there are basically three key issues which stem from the wording of 
the provision itself namely; first, the precise interpretation for the notion of 
plant variety, second, the meaning of the phrases ‘essentially biological 
processes for the production of plants’, and third, the interpretation or 
meaning of the second part of the provision ‘this provision shall not apply to 
microbiological processes or the products thereof’. Each of these will be 
addressed in turn. 
 
The term ‘variety’ is not defined in the EPC, although it is expressly defined in 
the UPOV. As far as patents for products are concerned, Article 53(b) excludes 
only plant varieties. Since the provision also refers to ‘plants’, it is clear that 
the legislature intended ‘plant varieties’ to mean something different from 
‘plants’.213 This is in fact the view which has been adopted by the EPO 
Technical Board of Appeal in $. In its decision, the Technical Board of 
Appeal concluded that the ‘very wording of Article 53(b) EPC before the semi-
colon precludes the equation of plants and plant varieties which would also be 
at variance with the general sense of the provision. 214 The Board concluded 
                                                 
212 CHRISTIE, Andrew, 1989. Patents for Plant Innovation. !#3 11, p. 395. 
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214   Note 22. In 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that Article 53(b) prohibits only the patenting of plants or their propagating 
material in the genetically fixed form of the plant variety. In other words, the 
$ decision confirms that Article 53(b) must be interpreted narrowly. 
This view was subsequently adopted and stated expressly by the EPO Board in 
6'"	.215 Both and 6' are important cases as they 
establish the principle that the exclusion from patentability under Article 53(b) 
was only applied to those plant varieties which were capable of being 
protected under the UPOV.  
 
Nevertheless, the later cases such as #"		7E@ and(	7EC 
have changed the accepted view on patentability of transgenic plants.  In the 
former, it was held that a transgenic plant embracing plant varieties within its 
subject-matter was not patentable. Wide claims, not specifically directed to 
plant varieties, but which would have included plant varieties within their 
scope and would have required the production of plant varieties to exemplify 
them, were refused. This was contrary to the previous practice of the EPO and 
its Boards of Appeal.  
 
The (	 case was widely regarded as a test case to determine the 
patentability of transgenic plants under the current EPO practice. Some of the 
key questions relating to the patentability of genetically modified plants were 
given a detailed consideration by the Technical Board of Appeal and were 
referred to the Enlarged Board of Appeal. In essence, the Enlarged Board of 
Appeal decided that Article 53(b) applies only to plant groupings which could 
be protected under plant variety rights. All other plant materials, including 
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plant groupings, other than those protectable under plant variety rights, were 
patentable. Claims made to plant groupings which encompass plant varieties 
(such as plant species) were patentable provided that the claims were not 
specifically directed to an individual plant variety.218 
 
Another issue to be considered is the extent to which a process for the 
production of a new plant is patentable. EPC Article 53(b) excludes from 
patentability ‘essentially biological processes for the production of plants.’ The 
phrase is rather unspecific, and this has triggered legal debates whether 
breeding methods which are only technical in a selection step but otherwise 
consist of biological steps are exempted form patentability as ‘essentially 
biological’. It has been postulated that an essentially biological process could 
be defined, most simply, as one where natural methods are the dominant 
influence. Under such an interpretation, the criterion is the relative importance 
of natural versus human influences.219 
 
The EPO guidelines for examination provide an interpretation to the term.220 
They state that: ‘A process for the production of plants or animals is 
essentially biological if it consists entirely of natural phenomena such as 
crossing or selection....a process of treating a plant or animal to improve its 
properties or yield or to promote or suppress its growth, for example, a 
method of pruning a tree, would not be essentially biological since although a 
biological process is involved the essence of the invention is technical…’. 
Hence, the question whether a process is ‘essentially biological’ is one of 
degree depending on the extent to which there is technical intervention by 
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man in the process; if such intervention plays a significant part in determining 
or controlling the result it is desired to achieve, the process would not be 
excluded.221 
 
The second part of Article 53(b) EPC pertaining to the interpretation or 
meaning of ‘microbiological processes or the products thereof’ was one of the 
key questions considered by the Enlarged Board of Appeal in (	.  The 
Board stated that the term ‘microbiological’ referred to those processes which 
involved the use of micro-organisms. Whilst plant cells are treated as micro-
organisms for the purpose of the EPC, this does not mean that this treatment 
should be extended to include plants produced using a process involving 
micro-organisms. As the plant variety rights system does not distinguish 
between the manner of production for the purpose of deciding grant, therefore 
the patent system equally should not do so for the purpose of applying Article 
53(b). With that, the Enlarged Board of Appeal effectively closed the door on 
using the second half of Article 53(b) to circumvent the exclusion of the first 
half.222 Hence, based on this observation by the Board, to consider a plant 
genetic engineering process as microbiological would be quite far-fetched. 
 
Following the decision in (	, as well as the amendment of the 
Implementing Rules, the current EPO practice is that, Article 53(b) applies 
only to plant groupings which can be protected under PVR. All other plant 
materials, including plant groupings, other than those protectable under PVR, 
are patentable. Claims made to plant groupings which encompass plant 
varieties (such as plant species) are patentable provided that the claims are 
                                                 
221 CHRISTIE, Andrew, 	, Note 212, p.398. 
222 LLEWELYN, Margaret and ADCOCK, Mike, 	 Note 27. pp. 314-315. 
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not specifically directed to an individual plant variety. Irrespective of the 
manner of production, no claim may be directed to a plant variety as such, 
and the second sentence in Article 53(b) cannot be used to circumvent this.223 
 
. : .!$#!,%$$*(+'!,#&!<#!+'!,#&!97D33=
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On 16 June 1998 the European Parliament and the Council of the EU passed 
the Directive No. 98/44/EC on the legal protection of biotechnological 
inventions. The Directive came into force on 30 July 1998, nearly ten years 
after the European Commission first proposed a draft directive to establish 
guidelines regarding biotechnological inventions. The Directive purports to 
harmonize the national laws of EU Member States relating to the protection of 
biotechnological inventions. The drafters of the Directive were aware that the 
biotechnological sector was, and still is, a rapidly developing sector, and that 
there was a need to establish a sound legal framework which would allow 
European businesses to develop and market products and processes arising 
from biotech inventions.  
 
The objectives lying behind the Directive are outlined in its Recitals. The need 
for the Directive is spelt out in Recital 9, where it is stated that: ‘Whereas in 
certain cases, such as the exclusion from patentability of plant and animal 
varieties and of essentially biological processes for the production of plants 
and animals, certain concepts in national laws based upon international patent 
and plant variety conventions have created uncertainty regarding the 
protection of biotechnological and certain microbiological inventions; whereas 
harmonisation is necessary to clarify the said uncertainty…’ . In essence, the 
                                                 
223 ! 
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Directive recognizes the increasingly important role of the biotechnology and 
genetic engineering industry and the necessity of adequate legal protection for 
research and development in these areas, so that they may be profitable. In 
this respect, it also acknowledges the requirements of the Agreement on 
Trade-Related Aspects of Intellectual Property Rights (TRIPS), to which the 
European Community and its Member States are signatories. TRIPS specifically 
provides that patent protection must be guaranteed for products and 
processes in all areas of technology. 
 
 
 
. : . .!!&%#-'$&$%
For the purpose of this thesis, some relevant Articles of the Directive will be 
examined. Besides, it will attempt to assess its implications for patent practice 
under the EPC. It should be emphasized at this point that the Directive is 
binding only on the EU Member States and does not necessarily have any 
direct effect on the EPC. Furthermore, it does not require the EU Member 
States to amend the EPC in accordance with its provisions, indeed it cannot do 
so since not all EPC Contracting States are members of the EU. The Directive 
is backed by the enforcement powers of the EU, which can coerce legislative 
action in Member States with the threat of sanctions. The power to coerce and 
enforce implementation of the objectives of the Directive contrasts with the 
relative lack of power of the EPC, which did not replace or supersede national 
laws. Having said that, the European Parliament and the Council of the EU 
have actually based many provisions of the Directive, in particular those 
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relating to patentability, on the text of the EPC in view of its interpretation by 
the EPO and its various Boards of Appeal.224 
 
The need for clarification of the issue of the exclusion from patentability of 
plant and animal varieties was one of the major driving forces behind the 
Directive. The issue is also interesting particularly in the light of the decision of 
the Enlarged Board of Appeal in (	, as it clearly illustrates that the 
Directive is likely to affect future interpretation and implementation of the 
EPC.225 The Directive has two components: articles and recitals. The articles 
are directly binding on Member States, while recitals provide a context in 
which both Member States and the courts can interpret the articles. The 
provisions of the Directive with regard to the patentable and non-patentable 
inventions are set out in Articles 3 and Article 4. Article 3(1)226 says that; ‘For 
the purposes of this Directive, inventions which are new, which involve an 
inventive step and which are susceptible of industrial application shall be 
patentable even if they concern a product consisting of or containing biological 
material or a process by means of which biological material is produced, 
processed or used.’ In the context of the Directive, 'biological material' is 
defined in Article 2(1)(a) as 'any material containing genetic information which 
is capable of reproducing itself or being reproduced in a biological system'. 
 
In Article 4, the Directive essentially restates the existing provisions of Article 
53 of the EPC in respect of exceptions to patentability. However it does include 
some subtle differences and sets out to provide some clarification of the 
                                                 
224 BALDOCK, Claire and KINGSBURY, Oliver, 2000. The Biotechnology Directive And Its 
Relationship To The EPC  %" 6- 3  Available at <http: 
http://www.boult.com/information/articleDetails.cfm?ArticleID=31> [Accessed 14 August 2008] 
225 ! 
226 This corresponds to Para. 1 of Schedule A2 to UK Patents Act 1977. 
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meanings of these exclusions which have resulted in uncertainties in practice 
under the EPC. Article 4 reads:  
‘1. The following shall not be patentable:  
(a) plant and animal varieties; 
(b) essentially biological processes for the production of plants or animals.  
2. Inventions which concern plants or animals shall be patentable if the 
technical feasibility of the invention is not confined to a particular plant or 
animal variety. 
3. Paragraph 1(b) shall be without prejudice to the patentability of inventions 
which concern a microbiological or other technical process or a product 
obtained by means of such a process.’ 
 
Article 4(2) in effect allows the patenting of inventions concerning plants and 
animals if the technical feasibility of the inventions is not confined to a 
particular plant or animal variety. The Directive indicates that a plant variety is 
defined in accordance with the EC Regulation No 2100/94 on plant variety 
rights which states that a plant variety 'shall be taken to mean a plant 
grouping within a single botanical taxon of the lowest known rank, which 
grouping can be: 
- defined by the expression of the characteristics that result from a given 
genotype or combination of genotypes, 
- distinguished from any other plant grouping by the expression of at least one 
of the said characteristics, and 
- considered as a unit with regard to its suitability for being propagated 
unchanged.' A plant grouping consists of entire plants or parts of plants as far 
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as such parts are capable of producing entire plants.227 The definition 
therefore covers, for example, seeds as well as complete plants. The intended 
scope of the definition of ‘plant variety’ is further addressed in Recitals 30 and 
31 of the Directive. 
 
It is interesting to note the observation by the European Court of Justice (ECJ) 
when the Directive was challenged in the case of J+(	
#5"77D. The ECJ held, referring to Recitals 
29-32 of the Directive, that a plant variety is defined by its whole genome.229 
Where a plant grouping is characterized by a specific gene, it is not precluded 
from patentability even if it comprises new varieties of plant.230 In other 
words, modification of a single gene that creates a transgenic plant does not 
represent enough change to the entire genome to qualify as a new plant 
variety.231 The effect of this decision is that, a transgenic plant of a plant 
grouping which contains modifications to its single gene is patentable, even 
though such transgenic plant embraces a new plant variety. However, if the 
modification could be proven or shown to affect the whole genome of plant 
grouping, which embraces and includes plant variety, then such plants ceases 
to be eligible for patent protection under the Directive, on the basis that a new 
                                                 
227 Article 5(2) and (3) Council Regulation (EC) No 2100/94 of 27 July 1994 on Community plant 
variety rights. 
228 Case C-377/98, ECJ. 
229 Recital 30 of the Directive reads: ‘Whereas the concept 'plant variety` is defined by the 
legislation protecting new varieties, pursuant to which a variety is defined by its whole genome 
and therefore possesses individuality and is clearly distinguishable from other varieties.’ Genome 
refers to all the genes contained in a single set of chromosomes, i.e. in a K "	. Each 
parent, through its reproductive cells, contributes its genome to its offspring. Refer JOHN, D., and 
ELIZABETH, M., ed., 2010. 
"+"". 6th ed. Oxford: Oxford University Press. p. 354. 
230 !  paras 44 and 45 of the judgment. By way of definition, gene denotes a unit of heredity 
composed of DNA. It can exist in different forms called K	, which determine which aspect of 
the characteristic is shown (e.g. tallness or shortness for the characteristic of height). Refer JOHN, 
D., and ELIZABETH, M., ed., 2010. 
"+"". 6th ed. Oxford: Oxford University Press. 
p. 348. 
231 Recital 31 of the Directive reads: ‘Whereas a plant grouping which is characterized by a 
particular gene (and not its whole genome) is not covered by the protection of new varieties and 
is therefore not excluded from patentability even if it comprises new varieties of plants.’ 
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plant variety is not patentable. The whole point is that a plant variety is a very 
specific kind of plant grouping, and that other kinds of plant grouping should 
be eligible for patenting. The essence from the decision by the ECJ is that a 
new plant grouping which is characterized by a particular gene (and not its 
whole genome) is a generic innovation, not a plant variety, and cannot be 
protected under plant variety protection laws; whereas such an innovation 
may be deserving of protection and therefore should be eligible for patent 
protection and not excluded from patentability even if it comprises plant 
varieties. 
 
Nevertheless, it seems that the wording of the Article 4(2) of the Directive 
does not clearly indicate whether it is intended that the phrase 'inventions 
which concern plants or animals' should extend to the plants and animals per 
se or whether it should be restricted only to processes for producing such 
plants and animals, thereby confining the patentee to unsatisfactory product 
by process protection for novel transgenic plants and animals produced by a 
novel process. 
 
In relation to Article 4 of the Directive and Article 53(b) EPC, the EPO’s 
practice is reflected in the decision of the Enlarged Board of Appeal in 
(	, wherein the Board indicated that genetically-modified plants were 
not to be treated as products of microbiological process. Hence, the exception 
to patentability on Article 53(b) applies to plant varieties irrespective of the 
way in which they are produced. At this juncture, it is worth noting that the 
Enlarged Board did make passing reference to the Directive, stating that its 
decision is in line with the provisions of Article 4. This definitive exclusion of 
plant and animal varieties from patent protection even where they are the 
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products of a microbiological process is incorporated into the additions to the 
Implementing Regulations of the EPC232 in order to bring it into line with the 
Directive.233 
 
Obviously it remains open for courts in the individual countries signatory to 
the EPC to apply different standards; however, to date, national courts have 
not attempted to overturn the principles applied by the EPO, and certainly the 
English courts have adopted the same approach as the EPO. Having said that, 
it must also recognized that inevitably the English courts have not always 
followed the decisions of the EPO because they have taken a different view of 
the evidence or, more usually, have been provided with evidence which was 
not before the EPO.234 
 
. : 4$!!*!&!$-!%#
In order to avoid any divergence of application or interpretation between the 
national granting offices and courts and the European Patent Office, on 6th 
June 1999, the Administrative Council of the EPO voted to amend its 
Implementing Rules to permit the EU directive to be used as a Supplementary 
Means of Interpretation.235 It is clear from the amendment that the EPC is now 
to be read in light of the provisions of the EU directive. These came into force 
on the 1st September 1999.  These provisions have to be followed unless it 
can be shown that they are inconsistent with the Convention. This means that 
                                                 
232 Rule 23c of the Implementing Regulations reads: ‘Biotechnological inventions shall also be 
patentable if they concern: (b) plants or animals if the technical feasibility of the invention is not 
confined to a particular plant or animal variety; (c) a microbiological or other technical process, or 
a product obtained by means of such a process other than a plant or animal variety. 
233 BALDOCK, Claire and KINGSBURY, Oliver, 	, Note 224. 
234 NOTT, Robin,	, note 4, pp. 564-565. 
235 Rule 23b of the Implementing Regulations: ‘(1) For European patent applications and patents 
concerning biotechnological inventions, the relevant provisions of the Convention shall be applied 
and interpreted in accordance with the provisions of this chapter. Directive 98/44/EC of 6 July 
1998 on the legal protection of biotechnological inventions shall be used as a supplementary 
means of interpretation.’ 
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there is now greater cohesion between the policy and practice of the EU and 
the EPO.236 
 
Essentially, effective and harmonized protection of biotechnology products is 
required for the internal market to function properly and for the biotech 
industry in Europe to fulfill its potential. From the point of view of industry, it 
would give greater certainty as to which inventions are likely to qualify for 
patent protection, and therefore which areas of research and development are 
most likely to yield sufficient return on investment.237  
 
Whilst there has been extensive legislative activity providing a relatively 
coherent system of protection for all type of genetic material, the situation in 
Europe remains an uncertain one. Besides, whilst the framework for grant is in 
place, the issue of the proper scope of the rights will remain unclear until 
tested in the courts. To date there has only been limited litigation and until 
such time as the courts develop a coherent jurisprudence at the national and 
EU levels it is not possible to state with certainty and predictability as to 
exactly what is protectable and what maybe excluded from protection.238 

. 7
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The way in which the regulations that cover agricultural biotechnology 
inventions (as set out in the EPC) are applied and interpreted is best 
exemplified by recent decisions that have been made by the European Patent 
Office (EPO) on individual patent cases. Since the EPC is somewhat ambiguous 
                                                 
236 LLWELEYN, Margaret, 2002. !"#%"/#	", 
Available at <http://www.iprsonline.org/resources/biotechnology.htm> [Accessed 15 August 
2008] 
237 As stressed in the European Union’s White Paper, ‘Growth, Competitiveness and Employment – 
The Challenges and Ways Forward into the 21st Century’, COM (93) 700. 
238 LLWELEYN, Margaret, 	, Note 236. 
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as to the exact scope of the exclusion of plant varieties and essentially 
biological processes for the production of plants, one has to rely on the 
interpretation of the Technical Boards of Appeal and of the Opposition 
Divisions of the EPO in order to get some insight into the limits of the 
exclusion of plant varieties.239 With the development of genetic engineering 
and the possibility of creating GM plants, the EPO found itself in untested 
waters with a lack of guidance from patent law. There has been considerable 
debate on the issue of what is protectable under patent and what is 
protectable under plant variety rights, and in the context of EPO’s case law – 
most notably  whether the exclusion under the first half of Article 53(b) EPC 
applies only to plant varieties protected under UPOV. At the EPO, a number of 
important decisions have been given in the field of plant genetics. For the 
purpose of this thesis, five cases decided by EPO and one case decided by the 
Supreme Court of Canada will be discussed in a considerable detail. These 
cases are selected because they are the landmark cases for the issues 
surrounding patentability of plant and plant varieties, and thus, to some 
extent serve as a useful guideline in determining the application and 
implementation of the patent laws in Europe.
 
<=

	
The first consideration of the distinction between plants and plant varieties by 
the Technical Board of Appeal of the EPO occurred in 1984 in the  
decision. In fact, this is one of the earliest test cases to determine whether the 
exclusion under the first half of Article 53(b) EPC, applied only to plant 
varieties protected under UPOV. In this case, the claim related to ‘propagating 
                                                 
239 OVERWALLE, Geertrui Van, 	, Note 178, p.22. 
240   Note 22. 
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material, treated with chemical agents, for certain genera of plants.’ The 
application referred to ‘cultivated plants’ bred from the coated propagating 
material without specific varieties being claimed individually. An objection was 
lodged on the ground that the claim fell within Article 53(b); however, the 
Technical Board of Appeal did not agree as no individual plant variety had 
been claimed and the opposition failed. The Board held that such a claim, 
without specific varieties being claimed individually, did not contravene the 
prohibition on the patenting of plant varieties in Article 53(b) EPC. In this 
regard, the Board said that plants and plant varieties cannot be treated as 
being the same thing for the purposes of applying Article 53(b). All that the 
Article excludes from protection are plant varieties. If the draftsmen had 
intended all plant materials to be excluded, then Article 53(b) would have 
been worded to have this effect.  
 
It is also interesting to note that the Board in this case provided a definition of 
a plant variety241 which to a large extent mirrors the principle which underpins 
the UPOV concept, namely a plant grouping which remains stable and uniform 
following repeated reproduction.242 The legislator did not wish to afford patent 
protection under the EPC to plant varieties of this kind, whether in the form of 
propagating material or of the plant itself. 
 
The Board points out that the very wording of Article 53(b) EPC before the 
semi-colon precludes the equation of plants and plant varieties, which would 
also be at variance with the general sense of the provision. Plant varieties 
                                                 
241 ‘The skilled person understands the term "plant varieties" to mean a multiplicity of plants which 
are largely the same in their characteristics and remain the same within specific tolerances after 
every propagation or every propagation cycle.’ 
242 LLEWELYN, Margaret and ADCOCK, Mike, 	 Note 27. pp. 294-295. 
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were excluded from European patent protection mainly because several of the 
signatory States to the EPC had developed special protection for plant 
breeding at national and international level. The Board maintained that the 
innovation in the claim did not lie within the sphere of plant breeding, which is 
concerned with the genetic modification of plants. Rather, it acted on the 
propagating material by means of chemical agents in order to make it 
resistant to agricultural chemicals. The new parameter for the propagating 
material, namely treatment with an oxime derivative, was not a criterion 
which can be characteristic of a plant variety as far as the protection of 
varieties is concerned. Therefore, there was no conflict between the protection 
of varieties or the patent as different forms of protection for propagating 
material treated in this way. It was not necessary for the object of the 
treatment always to be a plant variety, since the treatment could also be 
carried out on propagating material which did not meet the essential criteria of 
homogeneity or stability characteristic of a plant variety.243 The subject-matter 
of the claims244 was not an individual variety of plant distinguishable from any 
other variety, but the claims related to any cultivated plants in the form of 
their propagating material which had been chemically treated in a certain way. 
In this relation, Article 53(b) EPC prohibited only the patenting of plants or 
their propagating material in the genetically fixed form of the plant variety.  
 
In short, in this case, the claims covered merely the application of a chemical 
treatment and not plant varieties as such. This is due to the fact that it wss 
not necessary for the object of the treatment always to be a plant variety, 
since the treatment could also be carried out on propagating material which 
                                                 
243   Note 22. 
244
 Claims 13 and 14 of the application. 
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did not meet the essential criteria of homogeneity or stability characteristic of 
a plant variety. 
 
It is also worth noting the Board expressly affirmed the position of law that 
there is no conflict between areas reserved for national protection of varieties 
and the field of application of the EPC. On the other hand, innovations which 
cannot be given the protection afforded to varieties are still patentable if the 
general prerequisites are met.245 
 
<= !"#	
	$%
The approach in  was later applied by the Technical Board of Appeal 
in 6'< #	 case, where the Board held that ‘the term plant 
varieties’ means a multiplicity of plants which are largely the same in their 
characteristics (i.e. homogeneity) and remains the same within specific 
tolerances after every propagation or every propagation cycle, that is stability. 
The claims related to the processes for rapidly developing hybrids and 
commercially producing hybrid seeds in general, or belonging to the genus 
%		". The Board ruled that as the hybrid seed and plants from such seed 
were lacking stability in some traits of the whole generation population, they 
did not fall within the excluded category of plant varieties within the meaning 
of first part Article 53(b) EPC (‘European patents shall not be granted in 
respect of plant or animal varieties..’). In other words, the hybrid plant at 
issue was outside the exclusion of Article 53(b) EPC as it was created by a 
multi-step process and it would not breed true in nature. 
 
                                                 
245   Note 22. 
246   Note 23. 
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It is interesting to note that in analyzing the definition of ‘plant variety’, the 
Board acknowledged the fact that there was no definition of the term in the 
EPC. There was further no generally recognized taxonomic definition for 
‘variety’ as there is for ‘species’ or ‘genus’. In the case of the particular 
exception to patentability with regard to plant varieties, the legal history of 
Article 53(b) EPC made it clear that plant varieties were excluded from patent 
protection under the EPC mainly because several of the Signatory States had 
developed special legal protection for plant breeding at national and 
international level (the UPOV Convention) and such States were of the opinion 
that such special protection was better adapted to meet the interests of plant 
breeders.247 In 6', the concept of ‘plant varieties’ in Article 53(b) EPC 
was analyzed by the Board in the light of the corresponding provisions in the 
UPOV Convention. It arrived at the conclusion that the term ‘plant varieties’ 
means a multiplicity of plants which are largely the same in their 
characteristics (i.e. ‘homogeneity’) and remain the same within specific 
tolerances after every propagation or every propagation cycle (‘stability’). 
Thus, it was clear from the Board’s analysis that possession of both 
characteristics of ‘homogeneity’ and ‘stability’ would be a prerequisite for a 
‘plant variety’, within the meaning of Article 53(b) EPC specifically. 
 
Another important issue which was highlighted in this case was whether or not 
a (non-microbiological) process wss to be considered as ‘essentially biological’ 
within the meaning of Article 53(b) EPC. The claims were initially refused by 
the Examining Division on the ground that the subject-matter of claims 
constituted essentially biological processes for the production of plants for 
which a patent should not be granted pursuant to Article 53(b) EPC. The Board 
                                                 
247 , Note 23, point 12 of reasons for the decision. 
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eventually ruled that it had to be judged on the basis of the essence of the 
invention taking into account the totality of human intervention and its impact 
on the result achieved.  
 
In its decision, the Technical Board of Appeal stated that ‘like any exception to 
a general rule of this kind the exclusion of ‘essentially biological’ processes for 
the production of plants (or animals) had to be narrowly construed. This is 
underscored by the fact that this exclusion does not apply to microbiological 
processes or the products thereof, as stated in Article 53(b) EPC. It was the 
opinion of the Board that the necessity for human intervention alone wss not 
yet a sufficient criterion for it not being ‘essentially biological’. Human 
interference might only mean that the process was not a ‘purely biological’ 
process, without contributing anything beyond a trivial level. It was further not 
a matter simply of whether such intervention is of a quantitative or qualitative 
character.248 After analyzing all the processes in the claims, the Board came to 
the conclusion that the claimed processes in 6'<#	  could not 
be considered as ‘essentially biological’ within the meaning of Article 53(b) 
EPC and thus were patentable. 
 
Essentially, the above cases on the application of Article 53(b) addressed at 
length the meaning of the term ‘plant variety’. It appears reasonable to 
conclude that the exclusion of plant varieties as stipulated in Article 53(b) EPC 
had to be interpreted narrowly, so as to give the widest possible benefit to the 
patentee. The decisions clarify that this provision was not meant to exclude 
plants  	 from patentability but have to be seen in the context of the 
                                                 
248 !., point 6 of reasons of the decision. 
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UPOV Convention.249 By virtue of 6'&	 case, for a plant to be considered a 
plant variety, it must show capacity to survive on its own without human 
interference, thus it must be stable. If a plant is not stable it does not 
constitute a plant variety.250 
 
Nevertheless, neither case involved a genetically engineered variety and in 
neither case did the invention or its embodiment directly produce a new plant 
variety. In short, both the   and 6' cases struggled to 
distinguish the exclusion of an innovation right based on phenotypic 
characteristics from the subject-matter of patentable genetic or chemical or 
breeding inventions.251 
 
<=&	'	
	(%(
In 1990, the EPO granted European Patent No. 0242236 to Plant Genetic 
Systems NV in respect of processes and products relating to the herbicide 
‘Basta’. The patents gave rights over genetically engineered plant cells, and, 
thereafter, over all subsequent seeds and plants derived from the engineered 
cells. The aim of patented invention in this case was to develop plants and 
seeds which were resistant to a particular class of herbicides, thereby enabling 
selective protection against weeds and fungal diseases. It is important to note 
that the claims were not limited to particular plant species but referred to 
‘plants’ in general. Until this patent was challenged, the EPO had been willing 
                                                 
249 JAENICHEN, Hans-Rainer and SCHRELL, Andreas, 1993. The European Patent Office’s Recent 
Decisions on Patenting Plants. !#3 12, pp. 466-469, at p. 468. 
250
 Note that this case was decided prior to Regulation 2100/94 (EC Council Regulation 2100/94 
which established a system for Community plant variety rights (CPVR)), in which the DUS 
(Distinctness, Uniformity, Stability) criteria are explained. One might come to the conclusion that 
the reasons for the decisions influenced the European Community to legislate these criteria. 
251 FUNDER, Joshua V., 1999. Rethinking Patents for Plant Innovation. !#3 11, 551-574 at p. 
557. 
252   Note 24. 
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to allow patents for plants defined in this generalized way, namely in non-
variety-specific terms.253 
 
In 1992 Greenpeace filed an opposition to the patent on the grounds that it 
violated both parts of Article 53 EPC. This was heard in 1993 by the Opposition 
Division, which upheld the patent. Greenpeace immediately lodged an appeal 
which was heard by the Technical Board of Appeal in 1994. The Board then 
reviewed the patent, analyzing separately the following three categories: (i) 
the plant cells and seeds, (ii) the process for producing the transgenic plant, 
and (iii) the transgenic plant. The appeal by the Greenpeace on Article 53(b) 
was based on the submissions which could be divided into two main parts, 
namely; first, that material claimed constituted a plant variety, and second, 
that some claims were for products resulting from essentially biological 
processes, not a microbiological processes, hence excluded from 
patentability.254 
 
Under the first argument, Greenpeace asserted that the claims to plants and 
seeds would cover varieties formed from them, on the basis that the claims, 
‘although cleverly drafted in general terms, were in reality meant to cover 
plant varieties’ which would be contrary to Article 53(b). The Technical Board 
of Appeal held that the claimed seeds and plants complied with the definition 
of plant variety since they were distinguishable, uniform and genetically 
stable.255 Hence they were excluded from patentability. 
 
                                                 
253 CRESPI, R.S., 	, Note 10, p. 272. 
254 , note 24. 
255 Point 40.4 of the reasons for the decision. 
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In reaching its decision, the Board was clearly influenced by the fact that in 
the specific patent examples of producing the transgenic plant, the process 
began with named varieties. The Board found that the claim embraced and 
encompassed plant varieties, and it was therefore an attempt to evade the 
prohibition. The Board also pointed to the new definition of a variety as given 
in the revised UPOV 1991 and held that the genetically modified plants were 
themselves new varieties according to the new definition. The Board finally 
concluded that claims to genetically modified plant cells and to the process of 
producing genetically modified plants patentable, however claims to 
genetically modified plants themselves patentable. As the Board held in this 
case plant cells as such that culture much like bacteria and yeasts, do not fall 
under the definition of a plant or plant variety. In #"		, the 
Board widened the term ‘micro-organisms’ to include not only bacteria and 
yeasts, but also fungi, algae, protozoa and human, animal and plant cells, that 
is all generally unicellular organisms unseen to the naked eye, which can be 
propagated and manipulated in a laboratory, this including plasmids and 
viruses.256 In this regard, it could be submitted that this is a huge benefit for 
the pharmaceutical industry in particular. 
 
On the second argument by Greenpeace, the Board seemed to accept the 
argument and held that the claim could not be allowed under the exception 
provided by the second half of Article 53(b) (the microbiological process 
exception) since the process of producing and propagating the transgenic 
plants, although it involved a microbiological step, was not microbiological 
                                                 
256 See points 23 and 34 of the reasons for the decision, 	, Note 24; HEDLUND, Ebba and 
KALEN, Annika, 2006. ' "		 + + 
  	 Available at : <URL :  www.diva-
portal.org/diva/getDocument?urn_nbn_se_oru_diva-483-2__fulltext.pdf > [Accessed 17 
November 2008]   
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process when considered as a whole.257 In the Board's judgment, the concept 
of ‘microbiological processes’ under Article 53(b), second half-sentence, EPC, 
referred to processes in which micro-organisms or their parts, were used to 
make or to modify products or in which new micro-organisms were developed 
for specific uses. Consequently, the concept of ‘the products thereof’ under 
Article 53(b), second half-sentence, EPC, encompassed products which were 
made or modified by micro- organisms as well as new micro-organisms as 
such. The Board further stated that as modern biotechnology often used or 
developed multi-step processes for producing plants which included at least 
one microbiological process step (for example, the transformation of cells with 
recombinant DNA), it wss critical to determine whether such processes as a 
whole could be considered to represent ‘microbiological processes’ within the 
meaning of Article 53(b), second half-sentence, EPC, and whether, owing to 
this, the products of such processes (for example, plants) may be regarded as 
being ‘the products thereof’ for the purposes of this provision.258 In conclusion, 
the Board wss of the opinion that ‘technical processes including a 
microbiological step’ may not simply be equated with ‘microbiological 
processes’. Nor can the resulting final products of such technical processes (for 
example, plant varieties) be defined as ‘products of microbiological processes’ 
within the meaning of Article 53(b), second half- sentence, EPC. This part of 
the Board’s decision reflects the restrictive approach taken by the EPO in 
assessing the patentability of transgenic plants and the related processes to 
produce them. 
 
                                                 
257 ‘The plant according to Claim 21 is thus not merely the result of said initial step, but also of the 
subsequent series of relevant agrotechnical and biological steps.’ –Point 40.5 of the judgment. 
258
 Points 36-37 of the reasons for the decision. 
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#"		 appealed to the Enlarged Board of Appeal, which can 
review decisions of the Technical Boards in certain circumstances, including 
those where Technical Board decisions are inconsistent with one another. The 
Enlarged Board did not endorse the first part of the Technical Board’s analysis 
(that the claim ‘embraced’ varieties). On their second point (that the 
transgenic plants were varieties), the Enlarged Board expressed no opinion, 
holding that it could not intervene because this was a new point, which 
involved no inconsistency with previous decisions. 
 
At this juncture, it is to be noted that the EPO policy made a ‘U-turn’ with the 
# " 	 decision in relation to 6'. Plants  	 were no 
longer considered patentable, whereas plant cells were determined to be 
patentable.259 It is equally interesting to note the effect of this decision that, 
although the process technology could still be patented, the specific refusal of 
product claims for transgenic plants was a setback for the plant biotechnology 
industry, when the Technical Board upturned the hitherto prevailing 
interpretation of Article 53(b) EPC.260 In other words, the decision seems to 
indicate a more restrictive approach being taken within the EPO. The decisions 
appeared to suggest that Article 53(b) EPC prohibited all claims ‘embracing’ 
plant or animal varieties. Hence, a claim which contains the possibility of 
encompassing excluded material will nonetheless be excluded. In one aspect, 
this restrictive approach can be read as a covert recognition of the role of 
                                                 
259 However, the Board did not rule out protection for varieties  	. In a key part of its 
judgment (refer point 40.8 of the reasons for the decision), the Board said that if ‘the subject 
matter of this claim the product of a microbiological process’ then the exception to the exclusion 
would have operated and the claim would be valid by virtue of the second half or Article 53(b). 
260 CRESPI, R.S., 	, Note 10, pp. 272-274. 
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plant varieties play in protecting plant biotechnology following the revision of 
the UPOV Convention in 1991.261 
 
It is also worth noting the decision in #"		 caused a great 
deal of concern not only among those wishing to see a clear pro-plant 
patenting policy within the EPO but also among those who wished to see clear 
blue water between that which is protectable under patent law and that under 
plant variety rights.262 The concern which the case engendered was that it 
meant that, for the purpose of patent law, any single genetic change which 
was stable in its effect was considered to give rise to a variety. In addition, the 
distinction drawn by the Technical Board between essentially biological and 
microbiological was unclear and did not pinpoint when a process would be said 
to be no longer essentially biological.  
 
Accordingly, in view of the outstanding importance of the legal issues 
addressed in #"		 case, in September 1995, the President of 
the EPO, under Article 112 EPC,263 put the following question to the Enlarged 
Board of Appeals: 
‘Does a claim which relates to plants or animals but wherein specific plant or 
animal varieties are not individually claimed contravene the prohibition on 
patenting in Article 53(b) EPC, if it embraces plant or animal varieties?’ 
 
                                                 
261 LLEWELYN, Margaret, 	  Note 236, p. 511. 
262 The decision by the Technical Board of Appeal has been criticized in legal literature. See, for 
exaomple, ROBERTS, Tim, 1996. Patenting Plants Around the World. !#3 18, pp. 534-535. 
263 Article 112 EPC: (1) In order to ensure uniform application of the law, or if an important point 
of law arises: 
(a) the Board of Appeal shall, during proceedings on a case and either of its own motion or 
following a request from a party to the appeal, refer any question to the Enlarged Board of Appeal 
if it considers that a decision is required for the above purposes. If the Board of Appeal rejects the 
request, it shall give the reasons in its final decision. 
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However, instead of actually dealing with the important matter concerned, the 
Enlarged Board rejected the above referral of the case on the basis that the 
#"		 case did not conflict with prior law which had not dealt 
with the patentability of a genetically modified plant.264 This decision is 
disappointing to those who hoped that the Enlarged Board would be able to 
clarify the meaning of the exclusion of varieties from patentability. 
 
In short, following this decision, claims directed to genetically engineered 
plants whose phenotype, that is, whose entirety of recognizable characters, 
has been made distinguishable in a stable and uniform manner by means of 
genetic manipulation, are probably not allowable. The Board regarded the 
claim directed to such plants as ‘variety-comprising’ and hence +" as 
not patentable. Since claims directed to plants which have been produced by 
genetic engineering methods will probably always comprise varieties, but the 
plants are only in the rarest of cases the result of a microbiological process, it 
could be assumed that plants produced by genetic engineering methods are 
not patentable under the jurisdiction of the Board.265 
<&=)*	/	&
	+%%
In (	, the patent application at issue was related to transgenic plants 
and methods of preparing the same. The patent application with the title ‘Anti-
pathogenically effective compositions comprising lytic peptides and hydrolytic 
enzymes’ was refused by the Examining Division. The product claims of the 
application claimed transgenic plants having specific foreign genes in their 
                                                 
264 EBA G03/95 (reason 4), OJ EPO 1996, 169. 
265 SCHRELL, Andreas, 1996. Are Plants (Still) Patentable? Plant Genetic Systems (EPO Decision 
T356/93). !#3 4, pp. 242-244. 
266 , Note 25. 
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genome. Claim 19 as refused read as follows: ‘A transgenic plant and the seed 
thereof comprising recombinant DNA sequences encoding: a) one or more lytic 
peptides, which is not lysozyme, in combination with; b) one or more 
chitinases; and/or c) one or more beta-1,3-glucanases in a synergistically 
effective amount.’267 The expression of the foreign genes resulted in the 
production of anthipathogenically active substances which kill or inhibit the 
growth of disease-producing pathogens. The method claims of the application 
in Claim 23 claimed methods of preparing such plants, which essentially 
consisted of introducing genes into an ancestral plant by recombinant DNA 
sequence encoding. The claim read: ‘A method of preparing a transgenic plant 
which is able to synthesis one or more lytic peptides together with one or 
more chitinases;….’268 
The Examining Division refused the application on the basis that in the earlier 
case269, the Board had held that a claim to genetically engineered plants and 
seeds, although not directed to any specific plant varieties, encompassed plant 
varieties which were not products of a microbiological process and, 
consequently, was not allowable under Article 53(b) EPC. 
(	 lodged an appeal270 against this decision requesting that a patent be 
granted on the basis of the set of claims before the Examining Division. In 
particular it was argued that decision T 356/93 (#"		) had 
inappropriately interpreted Article 53(b) EPC and should not be followed. The 
                                                 
267 !  Decisions of the Boards of Appeal T 1054/96 is available at <http://legal.european-
patent-office.org/dg3/pdf/t961054ep1.pdf> [Accessed 08 October 2008] 
268 ! 
269 T 356/93 (OJ EPO 1995, 545). 
270 This appeal case became T 1054/96. Once the appeal was pending, the Examining Divisions 
stopped the further handling of those cases in which Applicant insisted on prosecuting said type of 
claim (for plants and animals). 
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Board issued a summons to oral proceedings, which took place on 13 October 
1997. 
At the end of the oral proceedings, the Technical Board announced its decision 
to refer to the Enlarged Board of Appeal the following questions about how to 
interpret the plant variety exception in Article 53(b) EPC and about what must 
be taken into account in such an interpretation:  
I. To what extent should the instances of the EPO examine an application in 
respect of whether the claims are allowable in view of the provision of Article 
53(b) EPC that patents shall not be granted in respect of plant varieties or 
essentially biological processes for the production of plants, which provision 
does not apply to microbiological processes or the products thereof, and how 
should a claim be interpreted for this purpose?  
II. Does a claim which relates to plants but wherein specific plant varieties are 
not individually claimed ipso facto avoid the prohibition on patenting in Article 
53(b) EPC even though it embraces plant varieties? 
III. Should the provisions of Article 64(2) EPC be taken into account when 
considering what claims are allowable? 
IV. Does a plant variety, in which each individual plant of that variety contains 
at least one specific gene introduced into an ancestral plant by recombinant 
gene technology, fall outside the provision of Article 53(b) EPC that patents 
shall not be granted in respect of plant varieties or essentially biological 
processes for the production of plants, which provision does not apply to 
microbiological processes or the products thereof? 
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As a matter of fact, three of the above questions are related to the 
interpretation and application of Article 53(b) EPC and one of the four 
questions is related to Article 64(2) EPC.271 For the purpose of this thesis, the 
decision and view of the Technical Board of Appeal in relation to the above 
four questions will be discussed first, before analyzing the decision given by 
the Enlarged Board of Appeal. 
In answering the first question on the issue of the approach and method of 
examination to be adopted by the EPO to ascertain the patentability of claims 
of plant varieties, the Board considered both the substantive and literal 
approaches to the examination. The Board concluded that the substantive 
approach is the correct one to be applied when examining claim 19 for 
allowability in the light of Article 53(b) EPC. Thus, every potential embodiment 
of the subject-matter of claim 19 is either a plant variety or not. Insofar as it 
is a plant variety, it is not patentable. Insofar as it is not a plant variety, it is 
patentable. Higher taxonomic categories such as species, genus, family or 
order may be relevant as a convenient description of the field of application 
amongst existing plants of an invention, but for a particular embodiment the 
only relevant question is whether it is a plant variety or not. An embodiment 
cannot by itself be a species, genus, family or order.  
The Board was not in favour of the literal approach as that would make 
examination for conformity with Article 53(b) EPC a very facile procedure. This 
is because if literal approach is the only way to examine the claim, all that is 
required of the patent office is to check that the words ‘plant variety’ (or the 
equivalent French and German terms) do not appear in any claims. If these 
                                                 
271 Article 64(2) EPC : ‘If the subject matter of the European patent is a process, the protection 
conferred by the patent shall extend to the products directly obtained by such process’. 
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words do not appear, then Article 53(b) EPC is satisfied in relation to a claim 
to a plant. In this regard, the Board has difficulty in believing that the drafters 
of the EPC (and those of the Strasbourg Convention) would have included the 
provision of Article 53(b) EPC merely to prevent these words appearing in a 
claim, but without intending the provision to have any substantive function. 
The Board also stressed the responsibility of the EPO if it were to adopt the 
literal approach which would, in effect, be to abdicate any responsibility for 
examining the substance of the claim, and the outcome of an application 
would depend on the verbal skill of the patent attorney concerned.272 
Another element of Question I as referred to the Enlarged Board of Appeal was 
the definition of the term ‘essentially biological process’ and whether Claim 23 
fell under this definition. The Board was of the view that claim 23 was not 
allowable under Articles 84 and 53(b)EPC. The claim was not clear and concise 
as no identifiable method steps were recited. Rather all ways of obtaining the 
stated plant were claimed, including ‘essentially biological processes for 
producing plants’ which would fall under the prohibition of Article 53(b) EPC 
second part of first half sentence. The Board admitted the fact that to 
determine a correct approach in interpreting the term ‘ essentially biological 
process’ was problematic as a value judgment can be arrived at by different 
approaches. The phrase ‘essentially biological process’ ‘biological’ has been 
interpreted sometimes as contrasting with ‘technical’ and sometimes as 
contrasting with ‘chemical’ or ‘physical’. Given that the trend of developments 
was that biological processes were becoming better understood and in that 
sense possibly more technical, while gene technology makes use of natural 
mechanisms and in that sense is biological. 
                                                 
272 , Note 247. 
127 
 
The other element in Question I related to the meaning of the term 
microbiological process and the products thereof. The Board referred to the 
earlier case, #"		, and concluded that genetically engineered 
varieties were covered by the prohibition of granting patents for plant varieties 
of Article 53(b) EPC even if they should in some sense be considered as the 
product of a microbiological process. The Board supported its view by citing 
the fact that it was more than ten years of scientific progress were necessary 
after the EPC was drafted before it became conceivable that varieties could be 
isolated with the help of techniques including microbiological steps. It, thus, 
could not have been the intention of the legislator to have plant varieties 
patentable as products of microbiological processes.273 
 
With regard to the second question to the Enlarged Board of Appeal in relation 
to the ‘more than a single variety’ approach, the Board expressed some 
considerable problems which were posed by such an approach. On a plain 
reading of the language of Article 53(b) EPC which stated that patents shall 
not be granted for plant varieties in the plural, if one were to deduce from this 
wording of Article 53(b) EPC that a patent shall not be granted for a single 
plant variety but may be granted if its claims cover more than one variety, the 
Board was of the opinion that does not appear to comply with the normal rules 
of logic. Hence, avoidance of the prohibition of Article 53(b) EPC would then 
merely mean drafting a claim to a plant with some characteristics of any 
actual embodiment left unspecified. This would ensure that, at least 
theoretically, the claim covered potentially more than one variety. 
 
                                                 
273 , Note 247, points 30 and 40 of the reasons for the decision. 
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The third question to the Enlarged Board of Appeal  pertainined to the 
application of the provisions of Article 64(2) EPC274 to the effect that the 
protection conferred by the patent to a process patent will also extend to the 
products directly obtained by such process. The Board confirmed the practice 
of the EPO which is to ignore the provisions of Article 64(2) EPC when 
examining the allowability of process claims with respect to Articles 52 to 57 
and 83 EPC, on the basis that such a provision addressed not to patent offices 
but only to courts in the Contracting States concerned with considering alleged 
infringements. Hence, the Board concluded that method claims for the 
manufacture of plants shall not be examined on their patentability in the light 
of Article 64(2) EPC. Therefore, applicants in the field of plant breeding by 
recombinant-DNA-technique have, in addition to all of the forms of available 
protection, protection for plants produced by the method as long as they are 
direct products of the method claimed.275 At this juncture, by virtue of Board’s 
view, it is therefore submitted that by obtaining a patent over a method of 
plant breeding, there is equally gained indirect patent protection over plant 
varieties.276  
 
The final question as referred to the Enlarged Board of Appeal was on the 
issue of patentability of plant varieties which is produced by recombinant gene 
technology, which is the product of microbiological process. In response to the 
issue, the Board emphasized the fact the EPC is already suited to deal with 
genetic engineering as applied to plant varieties, apart from the provision of 
Article 53(b) EPC.  In the Board’s view, there appears no reason why the mere 
                                                 
274 Article 64 (2) EPC says that: ‘If the subject-matter of the European patent is a process, the 
protection conferred by the patent shall extend to the products directly obtained by such process.’ 
275 , note 247, points 80 and 88 of the reasons for the decision. 
276 LLEWELYN, Margaret and ADCOCK, Mike, 	  Note 27, p. 309. 
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fact of being derived by genetic engineering should give the producers of such 
plant varieties a privileged position relative to breeders of plant varieties which 
meet all the requirements of Article 52(1) EPC277 but have not been arrived at 
by genetic engineering. 
The referral of the decision T 1054/96 was dealt with by the Enlarged Board of 
Appeal in G 1/98. It is particularly interesting to note that the Enlarged Board 
of Appeal indicated that it would favour the application because, in substance, 
it did not involve an application for plant variety. In effect, the decision  
overruled nearly all of the arguments presented by the Technical Board of 
Appeal. 
In its answers, the Enlarged Board pointed out that the first question referred 
to it by the Technical Board was very broad and overlapped with the remaining 
questions. Therefore, it was preferable to deal with Questions 2 to 4 before 
dealing with Question 1. In summary, Questions 2 to 4 were then answered as 
the following conclusions: 
Question 2: A claim wherein specific plant varieties are not individually 
claimed is not excluded from patentability under Article 53(b), even though it 
may embrace plant varieties. 
Question 3: When a claim to a process for the production of a plant variety is 
examined, Article 64(2) EPC is not to be taken into consideration. 
Question 4: The exception to patentability in Article 53(b), first half-sentence 
EPC applies to plant varieties irrespective of the way in which they were 
                                                 
277 Article 52(1) EPC says that: ‘European patents shall be granted for any inventions, in all fields 
of technology, provided that they are new, involve an inventive step and are susceptible of 
industrial application.’ 
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produced. Therefore, plant varieties containing genes introduced into an 
ancestral plant by recombinant gene technology are also excluded from 
patentability.278 
 
In answering Question 2, the Enlarged Board seemed to disagree with the 
Technical Board’s approach by emphasizing the fact that the subject-matter of 
a claim may not necessarily be equated with the scope of the claim. Yet the 
Enlarged Board admitted that it was not the wording but the substance of a 
claim which was decisive in assessing the subject-matter to which the claim 
was directed. In assessing the subject-matter of a claim, the underlying 
invention had to be identified. Thus, it was relevant how generic or specific the 
claimed invention was. The Enlarged Board further said that the applicant 
might claim his invention in the broadest possible form, that is the most 
general form for which all patentability requirements are fulfilled. At this 
juncture, the Enlarged Board expressed its disagreement with the Technical 
Board, as the former was of the opinion that in the event the applicant had 
made an invention of general applicability, a generic claim was not the 
consequence of the verbal skill of the attorney, but of the breadth of 
application of the invention.  
 
The Enlarged Board also analyzed the definition of ‘plant variety’, and came to 
the conclusion that that the claimed invention neither expressly nor implicitly 
defined a single variety, whether according to the definition of ‘plant variety’ in 
Article 1(vi) of the UPOV Convention 1991, or according to any of the other 
definitions of ‘plant variety’.279 In this sense, it simply meant that it did not 
                                                 
278 , Note 25. 
279 The Enlarge Board also refers to the definitions in Article 5(2) of the EC Regulation on 
Community Plant Variety Rights as well as under Rule 23b(4) EPC, which entered into force on 1 
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define a multiplicity of varieties which necessarily consists of several individual 
varieties. In the absence of the identification of specific varieties in the product 
claims, the subject-matter of the claimed invention was neither limited nor 
even directed to a variety or varieties.280 
 
The Enlarged Board went further to examine the historical legislative 
background which might contribute to an understanding of Article 53(b) EPC 
since the provisions on patentability closely followed the corresponding 
provisions in the Strasbourg Patent Convention (SPC). In fact, the Technical 
Board also took into consideration the intentions and considerations of the 
legislators when introducing Article 53(b) EPC. After a lengthy discussion on 
the historical background, the Enlarged Board eventually expresses its view 
that the purpose of Article 53(b) EPC corresponds to the purpose of Article 
2(b) SPC281 to the effect that European patents should not be granted for 
subject-matter for which the grant of patents was excluded under the ban on 
dual protection in the UPOV Convention 1961. Accordingly, inventions 
ineligible for protection under the plant breeders' rights system were intended 
to be patentable under the EPC provided they fulfilled the other requirements 
of patentability.282 The reason that the drafting of the two Articles differed was 
that the EPC draftsmen were working within the constraints of the old UPOV 
ban on dual protection of plant varieties, which was abandoned in UPOV 1991, 
the desire to unify patent law throughout the EPC Contracting States and the 
varying availability of plant variety right protection in the various EPC 
                                                                                                                                      
September1999, both are identical in substance to the definition  Article 1(vi) of the UPOV 
Convention 1991. 
280 , Note 25, point 3.1 of the reasons for the decision. 
281 Article 2(b) of the Strasbourg Patent Convention 1963 reads: The Contracting States shall not 
be bound to provide for the grant of patents in respect of plant or animal varieties or essentially 
biological processes for the production of plants or animals; this provision does not apply to 
micro-biological processes and the products thereof. 
282 , Note 25, points 3.6-3.7 of the reasons for the decision. 
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Contracting States. The Enlarged Board also makes an interesting observation 
of the legislators’ intention to protect by the plant breeders' rights system 
biological developments for which the patent system was less suited and to 
keep technical inventions related to plants within the patent system based on 
the historical background. 
 
In summary to the answer to Question 2, the Enlarged Board’s decision was 
that, according to Article 53(b) EPC, a patent is ‘in respect of plant varieties’ 
and shall not be granted if the claimed subject-matter is directed to plant 
varieties. In the absence of the identification of a specific plant variety in a 
product claim, the subject-matter of the claimed invention is not directed to a 
plant variety or varieties within the meaning of Article 53(b) EPC. The extent 
of the exclusion for patents is the obverse of the availability of plant variety 
rights. This is because the latter are only granted for specific plant varieties 
and not for technical teachings which can be implemented in an indefinite 
number of plant varieties.283 
 
For Question 3, the Enlarged Board pointed out that the question appeared to 
have lost its relevance in the light of the answer to the preceding question, 
hence, if a plant variety may be covered by a product claim, there was little 
room for the argument that protection for the variety derived from a claimed 
process could be inconsistent therewith. In fact, Question 3 was answered in 
conformity with the established case law according to which the protection 
conferred by a process patent is extended to the products obtained directly by 
the process, even if the products are not patentable  	. The Enlarged 
Board confirmed that this practice takes account of the purpose of the 
                                                 
283 !  point 3.10 of the reasons for the decision. 
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provision and is in accordance with its location in the EPC. The requirements 
on patentability to be examined by the EPO are contained in Part II, Chapter I 
EPC(Articles 52 to 57); Article 64(2) EPC belongs to Part II, Chapter III, 
containing provisions concerning the effects of patents and patent applications 
and is to be applied by the Courts responsible for deciding on infringement 
cases. 
 
The Enlarged Board in turn addressed Question 4 in relation to the term 
‘microbiological process’, that is whether the genetic modification of plant 
material might compromise a microbiological process within the meaning of 
Article 53(b), second half-sentence, EPC. According to the Enlarged Board, 
processes of genetic engineering, were not identical with microbiological 
processes. The term microbiological processes in the provision was used as 
synonymous with processes using micro-organisms. Micro-organisms are 
different from the parts of living beings used for the genetic modification of 
plants. On the other hand, it was true that cells and parts thereof were treated 
as micro-organisms under the current practice of the EPO.284  This appeared 
justified since modern biotechnology developed from traditional microbiology 
and cells were comparable to unicellular organisms. This does not, however, 
mean that genetically-modified plants were to be treated as products of 
microbiological processes within the meaning of Article 53(b), second half-
sentence EPC. Such an analogy and formal use of rules of interpretation would 
disregard the purpose of the exclusion in Article 53(b) EPC, that was to 
exclude from patentability subject-matter which is eligible for protection under 
the plant breeders' rights system.285  
                                                 
284 T 356/93, (#"		). 
285 , Note 25, point 5.2-5.3 of the reasons for the decision. 
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In answering Question 4, the Enlarged Board of Appeal supported the view of 
the Technical Board of Appeal that the mere fact of being obtained by means 
of genetic engineering did not give the producers of such plant varieties a 
privileged position relative to breeders of plant varieties resulting from 
traditional breeding only. Therefore, it did not make any difference for the 
requirements under the UPOV Convention or under the Regulation on Plant 
Variety Rights, how a variety was obtained. This simply meant that the term 
'plant variety' was appropriate for defining the borderline between patent 
protection and plant breeders' rights protection irrespective of the origin of the 
variety. The Enlarged Board also reasoned that refusing to allow genetically 
modified plants to be treated as products of microbiological processes would 
not preclude inventors from adequate intellectual property protection. This 
was due to the fact that a plant variety resulting from genetic engineering 
could qualify for protection under the UPOV Convention just as equally as 
those resulting from traditional breeding techniques.  
 
At this juncture, it is important to highlight that the Enlarged Board made 
reference to Article 4(1)b and (3) of the Biotechnology Directive,286 using 
language corresponding to Article 53(b) EPC, and concluded that the exclusion 
was intended to be interpreted in the sense outlined above, since Recital 32 of 
the Directive287 postulated that a new plant variety bred as a result of 
genetically modifying a particular plant variety was still excluded from patent 
                                                 
286 Article 4(1) of the EU Directive 98/44 reads: The following shall not be patentable: (b) 
essentially biological processes for the production of plants or animals. Article 4(3) reads: 
Paragraph 1(b) shall be without prejudice to the patentability of inventions which concern a 
microbiological or other technical process or a product obtained by means of such a process. 
287 Recital 32 of the EU Directive 98/44 reads: Whereas, however, if an invention consists only in 
genetically modifying a particular plant variety, and if a new plant variety is bred, it will still be 
excluded from patentability even if the genetic modification is the result not of an essentially 
biological process but of a biotechnological process. 
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protection, even if the genetic modification was the result of a biotechnological 
process.288 
 
With regard to Question 1, the Enlarged Board pointed out that the problems 
raised in this question were dealt with in the answers to Questions 2 to 4. The 
only problem that was not addressed in these answers was how to decide 
whether a process can be defined as ‘essentially biological’. However, the 
Board did not further address this problem, as the Applicant indicated that it 
was willing to amend the corresponding process claims to restrict the method 
claims to identifiable method steps in order to exclude essentially biological 
processes.289 
 
In essence the decision separated the subject matter of the claim from the 
scope of the claim. An application for a patent of a transgenic plant may within 
the scope of the claim cover plant varieties, but this does not mean that the 
claim or the patent application should be rejected. Such a patent protection 
can be obtained for a transgenic or genetically modified plant under the EPC 
as long as the claimed invention can be performed with different plant 
varieties which conditions for patent (novelty, inventive step and industrial 
application) could be met. In addition, if an application is made for a process 
patent and a plant variety falls within the scope of the claim for a process, this 
does not mean that the process itself is not patentable. The (	 case 
permits the patenting of plants provided a technical invention can be shown 
                                                 
288  Note 25, point 5.3 of the reasons for the decision. 
289 !  point 6 of the reasons for the decision. 
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and plant varieties are not claimed specifically. In short, patents over plants 
are now permitted under the EPC.290 
 
The Enlarged Board of Appeal decision in (	 reflected a wider pro-
patenting attitude in respect of protecting biotechnological inventions and has 
cleared some of the ambiguities in relation to the interpretation of the Article 
53(b) EPC. The case also highlighted the relationship between the plant 
breeders’ rights for plant varieties under the UPOV Convention and the ‘plant 
varieties’ exception to patentability under Article 53(b) EPC. In fact, (	 
has been regarded by many patent experts and commentators as one of the 
most significant plant patent cases affecting Europe in the sense that it has 
managed to elucidate the position and practice of EPO in patenting plant 
inventions other than plant varieties, as well as clarifying whether the 
exception to the exclusion applied to plant varieties produced by 
microbiological processes. Hence, as a consequence of the (	decision, it 
is now possible at the EPO to obtain broad claims directed to transgenic plants 
as long as they do not specifically relate to individualized varieties.291 In other 
words, a plant variety, or a group of plants that could be defined as a variety, 
cannot form the subject matter of a patent application no matter how they are 
generated, but can be patent-protected if they are embodiments of inventions 
that independently qualify for patent protection.  
 
                                                 
290 ADCOCK, Mike, 2005. The Monsanto v Schmieser case: A European Perspective. A !%3
!+"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pp. 1-10, Available at: < 
http://www.economia.uniroma2.it/conferenze/icabr2005/papers/Adcock_paper.pdf> [Accessed 26 
November 2008] 
291 JAENICHEN, Hans-Raner, MCDONELL, L.A., and HALEY, J.F.Jr., 2002. ,		/
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KG. p. 18. 
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The decision is in line with the EU Directive,292 in particular with Article 4(1) 
and (2), as well as the implementation of new Rule 23c(b) EPC, which was 
discussed earlier. Even though the EU Directive is not legally binding on the 
EPO Boards of Appeal, the (	 decision is consistent with the Directive’s 
provision as regard the patenting of plants. In fact, (	was the first case 
in which the EU Directive was used as a supplementary means of 
interpretation in helping to make the judgment. With the benefit of the ruling 
in the (	 case and the EU Directive 98/44, the exception to patentability 
of plant varieties seems to only exclude a plant-related invention if the subject 
matter claimed is a product which is strictly limited to a specific plant variety 
or specific plant varieties. Ultimately however, the European patent remains a 
viable option for biotechnologist with plant-related inventions, even with the 
plant varieties exception of Article 53(b) EPC.293 
 
<&=,	&& '#
	(
In 2002, the EPO granted a patent to a UK company, Plant Bioscience on a 
method for increasing a specific compound in %		" species, that is Broccoli, 
through conventional (marker assisted) breeding methods. Specifically, the 
patent related to claims to a method for the production of %		"" 
(broccoli) with elevated levels of certain "		, wherein the method 
comprises several steps of crossing and selection using wild %		"" 
species and double haploid breeding lines, in addition to a step comprising the 
                                                 
292 Between the time that the Technical Board of Appeal in (	 referred its questions to the 
Enlarged Board, and the Enlarged Board’s decision in G 01/98, the European Commission adopted 
the Directive 98/44 on the legal protection of biotechnological inventions. 
293 MCCLATCHEY, Katrina, 2004. The Impact of Novartis On The European Patent Convention’s 
Exception To Patentability For ‘Plant Varieties’. 9610"  2. Available at: < 
http://www.okjolt.org/articles/2004okjoltrev21.cfm> [Accessed 14 October 2008] 
294 Available at: <http://legal.european-patent-office.org/dg3/pdf/t050083ex1.pdf> [Accessed 14 
October 2008] 
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use of molecular markers to select hybrids with the desired genetic 
combination. In other words, the patent included the breeding methods, as 
well as the broccoli seeds and edible broccoli plants obtained through these 
breeding methods.  
 
The Patentee argued that the exclusion should be interpreted narrowly, and 
that use of the molecular markers constituted a technical step over and above 
the production of the hybrid broccoli. The method was not just an ‘essentially 
biological process’ as it consisted of a step which was not a natural 
phenomenon. In addition, the patentee argued that the method was 
patentable as it required the use of a non-natural starting material, and 
because the wild strains required human intervention to being them into 
contact with the broccoli breeding lines. 
 
The Appellants (who were the Opponents in the earlier Opposition 
Proceedings) argued that the use of the molecular markers insufficient to 
escape the exclusion provisions of Article 53(b). It was argued that Rule 
23b(5)295 does not contain an exhaustive definition of the excluded processes 
and that Article 53(b), which has a higher legislative rank than Rule 23b(5) 
according to Article 164(2) EPC, only excludes ‘essentially biological 
processes’. This definition included the method of the above patent (#
%	""6), even including the use of the molecular markers. 
 
                                                 
295 Following the EU Directive 98/44, Rule 23b(5) EPC was brought into force in 1999 in an 
attempt to clarify Article 53(b): ‘A process for the production of plants or animals is essentially 
biological if it consists  of natural phenomena such as crossing or selection’ (emphasis 
added).  
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The Technical Board of Appeal in the present case took the view that the 
introduction of Rule 23b(5) did not finally settle the question as to the 
interpretation of Article 53(b). An argument could be made that, unless the 
previous case law (most notably T 320/87 and T356/93) erred in its 
interpretation of Article 53(b), this interpretation  could not be overturned by a 
newly drafted rule of the Implementing Regulations.296 The Board pointed out 
an anomaly in that, according to Rule 23b(5) EPC, only processes which 
consist entirely of natural phenomena were considered to be essentially 
biological processes for the production of plants (Rule 23b(5) EPC). In 
addition, crossing and selection were given as examples of natural 
phenomena, when, in traditional plant breeding, the systematic crossing and 
selection would not occur without human intervention.297 
 
It is relevant to note that despite a review of the legislative history behind 
Article 53(b) and Rule 23b(5) EPC, the Technical Board of Appeal felt unable to 
reach a decision regarding the interpretation of the exclusion to patentability. 
Hence, the Technical Board of Appeal referred the following questions to the 
Enlarged Board of Appeal: 
 
1. Does a non-microbiological process for the production of plants which 
contains the steps of crossing and selecting plants escape the exclusion of 
Article 53(b) EPC merely because it contains, as a further step or as part of 
any of the steps of crossing and selection, an additional feature of a technical 
nature? 
                                                 
296 Kilburn & Strode, 2007. New EBA Referral from T 0083/05 – Breadth of Exclusion under Article 
53(b), Available at: < 
http://www.kstrode.co.uk/news/NewsDet.asp?RID=267&NewsType=Current> [Accessed 14 
October 2008] 
297 , note 247, pp. 36-37 of the decision. 
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2. If Question 1 is answered in the negative, what are the relevant criteria for 
distinguishing non-microbiological plant production processes excluded from 
patent protection under Article 53(b) EPC from non-excluded ones? In 
particular, is it relevant where the essence of the claimed invention lies and/or 
whether the additional feature of a technical nature contributes something to 
the claimed invention beyond a trivial level?298 
 
As at 1st December 2010, this Enlarged Board of Appeal Decision is currently 
pending under the reference number G 2/07.299 It is interesting to note that 
the review of case law relevant to the issue at hand identified that the mere 
requirement of human intervention in itself in a non-microbiological process 
was not necessarily sufficient for a process to not be ‘essentially biological’, 
but significant technical modifications to a process has been held to be 
sufficient. However, there has to date not been a decision which deals 
explicitly with the limits of the exclusion.300 
 
To sum up, the ruling of the Enlarged Board of Appeal will serve as a case law 
for all further patents on similar issues. It remains to be seen whether this 
referral will shed any light on this exclusion and the contradictory guidance 
regarding its interpretation. At this juncture, it is worth noting after starting 
the #%	""6 case in 2007, a second case related to ‘essentially 
biological processes for the production of plants and animals’ under Article 
53(b) EPC was forwarded to the Enlarged Board of Appeal of the EPO in May 
                                                 
298 !  p. 2. 
299 Refer < http://www.epo.org/patents/appeals/eba-decisions/pending.html> for ‘Referrals 
pending before the Enlarged Board of Appeal - Status: 9.5.2008’ [Accessed 02 July 2010] 
300 MCDONALD, Chris, 2007. EPO may Exclude Essentially Biological Processes for Plant 
Production, Available at: < http://www.withersrogers.co.uk/content/view/134/45/> [Accessed 14 
October 2008] 
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2008. The patent on tomatoes was owned by the Ministry of Agriculture of the 
State of Israel. The decision of these two cases will be considered in 
consolidated proceedings by the Enlarged Board of Appeal.301 Together with 
the first case (G2/07) this second case (G1/08) are hoped to become 
precedent for the question of patentability of ‘conventionally’ bred plants and 
animals in Europe. 
 
<&=	
#-&.*&/'	302 
On the premise that the issue of patentability of transgenic plant in Europe is 
now settled, the issue of the infringement of such a patent is seen as another 
challenge in this area. The real problem that has arisen with regard to patents 
that cover plant-related inventions is the issue of infringement through pollen 
drift, that is drift of patented genetically engineered crops. 
 
The biotechnology company Monsanto developed a 	-resistant gene 
for the canola plant which had the effect of producing canola that is resistant 
to their Roundup brand of herbicide. Hence, the patent application filed by 
Monsanto was for a technology that made plants resistant to 	 
herbicides such as Monsanto’s Roundup. The patent grants the company the 
exclusive right, privilege, and liberty of making, constructing, using, and 
selling the invention in Canada until the patent’s expiration on February 23, 
2010. Though Canada’s Plant Breeders’ Rights Act protects the intellectual 
                                                 
301 The Enlarged Board of Appeal of the EPO (EBoA), whose primary task is to clarify important 
points of law under the EPC, will hold public oral proceedings in cases G2/07  ("Broccoli") and 
G1/08 ("Tomatoes") on 20 and 21 July 2010 in Munich. This is because both cases are concerned 
with the exclusion of essentially biological processes for the production of plants under Article 53 
(b) EPC. A Technical Board of Appeal has referred questions to the EBoA relating to the degree 
and nature of human technical intervention, which is necessary for that provision not to apply.   
Refer < http://www.epo.org/topics/news/2010/20100203.html> [Accessed 07 July 2010] 
302 [2004] 1 S.C.R. 902, 2004 SCC 34. 
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property rights of seed developers, Monsanto felt a patent would provide more 
protection since it would deny farmers the right to save and re-use seeds 
containing the company’s patented genes and cells. In this regard, it is worth 
noting the patent would apply to the genes and cells containing the DNA that 
makes the plant 	-resistant; it would not apply to the plant itself. 
 
Monsanto marketed the seed as Roundup Ready Canola. Farmers using the 
system were able to control weed competition using Roundup, while avoiding 
damage to the Roundup-resistant crops. Users were required to enter into a 
formal agreement with Monsanto, which specifies that new seed must be 
purchased every year, and an annual licensing fee of C$15 per acre be paid. 
Roundup Ready Canola was introduced in Canada in 1996, and by 1998, it 
accounted for 25% of the country's canola area. 
 
In 1997, Percy Schmeiser, a canola breeder and grower in Bruno, 
Saskatchewan, discovered that a section of one of his fields contained canola 
that was resistant to herbicide Roundup. The origin of these Roundup-resistant 
plants is unclear, but it is possible that seed blew onto the Schmeiser property 
from neighbouring farms, where Roundup Ready Canola was being cultivated. 
A farmhand later harvested and saved the seed from this area, this seed was 
used to replant in 1998. That harvest was sold for feed. During 1998, over 
95% of Schmeiser's canola crop of approximately 1,000 acres (4 km²) was 
identified as the Roundup Ready variety.303 
 
Monsanto then sued Schmeiser for patent infringement, by keeping Roundup 
Ready canola seeds and failing to obtain a licence for the canola plants. 
                                                 
303 , note 302, pp.14-15. 
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Schmeiser maintained that this was accidental. Patents being in federal 
jurisdiction, the case went to Federal Court. At the Federal Court Trial Division, 
the trial judge found that Monsanto's patent was valid and infringed by 
Schmeiser. This finding was upheld by the Federal Court of Appeal. The case 
was further appealed to the Supreme Court of Canada. On May 21, 2004, the 
Supreme Court of Canada rendered its decision to uphold Monsanto’s claim of 
patent infringement against Schmeiser. By a narrow 5 to 4 majority, the court 
found that the patent was valid and that Schmeiser had infringed it. 
 
The Supreme Court held that Monsanto’s patent was valid irrespective of 
whether protection for the gene and cells extended to activities involving the 
plant. Although Monsanto only claimed protection for the genes and cells, ‘a 
purposive construction of the patent claims recognizes that the invention will 
be practised in plants regenerated from the patented cells...’ 304 
 
As the trial judge’s findings that Schmeiser saved, planted, harvested and sold 
the crop containing the patented gene and cells were uncontested (although 
the original plants came onto his land without his intervention), the issue was 
whether this amounted to ‘use’ of patented material. According to the majority 
who found Schmeiser  liable for infringing Monsanto’s patent, the acts of 
saving and planting the seed, then harvesting and selling plants containing the 
patented cells and genes, constituted ‘utilization’ of the patented material. 
Furthermore, by cultivating the canola without licence, Schmeiser was deemed 
to have ‘deprived [Monsanto] of the full enjoyment of the monopoly’.305 
 
                                                 
304 !, para 119, pp. 53-58. 
305 , note 302, para 71, p.38. 
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Interestingly, the majority interpreted existing case law relating to mechanical 
inventions as supporting the proposition that even if a product as a whole is 
not covered by a patent, if an important part or component of the product is 
patented, exploitation of the product may still result in infringement. Patented 
components are not usually intended to be used in isolation. Therefore, the 
judges maintained that infringement did not require use of the gene or cell in 
isolation.306 
 
Moreover, under a purposive interpretation of the claims, the majority found 
that the purpose of the patent was to sell plants or seeds containing the 
modified genes. They also said that Schmeiser had failed to rebut the 
presumption of use, as he had actively cultivated Roundup Ready canola as 
part of his business operations. They maintained that infringement does not 
require the use of Roundup, to account for the ‘stand-by’ utility of the 
herbicide tolerant trait (that is whether or not a farmer sprays Roundup, 
cultivating Roundup Ready canola means that the farmer may in future spray 
and benefit).307 
 
Based on the Supreme Court’s judgment, it is thus submitted that the 
presence of one patented gene in effect confers control over the entire plant, 
something that Monsanto cannot actually patent. Interestingly, in so accepting 
this ‘expansive’ conception of patents, the five judges seem to contradict their 
own 2002 decision, which saw the Supreme Court ruling that higher life forms 
cannot be patented in Canada308. In "	&	 case, these judges ruled that 
                                                 
306 !., p.4. 
307 ! 
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	> [2002] 4 S.C.R. 45, 2002 SCC 76. 
145 
 
higher life forms containing a single patented gene are effectively the property 
of the owner of the single patented gene.  
 
In this regard, many perceive the majority decision in Monsanto to be 
inconsistent with the Supreme Court of Canada’s holding in 	. 
However, the majority in Monsanto argued that their decision was, in fact, 
consistent with  	, noting that the gene and cell claims in 
Monsanto’s glyphosate-resistant plant patent were analogous to the plasmid 
and somatic cell culture claims which had been allowed by the Commissioner 
of Patents in Harvard’s patent for a genetically modified ‘oncomouse’. It was 
only the claim for the ‘oncomouse’ itself, as a higher life form, which was 
denied, and Monsanto did not claim modified plants in its patent. Notably, 
both the majority and minority in Monsanto agreed that the claims in 
Monsanto’s patent were valid.  
 
At this juncture, it is submitted that the truly difficult problem which had not 
been anticipated from the decision of Harvard Mouse was how to draw a line 
between non-patentable higher life forms and a patentable genetically 
modified cell. Essentially, higher life forms are not patentable, but their cells 
are; and since higher life forms are composed of cells, a patent on the cells of 
plant of animal would effectively give control over the plant or animal itself. An 
order for destruction of infringing plant cells, for example, would necessarily 
require destruction of the entire plant.309 
 
                                                 
309
 SIEBRASSE, N., Comment on 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	, Available at :< 
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Nevertheless, Schmeiser won a partial victory, when the court held that he did 
not have to pay Monsanto his profits from his 1998 crop, on the basis the 
presence of the gene in his crops had not afforded him any advantage and he 
had made no profits on the crop that were attributable to the invention.310 
 
Many members of the biotechnology industry welcomed the decision. 
Obviously, the majority in Monsanto recognized that many biotechnology 
inventions would only receive the full benefit of patent protection if the scope 
of the patent extended to genetically modified organisms as a whole. The 
majority asserted that it had only interpreted the Patent Act as it perceived it, 
and any amendments would be open to Parliament to pursue. Until and unless 
Parliament enacts amendments to the Patent Act that clarify issues on 
patentability of higher life forms (in particular transgenic plant) in Canada, the 
biotechnology community may need to rely on the distinction outlined by the 
majority judgment in Monsanto in support of patent infringement claims 
involving higher life forms. 
 
However, the decision still leaves some issues unresolved with respect to the 
scope of protection afforded to biotechnology-related inventions. The court, 
while confirming the validity of Monsanto’s patent on the transgene and 
modified cells, did not rule on the validity of patents on life forms, or whether 
it is right or wise to genetically modify plants. Obviously, the 2002 Supreme 
Court decision that higher life forms, such as plants, are non-patentable still 
stands. After all, Monsanto did not claim patent protection over a GM plant, 
only the modified genes and cells and the process for making them.  
 
                                                 
310 , note 302, p.48. 
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Having said that, what is now clear is the effect of the judgment;  that a 
patent owner’s rights on a patented gene and cells extend to the (non-
patentable) plant in which it is found, if the alleged infringer is judged to have 
used the patent; in "	&	 case, by saving, planting, harvesting and 
selling in a commercial context. In short, the practical effect of "	&	 
case was to render  	&	 prohibition of patenting of higher life 
forms almost entirely ineffectual. 
 
Another unresolved issue is perhaps Monsanto’s responsibility for its 
uncontainable technology, which was not considered by the judges in this 
case. It remains to be seen whether patent owners like Monsanto and other 
companies would be held liable for contaminating the farmers’ fields; whether 
they should be accountable for their technology? 
 
The fact that the court found that Monsanto was owed none of the value of 
Schmeiser’s crop may, however, be an important counter to the finding of 
patent infringement. Growing and re-growing contaminated seed may not 
oblige a farmer to pay Monsanto anything, presuming that they are not 
benefiting from the herbicide tolerant gene by spraying Roundup. 
 
This case is significant in the sense that it has attracted attention worldwide, 
raised awareness globally on many issues such as patents over transgenic 
plants and living organisms, GM crop contamination as well as the need to 
protect farmers’ rights. 
 
The decision of the majority provides support to the Canadian biotechnology 
industry in a number of ways. First, by acknowledging that patents on 
148 
 
modified genes, vectors, and cells containing modified genes have effect 
beyond the genes, vectors, and cells themselves, patents held by 
biotechnology researchers have greater scope and therefore greater value.  
 
Second, the effective scope of patent protection in Canada is now arguably 
similar to the scope of protection available to patentees in other industrially 
developed countries and regions, such as the United States and Europe. 
Therefore, the Canadian biotechnology industry can compete on a global level.  
 
Third, the majority acknowledged that the purpose of the patent obtained by 
Monsanto was to maintain a monopoly over the production and sale of 
glyphosate resistant plants. Arguably, if no protection were afforded to 
biotechnology inventions involving plants (or other higher life forms), there 
would be significantly less incentive to conduct research and invest in this area 
of technology. If an inventor has no recourse against unauthorized use of his 
invention, there is little reason to invest in such technology.311  
 
Fourth, the judgment provides an excellent balance between allowing effective 
enforcement of patent rights without unduly burdening the user. The majority 
in Schmeiser adopted a broad approach to defining patent ‘use’, but a narrow 
approach to remedy. This point is essential to the problem of the ‘innocent 
bystander’ who finds patented plants have entered onto his land without his 
knowledge. The Court was very clear that the issue was not raised on the 
facts, as Schmeiser was an intentional user, but the principles which were 
                                                 
311 LAW, G.S. and MARLES, J.A., 2004. Monsanto v Schmeiser: Patent Protection for Genetically 
Modified Genes and Cells in Canada,  6- 3-, 13 44-47, Available at 
:<http://www.law.ualberta.ca/centres/hli/userfiles/13-1-07_Law-Marles.pdf> [Accessed 25 June 
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established by the decision are nonetheless directly relevant. The broad 
definition of ‘use’ indicates that an innocent bystander would be strictly 
considered an infringer, but the more stringent requirements at the remedial 
stage suggest that an innocent bystander has little or nothing to fear in the 
final result. The welcome conclusion is that the plight of the innocent 
bystander under existing law is not nearly so perilous as is sometimes 
supposed.312 
 
It worth noting at this juncture that there have been a number of other 
litigations by Monsanto in asserting their patent rights, but the courts in other 
jurisdictions seemed to have another approach in deciding the issue. For 
example, on 6th of July 2010, the European Court of Justice (ECJ) handed 
down their judgment in the case of 	 0" 66  + %)
 9	 (Case C-428/08), a referral to the ECJ from the Rechtbank’s-
Gravenhage of the Netherlands. This case is of particular significance for 
patentees in the biotech industry since it has provided one of the first 
opportunities for the ECJ to address the scope of gene patents in Europe in 
light of Directive 98/44/EC (the Biotech Directive). Importantly, the ECJ, 
following the Advocate General’s Opinion, has concluded that the scope of 
protection for gene patents, as it relates to products incorporating the gene 
sequences claimed, does not extend to situations wherein the sequence does 
not perform the function for which it was patented. In another case (UK), 
	   [2007] EWHC 2257, the Judge found as a fact that the 
gene sequence was present in the imported soymeal, but held that the patent 
was not infringed. These two cases seem to suggest the fact that decision by 
                                                 
312 SIEBRASSE, N., 	, Note 309. 
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the Supreme Court of Canada in "	&	case is just too extensive or too 
expansive to be adopted in other similar cases elsewhere. 
 
All in all, the key principles as derived from the judgment are essentially 
supportive towards the biotechnology industry as a whole, hence developing 
countries like Malaysia may follow suit by adopting the similar approach in 
patenting of agricultural biotechnological inventions, in order to enhance and 
strengthen its current patent laws with the aim of accelerating its 
biotechnology growth. 

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After a thorough discussion and analysis of the case-law by the EPO and some 
landmark cases across Europe, it is submitted that the issue of patentability of 
agricultural biotechnological inventions, specifically plant varieties and 
transgenic plants, is still not free from uncertainties. Most of the cases were 
decided on their own merit, hence though, the principle and reasoning from 
the judgment serve as a useful guidance in this area. 
 
Based on the black-letter law, Article 53(b) EPC spells out that plant or animal 
varieties or essentially biological processes for the production of plants or 
animals are excluded from patentability, whereas microbiological processes or 
the products thereof are not.  
 
Early case law of the Technical Board of Appeal at the EPO such as #
" 		313 showed that a broad claim in a patent application to a 
transgenic plant applied to plant varieties and was excluded from patentability.  
                                                 
313 , note 24. 
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However, later cases showed that a claim directed to transgenic plants may 
not be excluded from patentability even if plant varieties fall within the scope 
of the claim. This is the decision by the Enlarged Board of Appeal decided Case 
G 1/98 (	<0	".314 Hence, it is now possible to patent a plant 
variety in Europe, by directing the claim onto transgenic plants (that embrace 
plant variety) rather than claiming over plant varieties 	.  
 
The decision in the (	 application significantly overturned the earlier 
decision and interpretation of the EPC that was based on the # "
		 decision and exemplified the state of patent law with regard to GM 
plants: GM plants can be protected by a patent in Europe if the invention is 
not limited to a single variety. Single varieties that have been generated using 
GM technology can be protected under the plant breeder rights legislation. 
 
In an effort to clarify the law as to what is patentable in biotechnology and 
also to harmonize the law in the European Union member states, Directive 
98/44/EC of the European Parliament and the Council on the Legal Protection 
of Biotechnological Inventions (European Directive) came into force in 1998 
after 10 years of debate and political struggle. Although this directive remains 
controversial among the member states, it clearly represents a much-needed 
landmark in patent law relating to biotechnology inventions. Again, this 
directive deems plant and animal varieties non-patentable. Although the 
concept of a plant variety is defined as in the UPOV Convention, the Directive 
further specifies that a plant variety is defined by its whole genome. 
Accordingly, a plant grouping that is defined by a particular gene only is not 
considered to be a plant variety. 
                                                 
314 , note 25. 
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An amended version of the EPC implementing regulations came into force on 1 
September 1999, in which certain provisions of the European Union Directive 
were incorporated, including the definitions of a plant variety as specified in 
the UPOV Convention and the Community Plant Variety Rights. Under Rule 
23c(b) EPC, inventions are patentable if they concern plants or animals if the 
technical feasibility of the invention is not confined to a particular plant or 
animal variety.  
 
It is interesting to note the pro-patenting attitude in respect of protecting 
biotechnological inventions in Europe based on the stance taken by the EPO in 
(	. Nevertheless, the (	 case received an unusual amount of 
public attention, which reflected the controversial way in which the public 
perceives GM plants. The EPO received more than 600 letters from individuals 
and organizations expressing concerns about the grant of patents that relate 
to living matter. Many expressed the view that such patents would be contrary 
to B "B or morality and are therefore excluded from patentability 
(Article 53(a) of the EPC). The Enlarged Board of Appeal argued that the 
contracting states of the EPC have not agreed on condemning the genetic 
engineering of plants 	 because it is contrary to morality. The Board also 
referred to Directive 98/44/EC of the European Parliament, which considers 
the protection of biotechnology inventions to be essential to encourage 
investment in the field.315 
 
                                                 
315 FLECK, B., and BALDOCK, C., 2003. Intellectual property protection for plant-related inventions 
in Europe. (3-	"	: D8:$D8D, Available at:   
<http://www.nature.com/nrg/journal/v4/n10/full/nrg1184.html#B5> [Accessed 23 June 2010] 
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The landmark case in Canada ("	’s case)316 which in effect legally 
acknowledged that patents on modified genes, vectors, and cells containing 
modified genes do extend to transgenic plant in which the genes is found, 
marks an interesting yet positive development for biotechnology industry. 
Nevertheless, the legal implication from the case only took effect in Canada 
alone. The Supreme Court of Canada apparently recognized that many 
biotechnology inventions will only receive the full benefit of patent protection if 
the scope of the patent extends to genetically modified organism as a whole. 
Although the approach of Canadian courts is somehow different as compared 
to the EPO, it renders the same effect as it is now possible to protect 
transgenic plants in Canada, not by patenting the plant 	  but by way of 
patenting the plant cells and genes, which practically and ultimately make up 
the whole transgenic plant. 
 
To sum up, patents over plants are now permitted under the EPC as patents 
can be granted for inventions that cover more than a single variety. This 
observation is built on the interpretation of the patentability of plant-related 
inventions in Europe on the basis of the amended EPC, the European Directive 
and recent European case law. However, it is important to bear in mind that 
any patent application that is directed to a plant-related invention must also 
fulfill other criteria that are laid out in the EPC, such as novelty, inventiveness 
and sufficiency of disclosure. For example, a controversial 'soya' patent owned 
by Monsanto (Patent EP301749 (1998)) was limited after it had been granted, 
owing to opposition from third parties. The soya patent concerned a method of 
genetically engineering plants, in particular soybean, by introducing a foreign 
gene through particle mediation. The patent also covered soybean seeds and 
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tissue that were obtained through this method. Under European patent law, a 
patent description must be sufficiently clear and complete so that it can be 
carried out by another party with a general knowledge of the field concerned. 
The Opposition Division found that the soya patent did not meet this 
requirement for sufficiency and limited the patent to soybean plants only, 
rather than to any kind of plant engineered using particle mediation.317 
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PVP is conceptually close to patent rights but differ insofar as the rights 
granted to commercial plant breeders are more circumscribed than under 
patent laws. Hence the interface between patent protection and that offered 
under the plant varieties legislation is a thorny issue, made more topical since 
the UPOV 1991 removed the former ban on double protection. It has been 
viewed by some scholars318  that the two systems should be viewed as 
complementary, operating in two different judicial niches, rather than as 
competitors for the same niche.  
 
The key issues in relation to IPR regimes over plants include the balance 
between the rights and obligations of breeders and farmers, and in creating a 
mutually reinforcing system. In this regard, patent rights and PVP in plant 
breeding should be seen as part of a wider strategy for developing an efficient 
and equitable agricultural biotechnology industry. 
 
Plant variety rights essentially represent a system of private property rights 
broadly similar to a patent system, but differing from such a system in many 
                                                 
8ECFLECK, B., and BALDOCK, C., ".
318 One of them is Andre Heitz, a senior counselor of UPOV, 	, note 17. 
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respects because it has to deal with the problems of living plant material. The 
self-reproducing capability of a plant, through the medium of seed or 
vegetative propagation, makes a new variety particularly vulnerable to 
unauthorized exploitation. The former share a number of characteristics with 
patent rights: they provide exclusive commercial rights to the holder, reward 
an inventive process, and are granted for a limited time after which they pass 
into the public domain. The term or duration of a patent is 20 years from the 
date of filing of the application319, whereas for plant variety rights, the period 
of protection has evolved over time but always with the idea that the rights 
conferred expire at the end of a specific period of protection. Under UPOV 
1978, the period of protection is of a minimum of 15 years. For vines, forest 
trees, fruit trees and ornamental trees, the minimum is 18 years. UPOV 1991 
extends the minimum period from 15 to 20 years. For trees and vines, the 
minimum is of 25 years.320 
 
The rights conferred to plant breeders differ from patent rights in several 
aspects; the scope, exceptions, administration, and assessment before the 
rights can be granted. These distinctions will be dealt with in turn.  
 
Firstly, in relation to scope and requirement of the rights, patents serve to 
protect any inventions, in all fields of technology, provided that they are new, 
involve an inventive step and are susceptible of industrial application.321 The 
term ‘new’ or ‘novelty’ under patent law denotes that such an invention has 
not been made available to the public by means of a written or oral 
description, by use, or in any other way, before the date of filing of the patent 
                                                 
319 Article 63 EPC. 
320 Article 19 UPOV 1991. 
321 Article 52 EPC. 
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application.322 In contrast, as far as plant varieties are concerned, they are 
only entitled for PVP if they fulfill the four basic criteria of novelty, 
distinctness, stability and uniformity or homogeneity, as provided under UPOV. 
At this juncture, it is important to note that the concept of novelty differs from 
that under patent law. Under UPOV, a variety is novel if it has not been sold or 
otherwise disposed of to others, by or with the consent of the breeder, for 
purposes of exploitation of the variety. Novelty is thus defined entirely by 
commercialization and not by the fact that the variety did not previously exist. 
UPOV gives a specific time frame for the application of novelty. To be novel, a 
variety must not have been commercialized in the country where the 
application is filed more than a year before the application and in other 
member countries more than four years (six years in the case of trees and 
vines).323 
 
Besides novelty, patent law also requires a patentable invention to fulfill the 
criterion of inventiveness. Hence, an invention shall be considered as involving 
an inventive step if, having regard to the state of the art, it is not obvious to a 
person skilled in the art.324 In other words, patents serve to protect novel 
results which are non-obvious. In order to ascertain whether or not the 
invention is obvious to one skilled in the art it is necessary to demonstrate the 
steps taken in arriving at the invention. The disclosure of the steps taken in 
order to arrive at the final result is requisite if the applicant is to succeed in 
showing that what s/he has done is inventive. This is shown by describing 
what was known before and demonstrating how what the inventor did was not 
an obvious step forward given what had been known before.  
                                                 
322 Article 54 (1) and (2) EPC. 
323 Article 6(1) UPOV 1991. 
324 Article 56 EPC. 
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In contrast, the plant variety rights system is not intended to protect non-
obvious results. Most plant breeding activity involves trying the obvious - if 
breeders were required to show that what they had done would not be obvious 
to a person skilled in the art then few if any rights would be granted. The 
rationale for the grant of a plant variety right is therefore not to protect 
inventiveness. There is no need for the breeder to disclose information about 
how the variety was developed the variety as he or she does not have to 
prove that their decision to pursue a particular line of research was unobvious.  
 
The key rationale for the grant of a plant variety right is the protection of the 
time invested in producing a new variety which is distinct from others of the 
same species, and which, over time, remains uniform and stable following 
reproduction.325 The requirement of uniformity and stability for a plant variety 
before protection can be granted poses some practical difficulties, as these 
requirements can only be proved after a certain period of time. In contrast to 
the paper assessment undertaken to determine whether an invention is 
patentable, a plant variety is subjected to two years of practical trials before 
the right is granted. These serve to show whether or not the variety is actually 
distinct, uniform and stable as opposed to simply relying on a written 
description provided by the breeder. The trials are undertaken by the granting 
offices in conjunction with breeding institutes, such as the UK’s National 
Institute of Agricultural Botany (NIAB).326 In Malaysia for instance, the period 
required for growing tests to prove uniformity and stability varies depending 
                                                 
325 LLEWELYN, Margaret, 2002. !"#%"/#	". 
[online]Available at: < http://www.iprsonline.org/resources/biotechnology.htm > [Accessed 01 
December 2008] 
326 LLEWELYN, Margaret, 	, note 287. 
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on types of plants, and it may extend up to ten, even to twenty years for 
plants like palm oil.327 The protection via PVP would only be available after all 
those stability and uniformity requirements of a plant variety are satisfied.  
 
In contrast with patent system, a grant of patent for an invention is only 
based on paper to satisfy the requirements of novelty, involve an inventive 
step and is susceptible of industrial application. In this regard, the patent 
system apparently serves as a quicker means in comparison to PVP, as it is 
able to provide faster protection in terms of time as there is no need to satisfy 
the requirements of uniformity and stability before a transgenic plant could be 
afforded with patent protection. 
 
Other than the requirements of the rights as discussed above, the rights 
conferred to plant breeders differ from patent rights insofar as they provide 
much more extensive exceptions to the rights conferred than patents. 
Breeders have exclusive rights to produce or reproduce protected varieties, to 
condition them for the purpose of propagation, to offer them for sale, to 
commercialize them, including exporting and importing them, and to stock 
them in view of production or commercialization. These rights are restricted by 
a number of exceptions that are compulsory in the UPOV context, on the basis 
of public interest. The rights of breeders do not extend to acts done privately 
and for non-commercial purposes, to acts done for experimental purposes, to 
the use of the protected variety for the purpose of breeding other varieties 
and the right to commercialize such other varieties as long as they are not 
essentially derived from the protected variety.  
                                                 
327 As confirmed by plant examiners during the interview session carried out on 24th July 2009 at 
Plant Variety Right Office, Department of Agriculture, Malaysia. 
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At this juncture, it is noteworthy that the patent system also provides an 
experimental use exception. This limited exception to the patent-holder’s 
monopoly exists in order to allow for unauthorized application of the patent in 
particular contexts without the fear of infringement proceedings. Although the 
content and scope of this exception differs between jurisdictions, the basic 
concept is that unauthorized use of the patent for experimental or research 
purposes will not constitute infringement.328 It has been contended that 
narrow experimental use exemptions inhibit R&D by discouraging innovators 
from improving patented inventions and by restricting access to state-of-the-
art technologies and research tools without the prior payment of a fee. On the 
other hand, a broad research exemption may discourage R&D by allowing 
innovators to design around inventions and develop competing technologies, 
thus reducing the ability of patent holders to recover returns on their 
investments. In order to ensure that patent law does not get in the way of 
new discoveries, thus balancing the interests of patent holders and society as 
the ultimate users at large, there is real a need of certainties with regard to 
the boundaries of the exemption.329 
 
While the research exemptions are compulsory, there exists a set of further 
exceptions under PVP which have been progressively reduced over time. The 
                                                 
328 For example, under UK Patents Act 1977, Section 60 (5) states that: ‘An act which, apart from 
this subsection, would constitute an infringement of a patent for an invention shall not do so if - 
(a) it is done privately and for purposes which are not commercial; (b) it is done for experimental 
purposes relating to the subject-matter of the invention’. The similar provision under Malaysia 
Patents Act 1983 is Section 37 (1) which says that : ‘The rights under the patent shall extend only 
to acts done for industrial or commercial purposes and in particular not to acts done only for 
scientific research’. 
329 For example, in July 2009, the UK Intellectual Property Office (UK-IPO) attempted to clear up 
uncertainty and doubt about an exception to patent law for researchers, moving to end a lack of 
clarity about which acts are illegal and which are allowed. The move follows the very first 
recommendation of the 2006 Gowers Review of Intellectual Property commissioned by the 
Treasury. Refer : <http://www.out-law.com/page-9244> [Accessed 04 July 2010]. 
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so-called farmer’s privilege falls into this category. Under UPOV 1978, the 
rights of breeders were circumscribed in such a way that plant breeders' rights 
did not interfere with farmers’ use of the legally obtained protected variety for 
propagating purposes on their own holdings. Under UPOV 1991, the rights of 
breeders have been extended to the harvested material of the protected 
variety and the farmer’s privilege has been made optional.330 These exceptions 
are essential to ensure that the protection granted does not restrict ongoing 
research or interfere with the legitimate interests of the agricultural 
community. 
 
The other point of distinction between patent protection and plant variety 
rights is in relation to the administration of the rights. Plant variety rights are 
generally administered by governmental agencies responsible for agricultural 
matters and not by offices concerned with trade and industry, as is the 
practice with patents.  
 
Interestingly, PVRs were at first conceived as an alternative to patent rights 
and it was accepted that the two kinds of intellectual property rights should be 
kept separate. Thus, under UPOV 1978, member states can only offer 
protection through one form of intellectual property rights. The grant of a PVR 
on a given variety implies that no other intellectual property right can be 
granted to the same variety. Under UPOV 1991, this restriction has been 
eliminated hence the issue of double protection is finally put to rest. 
 
Notwithstanding these differences as shown in the above discussion, slowly 
but steadily, PVRs are becoming more similar to rights conferred under patent 
                                                 
330 Article 15 UPOV 1991. 
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laws. This is evident after the latest revision of UPOV, in which the scope of 
PVRs has been expanded to give exclusive rights on the direct exploitation of 
the plant variety. This latest development made the PVRs more similar to the 
exclusive rights conferred upon the patentee through patents. This could be 
linked back to the intention of the PVR system when it was introduced, which 
was to give breeders broadly similar incentives and opportunities for reward as 
were available to inventors under the patent system. Besides, as the 1991 
amendment introduced the requirement of intellectual property protection for 
all plant genera and species and extended the duration of the right, it could 
also be described as a substantial strengthening of protection and an 
assimilation to the protection under the patent system.331 
 
Turning back to the issue of overlapping and interface between these two 
systems of protection, European law is of particular interest for the interface 
problems, for it contains a modern piece of legislation, namely the EU 
Directive on the protection of biotechnological inventions which was enacted, 
 , with the explicit goal of promoting the fruitful coexistence of the 
patent and PVR systems and which directly addresses relevant interface issues 
in several of its provisions.332 
 
For plant-related inventions and innovations, there remains the question 
whether the availability of patents and PVRs should be made exclusive, 
alternative or cumulative.333 Article 27(3)(b) TRIPS resembles the regulation 
                                                 
331 LENBEN, Markus, 2006. 0 9 %- #  # ) #" ,
0	" #	/ #	   . [online] Available at: < http:// 
papers.ssrn.com/sol3/papers.cfm?abstract_id=924343 > [Accessed  17 December 2008] 
332 MOUFANG, Rainer, 	, note 21, p. 3. 
333 By virtue of Article 27(3)(b) TRIPS Agreement, Member States may exclude from patentability 
plants and essentially biological processes for the production of plants. However, Members must 
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of UPOV 1991: neither a special form of protection is required nor is any form 
of cumulative protection excluded.334 European law appears to give priority to 
the PVR system: on the one hand, plant varieties may be protected by 
national PVRs or by a uniform Community-wide PVR.335 On the other hand, 
European patents are excluded for plant varieties and for essentially biological 
processes for the production of plants.336 Notwithstanding these provisions, 
the European legal framework does not really reduce the area of possible 
overlap between the two systems, since the patent system remains capable of 
covering plant-related innovations.  
 
At present, European patent law permits patent claims on plant in general, 
that is claims which are not restricted to one or more specific plant varieties. 
If, for example, a claim is directed to transgenic plants characterized by the 
insertion of a specific DNA sequence, it is considered not to be directed to 
plant varieties  	 (and thus not hit by the patent exclusion of plant 
varieties) since plant varieties are defined by their whole genome and, hence, 
are characterized by a multiplicity of genetic traits. Nevertheless, the scope of 
protection of such claims may also encompass plant varieties, namely when 
those varieties contain the specific DNA sequence.  
 
In short, the PVP systems are distinct from patents in allowing an option, 
under the 1991 Act, for farmers to save seed for subsequent seasons. Under 
patents, such actions would constitute infringement. The research exemption 
is one of the key components of PVP, as it promotes the development of new 
                                                                                                                                      
provide for the protection of plant varieties either by patents or by an effective 		 system 
or by any combination thereof. 
334 Article 27(3)(b) TRIPS simply states that plant varieties may be excluded from patentability. 
335 On the basis of the EC Council Regulation No. 2100/94 on Community plant variety rights. 
336 Article 53 (b) EPC and Article 4(1)(a) EU Biotech Directive. 
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plant varieties by making sure that protected germplasm sources remain 
available for plant breeding, with the overall goal of encouraging development 
of new varieties of plants. In terms of cost, PVP applications incur lower cost, 
as they can typically be completed by a breeder, while patent applications are 
under the purview of patent lawyers. Although the PVR system could maintain 
some exclusivity, it could not be avoided that protection gained by patents 
could be extended to plants belonging to a plant variety as a result of the 
abstract nature of IP rights. 337 
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Despite the key differences between the patent system and PVP, it is 
submitted that in comparison to PVP, patent system provides for a stronger 
protection for agricultural biotechnological inventions. The submission is 
premised on the patentability requirements that the invention must be new, 
involve an inventive step and be applicable for industrial application are 
relatively easier and quicker to be satisfied, as compared to DUS requirements 
to be fulfilled under PVP. The uniformity and stability requirements in most of 
the cases consume a long period of time, and protection via PVP would only be 
obtained once a plant variety could be shown as uniform and stable. In fact, 
the requirement of stability of a plant variety is one of key distinctions 
between a variety and what is patentable under the patent system.  
 
On the other hand, under the patent system, an inventor of a transgenic plant 
(which may embrace a plant variety) has the option to apply for patent 
protection right from the very early of research stage, for instance a patent on 
                                                 
337 MOUFANG, Rainer, 	, note 21, pp. 3-5. 
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genes or plant cells or process. This is because patent rules permit the 
inventor to apply to the patent office at a time when many details of the 
invention have still to be clarified. Further work and investment may be 
necessary before the invention becomes a marketable product. This aspect of 
the patent system provides some security for the inventor, an aspect that is 
missing under PVP, and may appeal to plant breeders.  
 
The recent developments in plant bioscience and biotechnology have 
demonstrated that there would not be much difficulty in satisfying those 
patentability requirements under patent laws. In this regard, a patent 
application could now be filed and granted in most jurisdictions for the 
invention in the form of transgenic plant provided the patentability 
requirements are met. 
 
In terms of scope of protection, it is submitted that the patent regime provides 
for stronger protection, as it protects what actually is patented. The scope of a 
patent is defined by its claims and often allows broad coverage of an 
invention, such as a plant cell containing a new chimeric gene that is 
applicable to several plant species. From the viewpoint of the inventors, in 
particular commercial breeders and private firms, patent protection for plant-
related inventions is much valued by developers of transgenic plants.338 One of 
the practical examples which is relevant to demonstrate the preferability of 
patent over PVP is the analysis by the Plant Intellectual Property project team 
                                                 
338 Refer statement made by the executive vice-president of Monsanto in a reaction to the 
judgment in 	"	,  	 Note 302. 
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which reported that ‘the team could not find anything which did not indicate a 
growing confidence in the patent system.’339 
 
In contrast to a patent, each plant breeders’ rights certificate covers a 
particular variety belonging to a particular plant species. The plant breeders’ 
rights certificate holder may exclude others from selling the protected variety, 
producing it for sale and making repeated use of the protected variety as a 
step to commercially produce another variety. Clearly, PVP is specifically 
designed to protect the propagating material (including seed, cuttings, 
divisions, tissue culture) and harvested material (cut flowers, fruit, foliage) of 
a new variety. In this regard, PVP apparently does not give protection to the 
plant variety as a whole, but rather concentrating on the propagating 
materials and harvested materials, on the reason that having control over 
these plant materials would effectively give exclusive rights to the breeders to 
market the variety, or to license the variety to others. In contrast with patent 
system which does give protection for patented genes, what being protected 
under the PVP is not the genes in protected varieties, but rather their unique 
combination expressed as a phenotype.340 
 
In addition, one of the oft-cited features of PVP apparently lies in its 
exemptions, such as the research exemptions and farmer’s privilege. These 
exemptions are aimed to balance the interests of breeders as the inventors of 
new plant varieties and farmers as the users of the protected varieties. At this 
juncture, it is to be stressed that like PVP, the patent system also provides for 
                                                 
339 The Plant Intellectual Property (PIP) Project was carried out from October 1998 until 2001 by 
the EU as part of the Fourth Framework Programme. Refer LLEWELYN, Margaret and ADCOCK, 
Mike, supra, Note 27, at p. 411. 
340 Phenotype denotes the appearance of each variety, based on the DUS criteria. 
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research exemptions in order to balance the rights and interests of inventors 
and society. Although the scope and boundaries of the exemptions under 
patent law are somehow uncertain, but as far as the European laws are 
concerned, the extent to which experimental use of patented inventions is 
permitted in Europe is currently governed by national patent laws.341 The 
provisions and availability of research exemptions which extends to acts done 
for experimental purposes relating to the subject matter of the patented 
invention provides a counter-argument for supporters of PVP, as patent 
system also provides for such exemptions which are available under PVP. 
 
. 00$%,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In summary, the exclusion from patentability for plant varieties has to be seen 
in relation to the UPOV Convention: plant varieties could and should be 
protected under this regime and this should remain as an option in the hands 
of breeders or inventors, whereas other plant-related inventions, which may 
also encompass plant varieties, not protectable under UPOV, should be 
patentable as any other invention under patent laws. Irrespective of Article 
53(b) EPC, the EPC as a whole is not opposed to forms of alternative or even 
cumulative protection for plant varieties. Having said that, the issue remains 
interesting and relevant in dealing with the international context of Article 53 
EPC, as patent law is not regarded as absolutely unsuitable for the protection 
of plant-related inventions on an international level. Neither TRIPS nor UPOV 
hinders the protection of plant varieties by patent law. 
 
                                                 
341 Art. 64 (1) of the European Patent Convention (EPC) provides that the rights conferred by a 
European patent in all designated countries to which the European patent extends shall be the 
same as those conferred by a national patent granted in that state. Article 64 (3) of the EPC 
provides that any infringement of a European patent shall be dealt with by national law. Thus no 
provision regarding defences to infringement is found in the EPC. 
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The case law in Europe seems to demonstrate the on-going tension in the 
interaction between patent law, and PVP legislation. Interestingly, the hybrid 
nature of the dual system seems to be working well. Therefore, it could be 
concluded that generally, based on the case law, the European patent remains 
an option for plant-related inventions. 
 
As far as Malaysia is concerned, the development and scenario in Europe with 
regard to the issue of patentability of plant-related inventions plays an 
important role in guiding and shaping a better patent system in the country 
which suits the local breeding industry and is conducive for the agricultural 
biotechnology growth. Chapter Six will incorporate a detailed discussion on 
ways forward for Malaysia in enhancing its current patent laws and PVP in 
order to compete at a global level. 
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Development of a new plant cultivar or variety requires a large input of time 
and effort. Some companies estimate that it takes ten to fifteen years to 
develop a new variety. Hence, in order to recover the costs of R&D, the 
breeder or inventor may seek to obtain exclusive marketing rights for the new 
variety. In this regard, one of the most important issues regarding agricultural 
biotechnology is the legal environment in which seeds are going to be 
produced and traded. Hence, in the discussion on the patentability of 
agricultural biotechnological inventions, one often refers to the United States 
of America, where the legal framework appears to be much more favourable 
for biotechnological inventions. In fact, the intellectual property regime in the 
U.S. has been described as one of the ‘friendliest’ in the world for 
biotechnology inventors.  
 
This chapter on the legal protection of agricultural biotechnological inventions 
in the U.S. is significant for the purpose of the research in the sense that the 
U.S. system represents the opposite approach in comparison to the European 
approach. The different approaches of these two important jurisdictions of IP 
legal framework is understandably justifiable on the basis of different size of 
the seed industry, nature of farming activities as well as research and 
development as undertaken by public or private institutions. The U.S. patent 
system in protecting plant innovation is relevant and useful as a guide for 
developing countries like Malaysia towards enhancing its own patent regime. 
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Nevertheless, one of the major concerns which is worth noting is the fact that 
the U.S. as a developed country has moved towards private funding and 
increased patenting in modern agricultural biotechnology, whereas Malaysia as 
a developing country is still depending on public funding to develop its 
biotechnology industry. 
 
In this chapter, the current IPR legislation in the U.S. will be discussed in 
considerable detail, namely the Plant Patent Act (PPA) of 1930, the Plant 
Variety Protection Act (PVPA) of 1970 as amended in 1994, and the Patent Act 
of 1952. The chapter commences with a brief discussion on the history and 
background of the U.S. statutory laws in providing protection for 
biotechnological inventions, which ultimately shapes the current legal 
framework and the American patent laws. The chapter follows with the 
discussion on the patentability requirement under the U.S. patent laws, as well 
as plant variety protection system, with relevant comparisons of the three 
forms of legal protection. 
 
The other part of Chapter Three is devoted to examining the recent 
developments in the patent protection of plant-based technology in the United 
States, and this includes a discussion of decided cases on the issue of patent 
for agricultural biotechnological inventions. Controversies revolving around 
plant patents are also discussed briefly. 
 
Chapter Three proceeds further to articulate the comparison of the U.S. and 
European approaches in protecting agricultural biotechnological inventions. 
This part of the discussion is important as these two legal systems represent 
170 
 
two major jurisdictions with different approaches in their IPRs for plant 
innovations. 
 
The final part of Chapter Three is devoted to insights as to the relevancy of 
the U.S. system to Malaysian IP laws. Malaysia as one of the developing 
countries has taken active efforts towards developing its IPRs legal system, 
but the question as to what extent the U.S. practice and approach in 
protecting their agricultural biotechnological inventions is useful to improve 
laws in Malaysia remains to be seen. 
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Since its creation more than 200 years ago, the U.S. patent system has played 
an important role in stimulating technological innovation by providing legal 
protection to inventions of every description and by disseminating useful 
technical information about them. Throughout its history the patent system 
has had to adapt to evolving conditions, and it continues to demonstrate 
flexibility and responsiveness today.342  
 
The U.S. Constitution authorizes Congress to ‘promote the Progress of Science 
and useful Arts, by securing for limited Times to Authors and Inventors the 
exclusive Right to their respective Writings and Discoveries…’343 Congress’ first 
legislation implementing the Constitutional provision came during the First 
Congress, when it enacted the Patent Act of 1790. This law formed the basis 
                                                 
342 MERRIL, STEPHEN A., et al. eds., 2004. #	,07E	. Washington, DC 
: National Academies Press., p.1. 
343 U.S. Constitution  Art I, § 8, cl. 8. 
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for patents within the U.S., creating general requirements of novelty, utility, 
non-obviousness and enablement/description.344 
 
As early as the 1890s, fruit and tree breeders noticed that clever customers 
could easily take new plant introductions and reproduce them through 
cuttings, grafts or other asexual methods and then they could sell the same 
plants themselves. When these breeders wanted protection for plant 
‘inventions’, they turned to the Patent Office to have their plants protected by 
patents. Before 1930, the federal government denied patent protection for 
plants and animals.345 The denial was on the basis that plants, even those 
created by man, were considered ‘products of nature’ and were therefore not 
eligible for patent protection.  Under the doctrine of ‘product of nature’, 
breeders’ products, even those artificially bred, were not the results of a 
creative process and hence were not inventions as such.346  
 
Even where a biological invention did not constitute a ‘product of nature’, the 
claim typically could not sufficiently describe the invention in accordance with 
the written description requirement. As the patent system, for various reasons 
as discussed above, was considered an inappropriate method of protecting 
new plants, there was an imminent need for special legal protection systems 
for plant breeding in the U.S.  
 
In response to pressure from the nursery industry to curb competitors’ 
reproduction of valuable plants via grafting, finally in 1930, the U.S Congress 
                                                 
344 Refer 35 U.S.C. § 101 (2000). 
345 6, 1889 Dec. Commn. Pat. 123 (1889). 
346 OVERWALLE, Van Geertui, 1999.  Patent Protection For Plants: A Comparison Of American And 
European Approaches. 610"., 39, 143. 
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took the initiative in patenting plants with the introduction of identical bills into 
the House and Senate, proposing to remove the ‘product of nature’ objection 
and to ease the enablement requirement with regard to plants.347 The 
legislation, which came to be known as the Plant Patent Act (PPA), established 
statutory patent protection for asexually reproduced plants. The rationale is 
that asexual propagation by divisions or cuttings produces clones, each of 
which is identical to the parent plant and to all other cuttings or clones taken 
from the parent, while the production of seeds by cross-pollination does not 
assure a true new plant variety having the characteristics desired. Hence, 
under this Act, tubers and seed-produced crops were excluded from the 
protection. Over the years the courts construed this law quite strictly to apply 
only to asexual propagation, infringed only when the act of acquiring shoots or 
plant material is proven, not merely by genetic similarity.348  
 
The PPA is an important piece of legislation as it afforded the agricultural 
industry the opportunity to participate in the benefits of the patent system, 
which had previously only been enjoyed in the industrial field. It managed to 
address the concerns of breeders by statutorily recognizing that plant breeders 
created products that were more than mere products of nature. Supported by 
celebrated plant breeders like Luther Burbank and inventors like Thomas 
Edison, the PPA relied on an analogy between new breeder-produced varieties 
and new mechanical, electrical, or chemical inventions.  
 
                                                 
8:C!. 
348 DHAR, T., FOLTZ, J., 2007. The Impact of Intellectual Property Rights in the Plant and Seed 
Industry. !: J.P. KESAN, ed. "%"!"#/	+
. Oxfordshire: CAB International, 2—7, p. 162. 
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Nevertheless, by prohibiting only asexual reproduction of varieties protected 
by plant patent, the PPA offered no protection for breeders of seed for 
commercial grain agriculture. Accordingly, seed saving, and appropriation by 
competitors, remained legal and commonplace. 
 
At this juncture, it is to be noted that before Congress passed the PPA, plant 
breeders were unable to simply apply for regular utility patents  on new plant 
varieties due to two main obstacles. First, the Patent Office at the time viewed 
plants, even newly invented varieties that would not exist but for human 
intervention, as non-patentable products of nature. In other words, so far as 
the Patent Office was concerned, there was no difference between stumbling 
on a new plant in the woods and developing a new plant in a breeding 
program. Second, plant breeders had trouble providing written disclosures that 
were detailed enough to satisfy the Patent Act requirements for utility patents. 
 
In 1952, the U.S. Congress passed a new patent act, the ‘Utility Patent Act’  
(UPA)349, which is still in force today.  The 1952 UPA is significant in the sense 
that it ‘rearranged existing statutory provisions and stated in statutory form 
matters previously recognized only in court decisions and Patent Office 
practice.’ The first Patent Act in 1790 defined subject matter as ’any new and 
useful art, machine, manufacture, or composition of matter, or any new or 
useful improvement thereof.’350 When the patent laws were codified in 1952, 
Congress replaced the word ‘art’ with ‘process’, due to its broader scope of 
interpretation, denoting a process, art or method.351 It is to be noted that 
                                                 
349 35 U.S.C. § 1-376 (1994). 
350 Act of Apr. 10, 1790, ch. 7, § 1,1 Stat. 109, 109-10. 
351
 35 U.S.C. 101(b) (2000). 
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despite the legislation of the UPA, till the end of the twentieth century, the 
U.S. utility patent statutes excluded patents on living organisms.  
 
By 1970, it became evident to Congress that due to biological advances, true-
to-type reproduction was possible for sexually reproduced plants, namely 
plants derived from a seed. Accordingly, patent protection for plants provided 
for in the PPA was extended to sexually reproduced plants in 1970 by the 
enactment of the Plant Variety Protection Act (PVPA) which was modeled on 
the UPOV Convention. The significant features of the PVPA are , it has 
a research as well as farmer’s use exemption. The research exemption allows 
the use of PVPA-protected seeds in research, whereas the farmer exemption 
allows farmers to replant from PVPA-protected seeds they grew the previous 
year. However, it does exclude the farmer from selling those seeds to other 
farmers, a practice commonly called ‘brown-bag seeds’. With the enactment of 
the PPA and the PVPA, the debate on protection for plants under the general 
Patent Act temporarily came to an end in the U.S. 
 
Over two centuries after the passing of the first Patent Act, in a landmark 
patent law decision, it was held that patent laws enacted by Congress were 
broad enough to allow a man-made microorganism to be patented. That was 
in the year 1980 when the Supreme Court stepped into the fray with its 5-4 
decision on 
  ,352 which held that genetically modified 
(GM) bacteria could be patented within the scope of U.S. patent statutes. This 
decision, which was the linchpin to the explosion of biotechnology patents in 
the late 1980s and 1990s, was nevertheless not clarified as being applicable to 
                                                 
352 447 U.S. 303. 
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plants until 1985 when, in ,353 a utility patent application for a 
type of corn seed, the Patent Office’s Board of Appeals concluded that
did apply to plants. The utility patent statutes have higher levels 
of standards for novelty and utility than the PVPA, and have neither a farmer’s 
nor research exemption. Given these changes, after 1985, seed producers had 
two methods to protect their IP; a PVP Certificate and a utility patent; and 
could even apply for protection from both property rights.354 
 
4 4''!%#
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The history of IPRs in the U.S. has created a number of different regimes for 
seed producers and new plant variety breeders. Each type of protection is 
governed by a specific law which dictates protection for specific types of plant 
varieties or plant-related inventions. The following discussion presents a brief 
overview and description of the salient aspects of current IPR legislation in 
force in the U.S. namely, the PPA, the PVP Certificate and utility patents under 
the Utility Patent Act (UPA). 
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The U.S. Patent and Trademark Office (USPTO), an arm of the Department of 
Commerce, manages plant and utility patents.355 Plant patents can be 
obtained only for asexually propagated plants (not seed propagated plants). 
The right to a plant patent stems from 35 U.S.C. 161356 which provides that: 
‘Whoever invents or discovers and asexually reproduces any distinct and new 
variety of plant, including cultivated sports, mutants, hybrids, and newly found 
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 227 U.S.P.Q. 443, WL71986 (1985). 
354
 DHAR, T., FOLTZ, J., 	, note 306, p. 163. 
355 35 U.S.C. §§ 1, 2, 101 and 161 (1994). 
356 The PPA is now embodied in Sections 161-164 of Title 35 of the U.S. Code. 
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seedlings, other than a tuber propagated plant or a plant found in an 
uncultivated state, may obtain a patent therefore, subject to the conditions 
and requirements of this title..’ 
 
The PPA thus extends patent protection not only to inventors but also 
‘discoverers’ of eligible subject matter (but only if asexually reproduced). It is 
to be noted that protection is limited specifically to plants and plants varieties 
which have already reproduced asexually. This limitation was an inherent part 
of the PPA and was apparently premised on the perception that plants 
produced other than asexually could not be produced reliably true-to-type. 
Asexual propagation includes propagation using vegetative parts such as 
rooting, cuttings, grafting, budding or tissue culturing, for example.  
 
The limited scope of the PPA, applying only to asexually reproduced plants, 
ensures that plant breeders reproduce their plants identically in every respect 
to the parent plant. It is noteworthy that despite the limitation in scope of its 
application, the PPA ‘was the first legislation anywhere in the world to grant 
patent rights to plant breeders.’357 Insofar as the patenting of asexually 
reproduced plants in the U.S. is concerned, both national treatment and the 
right of priority have been accorded to foreign plant breeders since enactment 
of the plant patent law in 1930.358 
 
The conditions for obtaining a patent under the PPA are considerably different 
than those under general patent law. For example, the PPA requires the plant 
                                                 
357 !'(	 !"
		, 69 F.3d 1560, 1563 (Fed Cir. 1995). 
358
 ! §§ 161- 164 (1994). 
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variety be ‘distinct’359, rather than ‘useful’360 as required for a general utility 
patent. Distinct characteristics may include habit, immunity from disease, soil 
conditions, colour of flower, leaf, fruit or stems, flavor, productivity, storage 
qualities, perfume, form, ease of asexual reproduction, and defectiveness. It is 
immaterial whether the characteristics are inferior or superior to those of the 
existing varieties.361  
 
Furthermore, the written description requirements of general patent law are 
less stringent in the PPA, requiring only a description ‘as complete as is 
reasonably possible’. The U.S. Court of Customs and Patent Appeals has 
interpreted this provision to mean that there is no enablement requirement in 
a plant patent application.362 This is due to the impossibility of producing the 
patented plant from a description, because it must be asexually reproduced. 
In fact, prior to the enactment of the PPA, plants were not considered 
amenable to the detailed description requirement necessary for utility patents. 
Perhaps for this reason, the PPA specifically exempts plant patents from the 
detailed description associated with utility patents. Nevertheless, the applicant 
ultimately bears the burden of clearly and precisely describing those 
characteristics which define the new variety.363 
 
With regard to the other conditions for obtaining a patent, both the PPA and 
the Patent Act include novelty and non-obviousness requirements. ‘Novelty’ 
refers to newness in its conception. The term ‘new’ has been interpreted not to 
mean the plant did not exist previously but to mean that the plant did not 
                                                 
359 !., §§ 161. 
360 !., §§ 101. 
361 Refer S. Rep. No. 315-71(1930). 
362 !  484 F.2d 488, 490-91 (Cust. & Pat App. 1973). 
363 !., at 491. 
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exist previously in a capacity in which it could reproduce itself.364 ‘Non-
obviousness’ requires that there be actual inventiveness at the time the 
invention was made.365 
 
As provided in 35 U.S.C. 161, the rights associated with a plant patent include 
the rights associated with a utility patent, and the ‘right to exclude’ has 
additional terms provided in 35 U.S.C. 163: ‘In the case of a plant patent, the 
grant shall include the right to exclude others from asexually reproducing the 
plant, and from using, offering for sale, or selling the plant so produced, or 
any of its parts, throughout the United States, or from importing the plant so 
reproduced, or any part thereof, into the United States.’ 
 
Plant applications are subject to the same examination process as any other 
national application. As such, the statutory provisions with regard to 
patentable subject matter, utility, novelty, obviousness, disclosure and claim 
specificity requirements apply.366 One requirement for a plant patent 
application perhaps unfamiliar to utility patent practitioners is that the 
applicant is required to designate a varietal name for the plant variety for 
which protection is sought. This requirement has been imposed in part to 
comply with the U.S.’ accession to the UPOV Convention, Article 13 of which 
requires the examiner to examine a varietal name.367 
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., 537 F.2d 1347, 1378 (5th Cir. 1976). 
365 35 U.S.C. §§ 103 (2000). 
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 35 U.S.C. §§ 101, 102, 103, and 112. 
367 U.S. Patent and Trademark Office, Manual of Patent Examining Procedure § 1612 (8th ed. 2001 
rev. 2008). 
179 
 
The U.S. Plant Variety Protection Act (PVPA) of 1970 was intended to give 
private plant breeders stronger incentives to develop superior varieties. The 
Act was passed to fill a gap left by the PPA. Plant Variety Protection (PVP) is a 
form of intellectual property created to ‘encourage the development of novel 
varieties of sexually reproduced plants and to make them available to the 
public, providing protection available to those who breed, develop, or discover 
them, and thereby promoting progress in agriculture in the public interest.’368 
Under the PVPA, patent-like certificates of protection (PVPCs) may be obtained 
for varieties of self-pollinating crops, such as cotton, soybeans, and wheat.  
 
The Plant Variety Protection Office, an agency within the Agricultural Marketing 
Service of the USDA, manages the PVPA.369 The PVPO maintains over two 
hundred databases constructed from many resources370 in order to assemble 
as complete a description for a crop species as is possible so that variety 
specific comparisons are possible. 
 
To qualify for a PVPA Certificate, the variety must be new, distinct, uniform 
and stable.371 These requirements are significantly less strict than those of the 
general patent law. ‘Uniformity’ under the PVPA requires that the variety be 
‘describable, predictable and commercially acceptable,’372 and ‘stability’ 
requires the variety ‘remain unchanged with regard to the essential and 
distinctive characteristics of the variety’ upon reproduction.373 Those 
requirements reduce the precise written description and enablement 
requirements. 
                                                 
368 Plant Variety Protection Act, Pub. L. No. 91-577, 84 Stat. 1542 (1970). 
369 7 U.S.C. § 2321 (1994). 
370 For example, national registries, seed catalogues, review boards, etc. 
371 7 U.S.C. §§ 2402 (a)(1)-(4)(2000). 
372 !  §§ 2402 (a)(3). 
373 !  §§ 2402 (a)(4). 
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The PVP right granted has a term of 20 years for most plant varieties, and 25 
years for tree and vines. The term starts from the date that the certificate is 
issued. The PVP rights are the rights to exclude others from selling, marketing, 
conditioning, stocking, offering for sale, reproducing, importing, exporting, or 
using the variety to produce (as distinguished from develop) a hybrid or 
different variety. However, the effectiveness of the PVPA is thought to have 
been limited by the lack of a utility principle, an extremely narrow scope of 
protection based on measuring phenotypic differences, and a farmer’s 
exemption. 
 
The significant features of the PVPA relate to the exemptions from 
infringement, which reduce the scope of its protection as compared to those 
covered under the Patent Act. First, the PVPA allows for a ‘Public Interest 
Exemption’, providing that ‘the Secretary may declare a protected variety 
open to use…in order to ensure an adequate supply of fiber, food or feed in 
this country and that the owner is unwilling or unable to supply the public 
needs for the variety at a price which may reasonably be deemed fair.’374 
Thus, the exemption authorizes compulsory licensing upon the determination 
of public need. 
 
The second exemption to the PVPA is the research exemption, which allows for 
the use and reproduction of a protected variety for plant breeding or other 
 + research.375 The exemption in effect allows anyone to use the 
protected seed in a laboratory or field breeding research to develop new lines. 
                                                 
374
 7 U.S.C. § 2404 (2000). 
375 7 U.S.C. § 2544 (2000). 
181 
 
Plant breeders dislike this exemption because it allows others to use the 
protected seed in their research. The exemption permits other researchers to 
develop new breeds using the protected seed and exploit the investments 
made by the certificate holder. Thus, a company may apparently take 
advantage of investment in money and research by the original inventor and 
reap financial rewards without the inventor’s consent. 
 
The third exemption is the farmer’s exemption. This exemption allows a 
farmer to use seed produced from a patented plant for production on his or 
her farm. The farmer may also sell the seed, so long as it is not for 
reproductive purposes.376 The farmer’s exemption was significantly diluted 
when Congress amended the PVPA in 1994. Congress struck the provision 
which allowed a farmer to sell seed for reproductive purposes to other 
farmers. Prior to 1994, the farmer’s exemption was given much attention and 
was interpreted to allow farmers to sell seeds directly to other farmers, as 
long as they only kept and sold enough to replant their own acreage. It is 
worth noting although breeders enjoy modest protection of their protected 
plant innovations from competitors under the PVPA, the saved seed exemption 
prevents PVP Certificate holders from compelling farmers to purchase the 
protected variety on an annual basis and in this regard, hinders the seed 
breeders’ ability to engage in the monopolistic behavior typical of most IP 
regimes. 
 
As far as the UPOV Convention is concerned, the U.S. became a member of 
the 1978 Act of the UPOV convention in 1981 in order to afford U.S. plant 
breeders protection in other countries. It is to be noted that in 1985, the 
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 7 U.S.C. § 2543 (2000). 
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Patent Board of Appeals and Interferences ruled that seeds, plant tissue 
cultures, and the plant itself are patentable subject matter under the utility 
patent statute. The legal implication of this ruling is that plant varieties which 
are protectable under the PVPA are also eligible for patent protection, whereas 
the 1978 Act of the UPOV convention does not allow double protection for 
plant varieties. 
 
In 1994, the PVPA was amended to be in conformity with the 1991 Act of the 
UPOV convention, but still only applies to sexually propagated plants. In 1999, 
the U.S. signed the 1991 Act of the UPOV convention, and has a reservation 
under Article 35(2) of the text (which allows plant patents rather than 
breeder's rights certificates to be granted).  
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While the U.S. patent law has been amended several times since 1930, certain 
core principles have remained the same and could not be changed without 
fundamentally altering the system. The power to create a patent system arises 
under Article I Section 8 of the Constitution, which authorized Congress to 
reward innovation by granting monopolies on inventions for a limited time. 
The power is exercised in Title 35 of the U.S. Code.377 Hence, other than plant 
patents under the PPA, utility patents are one of the three types of protection 
in the U.S. that apply to plants. The modern version of the patent statute 
became law in 1952. It was the first full revision of  U.S. patent law since the 
Patent Act of 1836.  Like plant patents, utility patents are also administered by 
the USPTO, Department of Commerce.  The Patent Act of 1952 is significant as 
it forms the foundation for all patent protection in the U.S. 
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General utility patents have provided protection for inventions outside the 
agricultural sector for many years while the USPTO, as has been mentioned in 
the preceding discussion, refused to apply the general Patent Act to living 
things, concluding that they were discoveries in nature rather than inventions. 
Although available since 1793, the use of utility patents in agriculture was 
traditionally confined to tractors, ploughs and countless other mechanical or 
chemical inventions. Finally, in 1980, the U.S. Supreme Court, in the landmark 
case of 
, found that Congress intended the patentable 
statutory subject matter to include ‘anything under the sun that is made by 
man.’378 This decision opened the door for the USPTO to issue patents for 
genetically engineered plants. This is because the interpretation of the Act 
concluded that general utility patents may serve as intellectual property 
protection for plant and animal genetics.379 
 
Prior to the Supreme Court’s decision in , many patent 
practitioners, and most of the lay community associated with plants and the 
seed trade, believed that utility patents were not obtainable for plants. This 
may, in fact, have been the official policy at the USPTO. Nevertheless, utility 
patents were being granted for methods of treating and breeding plants. In 
fact, on a few occasions,380 the USPTO had issued utility patents which 
contained product claims to plants and seeds.381 
                                                 
378 447 U.S. 303, 309 (1980). 
379  For example, in , 2 U.S.P.Q.2d (BNA) 1425 (Bd. Pat. App. & Interf. 1987) relying 
on the U.S. Supreme Court’s decision in , the Board of Patent Appeals held that 
oysters, although they were animals, qualified as patentable subject matter under § 101 of the 
Patent Act so long was they were made by man. 
380 An early example, Boehm, U.S. Patent 2,048,056, describes a method of hybridizing plants 
that includes tow-produt-by-process claims which begin ‘the plant which...’ (Claims 5 and 6). 
381
 SEAY, NICHOLAS J., 1989. Protecting The Seeds Of Innovation: Patenting Plants. !#6L. 
16 418, at p.427. 
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The Patent Act of 1952 conveys patent protection to ‘whoever invents or 
discovers any new and useful process, machine, manufacture or composition 
of matter, or any new and useful improvement thereof.’382 The U.S. Supreme 
Court, after examining the text and legislative history of the Patent Act, gave 
the terms ‘manufacture’ and ‘composition of matter’ a broad interpretation to 
include a live, human-made microorganism. The Court reiterated that 
discoveries in nature are not patentable, but stated that a non-naturally 
occurring manufacture or composition of matter that is a product of human 
ingenuity and has a distinctive name, character, and use is patentable subject 
matter under § 101 of the Act, even if it is living matter. 383 
 
The broad interpretation of the Act led the USPTO of issuing utility patents for 
plants, plant parts and seeds. The USPTO had issued nearly 2000 utility 
patents for plants by the time the U.S. Supreme Court issued a clear ruling 
that plants were patentable subject matter under the general Patent Act.384 As 
far as utility patent is concerned, in order for a plant breeder to obtain the 
protection under the Act, he or she must show that the plant is new, useful 
and non-obvious.385 
 
A plant is considered new if it was not known or used by others before its 
discovery.386 Moreover, to be new, the plant must be ‘one that literally had not 
existed before, rather than one that had existed in nature but was newly 
                                                 
382 35 U.S.C. § 101(2000). 
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 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 447 U.S. 303, at 308-310. 
384 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found.’387 Another condition to qualify for a utility patent is the invention must 
be useful.388 The ‘product of a patented process is useful if it may serve some 
identifiable purpose.’ The invention’s potential for commercial success is 
irrelevant; the standard is actual and identifiable usefulness.389 Under the 
Utility Guidelines, the applicant must demonstrate either a specific, substantial 
and credible utility, or a well-established utility. A single such names of utility 
suffices.390 
 
Next, a plant must be non-obvious.391 The ‘emphasis on non-obviousness is 
one of inquiry, not quality.’392 Non-obviousness requires the invention to entail 
a degree of skill and ingenuity greater than that possessed by one with an 
ordinary level of knowledge in the practice or trade. 
 
In addition, the applicant for a utility patent must meet the stringent 
description specifications of § 112 of the general patent law. An applicant is 
required to provide ‘ a written description of the invention, and of the manner 
and process of making and using it, in such full, clear, concise, and exact 
terms as to enable any person skilled in the art to which it pertains...to make 
and use the same.393 Today, advances in biotechnological knowledge and 
expertise in genetic modifications have allowed plant breeders to satisfy these 
demanding description requirements. 
 
                                                 
387 *%	 !"+$,#., 537 F.2d 1347, 1378 (5th Cir. 1976). 
388
 35 U.S.C. § 101(2000). 
389 !!	 #6., 545 F. Supp. 635, at 644-645 (D.Del. 1982). 
390 Refer Manual of Patent Examining Procedure, available at 
<http://www.uspto.gov/web/offices/pac/mpep/mpep_e8r6_2100.pdf> [Accessed 23 March 2010] 
391 35 U.S.C. § 101(2000). 
392 
., 383 U.S. 1, 17 (1966). 
393 35 U.S.C. § 112(2000). 
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A patent issued under the general Patent Act is good up to twenty years and 
conveys the ‘right to exclude others from making, using, offering for sale, or 
selling the invention throughout the United States or importing the invention 
into the United States, and, if the invention is a process, to exclude others 
from using, offering for sale, or selling throughout the United States, or 
importing into the United States, products made by that process.’394 
 
Utility patents, by prohibiting almost any unauthorized activity using the 
patented invention, eliminate the PVPA’s research ‘free-rider’ problem.395 
Competitors who develop equivalent plant varieties or even new, distinct 
varieties derived from the patented seed may be liable for patent 
infringement. 
 
4 4 3!!$)C$%#-'$#!,#$%
As living matter was found to be patentable under the Patent Act of 1952, the 
Patent Act’s patentable subject matter apparently overlaps with the subject 
matter included under the purview of the PPA and the PVPA. At this juncture, 
the question was whether the availability of one form of statutory protection 
precludes the availability of protection under another form. By virtue of the 
text of the Acts and the legislative history, neither of the plant-specific Acts 
expressly excludes any plant subject matter from protection under the general 
patent law. 
 
The issue of joint protection using both PVPC and PUP was resolved in 
December 2001 by the Supreme Court’s decision in   !" 
                                                 
394 35 U.S.C. § 154 (2000). 
395 7 U.S.C. § 2544. 
187 
 
#$%!& !",396 which held that concurrent protection under the 
PVPA and the utility patent statutes was legitimate. Interestingly, the Supreme 
Court addressed the differences in the Acts, but found that the differences did 
not present irreconcilable conflicts.397 Thus, the different Acts are to be read 
together. 
 
Hence, as of July 31, 2007, approximately 5,300 utility patents have been 
issued by USPTO for plant-related inventions. Out of this number, a total of 
1,168 utility patents granted to plant varieties that have not been genetically 
modified.398 Indeed, the PUP had the greatest effect on securing the strongest 
method of protection for agricultural biotechnological inventions, suggesting 
that PVPCs were a lesser form of IP. Nevertheless, contrary to widely held 
expectations, utility patents and plant patents in plants did not make PVPC 
obsolete.  
 
As far as the statistical data is concerned, the comparison of the popularity 
and actual utilization which is based on the actual number of PVPCs and plant 
patents applied and granted is shown in the Chart below (Chart 3.1). The 
number of applications and actual title grants clearly shows the increase in 
tandem for both types of protection, indicating that some factors have 
influences in the choice of protection, such as the cost, the application process 
and procedures as well as the appropriate method of protection for respective 
inventions and R&D outputs. In this sense, local inventors and breeders as 
well as foreign companies in the U.S. seem to have a wider option to select 
                                                 
396 ! 
397 !., at 134-137, 142. 
398 Data from USPTO. Refer <http://www.eapvp-
forum.org/topics/2010/pdf/20100323_01/d1_04.pdf>  [Accessed 08 July 2010]. 
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and decide on which type of protection would better suit their invention. 
Hence, developing countries like Malaysia would be able to learn and benefit 
from the current open style system of protection in the U.S., provided that the 
local small scale and medium size farming communities were not marginalized. 
Nevertheless, it is noteworthy that the nature of farming activities as well as 
the stage of R&D  and development differ, as Malaysia is still in its infancy as 
far as biotechnology R&D is concerned. 

'#4 0
Plant variety protection statistics for the period 2004 - 2008 under the Plant 
Variety Protection Act (A) and the Plant Patent Act (B) 
 
Source: USPTO and UPOV399 
                                                 
399 Refer : <http://www.upov.int/export/sites/upov/en/documents/c/43/c_43_07.pdf> [Accessed 
08 July 2010] 
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Number of plant patents granted (U.S. vs. Foreign Origin) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: USPTO 
 
Chart 3.2 shows the number of plant patents granted in the U.S. to both U.S. 
companies as well as foreign companies. The increasing trend in the number 
of plant patents granted in particular from the year 2000 onwards is 
foreseeable, in parallel to the growth of biotechnological industry in the U.S. 
The more interesting finding from the chart is that the plant patents granted 
to foreign companies outnumbers those granted to U.S. companies 
themselves. The trend could be attributed to the fact that those plant patents 
granted to foreign companies are centralized in the  horticultural industry 
which is dominated by foreign players. For example in 2006, the USPTO issued 
approximately 1,150 plant patents with 432 (38%) awarded to the U.S. 
inventors. This means that less than half of the plant patents are owned by 
U.S. companies. The next highest total was the Netherlands with 212 (19%) 
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plant patents.400 It is not surprising for Netherlands to own a substantial 
component of the plant patents in the U.S. as the country is the world leader 
in horticultural and ornamental plant breeding.  
 
In fact, asexual reproduction in flowering plants is common.  Other than those 
plants that propagate asexually via vegetative production,401 many different 
seed plants utilize one of a number of different methods of this form of 
reproduction. In this regard, it is clear that horticultural breeders and 
exporters like those from Netherlands and Germany choose to protect their 
plant inventions under plant patents. The protection afforded by a plant patent 
apparently is very popular as it has managed to attract many foreign 
companies to protect their agricultural biotechnological inventions via this 
system. 
 
The number of plant patents which have been granted to top six foreign 
applicants is represented in the Chart below (Chart 3.3). 
 
                                                 
400 Source : USPTO < http://www.uspto.gov/web/offices/ac/ido/oeip/taf/us_stat.htm>, 
<http://patentlibrarian.blogspot.com/2007/06/plant-patent-article-in-gardening.html> [Accessed 
08 July 2010];  
401 The principal types of vegetative reproduction structures are bulbs, corms, rhizomes and 
runners. 
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Number of plant patents (PPA) granted to top six foreign applicants 

Source: USPTO 

Despite the argument that the simultaneous existence of three partially 
overlapping forms of protection complicates the understanding of intellectual 
property protection to plant varieties, having such a system inevitably 
contributes to much wider options for both local and foreign inventors and 
breeders in the U.S.  



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Number of PVP Applications Foreign Origin vs. U.S. Origin 
 
 
 
 
 
 
 
 
 
 
Source: USPTO 
Note: The arrows indicate the year that the U.S. joined the 1978 Act and 1991 
Act of the UPOV convention. 
 
Chart 3.4 shows that from 1971 - the year after the PVP Act was passed, to 
2007, there was an increasing trend for the number of applications filed by 
both U.S. and foreign residents.   
 
The steady and gradual growth in the number of plant patents and the 
application of PVP in the U.S. reflects the increased innovation in the field of 
agricultural biotechnology. Continuing high rates of innovation suggest that 
both of the patent system and PVP are working well in providing the protection 
to the inventors and plant breeders in the U.S.  
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Application for Plant Protection Under Plant Variety Protection Act (PVPA) and 
Plant Patent Act (PPA) 
 
Source: USPTO 

Chart 3.5 summarizes the number of applications under both PVPA and PPA, 
comparing the total number of applications by U.S. residents and foreign 
residents for a period of four consecutive years, from year 2002 till 2006. 
Clearly, the total number of applications for PVPA is less than those 
applications filed under PPA, but the trend as reflected from the chart 
suggested that PVPA remains relevant for some of breeders in the U.S. 




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Granted plant patents distributed by ownership category (2008) 
 
Source: USPTO 
 
Chart 3.6 shows the plant patent granted to U.S. residents which include U.S. 
corporations and individuals, as compared to foreign individuals, corporations 
and government. The majority of total ownership of granted plant patents, 
which is 60 percent, is held by foreign residents, while the remaining 40 
percent is in the hands of U.S. residents. These facts appear to lead to the 
conclusion that the existence of three partially overlapping forms of protection 
for plant varieties and agricultural biotechnological inventions in the U.S. has 
managed to attract foreign companies and investors to seek for the best and 
most appropriate protection for their inventions. However, the low percentage 
of the ownership of plant patents by U.S. local companies and individuals 
would raise issues and concerns such as the marginalization of small farmers 
and breeders in competing with those large foreign corporations. At this 
195 
 
juncture, developing countries like Malaysia should be cautious if it were to 
adopt the pro-patent attitude practised in the U.S., in order not to jeopardize 
the interest of small farmers and breeders.  
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As an arm of the Department of Commerce, the USPTO is responsible for 
issuing both utility patents and plant patents to those agricultural 
biotechnological inventions which are novel, useful and non-obvious from the 
prior art. In contrast to utility patents and plant patents which are issued by 
the USPTO, a PVP Certificate is issued by the PVPO of the USDA Agricultural 
Marketing Service. Such certificates are granted on new, distinct, uniform and 
stable sexually propagated plants and tubers.  
 
In many ways, the statutory scheme under the PVPA parallels the PPA. 
Nevertheless, the PVPA and the PPA differ significantly in their purposes, the 
scope and nature of their protection. The PPA grants a plant patent to one who 
‘invents or discovers and asexually reproduces any distinct and new variety of 
plant.’402 The PVPA, however, entitles one to PVP if he has sexually reproduced 
the variety and otherwise met the requirements of the Act.403 As a result, 
protection under the PVPA extends to the entire plant variety, while the PPA 
only protects that specific plant and its progeny.404 This means that a PPA does 
not afford protection to a range of plants that would be similar to a plant 
described in the patent, but only to plants derived by asexual reproduction 
from the original plant that was the subject of the PPA application, while 
                                                 
402
 35 U.S.C. § 161 (2000). 
403
 7 U.S.C. § 2402 (2000). 
404 !'(	 !")
		, 69 F.3d 1560, 1566-70 (Fed. Cir. 1995). 
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protection under the PVPA extends to any variety that is essentially derived 
from a protected variety, unless the protected variety is an essentially derived 
variety, to any variety that is not clearly distinguishable from a protected 
variety, and to any variety whose production requires the repeated use of a 
protected variety. 
 
Due to the stringent requirements under general patent law, it is generally 
much more difficult to obtain a utility patent for plant than to obtain a plant 
patent or a PVPA Certificate. However, if an applicant can overcome these 
stringent requirements, a utility patent may be more desirable due to its 
greater scope of protection. In the wake of (and even before), utility 
patenting of plant varieties has increasingly gained popularity. For 
economically important crops like corn and soybeans, breeders are making the 
obvious choice by choosing utility patent protection. As at July 2010, there 
were approximately 2000 corn (hybrid plus pure line), and about 1700 of 
soybean variety patents, plus smaller numbers of a range of other crops.405 
The reason for the popularity is evident: a greater scope of protection. Utility 
patents provide the broadest scope of protection to plants as they cover not 
only the plant, but plant parts in harvested or processed forms, methods of 
producing hybrid seed, as well as the hybrid seed and plants.406 
 
                                                 
405 Refer USPTO Patent Full-Text and Image Database, 
<http://www.uspto.gov/web/patents/classification/uspc800/sched800.htm#C800S320:001> 
(follow the red ―P‖ hyperlinks for ―320.1 Maize‖ and ―312 Soybean‖) [Accessed 12 July 2010]. 
406 For example, US Patent No. 5,491,296, covering an inbred corn line developed by a breeder at 
Holden's Foundation Seeds, Inc., contains claims to a corn plant, pollen, ovules, tissue cultures, 
regenerated corn plants, hybrid corn seed developing suing this inbred as a parent, and methods 
for producing such hybrid corn seed; Refer USPTO Patent Full-Text and Image Database < 
http://patft.uspto.gov/netacgi/nph-
Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2Fsearch-
adv.htm&r=7&f=G&l=50&d=PALL&S1=5491296.UREF.&OS=ref/5491296&RS=REF/5491296> 
[Accessed 13 July 2010]. 
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Unlike the PVPA, the Patent Act does not contain exemptions that limit the 
scope of protection. There are three important exemptions in the PVPA. First, 
the PVPA's provision safeguarding the ‘public interest in wide usage’ allows the 
United States Department of Agriculture to declare an otherwise protected 
variety open on the basis of equitable remuneration to the owner, upon a 
finding that no more than two years of compulsory licensing of a protected 
variety is necessary in order to insure an adequate supply of fibre, food, or 
feed and that the owner is unwilling or unable to meet public demand at a 
price which may reasonably be deemed fair. The PVPA's second exemption 
permits a farmer to save seed from protected varieties and to use such saved 
seed in the production of a crop without infringement. Third, the PVPA's 
‘research exemption’ declares that the use and reproduction of a protected 
variety for plant breeding or other bona fide research shall not constitute 
infringement.407  
 
The PVPA also limits the protection to a single variety, and the PPA limits the 
protection to a specific plant, that is an asexually propagated plant. The Patent 
Act has neither of these limitations. Specifically, the PVPA protection falls short 
of a utility patent because a breeder can use a plant that is protected by a PVP 
Certificate to develop a new inbred line, but the breeder cannot use a plant 
patented under the general Patent act for such purposes. With greater 
protection under the Patent Act, it is submitted that utility patent are the most 
valuable form of intellectual property, hence a patentee has a better option 
under patent protection to serve his or her commercial interests. 
 
                                                 
407 7 U.S.C. § 2544 (2000); Prior to 1994, farmer’s exemption even allowed farmers to sell such 
saved seed to others without infringement. 
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Having said that, on first impression one may wonder what considerations 
could lead a plant breeder to choose the PVPA over the utility patent form of 
protection, particularly given the scope and flexibility of the protection 
available by a utility patent. It is interesting to note at this juncture that the 
PVPA offers certain advantages in comparison to the utility patent. It follows 
that despite the potential for broad protection for genetically engineered or 
otherwise improved plants by utility patents, the conventional plant breeder 
who discovers a distinctive new variety under cultivation or develops one by 
cross-breeding techniques is still free to use the PPA or PVPA to secure 
protection for the variety – and many have.408 This is a clear indication that 
the availability of utility patents for plants has not discouraged the 
conventional plant breeder from seeking PPA or PVPA protection.409  
 
One of the significant advantages of PVP is, unlike patent protection, applying 
for a PVP provides provisional protection. As soon as a PVP application is filed 
and the fee paid, the seed or plant variety may be marked ‘Unauthorized 
Propagation Prohibited’ or ‘Unauthorized Seed Multiplication Prohibited’.410 
 
Another benefit of PVPA protection for plant breeders is with regard to the 
novelty requirement. Under patent law, once a technology matures or 
                                                 
408 From 1971 to 1984, a total of 1297 PVPA Certificates were issued, while from 1985 to January 
31, 1999, 2760 were issued. Source : Progress Report of the Plant Variety Protection Office, 1999, 
Refer: 
<http://www.aipla.org/Content/ContentGroups/Issues_and_Advocacy/Amicus_Briefs1/jembrief.pd
f> [Accessed 09 April 2010]. 
409 Some of the plant breeders are practically protecting their inbred plants under both the PVPA 
and by utility patents. One example is Pioneer Hi-Bred International Inc (in the case of 
 !"#$%!& !"534 U.S. 124 (2001)) 
410 7 Code of Federal Regulations (C.F.R.) § 97.140 (2204) (regulations covering labelling are as 
follows: Upon filing an application for protection of a variety and payment of the prescribed fee, 
the owner, or his or her designee, may label the variety or containers of the seed of the variety or 
plants produced from such seed, substantially as follows: ‘Unauthorized Propagation Prohibited – 
(Unauthorized Seed Multiplication Prohibited) – U.S. Variety Protection Applied For. Where 
applicable, ‘PVPA 1994’ or ‘PVPA 1994-Unauthorized Sales for Reproductive Purposes Prohibited’ 
may be added to the notice.) 
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becomes better known, novelty may be lost because the invention would be 
readily ascertainable from common knowledge. Therefore, once a 
biotechnological technique used in plant breeding loses novelty, the seed no 
longer will be patentable. PVPA protection would still be available on seeds 
that lack the novelty requirement because PVPA protection is available for new 
varieties that are new, distinct, uniform and stable.411 Therefore, in such a 
scenario, plant breeders will be able to obtain PVPA protection on seeds that 
are not patentable. 
 
Since both types of protection have value, some applicants choose to obtain 
both types of protection. For example, inbred lines to develop hybrids often 
get protected in PVPO. Such protection provides provisional protection when 
the PVP application is filed. Many inventors, however, may want to prevent 
exemptions for research and thus, would also seek patent protection.412 After 
all, breeders can, and sometimes do, seek simultaneous PVP and UP protection 
for the same variety. While UP protection generally dominates PVP, PVP does 
specifically prohibit both importing and exporting a variety from the U.S.413 
while UP does not specifically prohibit exporting.414 In this regard, it is 
submitted that such strength of combined protection could have anti-
competitive effects by securing and strengthening the position of market 
leaders and limiting the entry of new competitors. It is thus not surprising that 
the seed industry in the U.S. is currently dominated by few dominant firms 
which control much of the seed supply. 
 
                                                 
411 7 U.S.C. § 2483 (1994). 
412 WHITE, Katherine E., 2004. An Efficient Way to Improve Patent Quality for Plant Varieties. (.
0"1!#., 3(1), pp. 84-85. Available at 
:<http://www.law.northwestern.edu/journal/njtip/v3/n1/5> [Accessed 08 March 2010]. 
413 7 U.S.C. § 2541(a)(2) (2006). 
414 35 U.S.C. § 271(a) (2006). 
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In addition, there is a perception of cost effectiveness and reliability among 
plant breeders in the PVPA system that does not yet exist with regard to utility 
patents. Just as some industries are considered ‘patent conscious’, and others 
are not, some proprietary plant breeders are accustomed to the PVPA system 
and its procedures and limitations, and may simply be reluctant to change as a 
matter of practice and procedure.415 
 
With regard to the differences between a plant patent and a utility patent, the 
former has at least two features that distinguish them from the latter. First, 
for plant patents, the requirement of 'distinctness' replaces the requirement 
for utility. The Fifth Circuit has defined distinctness as the 'aggregate of the 
plant's distinguishing characteristics, and the legislative history of the PPA 
provides a list of traits that may bear on it.’416 Second, the requirement for an 
enabling disclosure is much attenuated for plant patents.417 Relaxing the 
disclosure requirement was one of the chief reasons for adopting the PPA in 
the first place, for plant varieties were deemed incapable of precise verbal 
description for patent purposes. Besides, there may be a cost advantage, in 
certain circumstances, to proceed by way of plant patent rather than a utility 
patent. Plant patents may involve less attorney preparation and filing time and 
may avoid deposit costs.418  
 
The differences of the three types of legal protection are aptly summarized in 
the Table 3.1 below. 

                                                 
415 SEAY, NICHOLAS J., 	, note 381,at 435. 
416  *%	 !"+$,#., 537 F.2d 1347, 1378 (5th Cir. 1976). 
417 35 U.S.C. § 162. 
418  !., at p. 434. 
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The comparison of the UPA, the PPA and the PVPA 
   Patent Law (‘Utility’ 
or Invention)  
Plant Patent Law  Plant Variety 
Protection Law  
Applicable 
to  
Plant, plant part, 
gene, protein, 
method, etc.  
Asexually propagated 
plant and its 
asexually propagated 
progeny.  
Sexually (seed) 
propagated plant 
varieties  
Rights to 
exclude 
others  
from  
Making, using, 
selling, offering for 
sale and importing 
the plant, or any of 
its parts  
Making, using, 
selling, offering for 
sale and importing 
the plant, or any of 
its parts  
Selling, marketing, 
conditioning, 
stocking, offering for 
sale, reproducing, 
importing or 
exporting, using the 
variety to produce 
(as distinguished 
from develop) a 
hybrid or different 
variety  
Term of 
Protection  
20 years term from 
date of filing  
20 years term from 
date of filing  
20 years (25 years 
for trees or vines) 
from issuance of the 
certificate  
Exemption  nil nil Crop Exemption: A 
person (farmer) may 
save seeds for 
planting on the 
person’s land, but 
NO transfer to others 
for seed reproduction 
purposes   
 
Generally, the UPA, PPA and PVPA can be viewed as presenting 
complementary, rather than conflicting, alternatives to protecting plants. If an 
applicant could satisfy the written description and claiming requirements of 
Section 112 of the UPA for his plant, he should be entitled to the broader 
protection afforded by the UPA; conversely, if he cannot satisfy those 
requirements, he should only be entitled to the narrower protection afforded 
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by the PPA of PVPA. It is noteworthy that the standards for granting a plant 
utility patent are not notably different than for PVP, yet the scope of protection 
received is substantially greater. However, it is worth noting that, where a 
combined protection under both UPA & PVPA is granted, for example an 
inventor obtains rights under both UPA & PVPA for a new plant variety, conflict 
may arise with regards to the exceptions under the PVPA. Patent protection 
under the UPA would trump farmer's exemption under the PVPA, because such 
exemption neither exists nor recognized in the patent regime. 
 
The flexibility of protection under the UPA is unparalleled by either PVPA or 
PPA. The fact that multiple claims can be drafted, unlike the PPA and PVPA, 
allows drafting of claims specifically targeted to cover all possible 
infringement, which include method claims of breeding or growing the 
protected variety. This is important because neither the PVPA nor the PPA 
reach this type of activity. 
 
In short, the preceding discussion provides insights to support the conclusion 
that the three types of legal protection that is PPA, PVPA and UPA may co-
exist in harmony, though conflict may also exist, in providing a strong IP 
protection for plants and agricultural biotechnological inventions. 
Nevertheless, the strengths of the UPA are manifest in terms of the broad and 
comprehensive protection. On this premise, UPA protection may well dominate 
the plant IP arena, although there will continue to be situations where the PPA 
and PVPA will be the preferred or only form of IP protection available. 
 
4 3 +!&!$-!%# $) #! !* -'$#!,#$% )$' *',#'
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In recent years, the USPTO has been criticized for granting patents with overly 
broad claims that grant a monopoly over property that is in the public domain, 
or patents for inventions that are not new and are obvious in light of the prior 
art. Although these mistakes are inevitable, such errors are more detrimental 
in areas where the patented subject matter is in naturally occurring 
substances, such as agricultural biotechnology, because one cannot design or 
invent around a plant.419 

4 3 0!@2
The following discussion is focused on some important decided cases which 
ultimately shape the current laws in the U.S. vis-à-vis protection for 
agricultural biotechnological inventions. These cases are selected for the 
reasons that they are the landmark cases which played an important role in 
clarifying the legal issues revolving around IP protection for plants, in 
particular the three partially overlapping forms of protection for plants in the 
U.S. 
 
<=0'#*.
/1
In this case, the inventor sought to patent a genetically engineered bacterium 
whose function was to break down crude oil, a characteristic not inherently 
present in the bacteria. The Supreme Court stated that ‘the patentee has 
produced a new bacterium with markedly different characteristics from any 
found in nature and one having the potential for significant utility. His 
discovery is not nature’s handiwork, but his own….’421 
                                                 
419
 WHITE, 	, note 412. 
420 447 U.S. 303. 
421 
, 447 U.S. 303,  at 310 U.S.P.Q. at 197. 
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In its extensively reasoned opinion, the Supreme Court explained that 
Congress plainly contemplated the notion that patent laws should be given 
wide scope and intended statutory subject matter to ‘include anything under 
the sun that is made by man.’422 The Court opined that the patent laws were 
intended to be construed broadly and that limitations on patents should be 
subject to the legislative process, not the judgment of the courts. According to 
the Supreme Court, &	 microorganism was the result of human 
ingenuity and thus patentable: ‘His claim is not to a hitherto unknown natural 
phenomenon, but to a non-naturally occurring manufacture or composition of 
matter – a product of human ingenuity having a distinctive name, character 
[and] use.’423 
 
The Supreme Court also held that neither the PPA nor the PVPA were 
introduced to limit the field of application of the UPA. The Court explained that 
the purpose of these statutes was to remove several specific impediments to 
the protection of plants, most notably the idea that all plants, simply by virtue 
of being plants, are products of nature that fall outside the scope of patentable 
subject matter. The Court also explained that these statutes introduced a 
relaxation of the enabling requirements for plants. The Court added that the 
relevant distinction was not between ‘living and inanimate thing, but between 
products of nature, whether living or not, and human-made inventions.’424 
 
Nonetheless, it is to be noted that the question whether the &	 
holding opened the UPA for plant patents retained some lingering doubts. The 
                                                 
422! at 309, 206 U.S.P.Q. at 197. 
423 !  at 309-10, 206 U.S.P.Q. at 197. 
424!  at 313, 206 U.S.P.Q. at 199.  
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reasoning of the Supreme Court decision in  seemed to most 
practitioners, just as applicable to inventions in plants. After the decision in 
, the USPTO began examining patent applications for inventions in 
plants, and practitioners began to consider the availability of such protection 
upon encountering developments in plant technology. Some USPTO examiners 
also interpreted  to permit utility patents on plants. The USPTO 
then began to resist issuing utility applications on plants, perhaps feeling that 
the propriety of permitting such applications should be ruled by an appropriate 
appellate body.425 This uncertainty was eventually put to rest in 1985 by 
, which will be examined in the following discussion. 
 
<=23"#%
In   taking its cue from the Supreme Court’s expansive view of 
patentable subject matter endorsed in , the USPTO in  Board of 
Patent Appeals and Interference decision interpreted the subject matter of 35 
U.S.C. § 101 to include plants.  contested the patentability under 
Section 101 of inventions claiming plant life. The Commissioner argued a 
variation on some of the arguments addressed by the Supreme Court in 
 regarding the proper interpretation of Section 101. The 
Commissioner’s position in  was that since Congress specifically 
passed the PPA in 1930 and the PVPA in 1970 to provide patent-like protection 
for these specific types of plant life, it must have been Congress’ 
understanding that living organisms were not patentable subject matter under 
Section 101. Hence, in     the Commissioner argued for a 
statutory construction asserting that because Section 101, the PPA, and PVPA 
                                                 
425 SEAY, NICHOLAS J., 	, note 381. 
426 227 U.S.P.Q. 443, WL71986 (1985). 
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must be construed together, and under the rule of statutory construction, 
specific statutes are found to prevail a general statute, hence the PPA and the 
PVPA must be the exclusive forms of protection for plant life covered by those 
Acts.427 
 
It is to be noted that this argument was the basis of the USPTO’s position prior 
to   that utility patents were permitted only for hybrids and tuber-
propagated plants because those plants could not be covered under the PPA or 
the PVPA. The Board of Appeals and Interferences rejected this argument in 
 and found no conflict between the statutes, hence adopting the 
position that plants may be protected by the UPA.428 This position was formally 
adopted by the USPTO in a Notice from the Commissioner of Patents issued in 
October, 1985.429 Amazingly,  continued as the primary precedent 
without court challenge from 1985 until   !"#$
% in 2001. 
 
<=4.2..56-&.*",#-76-& 
Pioneer Hi-Bred International, Inc., the world’s largest seed corn producer, 
holds seventeen utility patents issued under 35 U.S.C. Section 101 that covers 
the manufacture, use, sale, and offer for sale of its hybrid corn seed products. 
Pioneer sells its patented hybrid seeds under a limited label licence that allows 
only the production of grain and/or forage. J.E.M. AG Supply, Inc., doing 
business as Farm Advantage, Inc., bought patented seeds from Pioneer in 
                                                 
427 , 227 U.S.P.Q. at 444. 
428 ! 
429 Patent Office Notice, Plant Life – Patentable Subject Matter (Oct. 8, 1985), published in 2 
COOPER, Iver P., 1982. %6-, U.S.: Clark Boardman Callaghan, App. H3, at 
App.H-6. 
430 534 U.S. 124 (2001); 122 S.Ct. 593 (2001). 
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bags bearing the license agreement and then resold the bags. Subsequently, 
Pioneer filed a patent infringement suit. In response, Farm Advantage filed a 
patent invalidity counterclaim, arguing that sexually reproducing plants, such 
as Pioneer's corn plants, are not patentable subject matter within section 101. 
Farm Advantage maintained that the Plant Patent Act of 1930 (PPA) and the 
Plant Variety Protection Act (PVPA) set forth the exclusive statutory means for 
protecting plant life. 
 
The general issue of this case is whether sexually reproducing plants, more 
specifically hybrid431 and inbred corn plants, are excluded from the scope of 35 
U.S.C. § 101 and, accordingly, are not permissible subject matter for a utility 
patent. The Supreme Court in a 6-2 split, affirmed the decision of the Federal 
Circuit and held that utility applications for plants may be granted. The court 
further stated that plant patents and PVP are not the exclusive means of 
protecting new varieties of plants. This noteworthy decision has presumably 
increased the likelihood that more utility patents will be sought in the 
future.432 
 
Clearly, the Supreme Court’s decision runs parallel to policy considerations. 
Allowing inventors of plants to obtain a limited period of exclusivity in return 
for full disclosure is fully consonant with the overriding purpose of the patent 
laws. The public benefits when plant inventors provide the full disclosure 
required by a utility patent, in contrast to the limited disclosure provided by 
plant patents or PVPA certificates. No policy reason justifies discriminating 
against, and denying utility patent protection to, an inventor who can meet 
                                                 
431 Hybrid corn plants are not ‘varieties’ since they lack the ability to be propagated unchanged. 
432 JANIS, MARK A., and KESAN, JAY P., 2002. U.S Plant Variety Protection: Sound and Fury...?. 
	63. 3, p. 727. 
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the disclosure requirements of 35 U.S.C. § 112 merely because the invention 
is embodied in plant. Rather, in recent years, utility patent protection for 
plants has assisted progress in many areas of agricultural science. 
 
Coming back to the case in issue, the parties did not dispute that both the PPA 
and the PVPA were enacted due to the difficulties encountered by plant 
breeders attempting to meet the written description requirement of 35 U.S.C. 
§ 112(1) and to overcome the doctrine that ‘products of nature’ were not 
patentable subject matter under 35 U.S.C. § 101.433 However, while the 
Petitioner (Farm Advantage) argued in this case that the legislative history of 
these two Acts evidenced that Congress intended to exclude plants from the 
ambit of Section 101, it is submitted that a better view is that, the Acts were 
intended to complement Section 101 protection, not to balkanize it by 
removing subject matter piecemeal from its scope.434 The Supreme Court 
agreed with the Respondent (Pioneer), holding that neither the PPA nor the 
PVPA limits the scope of §101’s coverage.   
 
In its judgment, the Supreme Court observed that neither the PPA’s original 
nor its recodified text indicates that its protection for asexually reproduced 
plants was intended to be exclusive. The 1930 PPA amended the general 
patent provision to protect only the asexual reproduction of a plant. And 
Congress’ 1952 revision, which placed plant patents into a separate Chapter 
15, was only a housekeeping measure that did not change the substantive 
rights or the relaxed requirements for such patents. Plant patents under the 
                                                 
433 Refer 
, 447 U.S. at 311-12, !'(	 !")
		, 
69 F.3d 1560, 1566-70  (Fed. Cir. 1995). 
434 This is the view of American Intellectual Property Law Association  in its brief for Amicus Curiae 
in support of respondent supporting affirmance, Available at: < 
http://www.aipla.org/Content/ContentGroups/Issues_and_Advocacy/Amicus_Briefs1/jembrief.pdf
> [Accessed 09 April 2010]. 
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PPA thus continue to have very limited coverage and less stringent 
requirements than §101 utility patents. Importantly, Chapter 15 nowhere 
states that plant patents are the exclusive means of granting intellectual 
property protection to plants. The arguments that petitioners advanced for 
why the PPA should preclude assigning utility patents for plants were 
unpersuasive because petitioners fail to take into account of the forward-
looking perspective of the utility patent statute and the reality of plant 
breeding in 1930.435 
 
In     !"  # $% !&  !", the Supreme Court 
relied on , a 1985 USPTO decision that followed . 
In     the USPTO held that plants were within the subject 
matter of Section 101. Thereafter, the USPTO has had a practice if giving 
utility patents to plants when a plant breeder shows that the plant he 
developed is new, useful and non-obvious. Using these requirements, the 
USPTO has issued over 1800 plant patents in 16 years.436 
 
At this juncture, it is noteworthy the possible underlying reason of why the 
Court discussed the USPTO’s decision to issue over 1800 patents is because of 
agribusiness in the U.S. Changing the USPTO system of giving utility patents 
to plants would inevitable cause enormous damage to investments made in 
the past 16 years. If the Court ruled in favour of the Farm Advantage, the 
Court would have to rescind more than 1800 seed patents which would affect 
the agribusiness and development in agricultural biotechnology.437
                                                 
435 , note 430. 
436 !., 122 S.Ct. at 605. 
437 In the U.S., agribusiness is an entity that has hundreds of paid lobbyists in Congress and has 
put millions of dollars into the Democratic and Republican House and Senate campaigns. 
210 
 
 
As a matter of fact, the scope of subject matter relating to plants today that 
can meet the requirements of Section 112 far exceeds single plant varieties, 
as defined by either the PPA or the PVPA. The protection afforded by plant 
patents and PVP Certificates extends only to plant ‘varieties’. This limited 
protection would not encompass the hybrid corn plants and seed covered by 
Pioneer’s patents. And, while that protection may have met the need to 
protect new varieties invented or discovered through the 1970s, by the early 
1990s agricultural biotechnologists could transform major field crops with 
genes preselected or mutated to add desired characteristics. The ability of 
plant scientists to alter and improve plants, therefore, had extended far 
beyond the creation of new varieties by conventional sexual cross breeding or 
asexual propagation. 
 
In short, the U.S. Supreme Court in # laid to rest the question of 
whether sexually reproduced plants were statutory subject matter under 
Section 101. The Court made clear that if inventors of new varieties of plants 
are able to meet the stringent patentability standards of Section 101 and 
Section 112, they will be entitled to utility patent protection. Additionally, the 
Court clarified that Section 101 can also be reconciled with the PPA and the 
PVPA. The three statutes may provide overlapping protection and are not 
mutually exclusive. Thus, breeders of new plant varieties are free to apply for 
protection under each regime and may benefit from the protection provided by 
each regime. 
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<&=-'!)	6-&.8.0/		
In this case, the owner of Imazio Nursery, Inc. (Imazio), was the inventor of 
the '336 patent which was entitled "Heather Named Erica Sunset." According 
to the '336 patent, Mr. Imazio discovered Erica Sunset heather in 1978 "as a 
seedling of unknown pollen parentage growing in a cultivated field of Erica 
persoluta, the variety believed to be the seed parent, where it was noticed 
because of its early blooming and particularly because of its reaching full 
bloom, from base to tip, more than a month before the parent plant begins to 
bloom." It was the early blooming of the Erica Sunset, during the Christmas 
and Valentine's Day seasons, that distinguished the Erica Sunset from other 
known varieties. Imazio sued Coastal for patent infringement alleging that 
Coastal's "Holiday Heather" infringed the '336 patent.  
 
This case is important as it resolved a basic issue on what constitutes 
infringement of a plant patent. The U.S. Court of Appeals, Federal Circuit held 
that the scope of a plant patent is limited to the asexual progeny of a patented 
plant variety. The Court further held that ‘variety’ encompasses a single plant: 
the plant shown and described in the specification of the plant patent. Thus, in 
order for there to be infringement of a plant patent, the infringing plant must 
be an asexual reproduction of the plant claimed. In other words, infringement 
of a plant patent must involve a physical appropriation of asexually 
reproduced progeny of the patented variety. As such, independent creation is 
a defence to a charge of infringement of a plant patent. 
 
                                                 
438 69 F.3d 1560, 36 USPQ 2d 1673 (Fed. Cir. 1995). 
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Interestingly, the case also provided guidelines as to scope of protection 
provided by the PVPA. The Court stated that ‘asexual reproduction is the 
cornerstone of plant patent protection while sexual reproduction is the 
distinguishing feature of plant variety protection.’ The court concluded that the 
scope of protection afforded as a result of sexual versus asexual reproduction 
must be different since with ‘asexual reproduction the same plant is produced 
but in the case of sexual reproduction, a different plant, albeit like the parent 
plants, is produced.’ This suggests that the protection provided by a PVP 
certificate is broader (at least in some respects) than that provided by plant 
patents. 
 
This decision apparently clarifies the law in this area and restricts the scope of 
protection available for plant patents in the U.S. Nevertheless some authors439 
have criticized on the decision by the Court, reasoning that holders of U.S. 
plant patents will no longer have the same rights as those granted by utility 
and design patents, but rather a right more similar to copyright rights but 
administered through the USPTO. This is because !' stands for the 
proposition that to establish infringement of a plant patent it is necessary to 
prove that the accused plant is derived from, namley a copy of, the actual 
plant which prompted the filing of the application for plant patent. 
 
In theory however, a plant patent owner could use genetic testing to prove the 
required copying under the !'&	 case standard. This may be easier said 
than done. First, a set of genetic markers that could be used to show 
derivation may not exist for the species at issue. Second, even if genetic 
                                                 
439 One of them is Vincent G. Gioia; Refer GIOIA, VINCENT G., 1997. Plant Patents – R.I.P. #
109++"&. 79, 516. 
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markers were available, they may not prove sufficiently variable to distinguish 
actual copying from mere genetic similarity. Third, obtaining such evidence 
and presenting it at trial will require a technical expert trained in genetic 
testing, further adding to the cost of litigation. Finally, if all of the foregoing 
can be achieved, it is still not a trivial exercise to obtain a jury verdict based 
solely on genetic evidence.440 Having said that, in view of rapid developments 
in the field of biotechnology and genetic engineering, it will eventually be 
possible, though not easy, to furnish the required proof of infringement as 
decided in !'&	 case. 

<&=9#,	.6-&.*.
:;#.
 330
This case was a fight between two giants of the chrysanthemum business in 
the U.S., involving issues , relating to the plant patent law. The case 
was decided by 5th Circuit in 1976, but the principle and application of the PPA 
as demonstrated in this case still stands. In this case, Yoder Brothers (Yoder), 
plaintiff in the district court, sued, alleging infringement of twenty-one 
chrysanthemum plant patents by California-Florida Plant Corp. (CFPC) and 
California-Florida Plant Corp. of Florida (CFPCF) (sometimes referred to 
collectively as Cal-Florida). CFPC and CFPCF denied the infringement and filed 
antitrust counterclaims. As to seven of the chrysanthemum plant patents, the 
lower court directed verdicts for Yoder that the patents were valid and 
infringed and awarded treble damages. 
 
                                                 
440HANSON, R., and HIGHLAND, S., 2004. Protecting Plant Inventions. !: HOPKINS, A., and 
WANG, ZENG-YU, 
	#%. Netherlands: Springer. 2004, pp.381-395. 
441 537 F.2d 1347, 1378 (5th Cir. 1976). 
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As far as the background of the case was concerned, chrysanthemums had 
been subject to intensive breeding efforts over the preceding thirty years;442 
each individual specimen was a genetically unique complex organism. New 
varieties of chrysanthemums were developed in two major ways; by sexual 
reproduction and by mutagenic techniques. Sexual reproduction, the result of 
self or cross pollination, produces a genetically unique seedling, the 
characteristics of which are impossible to predict. Mutagenic techniques simply 
accelerate the natural rate of mutation in the chrysanthemum plant itself. A 
central fact of life in the chrysanthemum industry is the ease with which 
cuttings can be taken from parent plants: from one chrysanthemum, it is 
theoretically possible to develop an infinitely large stock, by taking cuttings, 
maturing some into flowered plants, taking more cuttings, and so on. 
 
Yoder started patenting some of its new varieties under the Plant Patent Act 
around the end of 1971, and in fact managed to secure plant patents on all 
new varieties it had introduced to the trade. Cal-Florida companies were the 
propagator-distributors, which built up mother stock from sources such as 
breeders, retail florists, or their existing flowers, and reproduced cuttings from 
that mother stock. In a sense, they were simply mass producers of cuttings. 
On the issue of patent infringement as alleged by Yoder, Cal-Florida 
companies asserted the invalidity of twenty-two U.S. plant patents. 
 
In delivering its judgment, the Court interpreted and clarified the requirements 
of a plant patent, that is novelty, utility and obviousness. For plant patents, 
the requirement of distinctness replaced that of utility, and the additional 
requirement of asexual reproduction was introduced. The concept of novelty 
                                                 
442 30 years here refers to the year from which the case was decided that is in year 1976. 
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referred to novelty of conception, rather than novelty of use; no single prior 
art structure can exist in which all of the elements serve substantially the 
same function. As applied to plants, the Patent Office Board of Appeals held 
that a ‘new’ plant had to be one that literally had not existed before, rather 
than one that had existed in nature but was newly found, such as an exotic 
plant from a remote part of the earth.443 
 
Interestingly, in defining ‘distinctness’, the Court made a reference to the 
legislative history of the Plant Patent Act, and accordingly observed that the 
characteristics that may distinguish a new variety would include, among 
others, those of habit; immunity from disease; or soil conditions; colour of 
flower, leaf, fruit or stems; flavour; productivity, including ever-bearing 
qualities in case of fruits; storage qualities; perfume; form; and ease of 
asexual reproduction. Within any one of the above or other classes of 
characteristics the differences which would suffice to make the variety a 
distinct variety, will necessarily be differences of degree. 
 
The Court was of the view that the third requirement, non-obviousness, was 
the hardest to apply to plants. Acknowledging the fact that in the case of 
plants, to develop or discover a new variety that retained the desirable 
qualities of the parent stock and added significant improvements, and to 
preserve the new specimen by asexual reproduction constituted no small feat, 
the Federal Circuit held that there was no meaningful way to apply the 
ordinary test of non-obviousness to plant patents, hence the statutory 
distinctness requirement was sufficient to satisfy the more general statutory 
requirements of patentability. The statutory criterion of distinctness was 
                                                 
443 Supra, note 441, paras 149-152. 
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narrowly construed as applied both to patentability and to issues of 
infringement. In either context proof of a single significant distinguishing 
characteristic, whether taxonomic or functional, was sufficient to establish the 
existence of a distinct variety. The legislative history of the PPA indicated that 
in order for the new variety to be distinct it must have characteristics clearly 
distinguishable from those of existing varieties, and it was immaterial whether 
in the judgment of the Patent Office the new characteristics were inferior or 
superior to those of existing varieties. 444 Experience had shown the absurdity 
of many views held as to the value of new varieties at the time of their 
creation. 
 
It is noteworthy that the Court made it clear, for purposes of plant patent 
infringement, that the patentee must prove that the alleged infringing plant 
was an asexual reproduction, that it was the progeny of the patented plant. 
This is because, it is quite possible that infringement of a plant patent would 
occur only if stock obtained is used, given the extreme unlikelihood that any 
other plant could actually infringe. If the alleged infringer could somehow 
prove that he had developed the plant in question independently, then he 
would not be liable in damages or subject to an injunction for infringement. 
This example illustrates the extreme extent to which asexual reproduction is 
the heart of the plant patent system: the whole key to the ‘invention’ of a new 
plant is the discovery of new traits plus the foresight and appreciation to take 
the step of asexual reproduction.445 
 
                                                 
444 !  paras 163-170. 
445 !  para 171. 
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This case was cited in the case of !'::@ (as discussed earlier). In fact, Cal-
Florida was trying to persuade the Court on cross appeal, asserting that the 
absence of flowering plants grown from the cuttings it had admittedly taken 
from Yoder's patented plants was fatal to Yoder's infringement counts. This is 
because the patent claim in each instance described a mature flowering plant, 
and it was Cal-Florida's position that only another mature flowering plant could 
directly infringe. The Court ruled that the act of asexual reproduction was 
complete at the time the cutting was taken, hence it was not necessary to 
prove that the cuttings actually matured into flowered plants to show 
infringement. Under such a rule, it would be virtually impossible for a 
propagator-distributor directly to infringe a patent, despite the vital role he 
played in dissemination of plant material. In this regard, it is submitted that 
the protection afforded under PPA is very strong and comprehensive, covering 
any acts of reproducing asexually the plant or selling or using the plant so 
reproduced. 
 
The Yoder case is significant in the sense that the requirements and effects of 
asexual reproduction as a prerequisite to plant patent protection have been 
recognized by the courts and the Patent Office. Although the case was decided 
in 1976, the principles relating to the implementation of PPA stand as good 
law until today. It is evident from the case that breeders and inventors from 
the horticultural industry have been benefitted from the strong protection 
offered under the plant patent system. After all, plant breeding is an 
expensive, complex procedure, which is eventually meant for the development 
of new varieties for consumers. The breeder must possess the skill and 
discrimination to spot potential new varieties and recognize whether they 
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possess desirable traits; facilities for elaborate testing and development must 
be available. Hence, the exclusive rights of the patent owners over their 
patented varieties are justifiable. 
 
<&=5	<#
.*.=33:
The Supreme Court in Asgrow’s case resolved an ambiguity concerning what 
limit, if any, the PVPA placed on the quantity of saved seed one farmer might 
sell to another under the farmers’ exemption. The farmers’ exemption allows 
farmers (if they are not in the seed business themselves) to replant their fields 
with seed produced by plants grown in earlier years from protected seed.448 
 
Petitioner, Asgrow Seed Company was the holder of PVPA certificates 
protecting two novel varieties of soybean seed, which it called A1937 and 
A2234. Respondents, Dennis and Becky Winterboer, were Iowa farmers. In 
addition to growing crops for sale as food and livestock feed, since 1987 the 
Winterboers had derived a sizable portion of their income from ‘brown bag’ 
sales of their crops to other farmers to use as seed. A brown bag sale occurs 
when a farmer purchases seed from a seed company, such as Asgrow, plants 
the seed in his own fields, harvests the crop, cleans it, and then sells the 
reproduced seed to other farmers (usually in nondescript brown bags) for 
them to plant as crop seed on their own farms. During 1990, the Winterboers 
planted 265 acres of A1937 and A2234, and sold the entire saleable crop to 
others for use as seed, at a lower price as compared to the price of varieties 
directly obtained from Asgrow.  
 
                                                 
447 115 S. Ct. 788, 790 (1995). 
448 7 U.S.C. § 2543. 
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Asgrow brought suit of infringement against the Winterboers in the Federal 
District Court for the Northern District of Iowa, seeking damages and a 
permanent injunction against sale of seed harvested from crops grown from 
A1937 and A2234. The Winterboers did not deny that Asgrow held valid 
certificates of protection covering A1937 and A2243, and that they had sold 
seed produced from those varieties for others to use as seed. Their defence 
rested upon the contention that their sales fell within the statutory exemption 
from infringement liability found in 7 U.S.C. § 2543. The District Court granted 
summary judgment in favour of Asgrow,449 but it was later reversed by the 
U.S. Court of Appeals for the Federal Circuit.  
 
Asgrow appealed, and the Supreme Court granted certiorari.450 Justice Scalia, 
writing for the majority, reversed the Federal Circuit. The majority interpreted 
the PVPA as permitting the sale of seeds saved for purposed of replanting on 
the farmer’s own acreage with the farmer’s primary farming occupation being 
such that the sale of crops for reasons other than reproductive purposes 
constituted the preponderance of the farmer’s business in the protected 
seed.451 In short, the Supreme Court interpreted the PVPA’s seed saving 
exemption so narrowly as to disallow many farmer-to-farmer ‘brown bag’ 
resales, viewing seeds as a licensed commodity. It is noteworthy that the 
Supreme Court justified its ruling as affording adequate encouragement for 
research and marketing and to yield for the public the benefits of new 
varieties. As far as small farmers and farmer’s rights werere concerned, the 
case  was viewed as an indicatiion of the trend of large businesses (the holder 
                                                 
449 795 F. Supp. 915 (1991). 
450 Shortly before the court rendered its decision, Congress amended the PVPA to bring it into line 
with the revised, 1991 UPOV Convention. Theses amendment narrowed the farmers' exemption 
even further, requiring farmers to secure the permission of the certificate holder before making 
any 'brown bag' sales. Refer § 2543 on ‘Right to save seed; crop exemption’. 
451 , note 438. 
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of a PVPA certificate, or even a utility patent) suing their small farm 
customers, that is the farmer as the end-user, rather than other large 
businesses or their market competitors. 
 
4 3 0 0 ! *%),%,! $) #! ,!@2 % 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Plants are perhaps the most thoroughly covered objects of IP protection in the 
U.S. The Supreme Court’s decision in 
  :?7 was 
instrumental in spurring the creation of a dynamic and flourishing biotech 
industry in the U.S.  By finding that subject matter derived from nature is 
eligible for patenting if it is modified by man into something new, useful and 
unobvious, the Court provided assurance to biotech companies and their 
investors that emerging technologies were protected by the patent system 
even if they could not have been foreseen when the system was created 200 
years earlier. 
 
As far as agricultural biotechnology is concerned, since the Court’s decision in 
1980, the biotechnology industry in the U.S. has improved and saved lives 
around the world through increased crop yields.  The U.S. biotechnology 
industry is a key component of its innovation economy, supporting more than 
7.5 million jobs throughout the country and providing the US with a global 
competitive advantage.453 The U.S. is presently the world leader in agricultural 
biotechnology, exporting roughly seventy-five percent of the world’s 
bioengineered materials.454 
                                                 
452 , note 420. 
453 Refer : <http://www.bio.org/news/pressreleases/newsitem.asp?id=2010_0616_03>  
[Accessed 13 July 2010]. 
454 JASEMINE, CHAMBERS, 2002. Patent eligibility of biotechnological inventions in the United 
States, Europe, and Japan: How much patent policy is public policy?. 0 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It is clear that in 
,455 the Supreme Court in effect laid 
the legal foundation that has contributed towards establishing the U.S. as the 
global biotech patent leader. While this case dealt specifically with a form of 
bacteria, the holding had significant implications for plant life. The Court's 
generous interpretation of the PPA and the passage of the PVPA established a 
new standard for invention that focused on ‘natural’ products and products of 
‘human effort. In this regard, it is noteworthy that 
:?@ 
has opened the floodgates for broader definitions of what is patentable. The 
decision, in addition to accommodating the high-tech direction of agricultural 
R&D, provided fairly strong patent protection for important aspects of 
agricultural inventions. 
 
With this foundation in place, #:?C helped to clarify the actual 
stand on patenting of transgenic plants. , which dealt with patenting of 
maize plant technologies that included seeds, allowed plant patents to be 
included under the broad category of utility patents. Utility patents are 
preferred by plant breeders because they allow patenting of the individual 
components of varieties. After , the PTO granted over 1800 expansive 
utility patents for germplasm. 
 
In 2001, the Court again expanded the definition of what is patentable, which 
in effect diluted the PPA and PVPA exemptions. In #
                                                                                                                                      
! 3-.[online] Available at : <http://www.allbusiness.com/legal/intellectual-
property-patent/915888-1.html> [Accessed 13 July 2010]. 
455 , note 420. 
456 , note 420. 
457 , note 426. 
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$%!,458 Pioneer Hi-Bred, a large seed company, sued a small 
Iowa seed supply company, Farm Advantage, for violating patents on hybrid 
corn seed. Justice Thomas, writing for the majority, concluded that newly 
developed plant breeds are covered by expansive utility patents and that 
neither the PPA nor the PVPA can limit the scope of a utility patent. The 
majority's broad interpretation of the legislation reinforced the position of seed 
patent holders and transgenic plant inventors. The Supreme Court thus 
opened the door for widespread use of utility patent protection for protecting 
potentially any economically important plant variety. 
 
Cases such as *%	:?A and 	-:@; are significant in the sense 
that they serve to clarify the interpretation of the patent laws and PVPA. These 
cases are essentially indicative and good markers of the U.S. courts’ approach 
in ensuring the continuous, concerted effort of protecting inventors and plant 
breeders’ investment in the development of plant varieties.  
 
4 3 . $!,$%#'$&!'!$&!'-%#-#!%#%#!  
The protection afforded by the general patent statutes creates incentives for 
inventors and companies to research and develop new products to benefit 
mankind by allowing them to make a profit in the twenty year period allowed 
for inventors to market their invention free from competition.461 Although 
patent laws are responsible for providing scientists and inventors with 
incentives to produce new products, the use of biotechnology in agriculture 
spawns debate because of the potential effects on farmers. Scholars worry 
                                                 
458 , note 430. 
459
 , note 440. 
460 , note 446. 
461 35 U.S.C. § 101 (1994). 
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that intellectual property laws would allow large corporations to profit from 
agricultural biotechnology (agribiotech) at the expense of farmers. Farmers 
fear that allowing agribiotech companies patent protection will force the 
agriculturists to pay royalties for the purchase of genetically altered plants. 
This obligation to pay royalties and increased costs likely will reduce the 
annual net profits of farmers. Farmers even fear that the increased costs of 
seed coupled with low crop prices will drive many of them out of business.462 
 
Legal challenges stem from licensing agreements and intellectual property 
protection that accompany patented seeds. These licensing agreements from 
agribiotech companies are feared to lead to the ‘industrialization’ of farming by 
requiring farmers to use limited licences with seed purchases and to 
encourage the use of contract production.463 For example, Monsanto464 does 
not simply sell seed to farmers, it also requires farmers to buy  licences to use 
the company’s seed technology. To use Monsanto’s Roundup Ready soy beans, 
the farmer must agree to use the seed only once. Another example is 
Pioneer’s465 practice of placing tags on its bags of corn that limits the farmer 
to planting the seed for only one year. Such licences often forbid the farmer 
from the traditional practice of saving seed to replant the following year. This 
licence contradicts farmers’ traditional practice of saving seed from one year 
to re-plant the next year and increase their operating costs. Many farmers 
claim they cannot afford to purchase more expensive bioengineered seed each 
                                                 
462
 NILLES, ANDREW F., 2000. Plant Patent Law: The Federal Circuit Sows the Seed to Allow 
Agriculture to Grow 61.63. 35, pp. 355-373, at p.361. 
463 HAMILTON, NEIL D., 1997. Reaping What We Have Sown: Public Policy Consequences of 
Agricultural Industrialization And The Legal Implications Of A Changing Production System, 

63. 45, 289-310, at p.295. 
464 Monsanto is an agribiotech company engaged in the manufacturing and selling agricultural 
products including herbicides. It is also engaged in biotech R&D of crops. Refer : <http:// 
http://www.monsanto.com/>. 
465 Pioneer is an agribiotech company that produces genetically engineered crops and is the 
world’s largest seed corn producer. Refer #M%!&!" !" 49 
U.SD.P.Q. 2d 1813. 
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year. On the contrary, agribiotech companies claim the licences are necessary 
to protect their investments in R&D466 and have instituted lawsuits against 
farmers who saved seed for future planting.467 
 
Contracts placing specific restrictions on farmers’ ability to save seed have 
engendered significant controversy. Farmers’ demanded that there should be a 
balance between the farmers’ traditional right to save seed with the cost 
required to develop improved varieties through genetic engineering. At the 
same time, there are always compelling arguments from patent owners for 
preserving incentives to develop improved varieties to benefit farmers. 
 
The current patent laws in the U.S. give unquestionable right to agribiotech 
companies to patent plants. As discussed in the preceding part of this chapter, 
the issue of whether plants are patentable under the general patent statutes 
was decided by the U.S. Court of Appeals for the Federal Circuit. In 
 !". v #$%!, it was held that seeds and seed-
grown plants are patentable subject matter under the general patent 
statutes.468 Some commentators were of the opinion that the Supreme Court 
majority’s decision in #&scase prohibits farmers from saving seed for the 
following year’s crop and thus erodes the farmer’s right to save seeds for the 
benefit of society, an act which is permitted via exemptions in the PVPA. The 
dissenting opinion in Pioneer remarked that a grant of utility patents to plants 
would destroy the two important exemptions under the PVPA; first, that a 
farmer would not face patent infringement if he saved the seeds and planted 
them in future years, and second, that the PVPA permitted the use and 
                                                 
466 HAMILTON, 	 note 463.
467 NILLES, 	 note 462. 
468 HAMILTON, " 
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reproduction of a protected variety for plant breeding or other bona fide 
research.  
Until and unless the Congress makes an amendment to the UPA – by carving 
out an exception that PVPA to be the exclusive means of protection of new 
plant varieties and that farmers have the right to save seed,469 the current law 
in force at present is that plant and plant varieties which include seeds are 
eligible to be protected under the UPA. Allowing plant patents will continue to 
allow plant breeders to develop newer and better varieties of crops, which 
eventually increase crop yields, reduce the need for pesticide use, and 
promote no-till farming, all of which benefit the farmer economically.470 
 
4 3 4!,!%#!&!$-!%# %-%#"$,!%,!%-$"!!))!,#$%
#!  ,''!%#2$%-%#@'!#!%&!%#$%
Modern biotechnology allows plant breeders to select genes that produce 
beneficial traits and move them from one organism to another. Plant 
biotechnology is far more precise and selective than crossbreeding in 
producing desired agronomic traits. Farmers throughout the world spend an 
estimated USD36 billion a year to buy seeds for crops, especially those with 
sought after traits such as hardiness and pest-resistance.471 They are unable 
to grow these seeds themselves because the very act of sexual reproduction 
                                                 
469 All that is needed to overturn the majority’s opinion in the Supreme Court decision is one 
sentence added to the PVPA. This sentence would simply affirm that the PVPA is intended by 
Congress to be the sole manner of gaining intellectual property rights over seeds. Rodney Nelson 
of Nelson Farm Enterprise suggested this addition to the statutes in a letter to North Dakota 
Senators Dorgan and Conrad and Rep. Pomeroy, Refer : 
<http://www.cropchoice.com/leadstrya594.html?recid=540> [Accessed 12 April 2010]. 
470 For example, in a 1997 survey of the corn belt, % corn users produced an average of 13.5 
more bushels of corn more per acre than non-% corn users. Also, Roundup Ready soybeans cost 
twelve dollars less per acre for weed control and lead to 4.5 more bushels of soybeans per acre. 
Refer NILLES, 	 note 389,pp. 370-371. % corn is a variant of maize, genetically altered by 
methods of to express the bacterial %=%"			) toxin, which is poisonous to insect 
pests. The corn is genetically engineered to provide protection against the European corn borer. 
Refer US Department of Agriculture < 
http://www.ers.usda.gov/briefing/biotechnology/glossary.htm> [Accessed 01 December 2010] 
471 ANON., 2010. Asexual Plant Reproduction May Seed New Approach for Agriculture. ""

 [online], Available at: < 
http://www.sciencedaily.com/releases/2010/03/100308132035.htm> [Accessed 20 July 2010] 
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erases many of those carefully selected traits. So year after year, farmers 
must purchase new supplies of specially-produced seeds. Sexual reproduction 
in plants involves the generation of male and female gametes that each carry 
half of the organism's genes. Flowering plants exhibit the most advanced form 
of sexual plant reproduction, producing pollen-derived sperm cells that join 
with egg cells to produce seeds. Each seed, then, is genetically unique. There 
are several types of asexual reproduction in plants, but all produce the same 
result: genetically identical daughter plants. 
 
It is worth noting the latest development in plant bioscience and 
biotechnology, which has reported a success and indeed a breakthrough. This 
happened recently when a group of scientists were reported to have moved a 
step closer to turning sexually-reproducing plants into asexual reproducers. 
Vielle-Calzada, a plant researcher at the Center for Research and Advanced 
Studies of the National Polytechnic Institute in Irapuato, Mexico, together with 
his colleagues, have been working and studying on a specific type of plant 
named  ‘		&  a small flowering mustard plant with a compact 
and well understood genome and which does not reproduce asexually. These 
scientists have managed to show that silencing a protein called ‘A& 
causes the plant to begin reproducing asexually instead.472 In other words, in 
the process, the plant was able to produce a clone of itself asexually. The 
finding is significant as it could have profound implications for agriculture and 
would eventually affect the current system of IP protection in the U.S. and 
worldwide. From farmers’ and breeders’ perspective, such a finding would 
allow them to simplify the labor-intensive cross-hybridization methods they 
now use to produce hearty seeds with desirable traits. 
                                                 
472 !. 
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From the legal aspect, if in the future all sexually propagated plants could be 
propagated asexually, it would diminish the role and value of PVPA, which is 
meant for the protection of sexually propagated plants. Nevertheless, the 
finding is still at the infancy stage and there are lots of stages and thousands 
of laboratory experiments to be done by those researchers towards creating a 
fully asexual 		 plant. This is because the current mutants do not 
develop completely asexual seeds. But by highlighting the infant success in 
plant reproduction, those scientists have actually moved a step closer to a 
slew of agricultural possibilities. They are now focusing on the ways and 
methods to discover and to trigger the second and final step of making sexual 
plants asexual.473 With that in mind, the UPA seems to be in a better position 
and would stand in the list of preference by breeders and inventors as it offers 
the broadest level of protection provided the patentability requirements are 
met.  
 
4 8$-'$%$)#!  %'$-!%--'$,!
Other industrialized countries have been slower than the U.S. to grant patent 
protection on living organisms which include transgenic plants and new plant 
varieties. A breakthrough occurred in 1999,474 when the EPO began to grant 
patents on genetically engineered cops. A comparison between the European 
and the U.S. contexts shows that there are striking similarities and differences 
between the European and the U.S. approaches to the establishment of 
protection for plants under the general Patents Acts. Initially, under the first-
generation Patent Acts, the European and the U.S. framework ran parallel. The 
                                                 
473 ! 
474 (	’ case, 	, note 266. 
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language of the first-generation patents acts475 was equally unclear in both the 
U.S. and Europe with respect to the patentability of plants. Equally similar 
were the first-generation objections raised to deny patent protection to plants 
in Europe and in the U.S. 476 
 
Subsequently, the perception that general patent law was inappropriate for 
the protection of plants resulted in the establishment of plant-tailored 
protection systems in both Europe and the U.S. The divergence between 
European and American approaches occurred with the enactment of the 
second-generation Patent Acts. The EPC and its member states adopted an 
explicit exclusionary provision regarding plant varieties, while the 1952 U.S. 
Patent Act contained no similar clause – but neither did U.S. patent law 
contain a provision that explicitly allowed the patentability of plants. 
 
The chasm between European and American patent law which was created 
with the inception of the EPC was quickly bridged. General discontent over 
inadequate plant protection systems and the confusion regarding the status of 
the law led to a resurgence of demand for plant protection under general 
patent acts in both Europe and the U.S. The gap between the European and 
the U.S. plant-patent policies reopened in 1995 when the EPO decided, in 
#"		 =#> case, to cease granting patent claims on plant 
 	  and this gap remains open as result of the affirmation of the PGS 
decision in (	 case As a result, the question whether plants may be 
                                                 
475 In the U.S., first-generation patent acts refer to first U.S. Patent Act of 1790, which was later 
on replaced three years later. The revision to the Act was made in 1836 and 1870. First-
generation patent acts in Europe denote various national patent acts in continental Europe which 
were established starting around the middle of the 19th century such as the Belgian Patent Act of 
1854 and the German Patent Act of 1877. 
476 OVERWALLE, 	 Note 346. 
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protected under the general patent act must now be answered differently in 
the U.S. than in Europe.477 
 
The difference between these two jurisdictions can also be seen in terms of 
application and scope of the research exemption which is generally available 
under patent laws. Most national patent laws permit third parties to engage in 
experimentation or research related to the patented invention. As far as the 
U.S. patent laws are concerned, there is no explicit research exemption in the 
Patent Act of 1952, but judicial decisions have allowed the ‘experimental use’ 
of a patented invention as a defence to an allegation of infringement. Despite 
its value in meeting the goals of the patent regime, the experimental use 
exception has been interpreted by the Federal Circuit in 2002478 in a manner 
that has significantly narrowed its scope and rendered its availability 
uncertain. The decision in effect has substantially eliminated the experimental 
use defense to patent infringement, especially where university-industry 
collaborative research is concerned. At present, most organizations carrying 
out research or experimental work involving patented inventions in the U.S. 
could find themselves liable for patent infringement. Notably, there have been 
no reported decisions wherein the experimental use exceptions has been 
considered specifically in the context of plant biotechnology. Nevertheless, the 
experimental use defense is submitted to remain relevant to the discussion of 
plant biotechnology and research initiatives related to agriculture in 
developing countries like Malaysia. 
                                                 
477 ! 
478 In the case of  
5	, 307 F.3d 1351, 1362 (Fed. Cir. 2002), it was held 
that ‘…regardless of whether a particular institution or entity is engaged in an endeavour for 
commercial gain, so long as the act as in furtherance of the alleged infringer’s legitimate business 
and is not solely for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry, the 
act does not qualify for the very narrow and strictly limited experimental use defense. Moreover, 
the profit or non-profits status of the user is not determinative.’ 
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The approach in Europe is somewhat different compared to the American 
approach. Member States in Europe have adopted research exemptions, 
inspired by Article 27(b) of the Community Patent Convention (1989 
version),479 and whose scope is generally broader than that of the American 
one. The experimental use exception in the UK is enshrined in section 60(5) of 
the Patents Act 1977 which says that: ‘An act which, apart from this 
subsection, would constitute an infringement of a patent for an invention shall 
not do so if –(a) it is done privately and for purposes which are not 
commercial; (b) it is done for experimental purposes relating to the subject-
matter of the invention.’ However, judicial interpretation of the experimental 
use exception in the UK has been relatively scarce. Indeed, in Europe at large 
and especially in relation to the intersection of biotechnology and the 
experimental use exception, case law is exceedingly sparse. While some 
guidance may be extracted from the new judgments which have been 
delivered in the UK, it is all too easy to limit their precedential value to the 
specific facts and patented technologies which gave rise to the dispute in 
question.480 
 
In the U.S., the debate on patent protection for plants was settled when the 
courts filled the legal vacuum created under the pre-1952 patent acts (and 
prolonged by the 1952 Patent Act) in favour of UPA. In Europe the discussion 
is probably not over, and the picture is still obscure. On the one hand there is 
current EPO case law, according to which plant varieties are non-patentable 
                                                 
479 Refer : <http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:41989A0695(01):EN:HTML>  [ Accessed 26 
July 2010] 
480 For example, in the case of 	++" [1985] RPC 515 
(CA), the Court of Appeal interpreted Section 60(5)(b) as was not so broad to encompass trials 
conducted by third parties and on lands other than the defendant’s premises. 
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subject matter, while on the other hand there is the Biotechnology Directive of 
the European Parliament and of the Council which allows patents for plants, 
but denies patents for plant varieties. At this juncture, it is to be noted that 
some legal jurists481 in the area of plant biotechnology have been proposing 
the EPO to accept the fact that patent protection for plants can be justified 
from a legal point of view, and perhaps rescind Article53(b) of the EPC. The 
suggestion was made with the aim of paving the way for plants to be covered 
by patents and removing any ambiguities and uncertainties on the issue of 
patent protection for plants (which includes plant varieties), hence realigning 
the Europe’s position with the U.S. in the area patent protection for plants. 
 
4 6 $2 '!!&%#  #!    (#! #$ (% 
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The patent laws of developed nations such as the U.S. are noted for providing 
the broadest protection for biotechnological inventions. Today, in the U.S., 
utility patents have been issued on both field crops, such as corns, soybeans 
and cotton, and vegetables, such as tomatoes and squash, having properties 
enhanced by both conventional breeding techniques and by direct gene 
transfer. This patenting activity has not deterred farmers from adopting this 
new technology. The U.S. farmers plant more than 70% of the biotech crops 
grown globally. For example, in 2000, about 61% of all cotton and about 54% 
of all soybeans planted in the U.S. were transgenic. As a matter of fact, these 
crops are no longer laboratory curiosities, they are now in the field. Many U.S. 
farmers who grow genetically modified (GM) crops are realizing substantial 
economic and environmental benefits, such as lower production costs, fewer 
pest problems, reduced use of pesticides, and better yields, compared with 
                                                 
481 One of them is Geertrui Van Overwalle, 	Note 304. 
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conventional crops.482 In comparison in Malaysia, the scenario is very much 
different. Although significant progress is being made in developing GM crops 
such as rice, papaya, pomelo, orchid, pineapple, oil palm, chili, rubber, and so 
forth, there is still no commercial release of GM crops, but they are all 
confined to field trials.483 It would take at least a couple of years before these 
GM crops could be released commercially, due to the heightened awareness 
and concern over the effects of GM crops among Malaysians in particular and 
in developing countries in general. 
 
With regard to the IP laws on protecting the agricultural biotechnological 
inventions, apparently there is no other country offers so many opportunities 
for IP coverage of plants; the current state of the law in the U.S. offers 
opportunities for plural regimes of protection as utility patents, PPA and PVPA 
and these cover any particular plant. It may be patentable under the PPA if it 
is asexually reproduced; it may be patentable under the general utility patent 
statute if it is new, useful and non-obvious; and it may be eligible for PVPA 
protection if it is new, distinct, stable and uniform plant. In this position, the 
U.S. system is truly unique in the world as no one else offers such an 
expansive opportunity for plant protection. In fact, the U.S. leads the global 
strengthening of IP protection, and has been the leader in development and 
commercialization of biotechnology in agriculture in the form of transgenic 
crops. Countries that invest little in research and development obtain a 
temporary advantage by limiting patent protection and free riding on the 
research investments of the more developed countries. The scope of patent 
                                                 
482 This has been reported by the US National Research Council. Refer : 
<http://www.finfacts.ie/irishfinancenews/article_1019470.shtml> [Accessed  22 April 2010] 
483 The fact is confirmed by MARDI during the semi-structured interview carried out in mid 2008 
for this thesis research purposes. Also refer to : <http://www.agbioforum.org/v7n12/v7n12a01-
hautea.htm> [Accessed 22 April 2010] 
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eligible subject matter typically expands as a nation realizes increasing 
economic growth and industrialization, and this is to some extent is very true 
for a developing country like Malaysia. As far as Malaysian IPRs system is 
concerned, patents are currently not available for plant varieties.484 Hence, the 
Malaysian Protection of New Plant Varieties Act 2004 was introduced with the 
aim of giving adequate protection to breeders of new plant varieties. There is 
no court decision on whether a transgenic plant (which may embrace plant 
varieties) could be protected under the Patents Act 1983, but it is submitted 
that the answer is in affirmative, as the exception from patentability is only 
meant for plant varieties. 
 
Innovations in agricultural biotechnology in the U.S. have evolved greatly. The 
important role of the publicly funded institutions in R&D biotech is now in the 
hands a few privately funded firms, and has clustered around a few key crops, 
such as soybean, cotton, maize and canola, while ignoring other ‘orphan’ 
crops. Developed countries like the U.S. have moved towards complex, 
modern biotechnology, relying on private funding and increased patenting, 
whereas developing countries like Malaysia, are still depending on public 
funding and conventional breeding. As far as the Malaysian situation is 
concerned, the Government and other public bodies continue to be the 
primary sources of R&D funding, providing financial support to an 
overwhelming proportion of their R&D activities. Thus, the R&D models of the 
U.S. as the leader in biotechnology and a developed country, and Malaysia as 
a developing country fundamentally differ. 
 
                                                 
484 Section 13(b) Malaysian Patents Act 1983. 
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In developing countries like Malaysia, the right of farmers to save, exchange 
and save seeds, and sell their harvest is a matter of high importance, as well 
as preserving and ensuring the continuation of traditional farming practices, 
side by side with the development of modern agricultural biotechnology. 
Whereas in the U.S, in spite of some controversies over plant patents and the 
limited right of farmers to save seed, the greater influence and lobbying from 
nursery owners and large biotech companies is actually contributing to the 
current system and IP laws in the U.S.  
 
Among developing countries, there has been a deep suspicion about IP 
protection. Most view it as colonialism by developed countries. Genetic 
engineering, along with the extension of IP protection to plants, has led to the 
acquisition of most of the world’s seed production capacity by a small number 
of mega life science companies.485 Although Malaysia aspires towards the 
transformation into a highly industrialized nation by 2020, the different 
scenario in terms of much slower progress of its R&D biotech, and different 
nature of farming industries eventually shape the most suitable IP laws and 
legal system. Although the national legislation such as the Malaysian Patents 
Act 1983 is in need of some revision and amendment to keep pace with the 
latest biotechnological advancements, the paramount consideration is given to 
protect the interest of small and medium sized local farmers, as well as local 
biotech companies, and to ensure that the R&D outputs generated by the 
public funded institutions benefit the local breeders and farmers ultimately. 
 
                                                 
485 J.P.KESAN, 2007. Seeds of Change: A Link among the Legal, Economic and Agricultural 
Biotechnology Communities. !: J.P. KESAN, ed. 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The property right of agricultural biotechnological inventions is a topic of much 
debate. Scholars and policymakers debate the pros and cons of different 
property regimes that protect plant innovation. The need to protect against 
unauthorized use of plants arises not only from the inherent value of the 
plants, but also because they are so easily misappropriated. Once a plant is 
sold, it can be reproduced essentially in perpetuity, each time producing an 
identical copy of the original plant, in particular those plants which can be 
reproduced asexually. According to the literature, the effective protection of 
property rights offers adequate incentives for R&D in a biotechnology market 
controlled by private firms. When it comes to contemporary patent protection 
for new plants and other living things, it is important to note that in the U.S., 
two important statutory changes provide, as has been discussed throughout 
this chapter. One took place in 1930, and the other in 1970. In both instances, 
Congress responded to what industry players said was an inability to get utility 
patent protection for their inventions on an equal footing with other industries. 
Congress expanded the scope of patentable subject matter on both occasions. 
 
As far as the American situation is concerned, the growth of private research 
is parallel with the consolidation of the private sector in multinational 
corporations, gradually replacing the significant role of governmental research 
institutions in biotechnology. On the contrary, developing countries such as 
Malaysia are still relying on government funded institutions to carry out most 
of the R&D in biotechnology. The difference in approach is understandably due 
to the different levels of commercial agricultural development leading to 
different political considerations in the development of their respective 
intellectual property rights.  
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It is submitted that the current system as being practised in the U.S. (namely 
the three-tier protection for plant innovation) would not totally fit the situation 
in Malaysia. In other words, the U.S. system is not the ideal model for a 
developing country like Malaysia, hence there is no way that Malaysia could 
adopt the American approach wholly. Nevertheless, the patent system as 
being practised in the U.S. would to some extent serves as a good guidance 
and hence would be relevant to Malaysia in some ways. For example, it has 
been shown from the charts and statistics in the preceding discussion, that the 
PVP system which offers much simpler procedure and lower fees essentially 
remains relevant among small and medium size companies in the U.S., while 
the PPA is much more popular among foreign applicants, dominating a 
substantial percentage of plant patent applications and patent grants. In a 
developing country like Malaysia wherein small and medium size farming 
communities constitute an important segment of the industry, it is submitted 
that the alternative, simpler system as available under the new statute 
(PNPVA) would gradually gain popularity among local breeders, though the 
effectiveness of the protection remains to be seen, vis-à-vis its exceptions and 
relatively generous exemptions.  
 
Based on the U.S. experience as well, there is also very high probability that if 
Malaysia were to strengthen its current patent laws, for example, by lifting the 
ban on patenting plant varieties, multi-national corporations and big 
international players would be the ones in the front row to file their patent 
applications, rather than the small farmers of local RIs. 
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The current Malaysian Patents Act 1983 expressly excludes plant varieties 
from patentability; until and unless the provision of the Act is amended, it 
remains to be seen whether there is a real need for lifting the ban in the near 
future, in view of the recent implementation of the Malaysian Protection of 
New Plant Varieties Act 2004 (PNPVA). The fact that patent protection, other 
than the plant itself, would cover processes and compositions important in the 
development of transgenic plants, such as regeneration and transformation 
methods, genes for insect, herbicide, and disease resistance, and vectors and 
promoters for the expression of such genes in plants, is leading to inevitable 
submission that in order for Malaysia to boost the growth of its agricultural 
biotechnology industry, a strong protection under patent laws is necessary to 
assure extensive protection for inventors in plant biotechnology. After all, such 
new varieties of plants take decades and often constitute the major portion of 
a biotechnology company’s competitive advantage. 
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Biotechnology has been internationally acknowledged as the scientific and 
technological revolution of the 21st century. As far as Malaysia is concerned, 
biotechnology is set to be a major contributor to its economic growth. 
Although it is still in its infancy stage, its potential is enormous. With the 
nation’s rich biodiversity, cost-competitive labour and strong agricultural base, 
Malaysia stands to gain from its biotechnological development that will 
position the country as a key global player by 2020. The country aims to gain 
a slice of the lucrative global biotechnology market. In fact, it is ready to learn 
from and emulate the best biotechnology research and development (R&D) 
and industry practices and has set its sights on doubling the number of its 
biotechnology and biotechnology-related companies to 400 by 2010. The 
target was plausible as based on the Malaysian Biotech Corp Country Report 
2009/2010486, as at 30 September 2009, a total number of 349 biotechnology 
companies were identified in Malaysia, a three-fold increase from 117 
companies in 2005.  
 
Malaysia stands as the 4th mega-diversity nation in Asia and 12th in the world, 
and is blessed with rich natural resources such as the world’s oldest rainforest, 
an estimated 12,500 flowering plants species and more than 100,000 animal 
                                                 
486 The report is available at : < 
http://www.biotechcorp.com.my/Documents/AboutBiotechCorp/country%20report%20double.pdf
> [Accessed  01 December 2010] 
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species.487 With this uniqueness, the country realizes its biotechnology 
potential, hence aims to set itself apart from its Asian neighbours and rivals. 
As far as Malaysia is concerned, the niche area is primarily agricultural 
biotechnology, other than healthcare biotechnology and industrial 
biotechnology.488 The country’s global biotechnology competitiveness is shown 
in the chart below: 
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!3 0
 
Malaysia’s Global Biotechnology Competitiveness as at 2006 
 
 
Source: Ernst and Young489 
 
                                                 
487  THE MALAYSIAN MINISTRY OF SCIENCE, TECHNOLOGY AND THE ENVIRONMENT, 1998. ,	
( 3 0 0 +" 9+ 0 #	 9+ 0  9 %" 
	, 
Available at:< http://www.cbd.int/doc/world/my/my-nr-01-en.pdf> [Accessed 01 December 
2010] 
488
 Refer <http://www.biotechcorp.com.my/rakyat.html> [Accessed 20 January 2009] 
489 Biotech Corp Annual Report 2007, p.4, Available at: < 
http://www.biotechcorp.com.my/pdf/anual_report_9608.pdf> [Accessed  21 January 2009] 
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This chapter examines the growth and development of Malaysia’s 
biotechnological sector, focusing on agricultural biotechnology. In this regard, 
the chapter will essentially cover the discussion on the Malaysian National 
Biotechnology Policy (NBP), the legal and regulatory framework affecting  
agricultural biotechnology in Malaysia, the impediments encountered by the 
industry to the success of biotechnological R&D, as well as the role of the 
agencies and companies in Malaysia which are involved in agricultural 
biotechnology. A critical look at and a detailed discussion of the role of the 
local agencies and companies that contribute to the growth and development 
of agricultural biotechnology is crucial as they would be one of the determining 
factors to the success of the industry in Malaysia. 
 
3 .!#$%$#!,%$$*(
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Biotechnology was identified as a key technology that could drive and support 
the nation to evolve into a knowledge-based economy. Hence, the Malaysian 
Government in its Ninth Malaysian Plan (2006-2010) is making a concerted 
effort to create an environment that is conducive to innovation and investment 
in biotechnology. During the Plan period, the emphasis is on building the 
capacity and capability of human resources as well as research institutions 
(RIs). In creating such a conducive environment for the development of the 
country’s biotechnology sector, the Government launched the National 
Biotechnology Policy (NBP) in 2005.  
 
The NBP provides for a more integrated framework of industry development, 
outlining a comprehensive set of goals, priorities and strategies. It is 
formulated so as to use biotechnology as a mechanism for spurring Malaysia’s 
economic growth, enhancing the wealth as well as the prosperity of the 
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country. The NBP is envisioned to further develop R&D and industrial 
biotechnology and strengthen the country’s existing core competencies and 
infrastructure. As in the case of other Asian countries, government policy has 
provided the principal impetus for a biotechnology industry. Hence, at the 
initial stage, the Government will be the main driver for biotechnology 
development by providing strategic direction, infrastructure development and 
funding. This will provide an integrated platform for participation by  scientific, 
business and funding groups to ensure an eco-system that is capable of 
sustaining Malaysia’s growth and progress in biotechnology. 
 
The NBP has nine strategic thrusts,490 but for the purpose of this thesis, only 
four thrusts will be specifically discussed, being the most relevant to the area 
of research. Thrust number one is on agricultural biotechnology. For this 
thrust, the mission under the Policy is to transform and enhance the creation 
of value creation by the agricultural sector through biotechnology. The other 
important thrust is the fourth one, which is on R&D and technology 
acquisition. Under this thrust, the Malaysian Government is committed to 
establishing centres of biotechnology excellence through R&D, as well as 
technology acquisition. Thrust number seven, which is on the legal and 
regulatory framework, is equally significant and very much relevant to this 
thesis, as it aims to strengthen the legal and regulatory framework by 
reviewing ownership of IP and regulations relating to biotechnology processes 
and business. Finally, thrust number nine relates to the government’s support 
and commitment in order to realize the execution of policy. This has been 
done through the establishment of a dedicated and professional government 
                                                 
490 Refer <http://www.biotechcorp.com.my/biotechinmalaysia/nationalpolicy.htm> [Accessed 20 
January 2009] 
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agency to spearhead the development of the biotechnology industry with the 
incorporation of the Malaysian Biotechnology Corporation (BiotechCorp). The 
targets that have been achieved by BiotechCorp  to some extent serve as one 
of the vital yardsticks and measurement to the success of the biotechnology 
industry in Malaysia.491 
 
As far as the NBP is concerned, the initiatives under the Policy are 
implemented within the timeframe of the Biotechnology Master Plan from 2005 
to 2020, which embrace three phases: Phase 1 is on capacity building from 
the year 2005 until 2010, Phase 2 is on commercialization of biotechnology, 
which is to commence from the year 2011 until 2015, and finally Phase 3 
which is targeted on the country emerging as a global biotechnology 
participant, which is planned to begin from the year 2016 to 2020 and 
beyond.492  
 
At present, the focus is directed towards implementing the plans in Phase 1, 
which include the efforts to provide biotechnology development incentives, to 
improve human capital and skills development, to improve job creation, to 
intensify R&D, to accelerate development in agricultural biotechnology, to 
strengthen the legal and IP framework as well as to develop BioNexus 
companies.  
 
In Phase 2, which is scheduled to commence in the year 2011 until 2015, the 
plans mainly include intensifying foreign direct investment participation and 
                                                 
491 The targets achieved by Biotech Corp in the development of biotechnology industry in Malaysia 
is published in its review – Refer The Biotech Review 2005-2007, Available at: 
<http://www.biotechcorp.com.my/pdf/270508c_final_report.pdf> [Accessed 02 February 2009] 
492 , note 487, p.6. 
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technology acquisition, expanding the pool of knowledge workers, developing 
capability in technology licensing, improving new products development and to 
create global brands.  
 
Phase 3 will continue with all the abovementioned plans but eventually the 
ultimate aim is to strengthen branding of Malaysia as a global biotechnology 
hub. A cursory look at all these plans would suggest that there is a lot of work 
to be done by the Government in particular, which in turn delegated to 
relevant ministries and agencies, most notably BiotechCorp from the very 
early stage of its establishment in the year 2005. The role of BiotechCorp will 
be discussed in greater detail in the latter part of this chapter.  
 
By implementing its comprehensive Biotechnology Policy in a concerted and 
coherent manner, tapping into its rich natural resources and biodiversity, as 
well as building on its existing capabilities, Malaysia is hopeful of becoming a 
preferred destination for innovation and investment in biotechnology. In a 
published report by the BiotechCorp493 measuring the progress of the 
Malaysian biotechnology sector, it is evident that many projects have been 
realized in accordance with the target. Since 2006, the outcome of successful 
partnerships and collaborations internationally and within Malaysia is reflected 
in the establishment and growth of biotechnology companies in Malaysia. 
Across sectors in agriculture, healthcare and industrial biotechnology, Malaysia 
continues to formulate and initiate collaborations and partnerships around the 
world – particularly in key learning and market centres in the U.S., South 
America, the UK, France, Germany, India, China, South Korea and Japan.494 
                                                 
493 , note 489. 
494 !., at p. 15. 
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Within the industry, BioNexus status was granted to 15 companies in 
agriculture biotechnology, 19 in healthcare biotechnology and 2 in 
bioinformatics from the year 2005 to 2007. Currently, a total of 137 
companies495 have been awarded with BioNexus status that span agriculture, 
healthcare and industrial biotechnology. BioNexus status is a recognition 
awarded by the Malaysian  Government through BiotechCorp to qualified 
companies that participate in and undertake value-added biotechnology 
business. Such companies are generally entitled to certain tax incentives, as 
well as enjoying a set of incentives and privileges contained within the 
BioNexus Bill Of Guarantees.496 The number of BioNexus companies and their 
total investment are shown in the charts below. 
'#3 0
Number of BioNexus Companies according to specific sector (as at 31st 
December 2007). 
 
 
                                                 
495 As at December 2009. Source : Biotech Corp. 
496 9"  pp. 39-40. 
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Source: BiotechCorp 
 
'#3 .
Total BioNexus Investment according to specific sector (RM mil). 
 
Source: BiotechCorp 
 
As far as project activities are concerned, in the field of agriculture, local 
biotechnology companies are involved in a range of activities, from plant 
genomics, animal health, diagnostics and biologics, fertilizer and soil 
enhancers, plant propagation via tissue culture, nutraceuticals, tissue culture 
to orchid tissue culturing. Broader efforts in building international alliances in 
agriculture biotechnology continue to be expanded through investment forums 
and stakeholder meetings with leading life sciences and biotechnology 
companies in the U.S., Germany and India. It is worth re-emphasizing that 
since Malaysia is essentially an agricultural country, agricultural biotechnology 
can be the right focus as biotechnological tools can be specifically applied to 
the different facets of agricultural activities already existing in the country. 
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All in all, based on the report and review published by BiotechCorp, it is 
observed that Malaysia is currently moving towards the right direction, albeit 
at a gradual and steady pace in developing its biotechnology industry.  This is 
reinforced by the fact that the overall development of the biotechnology 
industry was encouraging and the company's ventures were bearing fruits in 
managing to generate revenue of almost half a billion ringgit by the end of 
year 2009.497 
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Malaysia is a member of the World Intellectual Property Organization 
(WIPO)498 and a signatory to the Paris Convention499 and Berne Convention500 
which govern IPRs. In 2006 Malaysia acceded to the Patent Cooperation 
Treaty501. In addition, Malaysia is also a signatory to the TRIPS Agreement502 
signed under the auspices of the World Trade Organization (WTO).   
 
Therefore, Malaysia's intellectual property (IP) rights regime is in compliance 
with international best practice and provides for adequate protection to both 
local and foreign applicants. According to the Global Competitiveness Report 
2009, Malaysia is ranked 37 out of 133 countries (refer Table 4.2  below) in 
terms of intellectual property protection and has one of the strongest IP 
regimes in Asia.  
                                                 
497 The Chief executive officer of Biotech Corp Datuk Iskandar Mizal Mahmood revealed the fact 
and figures during a media briefing on the BioMalaysia 2009 Conference and Exhibition in 
November 2009. Refer: 
http://melbio.com.my/index.php?option=com_content&view=article&id=50%3Abiotechcorp-on-
track-to-help-21-new-bionexus-firms16102009&catid=29%3Afrom-bench-to-
business&Itemid=18&lang=en> [Accessed 09 February 2010] 
498 Malaysia is a member of WIPO since January 1989. 
499 Malaysia is a signatory of Paris Convention since January 1989. 
500 Malaysia is a signatory of Berne Convention since October 1990. 
501 Malaysia is a signatory of PCT since August 2006. 
502
 Malaysia is a signatory of TRIPS since January 1995. 
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Global Competitiveness Report 2009 – Intellectual Property Protection 
%1 $%#'( ,$'!<0@:=
1 Singapore 6.2 
2 Sweden 6.1 
3 Finland 6.1 
4 Switzerland 6.1 
5 Austria 6.1 
6 Denmark 6.0 
7 New Zealand 6.0 
8 Luxembourg 5.9 
9 Netherlands 5.8 
10 France 5.8 
20 Japan 5.4 
23 Hong Kong SAR 5.3 
27 Taiwan, China 5.0 
37 Malaysia 4.5 
 
Source: World Economic Forum, Executive Opinion Survey 2008, 2009 
 
The TRIPS Agreement which is the main international instrument dealing with 
IPRs generally, prescribes minimum conditions that all member countries must 
incorporate into their laws for the protection of IPRs. As Malaysia is a member 
of the WTO, it must abide by the minimum standards of IP protection set in 
the TRIPS Agreement and is afforded flexibilities in its implementation. 
Therefore, in the year 2000, the Malaysian Parliament amended the Copyright 
Act 1987, the Patents Act 1983, the Trademark Act 1976, as well as legislation 
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on layout designs of integrated circuits503 and geographical indications504 in 
order to bring Malaysia into compliance with its obligations under the WTO 
TRIPS Agreement. In 2004, Malaysia passed the ‘Protection of New Plant 
Varieties Act 2004’ (PNPVA) in line with the requirements of Article 27(3)(b)of 
the TRIPS Agreement. Malaysia's IP laws are in conformance with international 
standards and have been reviewed by the TRIPs Council periodically.505 
 
Another important international instrument in relation to IP protection is the 
UPOV Convention, which was mainly created by breeders for the new crop 
varieties they developed and commercialized. The PVP laws of different 
countries were harmonized through UPOV 1978 and the latest version of 1991. 
The UPOV 1991 has considerably enhanced the protection afforded to breeders 
especially when compared to its 1978 version. As far as Malaysia is concerned, 
it is not yet a member of UPOV, though it has submitted its intention to join 
the treaty and has in fact initiated the procedure of accession to the UPOV 
Convention since the year 2004, after the passing of the PNPVA. 
 
Other than the TRIPS Agreement, the PCT and the UPOV Convention, Malaysia 
also intends to be a party to the Budapest Treaty on the International 
Recognition of the Deposit of Microorganisms for the Purposes of Patent 
Procedure in the near future. 

The enhancement of legal and regulatory expertise – with a focus on IP - is a 
key to the continued growth and progress of biotechnology. Hence, this 
                                                 
503 Layout Designs of Integrated Circuits Act of 2000. 
504 Geographical Indications Act 2000. 
505 Refer <http://www.mida.gov.my/en_v2/index.php?page=IP-protection> [Accessed 05 
February 2009] 
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section will cover an examination of the current legislation affecting 
biotechnology with a specific focus on IP and related laws.  
 
IP protection in Malaysia comprises of patents, trademarks, industrial designs, 
copyright, geographical indications and layout designs of integrated circuits, 
but for the purpose of this thesis, biotechnology law refers to the areas of law 
which span over a wide spectrum in the biotechnology industry including: 
(i) IP protection, namely legally protected rights in the form of patents, as well 
as utility innovation for a lesser extent invention. 
(ii)  Protection by way of plant variety rights. 
 
The primary function of biotechnology law as in other branches of law is to 
protect the interests of the parties involved, such as the protection of the 
invention by way of patent registration506 and plant variety rights registration 
system. For example, the rationale behind granting a patent, other than to 
reward the inventor, is also to encourage public disclosure of an invention so 
that when the patent expires, the public can have free access to the invention. 
Thus, the ultimate goal of the patent process is to serve the public interest. 
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As far as the Malaysian IP system is concerned, there are two main regimes 
which are currently in force; via patent law and plant variety protection law. 
Patent law in Malaysia refers to the Patents Act 1983, supplemented by the 
Patents Regulations 1986, while plant variety protection law in Malaysia is 
governed by the Protection of New Plant Varieties Act 2004 (PNPVA), 
                                                 
506 HAMZAH, Zaid, 2005. %"6-1 Malaysia : Malayan Law Journal. p. 35. 
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supplemented by the Protection of New Plant Varieties Regulations 2008. 
These two methods of protection will be discussed in turn. 

3 4 . 0
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The Patents Act 1983 and the Patents Regulations 1986 govern patent 
protection in Malaysia. A patent is an exclusive right granted for an invention, 
which is a product or a process that provides a new way of doing something, 
or offers a new technical solution to a problem. An applicant may file a patent 
application directly if he is domiciled or resident in Malaysia. A foreign 
application can only be filed through a registered patent agent in Malaysia 
acting on behalf of the applicant. Similar to legislation in other countries, an 
invention is patentable if it is new, involves an inventive step and is 
industrially applicable. In accordance with TRIPS, the Patents Act stipulates a 
protection period of 20 years from the date of filing of an application.  
 
A similar right to patent is ‘utility innovation’, which denotes any innovation 
which creates a new product or process, or any new improvement of a known 
product of process, which can be made or used in any kind of industry, and 
includes an invention. For a certificate for utility innovation to be granted, 
absolute novelty is required as in an application for grant of patent. Thus, the 
novelty required is on a world-wide basis and is new if it has not been 
disclosed anywhere in the world. Nevertheless, by the definition in the 1983 
Act of 'utility innovation', the requirement of inventive step is relatively low 
and more easily satisfied compared to that required for a grant of patent. In 
other words, it is an exclusive right granted for a ‘minor’ invention which does 
not require satisfying the test of inventiveness as required of a patent. Under 
the Act, the utility innovation certificate provides for an initial duration of ten 
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years protection from the date of filing of the application and is renewable for 
further two consecutive terms of five years each subject to use. The owner of 
a patent has the right to exploit the patented invention, to assign or transmit 
the patent, and to conclude a licensed contract. 
 
<=
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The flowchart507 below shows the patent application procedure as administered 
under MyIPO, from the stage of submitting the patent application to the stage 
of preliminary and substantive examination before a certificate of grant is 
issued.  
 
'#3 4
Flowchart Patent Application and Granting Procedure (Patents Act 1983) 
                                                 
507 Refer : 
<http://www.myipo.gov.my/index.php?option=com_content&view=article&id=232&Itemid=265> 
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MyIPO has also confirmed that currently, the average of the whole process 
before a patent is granted ranges from four and half years to five years. It all 
depends on when the substantive examination is carried out, as the patent 
applicant may defer their request for substantive examination for up to 4 
years.508 As at July 2009, MyIPO Patent Division has 71 patent examiners, out 
                                                 
508 Under Patent Regulations 1986, R27B(2) The prescribed period of maximum deferment is: 
(i) 3 years from the filing date for requesting substantive examination; 
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of which 7 examiners specialize in engineering and biotechnology-related 
inventions. 
 
Malaysia acceded to the Patent Cooperation Treaty (PCT) in the year 2006 and 
effective from 16 August 2006, the PCT International Application can be made 
at MyIPO. The PCT system enables the applicant to make a single application 
in Malaysia (the international application) and then ‘designate’ as many other 
countries that are involved in the PCT.  It is to be noted that the PCT system is 
a patent  ‘filing’ system, and not a patent  ‘granting’ system, hence there is no 
PCT patent or international patent. 
 
<=,$-!$)
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In relation to the threshold of patentability under the Patents Act 1983, it 
generally follows the standard of other jurisdiction’s patent regime, in 
particular the practice of the EPO. In other words, the threshold is at par with 
the international standard. Nevertheless, on the patent examination process, 
there is an emerging challenge encountered by patent examiners at MyIPO 
pertaining to the need for new knowledge, latest inventions and developments 
in biotechnology. One of the ways to enhance the knowledge, skills and 
expertise of the patent examiners is via intensive trainin for them in the field 
of biotechnology specifically.509 
 
It is important to note that the Patents Act 1983 does not allow the patenting 
of animals or plant varieties or naturally-occurring microorganisms. The 
                                                                                                                                      
(ii) 4 years from the filing date for requesting modified substantive examination; 
(iii) 3 years from the filing date for providing corresponding foreign search/examination results. 
According to subsection 29A(7) Patents Act 1983, no deferment may be sought nor granted for a 
period greater than the 3 and 4 year periods referred to above. 
509 For example, the Establishment of Biotech Guidelines & Training of Examiners, 27 February – 
10 March 2006, Kuala Lumpur. 
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express exclusion of patentability on plant varieties can be found in Section 
13(2)(b) of the 1983 Act, which reads:  ‘…the following shall not be 
patentable: 
(b) plant or animal varieties or essentially biological processes for the 
production of plants or animals, other than man-made living micro-organisms, 
micro-biological processes and the products of such microorganism processes.’ 
 
The Malaysian provision is consistent with the TRIPS Agreement as enshrined 
in Article 27.3(b). The above exclusion relates only to plant varieties, but 
inventions involving plants would generally be patentable. The position of a 
genetically modified variety is thus not patentable but a plant invention that 
consists of genetically modified cell-lines would be patentable. This means that 
a plant invention can only be registered under the breeder’s system if it 
constitutes a variety.510 At this juncture, it is to be noted that despite 
Malaysia’s manifest intention to excel in the biotechnology industry, as far as 
its patent law is concerned, there has not been much effort in terms of 
amending Patents Act 1983 to reflect the envisaged goal. Nevertheless, MyIPO 
has recently started initiatives to review the IP related legislation to keep pace 
with the latest technological development, and the exercise will include the 
review of the Patents Act 1983.  
 
As far as a patent application is concerned, MyIPO does not and has neither 
authority nor facility to accept any sample, specimen or prototype for any 
invention for all fields of technology. This is due to the fact that Malaysia is not 
yet a member of the Budapest Treaty on the International Recognition of the 
                                                 
510 AZMI, Ida Madieha Abdul Ghani, 2004. The Protection of Plant Varieties in Malaysia, 0
+.!"# 7, pp. 877-890, at p. 882. 
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Deposit of Microorganisms for the Purposes of Patent Procedure. As of 31st 
January 2009, 72 countries are parties to the Treaty which allows a person 
who wishes to patent an invention internationally need only to deposit the 
microorganism at one recognized institution instead of in each country for 
recognition in all countries who are party to this treaty. This enhances 
efficiency in filing patents and is of significant benefit for the biotechnology 
sector in Malaysia. In relation to this, Malaysia is currently working towards 
the establishment of International Depository Authority (IDA). The IDA project 
is in fact a joint MyIPO-BiotechCorp project to establish and enhance patent 
procedure in Malaysia. The establishment of an IDA in Malaysia will ultimately 
complement the development of the biotechnology industry in Malaysia other 
than meeting Malaysia’s future obligation under the Budapest Treaty.511 
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With regard to statistical data, the statistics of biotechnology in Malaysia are 
difficult to obtain as it is relatively a newly emerging industry, compared to 
other industries such as manufacturing. Hence, the properly documented 
current data on biotechnology patent is only available on general basis, for 
example, MyIPO confirmed that there was a total of 385 biotechnology patents 
application in the year 2008.512  
 
The summary of patent biotechnology applications and granted applications 
from the year 1986 to 2008 as provided by MyIPO is incorporated in the table 
below: 

                                                 
511 , Note 489, at p.30. 
512 Source : Patent Division, MyIPO. 
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Statistics of biotechnology patent application and granted from 1986 - 2008 
 
$ 	--,#$% '%#!
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* Total applications Malaysia and foreign 
Source: Patent Division, MyIPO. 
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Statistics of biotechnology patent application 2008 
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Source: Patent Division, MyIPO. 
 
The above data and figures simply show that the country’s rich natural 
resources and scientific expertise have not yet been commercialized to reap 
the optimum benefits. Local research and development has yet to lead to the 
application for new patents or launching of new biotechnology enterprises on a 
large scale. This is evidenced from the fact that by end of year 2008, only a 
total of 8 patents on biotechnology were granted to local applicants.513 The 
table also shows that out of a total 385 biotechnology patent applications in 
2008, only 64 came from Malaysia, and these local applicants range from 
individuals, universities, research institutes and companies. Local universities 
                                                 
513 Source and data was provided by Patent Division MyIPO during the interview conducted at 
MyIPO office on 16th July 2009. 
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contribute to the highest number of applications; a total of 43 out of 64 
biotechnology patent applications. This could be attributed to the fact that the 
Malaysian government in creating an enabling environment for biotechnology 
has been allocating  substantial monetary funding for public universities, as 
well as research institutions, to be utilized in R&D,   biotechnology 
research.514 After all, R&D in biotechnology in Malaysia is dominated by the 
government funded RIs and universities, hence the statistics merely confirm 
and reflect the current scenario in the country. 
 
Having said that, public sector institutions which have been undertaking the 
main responsibilities in biotechnology R&D are; Malaysian Agricultural 
Research and Development Institute (MARDI), Forest Research Institute of 
Malaysia (FRIM), Malaysian Rubber Board (MRB), Malaysian Cocoa Board 
(MCB), and Malaysian Palm Oil Board (MPOB). It is interesting to note that all 
these RIs are the patent owners of their research output on their respective 
fields, and this reflect their awareness on the importance of patent protection 
over their inventions.515 For example, the first patent owned by MRB was 
granted as early as 1934 in relation to improvements relating to the treatment 
of rubber latex.516 In additions, these RIs have a number of patents abroad in 
order to protect their inventions in other jurisdictions. 
 
Coming back to the breeder’s right and patent right, indeed, the boundary 
between breeder’s right and patent right has been subject to various debates, 
                                                 
514 For example, under the Ninth Malaysia Plan (2006-2010), it is stated that the Biotechnology 
R&D Grant Scheme established in 2001 under the National Biotechnology Directorate approved a 
total of RM95.3 million for 47 biotechnology research projects, which includes public universities 
and research institutions. 
515 This observation is based on the semi-structured interviews which were carried out on these 
research institutions from April 2008 – October 2008. The detailed analysis of the interview is 
incorporated in Chapter 5. 
516 Refer <http://www.lgm.gov.my/general/patents.html> 
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as have been highlighted in the preceding discussion in Chapter Two of this 
thesis. There has yet to be any case in Malaysia that considers on the scope of 
the exclusion of patent rights on plant varieties. Cases from the UK and 
Europe as highlighted in Chapter Two thus, can lend significant assistance in 
understanding the issue.517 As far as MyIPO’s approach is concerned, the 
patent examiners at MyIPO are taking the stance that there is no overlapping 
and there should not be any overlap between patents and plant variety rights. 
This approach is based on the premise that criteria for patentable inventions 
are clearly spelt out in the 1983 Act, leaving little room for ambiguity. 
Practically, the patent examiner would screen all the patent applications 
submitted to the office from the very beginning, hence any applications that 
may amount to or may encroach the sphere of the plant variety right is 
rejected outright.518 Nevertheless, the office has yet to encounter any such 
cases, as the patent agents are generally aware of the exclusion of plant 
variety from patentability as spelt out in the 1983 Act.  
 
At this juncture, it is to be noted that MyIPO has produced the draft of its 
official guidelines for the examination of biotechnological patent applications. 
MyIPO is currently in the course of finalizing the draft, subject to the response 
of stakeholders via various meetings and discussions.519  
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An application for a patent in Malaysia must be filed with the Patent 
Registration Office of MyIPO. The Patent Registration Office is responsible for 
                                                 
517 AZMI, Ida Madieha Abdul Ghani, 2003. # 6- ! 	/ 		   
Malaysia: Sweet & Maxwell Asia. p. 313. 
518 This approach is confirmed by Patent Division MyIPO during the interview conducted at MyIPO 
office on 16th July 2009. The latest update from MyIPO received via email in September 2010 
confirmed that the draft was yet to be finalized. 
519 !  
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the administration, processing and registration of patents and certificate for 
utility innovations. The application may be submitted to the Patent 
Registration Office by hand or mail.  
 
Alternatively, the application may be submitted through an online filing system 
under PANTAS520. The online filing system was introduced for the purpose of 
providing a more systematic system and database, as well as to speed up the 
patent filing process. MyIPO has been able to grant patent in the fourth year 
from the date of filing provided all requirements are fulfilled. For the purpose 
of this thesis, a quick and random search via PANTAS had been carried out 
with the aim of collecting some useful and relevant data with regard to 
agricultural biotechnology patents filed with MyIPO. The search under ‘plant’ 
patent category revealed that there are approximately 1865 patents which are 
related to the broad category of plants.521 Nevertheless, one of the limitations 
of PANTAS is that the current database does not include the applications below 
18 months from the date of application. 
 
A further search of the patents which are related to plants shows that a 
substantial number of patents are filed and granted under the wide heading of 
process or method, for example, ‘a method and composition for the production 
of transgenic plants’.522 A detailed search523 on some these type of patents 
evidenced that MyIPO has no problem in granting patents on methods of 
producing a transgenic plant. For example, Malaysian Patent Number (PN) MY-
135879-A is a patent granted on ‘methods for producing genetically modified 
                                                 
520 Refer : <https://pantas.myipo.gov.my> [Accessed 13 September 2010] 
521 !  The figure is correct as at September 2010.  
522 !  Application Number : 20013705, status : adverse full substantial examination, filed on 
13/08/2001. 
523 This kind of detailed search attracts some fees, payable to MyIPO, at the rate of MYR 30.00 per 
patent details download. 
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plants, particularly woody plants, and most particularly plants of the 
eucalyptus and pinus species, involving transformation of target plant material 
with a desired genetic construct..’524 
 
An interesting discovery was also made during the random search via PANTAS. 
For example, a patent filed on 5th June 2000 under the title ‘seedless 
tomato’525 was deemed refused, whereas a patent on herbicide resistant rice526 
was granted on 31st January 2008. These data reflect the approach taken by 
MyIPO in dealing with the issue of patenting transgenic plants, as there is no 
express provision in the Patents Act 1983 on patentability of transgenic plants. 
Hence, it is submitted that those transgenic plants are patentable under 
patent laws in Malaysia, as the only exclusion is meant for plant varieties.527 
Back to the above examples of refusal of patent on seedless tomato, one of 
the refusal grounds528 is probably on,   the very broad extensive 
patent claim, as the patent title itself reads ‘seedless tomato and method for 
producing a seedless tomato, hybrid tomato plants capable of producing said 
seedless tomatoes and cultivation material therefore, and food products 
obtained from said seedless tomatoes.’ It is doubtful whether the patent, say if 
granted, would cover the broad ‘food products obtained from seedless 
tomatoes.’ Nevertheless, it is to be noted that the actual reasons behind the 
rejection of the seedless patent tomato were unascertainable during the online 
random search, as there was a certain amount of fees imposed to extract the 
details of the patent application in the PANTAS database. 

                                                 
524 PANTAS, "., Patent Application Number : 20001005, granted on 31st July 2008. 
525 !  Patent Application Number : 20002511. 
526 !  Malaysian Patent (PN) MY-134925-A. 
527 Section 13 (1)(b) Malaysian Patents Act 1983. 
528 PANTAS does not provide details of refusal of a patent claim. 
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In terms of classifying a patent application, to ascertain whether an invention 
falls under the biotechnology class, patent examiners are currently using the 
International Patent Classification (IPC) as their reference. In other words, all 
patent applications submitted to MyIPO will go through the ‘screening process’ 
under the preliminary examination529 in order to determine whether a patent 
application falls under biotechnological classification.  
 
At this stage, the title of the application and its abstract as submitted to 
MyIPO plays a vital role in establishing the class of the invention. The IPC 
which was established by the Strasbourg Agreement 1971, and provides for a 
hierarchical system of language independent symbols for the classification of 
patents and utility models according to the different areas of technology to 
which they pertain.530 The IPC which is utilized by Patent Division of MyIPO is 
produced below: 

"!3 3
International Patent Classification (IPC) – Biotechnological Invention 
$ 
 (-!)
1 A01H Transgenic Plants 
2 A01N 39/00- 39/65 Moas Pesticides 
3 A01K 67/027 Transgenic Animal 
4 A61K 48/00 Gene Therapy 
5 A61K 38/00 Medicinal Preparation 
   (Pharmaceutical) 
6 A61K 39/12 Viral Antigen 
7 A23J,C,L Food Fodder 
8 C12N9 Enzymes 
                                                 
529 R26 of the Patent Regulations 1986. 
530 A guide to the IPC 2009 version is available at WIPO’s website. Refer < 
http://www.wipo.int/export/sites/www/classifications/ipc/en/guide/guide_ipc_2009.pdf> 
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9 C12N11 Enzymes 
10 C12N15 Genetic Engineering 
11 C12N1 Bacteria 
12 C12N5 Cell Culture 
13 C12N7 Virus 
14 C07K 14 Pepticides 
15 C07K 17/705 Receptors 
16 C07K 16 Antibodies 
17 C07K 14 Peptides 
18 C12N 9 Peptides 
19 C07K 16 Peptides 
20 C07K 16 Antibodies 
21 C12P 21/06 Antibodies 
22 C12Q 1/68 Gene Diagnostic, Amplifications, 
   Diagnostic Antibodies 
23 C12R 1/00 Microorganism 
24 C12P  Fermentation Chemicals 
25 C12G Alcoholic Beverage 
26 G01N 33/53 Diagnostic Immunassy 
27 C11D 3/386 Detergent Preparation 
28 C21H 21/00 Paper Industries 
   Enzyme To Make Paper 
29 D06M 16/00 Enzymes Use In Textile 
           Source: Patent Division, MyIPO. 
 
 
The examination process of every patent application which is submitted to 
MyIPO is conducted by three different sections of Patent Division namely the 
Formality Section, the Engineering Section and the Applied Science Section. 
The biotechnological patent examination is under the responsibility of the 
Applied Science Section.  
 
It is observed that the dedicated, skilled team of patent examiners under 
MyIPO has been one of the significant driving forces towards a strong legal 
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infrastructure and effective administration. Such dedication and skills are 
important to enhance greater creativity and exploitation of intellectual 
property in general, and a more efficient patent system in Malaysia in 
particular. 
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Since the early nineteenth century, in agriculture and forestry, the 
introduction of new varieties was an essential component to maintain and 
sustain good and high crop productivity and quality. New varieties are 
constantly being bred for higher yields, for better agronomic traits like taste, 
for resistance against pest or diseases, for tolerance to saline or drought 
conditions. Malaysia sees the introduction of new varieties of plants as an 
important component in commercial agriculture in terms of maintaining 
productivity and competitiveness. Breeding of new varieties of plants 
essentially requires substantial investment in terms of time, skills, labour, 
material resources and capital. In order to encourage such investment, the 
Malaysian Government has taken the necessary step with the main aim to 
provide exclusive rights to plant breeders to enable them to recover their 
investment and also to reap benefits of their innovative skill and creativity.531 
The approach is in fact in consonance with the Third National Agriculture Policy 
(1998-2010).532 
 
                                                 
531 Agriculture minister wants introduction of new varieties of plants, Available at: < 
http://biz.thestar.com.my/news/story.asp?file=/2006/11/6/business/20061106175335&sec=busi
ness> [Accessed 05 February 2009] 
532 The policy paper outlines the government's policy on the development of the Malaysian 
agriculture sector. Refer 
<http://www.moa.gov.my/moa/index.php?option=com_content&task=blogcategory&id=212&Ite
mid=152> [Accessed 05 February 2009] 
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Being a member of the WTO and a signatory to the TRIPS Agreement, which 
under Article 27(3)(b), stipulates that member countries shall provide for the 
protection of plant varieties by a patent or by an effective 		 system 
or by any combination thereof, Malaysia has been under pressure to put into 
place a protection regime for plant varieties. In this sense, the promulgation of 
the Protection of New Plant Varieties Act 2004 constitutes a step in the right 
direction.533 Other than fulfilling its obligation under the TRIPS Agreement, the 
Act was introduced with a number of significant aims, , to encourage 
local plant breeders to produce more superior varieties, while local farming 
communities can also have greater access to more superior varieties from 
abroad. The Act also provides recognition and protection of contribution made 
by farmers, local communities and indigenous people towards the creation of 
new plant varieties,534 as well as encouraging investment and development of 
the breeding of new plant varieties in both public and private sectors. 
 
With regard to the creation of new plant varieties, an informal breeding 
system has already been in place since the 1930s, from which time the 
Malaysian Department of Agriculture (DOA) registered fruit clones for 
certification purposes. However, this informal system does not bring about a 
formal protection for the creators of varieties. Since then, more than 100 
varieties of  (an edible fruit) have been registered, 200 varieties of 
	, 35 of jackfruits, and 40 of " and other varieties of fruit 
plants. This informal registration of the breeding system is part and parcel of 
the larger current interest in recording the biological resources in the country 
                                                 
533 AZMI, 	Note 515. 
534 Section 13(1) Protection of New Plant Varieties Act 2004. 
265 
 
as well as documenting traditional varieties.535 The DOA was officially 
acknowledged as the National Registrar of Varieties in 1994 by the Ministry of 
Agriculture. Therefore, the responsibility in implementing the 2004 Act has 
been entrusted to the DOA.536 
 
It is equally interesting to note that the 2004 Act is essentially a pan-
Malaysian by nature, which is applicable to all plants but excludes 
microorganisms.537 The drafting of the Act was done through consultation 
process with various relevant ministries and other government agencies, 
research institutions and non-governmental organizations including the Third 
World Network.538 The main provisions of the Act were substantially based on 
the UPOV model 1978 version, due to the fact that at the time when the work 
on drafting of the Act commenced, the UPOV 1978 version was the only model 
available at that time.539 Hence the Act bears significant resemblance with the 
UPOV 1978, besides the reference to the Convention of Biological Diversity 
(CBD) and existing IPR systems in Japan, Australia, India and Thailand.  
 
The 2004 Act is ‘unique’ to meet the needs of the country and protects small 
farmers and local researchers. Notably, the Act contains unique stands on 
various issues such as traditional varieties, farmers’ rights, indigenous peoples 
and local communities’ rights. This is reflected in the Preamble of the Act 
which states the objectives of the Act as ‘to provide for the protection of the 
rights of breeders of new plant varieties, and the recognition and protection of 
                                                 
535 AZMI," pp. 877-878. 
536 Refer http://pvpbkkt.doa.gov.my/> [Accessed 10 February 2009] 
537 Section 2 (Interpretation of ‘plant’) of the Protection of New Plant Varieties Act 2004. 
538 AZMI, 	 Note 430, p. 878. 
539 This is confirmed by the Malaysian Plant Variety Office during the (semi-structured) interview 
session on 24th July 2009, held at the Plant Variety Office, Department of Agriculture at Putrajaya, 
Malaysia.  
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contribution made by farmers, local communities and indigenous people 
towards the creation of new plant varieties; to encourage investment in and 
development of the breeding of new plant varieties in both public and private 
sectors; and to provide for related matters.’ 
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The 2004 Act adopted the UPOV system and mandates the threshold of 
registrability to be new, distinct, uniform and stable,540 hence the practice of 
examination of plant varieties in Malaysia is to be on a par with international 
practice. The kind of exclusive rights granted to the breeder are also 
consistent with that of the UPOV Convention. Section 30(1) of the Act 
expressly provides that: ‘…a holder of a breeder’s right shall, in respect of the 
registered plant variety for which the right is granted, have the right to carry 
out all or any of the following acts on a commercial basis: 
(a) producing or reproducing; 
(b) conditioning for the purpose of propagation; 
(c) offering for sale; 
(d) marketing, inclusive of selling; 
(e) exporting; 
(f) importing; 
(g) stocking the material for the purposes mentioned in 
paragraphs (a) to (f).’ 
 
                                                 
540 Section 14(1) of the Act. 
267 
 
Subsection(2) of the section further clarifies the scope of the breeder’s right: 
‘The breeder’s right shall also extend to — 
(a) any propagating material of the registered plant variety, harvested 
material of the registered plant variety and the entire or any part of a plant 
variety where the propagating material of that plant variety is obtained 
through unauthorized means from the registered plant variety; 
(b) plant varieties which are essentially derived from the registered plant 
variety, if the registered plant variety is not essentially derived from another 
plant variety; 
(c) plant varieties which are not clearly distinguishable from the registered 
plant variety; or 
(d) the production of other plant varieties which require the repeated use of 
the registered plant variety. 
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It is clear from paragraph (c) of subsection (2) that the scope of breeders’ 
rights in Malaysia encompasses the ‘essentially derived varieties’. The 
definition of this term has been discussed in Chapter 2 of this thesis, being 
one of the important enhancements in the UPOV 1991 version. In this regard, 
the 2004 Act apparently incorporates the provision of the latter version of 
UPOV, notwithstanding the fact that most of the provisions are based on the 
earlier version, namely the UPOV 1978. The incorporation of the term 
‘essentially derived varieties’ in the 2004 Act could be attributed to the 
intended aim of the Act in order to provide strong protection to the breeders. 
This could be done by preventing the exploitation of mutations of protected 
varieties, as well as varieties that had undergone a minor change in relation to 
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the initial variety without the holder or the owner of the initial variety right 
being able to share in the revenues. 
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Another important provision is with regard to the research exceptions, as 
breeders are always concerned whether they will be restrained from 
researching on the registered varieties with the intention of developing new 
ones. Section 31(1) of the Act caters for such a concern: ‘The breeder’s right 
shall not extend to — 
(a) any act done privately on a non-commercial basis; 
(b) any act done for an experimental purpose; 
(c) any act done for the purpose of breeding other plant varieties and any act 
referred to in paragraphs 30(1)(a) to (g) in respect of such other plant 
varieties, except where such other plant varieties have been essentially 
derived from the registered plant variety; 
(d) any act of propagation by small farmers using the harvested material of 
the registered plant variety planted on their own holdings; 
(e) any exchange of reasonable amounts of propagating materials among 
small farmers; and 
(f) the sale of farm-saved seeds in situations where a small farmer cannot 
make use of the farm-saved seeds on his own holding due to natural disaster 
or emergency or any other factor beyond the control of the small farmer, if the 
amount sold is not more than what is required in his own holding.’ 
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The above provisions on the research exceptions generally accord with the 
UPOV 1991.541 This so-called ‘research exemption’ is particularly important for 
breeders, who traditionally work by incremental improvement of existing 
materials. If they do not have access to new materials, to make further 
improvements, their work is severely hindered. It follows from this, that it is 
never an infringement of a plant variety right if a breeder were to use the 
variety for further breeding. This does not include, of course, the use in 
commercial production. Equally, in general, it is not an infringement of a PVP 
to exploit or sell the new variety bred.  
 
<='!'5
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Subsections (d) to (f) of Section 31(1) are the three special exceptions to 
cater for the small farmers. This is to ensure that farmers are not economically 
penalized by the conferral of exclusive rights over plants and propagating 
materials.542 It is to be noted that such privileges can only be claimed by 
‘small farmers’, which denote farmers whose farming operation do not exceed 
the size of holding as prescribed by the Minister. The Protection of New Plant 
Varieties Regulations 2008 in Section 2 defines the term ‘small farmer’ as that 
the size of his or its holding for farming operations shall not exceed 0.2 
hectare. The determination of the size of the land namely 0.2 hectare was 
done by reference to the average size of the farm owned by ornamental flower 
producers and growers. This is parallel to the objectives of the 2004 Act 
namely to protect the interests of the local farmers and breeders, and this 
                                                 
541 Refer Article 15(1) UPOV 1991: [Compulsory exceptions] The breeder’s right shall not extend 
to 
(i) acts done privately and for non-commercial purposes, 
(ii) acts done for experimental purposes and 
(iii) acts done for the purpose of breeding other varieties, and, except where the provisions of 
Article 14(5) apply, acts referred to in Article 14(1) to (4) in respect of such other varieties. 
542 AZMI, 	 Note 515, p. 890. 
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includes ornamental flowers’ producers and growers, whom largely fall under 
the category of ‘small farmers’ under the Act.  
 
Initially, during the drafting stage of the Regulation, the size of the land in 
relation to small farmers was proposed as 1.2 hectare with reference to a 
paddy farm, but ultimately after the process of negotiation with the relevant 
agencies and authorities, the figure of 0.2 hectare was finalized to be 
incorporated into the Regulation to denote small farmer. This size of farm is 
essentially meant for all types of farmers inclusive of paddy, ornamental 
flowers, fruits, as well as other types of plants. At this juncture, the protection 
under the Act which is available to small farmers is also automatically 
available for those farm owners for hobbies purpose, for example to grow and 
cultivate ornamental flowers on house compound, as long as the farm does 
not exceed 0.2 hectare.543 
 
With these exceptions, the long held reservations against the perceived 
inequities that farmers may suffer as a result of exclusive rights over plants 
and propagating materials would diminish considerably. In fact, the special 
privileges granted to farmers accords with the optional exception in Article 
15(2) of the UPOV Convention in allowing contracting parties to: ‘…restrict the 
breeder’s right in relation to any variety in order to permit farmers to use for 
propagating purposes, on their own holdings, the product of the harvest which 
they have obtained by planting, on their own holdings, the protected 
variety…’. The Malaysian provision, however, goes beyond the context of 
                                                 
543 The source is based on the interview; 	, Note 536. The statistics of the current percentage 
of small farmers in Malaysia is not available, due to the fact the term ‘small farmers’ also 
encompasses individual owners, whose farming is based on hobbies and personal interests, and 
the land is part of their house compound/residence. 
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Article 15(2), as it also legitimizes the exchange of harvested materials among 
small farmers, in addition to the propagation of such materials. In cases of 
emergency, the farmers are even allowed to sell the farm-saved seeds to 
others.544 
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One of the unique parts of the 2004 Act pertains to the traditional variety or a 
variety developed by the local community. The threshold of registration for 
traditional varieties is somewhat lower than the usual UPOV-type system, 
namely new, distinct, uniform and stable as the criteria. With traditional 
varieties, the plant variety may be registered if it is new, distinct and 
identifiable.545 The requirements of uniformity and stability are waived in 
relation to traditional varieties, and they enjoy a much shorter period of 
protection, that is fifteen years.546  
 
The lower threshold for traditional varieties is parallel to the objective of the 
Act in order to give protection and recognition of contribution made by 
farmers, local communities and indigenous people towards the creation of new 
plant varieties, specifically the traditional varieties. Most significantly, the 
provision reflects the express recognition to the contribution made by farmers 
to the national agricultural industry.547  
 
                                                 
544 ! 
545 Section 14(e) of the 2004 Act: a plant variety is identifiable if— (i) it can be distinguished from 
any other plant grouping by the expression of one characteristic and that characteristic is 
identifiable within individual plants or within and across a group of plants; and (ii) such 
characteristics can be identified by any person skilled in the relevant art. 
546 Section 32(1)(b) of the Protection of New Plant Varieties Act 2004. 
547 AZMI, 	 Note 515, pp. 888-889. 
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Obviously, Malaysia is adopting a 	 	 approach in designing and 
incorporating a unique system for protection of traditional varieties in the 
2004 Act. The protection is of paramount importance for local farmers’ 
interests in Malaysia. It is to be noted that under normal circumstances of the 
UPOV criteria, farmers’ varieties are unlikely to gain protection as new plant 
varieties since it would be difficult for farmers to show that their varieties 
meet these conditions. As a matter of fact, farmers’ varieties in Malaysia, for 
example rice varieties planted by traditional rice farmers are highly diverse 
and, by virtue of their 	 cultivation, keep evolving in the field and exhibit 
new characteristics as a result of adaptation to changes in the ecology. While 
they are distinct and identifiable, they may not be uniform or stable. In this 
regard, the 2004 Act is an important avenue for traditional farmers, local 
communities and indigenous people to obtain legal protection and due 
recognition for their contribution in the country’s plant breeding sector as a 
whole.548 
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The processes and stages of obtaining a protection for new plant varieties are 
summarized in the following flow chart: 
                                                 
548 Some example of traditional varieties of rice are ‘Beras Bajong’ and ‘Beras Biris’ which are 
developed and planted by traditional local farmers of Sarawak. These two promising varieties have 
recently been given certification by Department of Agriculture. Refer newspaper report at : < 
http://www.theborneopost.com/?p=598> [Accessed 11 February 2010] 
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Flow chart for registration and grant of breeder’s right 
 
Source: Malaysian Department of Agriculture (DOA) 
 
The estimated duration from the stage of filing an application for registration 
until the grant of breeder’s right varies depending on the type of plant variety. 
The technical examination would consume the longest duration to ascertain 
the requirement of ‘distinct, uniform, stable and identifiable’ of the variety. 
The substantive examination via on-site inspection and a growing test is very 
much dependant on the type of plant. For example, for short term crops or 
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plants, the examination process range from twelve to twenty-four months; for 
an intermediate term plant such as rubber tree, it ranges from twenty-four to 
sixty months; whereas for a long-term crop like oil palm, it ranges up to 
hundred and twenty months (approximately 10 years).  
 
At this juncture, it is relevant to note that it is the normal practice of an 
applicant who wants to file an application in order to obtain the certificate of 
plant breeders’ right to plant the crop like oil palm at their own plantation for 
them to do their own monitoring and assessment. Hence, in most instances, 
the plant or crop namely the oil palm has already reached its eighth year when 
the application is submitted to the plant variety office. The examination by 
examiners from DOA would then be carried out for the remaining two years 
duration. Therefore, the whole examination process takes up to ten years 
wholly. The reason of DOA to start the examination at the eighth year after 
the oil palm is planted is due to the unique traits of oil palm which is found to 
be stable after the eighth year of its planting. Nevertheless, it is admitted by 
the DOA that there may arise some difficulties for foreign application or 
application from abroad seeking for protection under the 2004 Act, as their 
crop is required to be replanted in Malaysia for the examination purposes 
before a certificate of breeder’s right can be granted. 
 
The particular specific duration which is required for examination is essential 
to assess and ascertain the stability of a plant variety before the grant of the 
breeder’s right. The examination is exercised based on the Administrative 
Guidelines On Application And Registration Of New Varieties Of Plants 2008.549  
 
                                                 
549 Available at: <http://pvpbkkt.doa.gov.my/> 
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As far as the presently introduced system is concerned, it differs from the 
informal registration system in a few aspects. One of the differences is, the 
informal registration system which has been in place since 1930’s  was merely 
a register and listing, and was not based on the international standard. Hence, 
there is no protection afforded to the plant breeders even though they opted 
to register their varieties in the register. The listings or register which was 
done on voluntary basis and administered under the DOA, was mainly for the 
purpose of updating the information, as well as to facilitate the 
commercialization in the event that the breeder decided to grow the variety on 
a large scale. This is because, as part of the process and procedure, there was 
a need for a proper committee to be set up, as well certain presentation of the 
proposed project to be done for the approval by the horticulture unit under the 
DOA.550 
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With regard to the implementation of the 2004 Act, the Protection of New 
Plant Varieties Regulations 2008 has been gazetted and came into operation 
on 20th October 2008. Following this, the Malaysian PVP office started to 
accept applications for registration from 1st November 2008. Applications are 
made using form PVBT 1 together with the guidelines and appropriate 
technical questionnaire.551 Foreign applications can be made through an agent 
who is a resident or who has a registered office in Malaysia. The Regulations 
substantially cover the important aspect of the breeder’s right system such as 
the filing of application, preliminary and substantive examination, deposit of 
                                                 
550 The source of information is based on the interview;	, Note 536. 
551
 9"  refer the guidelines. 
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samples, registration of new plant variety and grant of breeder’s right as well 
as compulsory licence.  
 
At present, there are 45 examiners nationwide who work for research 
institutes, government agencies, and the like. This includes 16 examiners who 
work exclusively for the DOA. The New Plant Varieties Test Center in Serdang 
Selangor which was established in the year 2008, is equipped with facilities 
such as fields and greenhouses for conducting growing tests.552 In order to 
enhance the examination skills and expertise of the examiners, training has 
been conducted in Malaysia. For example, in March 2009, the "Domestic 
Training Program on the Plant Variety Protection System" was held  as a part 
of the specialist dispatching project of the East Asia Plant Variety Protection 
Forum, focusing on ways of conducting growing tests and on-site inspection.553 
 
The summary of the plant varieties application is published on the Malaysian 
Department of Agriculture’s (DOA) website554 and the list is updated regularly. 
As at September 2010, the total number and status of application are as 
follows: 
 
 
 
 
 
 
                                                 
552 Refer <http://www.eapvp-forum.org/topics/2009/20090320_04.html> [Accessed 14 
September 2010] 
553 ! 
554 Refer <http://pvpbkkt.doa.gov.my/> 
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"!3 6
Number of application for plant varieties application submitted to the DOA 

%#'!#!
#&!"!')	--,#$%
+!,!"!'.//7G!-#!"!'./0/
Fruits 6 
Ornamentals 7 
Industrial Crops 9 
Forest Pants 19 
Cereals 11 
Vegetables 1 
Mushroom 1 
TOTAL APPLICATIONS 54 
Source: DOA 

"!3 :
Status of the plant varieties application 
##)	--,#$% #&!+!,!"!'.//7@!-#!"!'./0/
Application Accepted 54 
Application Granted PVR 0 
Application Withdrawn 0 
Application Refused 0 
Application Revoked 0 
Application Cancelled 0 
Source: DOA 
 
The total number of the application which has been received by the PVP Office 
for a period of 22 months (December 2008 – September 2010) is relatively 
small and this could be attributed to the fact that the PVP Regulation is still 
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new and has been in force since October 2009. It is expected that more 
applications will be received by the PVP Office in the year 2011 from various 
government agencies such as MARDI which is actively carrying out the on-
going agricultural-based researches. The PVP Office’s target was to receive a 
total of 50 applications by end of 2010 and apparently the target was 
achieved.555 The Office also confirmed that they have received numerous 
inquiries on the matters related to the registration procedures of the new 
system, which shows to some extent escalating interest in the protection of 
plant varieties among Malaysian plant breeders. As far as the applications are 
concerned, a high percentage comes from the research institutions like MARDI 
which filed applications to protect its R&D findings and invention whereas the 
remainder comes from private companies, which include,     the 
application to protect new varieties of mushroom and pineapple. 
 
In is interesting to note that the PVP Office has pro-actively promoted the 
newly introduced system of protection for plant variety via various awareness 
programs such as seminars for public and plant breeders. The effort is 
significant towards achieving the objectives of the 2004 Act in particular, even 
though there has yet to be any application from indigenous people to protect 
their plant variety. As has been mentioned in the preceding discussion, one of 
the important objectives of the 2004 Act is to provide recognition and 
protection of contribution made by farmers, local communities and indigenous 
people towards the creation of new plant varieties. In fact, one of the teething 
challenges encountered by the Office is to identify and encourage breeders 
from small industry to submit applications for protection under the new 
system. For example, ornamental flower growers and producers in Cameron 
                                                 
555 , note 536. 
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Highlands Pahang are not really interested in application due to lack of 
awareness of the benefits from the protection of their variety. In addition, 
they have been relying on foreign seed producers for their ornamentals, hence 
there is a lack of initiatives and interest in producing their own new variety. 
 
In short, the newly introduced N	 	& system of protection plays an 
important part towards providing the protection of the rights of breeders of 
new plant varieties as well as in development of legal protection for 
agricultural biotechnology in Malaysia. 
 
<=$2'
,,!$%
It should be noted that as at to-date, Malaysia has yet to become a Member of 
UPOV. Although the current Malaysian Act can be said to be 90 percent UPOV-
compliant, some provisions would have to be amended if Malaysia were to 
ratify UPOV 1991. By virtue of Article 34(2) of the 1991 Act, it therefore has to 
deposit an instrument of accession in order to become a Contracting Party on 
the basis of the 1991 Act. Under article 34(3) of the 1991 Act, an instrument 
of accession can only be deposited if the State in question has requested the 
advice of the UPOV Council on the conformity of its laws with the provisions of 
the 1991 Act and if the decision of the Council embodying the advice is 
positive.556 
 
Malaysia has the intention of joining the UPOV fraternity with the aims 
  to enable access to improved foreign varieties such as ornamental 
                                                 
556 UPOV Document – Twenty Second Extraordinary Session: Examination Of The Conformity Of 
The Protection Of New Plant Varieties Act 2004 Of Malaysia With The 1991 Act Of The UPOV 
Convention, 2005. Available at: 
<http://www.upov.int/en/documents/c_extr/22/c_extr_22_2.pdf> [Accessed 12 February 2009]  
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flowering plants from UPOV member countries, as well as to profit from the 
rich experience developed under the UPOV Convention, in particular regarding 
the technical guidelines adopted, and from the technical assistance that the 
UPOV could provide. In order the realize this intention, it has submitted its 
application in November 2004557 requesting the UPOV Council to conduct a 
preliminary examination on the conformity of the Malaysian 2004 Act in 
relation to the provisions of the 1991 Act of the UPOV Convention.  
 
After the preliminary examination of the UPOV Consultative Committee, the 
Council reported558 that although its main provisions incorporates most of the 
substance of the 1991 Act, the 2004 Act still required some additional 
provisions and amendments, (as provided in document C(Extr.)/22/2),559 in 
order to remedy the deviations from strict conformity, hence to fully conform 
with the 1991 Act. The Council accordingly advised that the Act would need to 
be resubmitted to the Consultative Committee once the additional provisions 
and amendments had been incorporated.  
 
As far as the examination is concerned, the UPOV Council has highlighted a 
number of provisions in the 2004 Act which is not in conformity with the 1991 
Act (and hence need to be amended). For example, it pointed out that the 
rights granted under Section 14(2) of the 2004 Act fall outside the scope of 
the 1991 Act, since they refer to a specific group of applicants, a different 
subject matter, different conditions of protection and a different duration of 
                                                 
557 This is based on the official letter submitted by Malaysian Department of Agriculture to the 
UPOV Vice Secretary-General dated 10th November 2004. 
558 Refer <http://www.upov.int/export/sites/upov/en/documents/c_extr/22/c_extr_22_3.pdf> 
[Accessed 12 February 2009]  
559 AZMI, 	  Note 508. 
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the right. Section 14(2) of the Act reads: ‘Notwithstanding subsection (1)560, 
where a plant variety is bred, or discovered and developed by a farmer, local 
community or indigenous people, the plant variety may be registered as a new 
plant variety and granted a breeder’s right if the plant variety is new, distinct 
and identifiable.’ The UPOV Council was of the view that the rights granted 
under subsection (2) that requires a variety to be new, distinct and 
identifiable, would have the possible impact of hindering the protection under  
subsection (1), that is the application of the provisions of the 1991 Act, which 
requires the plant variety to be new, distinct, uniform and stable in order to 
qualify for the protection. In this regard, it was the Council’s recommendation 
to clearly separate the provisions dealing with that particular right from the 
provisions modeled after the 1991 Act.  
 
With regard to the Council’s recommendation, it is apparent that the provision 
on the lower threshold of registrability for traditional varieties is of paramount 
importance which is purposely incorporated for the protection of the rights of 
informal breeders which include farmers, local communities and indigenous 
people, hence to separate the provision from the current 2004 Act is neither 
viable nor justifiable. After all, the provision is parallel and in fact the 
reflection of the Preamble to the Malaysian PVP Act which provides for three 
objectives of the Act, one of which is for the recognition and protection of 
contributions made by farmers, local communities and indigenous people 
towards the creation of new plant varieties. Perhaps one possible way to 
comply with the UPOV’s Council recommendation but at the same time to 
uphold and maintain these rights is by having a totally separate Act for the 
                                                 
560 Subsection (1) reads: ‘Subject to sections 15 and 16, a plant variety shall be registered as a 
new plant variety and granted a breeder’s right if the plant variety is new, distinct, uniform and 
stable.’ 
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exclusive protection of farmers, local communities and indigenous people in 
Malaysia. Having said that, it is worth noting the process of drafting until the 
final process of passing an Act by Malaysian legislature is a very long, 
painstaking process, before a new Act could be passed and implemented, 
hence to produce a separate Act for the protection of farmers is possible yet 
time-consuming. It took Malaysia ten years from the time it first embarked on 
the process to finally pass the Malaysian PVP Act (PNPVA). 
 
Another example from the analysis of the UPOV Council is concerning the 
genera and species to be protected. The 2004 Act does not provide for the 
genera and species to be protected. The Council pointed out that, in 
accordance with Article 3(2)(i) of the 1991 Act, when depositing its instrument 
of accession, Malaysia must notify a list of at least 15 genera and species to 
which it has to apply the 1991 Act. Hence, the Council recommended for 
clarification in the regulations whether the Act applies to all or to a particular 
list of genera and species.561 In this regard, it is to be noted that the presently 
introduced system in Malaysia is practising the approach of ‘open listing’, 
allowing all types of new variety to be registered, but giving priority of 
protection to 25 types of plant genera and species. The priority list covers few 
plant categories namely ornamentals, fruits, industrial crops, cereal crop and 
forest plantation crops.562 Therefore, in the event that there is an application 
of a new plant variety which does not fall under the priority list, the processing 
would be subjected to availability of technical expertise and technical data. 
This in effect means that the plant variety right office may require a longer 
period of time to process such application.  
                                                 
561 AZMI, 	  Note 508, p.2. 
562 The full list of the ‘priority list’ is available at the DOA’s website. Refer 
<http://pvpbkkt.doa.gov.my> 
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The following table aptly summarizes the extent of the compliance of 
Malaysian provision vis-à-vis the UPOV provisions: 

"!3 7
The PNPVA 2004 versus UPOV provision: the extent of compliance 
 

'#,'
(%-'$&$%
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%#'!#!	,#
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$%

@
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-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1 Conditions for 
protection 
New 
Distinct 
Uniform 
Stable 
New 
Distinct 
Uniform 
Stable 
yes 
2 Scope of 
protection 
(a) Production or 
reproduction, 
(b)conditioning for the 
purposes of 
propagation 
(c)offering for sale 
(d)selling or other 
marketing 
(e)exporting 
(f)importing, and 
(g)stocking for any of 
the purposes referred 
to above 
(a) Production or 
reproduction, 
(b)conditioning for 
the purposes of 
propagation 
(c)offering for sale 
(d)selling or other 
marketing 
(e)exporting 
(f)importing, and 
(g)stocking for any 
of the purposes 
referred to above 
yes 
3 Genera and 
species 
‘Open listing’, with 
priority given to a list 
of crops in accordance 
with national interest 
At least 15 plant 
genera or species 
no 
4 Provision on 
essentially 
derived 
varieties 
yes yes 
yes 
5 Possibility of 
double 
protection 
(that is both 
under patent 
and plant 
breeder’s right) 
Plant varieties 	 
are specifically 
excluded from 
patentability under 
Patents Act 1983 
Possible (UPOV 
1991) 
yes 
6 Researchers’ 
privilege/rights 
yes yes 
yes 
7 Farmers’ 
privilege/rights 
Three special 
exceptions for small 
In the form of an 
exception in UPOV 
yes 
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farmers 1991. 
8 Duration of 
protection 
25 years for  trees 
and vines, 20 years 
for all other plants 
(with the exception of 
traditional varieties) 
25 years for  trees 
and vines, 20 
years for all other 
plants 
yes 
9 Compulsory 
licensing 
yes yes yes 
10 Unique 
features (	
	 
approach) 
(i)Traditional varieties 
with lower threshold 
of registrability ie 
new, distinct and 
identifiable 
(ii) duration of 
protection is 15 years 
for traditional varieties 
- no 
 
 
It has been revealed by the DOA that the effort and steps towards acceding to 
the UPOV Convention is currently put on hold, as the Government has 
prioritized the implementation of the Act over the UPOV accession. The 
Government would like to see the response from the breeders as the Act has 
just been implemented. The agenda of accession to UPOV has not been totally 
abandoned yet it is held in abeyance for a period of time which is 
unascertainable, but it would definitely revive when the need for the accession 
re-emerges in the near future, or perhaps with the pressure from the UPOV 
Council or other developed countries. 
 
3 3!-!!%##$#!,,!$)$#!,%$$*(
Despite the existing awareness of the economic potential of the new 
biotechnology, as well as the concerns in regard to its adverse effects on 
developing countries, the growth of biotechnology in many Asian countries has 
remained relatively slow.  India, Korea, Malaysia, the Philippines and Thailand 
have built-up national capabilities in biotechnology to introduce technological 
advances quickly into production.  They would probably be able to increase 
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their share in the global biotechnology harvest.563  The preceding discussion 
reveals that Malaysian Government in particular has taken up a number of 
pro-active steps in order to boost the growth of biotechnology in the country.  
 
<=?!1,!%#),,'#,
As far as Malaysia is concerned, there are a number of impediments or 
problems responsible for the slow growth of biotechnology R&D and the 
industry in the country. One of the main problems which has been identified is 
the weak scientific critical mass to set the industry going. On-going and 
proposed activities to support the growth in the biotechnology industry 
undoubtedly require a cadre of specifically trained manpower in this field. 
Malaysia’s shortage of skilled labor is most oft-cited impediment to economic 
growth cited in numerous studies.  
In the field of science and technology, Malaysia has an acute shortage of 
experts and highly qualified professionals, scientists, and academics. The 
problem is further aggravated by the general decline of the study of life 
sciences, in terms of the number of students doing undergraduate study in 
major universities in Malaysia. Figures indicate that in 1998, the number of 
scientists and engineers per one million population was 500, whereas demand 
is expected to be 1,000 scientists per one million.564 A look at the projected 
output of universities over a 10-year period from 1985, reveals that there will 
be more arts students than science and technical graduates. The greater 
                                                 
563 RIAZUDDIN, S., Country Paper On ‘Biotechnology’. Paper presented at "
9%	 % 7:$7?7;;@. [online], Available at : 
<URL:http://www.binasia.net/binasiadownload/Pakistan_COUNTRY_PAPER_EGM_Jan06.doc>[Acc
essed 23 February 2009] 
564 Ministry of Science, Technology & Innovation (MOSTI) Malaysia, 09#	"#
$ 
 	 !  J-$%	 ", Available at : 
<http://www.nitc.my/index.cfm?&menuid=61> [Accessed 01 December 2010]. 
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proportion of graduating students from public education institutions were from 
the Social Sciences and Humanities. The number of students from the public 
and private universities graduating in Natural Science and Engineering courses 
grew in numbers from just 5,588 in 19925 to 12,911 in 2002.565 Despite this 
increasing trend, the numbers of science and engineering graduates in 
Malaysia is still inadequate. To remain competitive, Malaysia has to acquire a 
large pool of scientists and technologists to meet the challenges and 
opportunities of the 21st century 
 
<=%1*!"!#2!!%#!"$#!,%$$*(%#'(%#!>+
Another significant impediment is a lack of linkages between the industry and 
R&D. Some research programs, for example, in the government-based 
agencies and public universities are designed and pursued without 
involvement or even a consultation with the local industry. Consequently, 
support of the private sector is non-existent. This is apparently one of the 
main problems in developing countries, including Malaysia, where there are 
laboratory researchers who work in isolation, completely separated from the 
end-users.  There are neither any consultations with the industry to identify 
the relevance of projects to national needs nor industry participation to take 
the laboratory research to the end-users.  Laboratory research problems are 
selected to satisfy intellectual appetite rather than to solve specific problems 
relevance to national needs. 
 
                                                 
565 AHMAD, F., and KRISHNA, V.V., 2006. The Science and Technology System of Malaysia, 
Available at: 
<http://portal.unesco.org/education/en/files/55597/11999609765MALAYSIA.pdf/MALAYSIA.pdf> 
[Accessed 01 December 2010] 
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<=!),#$'%-#!%#--,#$%
Another oft-cited impediment to the growth of biotechnology R&D and industry 
in Malaysia is the delay in the processing of patent and trademark registration. 
The process of registration of these types of IP which is in general a lengthy 
process, complicated and slow, poses further challenges at the 
commercialization level of an invention or end-product. In Malaysia, MyIPO is 
responsible for the development and management of the intellectual property 
system in Malaysia. At the same time, it is responsible for the implementation 
of the following Acts; Trade Mark Act 1976, Patent Act 1983, Copyright Act 
1987, Industrial Design Act 1996, Layout Designs and Integrated Circuit Act 
2000 and the Geographical Indications Act 2000. Prior to 2007, an average 
patent registration process took 5 to 6 years before a patent could be 
successfully registered.566 The delay was mainly because of the patent search 
process.  
 
<&=*!%!%#!%#!'-'!##$%$)$!-#!%#-'$&$%
It has been asserted that there is apparent lack of clarity on the interpretation 
and examination guidelines on biotech-related inventions. This goes back to 
the criteria for patentability of an invention, which includes biotech-related 
inventions. As has been mentioned in the previous discussion, the criteria for 
patentability of an invention under the Malaysian Patents Act 1983 are that 
the invention is new, involves an inventive step and has industrial 
applicability567, in parallel to Article 27(1) of TRIPS Agreement. From the view 
of Patent Division MyIPO, the above assertion and perception on a lack of 
                                                 
566 The data was obtained from Patent Division, MyIPO during the interview session carried out in 
July 2009. 
567 Section 11 Patents Act 1983. 
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clarity during the patent examination process is not true. This is based on the 
premise that the patent examiners generally follow the UK approach in 
interpreting certain terms or concepts vis-à-vis patentability. The examination 
process is made clearer and easier with the help of a detailed, comprehensive, 
official manual of MyIPO namely ‘Guidelines For Patent Examination’.568 For 
example, a detailed explanation and interpretation is provided for the 
important terms pertaining to patentability such as ‘inventions’, ‘industrial 
application’, ‘novelty’, and ‘inventive step’.569 
 
<=,1$),'#(%!#!'%%*#!!B,$%)'$-#!%#"#(
Excluded subject matter570 includes discoveries, plant or animal varieties or 
essentially biological processes for the production of plants and animals. 
However, man-made living microorganisms and microbiological processes, and 
genetically modified plants that do not amount to a plant variety are 
patentable. 
 
The excluded subject matter mirrors that prohibited under Article 52 of the 
EPC. So it is not surprising that MyIPO had an expert from the EPO, advising 
on the guidelines for the examination of biotechnological patent applications 
filed in Malaysia. For example, in year 2006,  Dr Jürg Bilang, a biotechnology 
expert from the EPO, undertook a training session for some 25 examiners in 
the field of biotechnology571.  The program covered patent examination 
procedures with particular emphasis on the field of biotechnology, that is 
patentability of plants and animals, patenting of gene sequences, patentability 
                                                 
568 The manual is available at: < http://www.myipo.gov.my/files/PT_Guidelines.pdf> 
569 !., refer Chapter IV of the manual. 
570 Section 13 Patents Act 1983. 
571
 Establishment of Biotech Guidelines & Training of Examiners, 27 February – 10 March 2006, 
Kuala Lumpur. 
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of 3D structures. He also assisted MyIPO in drafting guidelines on search and 
examination in the field of biotechnology. 
 
MyIPO's guidelines follow closely, if they are not identical to, the EU Directive 
98/44/EC on the legal protection of biotechnological inventions. In fact, MyIPO 
has set up a joint committee to formulate a policy for patenting 
biotechnological inventions in Malaysia. The MyIPO's official guidelines for the 
examination of biotechnological patent applications will be finalized and is 
expected to be published after Malaysia becomes a member of the Budapest 
Treaty for the deposit of microorganisms and other biological materials for the 
patent procedure. 
 
<"=
'$"!%,!'#%%*A%&!%#&!#!-5
As far as patentability of an invention is concerned, another oft-cited challenge 
is the threshold of the requirements, which encompasses the interpretation of 
‘inventive step’ and ‘industrial application’. Contrary to the perceived lack of 
clarity in the interpretation, the Patent Division of MyIPO firmly maintains that 
these terms are clearly interpreted in the official MyIPO Patent Manual, hence 
there is no vagueness in the interpretation.572 In this regard, the term 
‘inventive step’ is defined in the manual under Chapter IV, Rule 10.1 as: 
‘An invention shall be considered as involving an inventive step if, having 
regard to any matter which forms part of the prior art…such inventive step 
would not have been obvious to a person having ordinary skill in the art.’ 
 
It is further elaborated under the rule that novelty and inventive step are two 
different criteria, in the sense that novelty exists if there is any real difference 
                                                 
572 , Note 511. 
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between the invention and the known art, while the question of inventiveness 
only arises if there is novelty. While the claim should in each case be directed 
to technical features and not merely to an idea, in order to assess whether an 
inventive step is present, there are various ways in which an invention may be 
arrived at. One typical example as provided in Rule 10.5 of the manual is that 
an invention may be based on the devising of a solution to a known problem; 
for example, the problem of permanently marking farm animals such as cows 
without causing pain to the animals or damage to the hide has existed since 
farming began. The solution (“freeze-branding”) consists in applying the 
discovery that the hide can be permanently depigmented by freezing. 
 
In short, Rule 10 (which contains eight sub-rules) of the patent manual as a 
whole serves as a useful and comprehensive guide to the patent examiners in 
assessing the criteria of ‘inventive step’, thus rules out any oft-cited 
perception of lack of clarity in the interpretation of this particular term and 
concept. 
 
<,=
'$"!%!#!'%%*A%#'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,#$%5
Another term worth discussing vis-à-vis patentability is ‘industrial application’ 
in relation to biotech patent. Since MyIPO is closely following the approach of 
the UK and EPO, it is interesting to highlight the recent development of judicial 
interpretation of this term. The UK court, in considering the industrial 
application of biotech patent claims, rules that speculative uses for a protein 
are not sufficient to fulfill the requirement of industrial application since a 
patent is not a ‘hunting licence’ to find a use for an invention.573  In relation to 
                                                 
573
 6""	 !" [2008] EWHC 1903 (Pat), Kitchin J, 31 
July 2008. 
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the MyIPO patent manual, Rule 5 which is provided for Section 16 Patents Act 
1983 defines the term ‘industry’ as to be understood in its broad sense. This 
includes any physical activity of ‘technical character’ namely an activity which 
belongs to the useful or practical arts as distinct from the purely intellectual or 
aesthetic arts.  
 
In this regard, it is noteworthy that ‘industrial application’ does not necessarily 
imply the use of a machine or the manufacture of an article, hence it could 
also cover a process for dispersing fog, or a process for converting energy 
from one form to another. The manual also mentions another example, 
namely, methods of testing, which is interestingly regarded as inventions 
susceptible of industrial application and therefore patentable. All the examples 
as incorporated in the manual reflects the ‘actual’ (as opposed to the 
‘speculative’) industrial application. The Patent Division of MyIPO confirms574 
that during the patent examination processes, the patent examiners  
substantially rely on the title, abstract and description of a patent application, 
and this includes the compliance with the requirement of industrial application. 
 
<&=!$%,$!',#$%
Other than the above impediments, the slow growth of biotechnology R&D and 
industry is also attributed to the fact of underdeveloped IP asset management 
from the point of discovery to the point of commercialization of the 
biotechnological products. Typically, commercialization of new IP is enabled 
via partnerships with established business firms. However, establishing 
licensing agreements with existing industrial players does not maximize the 
commercial potential of the innovation. This is a common scenario in Malaysia, 
                                                 
574 , Note 511. 
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especially when dealing with breakthrough technologies arising from basic 
research, for instance from university’s research. In this regard, the proposed 
strategy and best practice will consist in initiating strategic partnerships with 
the industrial and financial sectors to ensure the successful commercial 
exploitation of the innovations transferred by the universities and research 
institutions.  
 
The commercialization rate of publicly funded research in Malaysia is still low. 
Typically, the low rate of commercialization of R&D findings is attributed to 
facts such as the lack of funding mechanisms for research, unawareness or 
lack of concern among the researchers about the commercial potential of their 
findings, research focus which is only limited to publications rather than a 
culture of commercializing research products and paucity of networking 
mechanisms to link key parties necessary in commercializing research 
findings.575 
 
<&=$2-!',!%#*!$)*$"-(!'
As far as the Malaysian situation is concerned, another problem which has 
been identified is a lack of indigenous global players576 which have the 
capacity and capability to contribute to the growth of local biotechnology 
industry. The situation is further aggravated by the fact that there is a very 
limited number of world class companies that are willing to venture or invest 
                                                 
575 These factors are the findings from the National Survey of Public Research Commercialization 
in 2003 under Malaysia Ministry of Science and Innovation (MOSTI). Refer : 
<http://www.slideshare.net/CAS.IP/licensing-of-modified-virgin-coconut-oil-in-malaysia-
3585197> [Accessed 08 September 2010] 
576 For example, one of the prominent local global players is Sime Darby Berhad 
<http://www.simedarby.com/> 
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in the country. A biotechnology proponent says there are few significant 
biotech foreign investments in Malaysia.577 

3 3 0$!!))$'#%#,1%*#!-!!%#
The Government and relevant bodies such as BiotechCorp and MyIPO are fully 
aware of the impediments to the successful growth of the biotechnology 
industry in Malaysia. In order to improve this situation, the Government took 
the initiative to establish ‘the Special Taskforce to Facilitate Business’ or 
PEMUDAH (taken from the taskforce’s Malay name ‘#	 #	 J	
#"#&) on 7th February 2007.578 Approval has since been 
given for MyIPO to engage additional staff for the purpose of patent 
examination. With the additional staff, as at 31 December 2007, MyIPO had 
cleared the backlog going back to October 2004. MyIPO aims to clear the 
backlog and reduce duration of registration to 3 – 4 years, hence improving 
the current average process of four and half years to five years. 
 
On top of the abovementioned initiative, MyIPO and BiotechCorp have 
ventured into a joint project, namely ‘The Patent Examiner Outsourcing 
Program’ with the aim to resolve the current patent examination backlog and 
enhance the ability of MyIPO to grant biotechnology patents within a shorter 
period of time. By end of the year 2007, a total of four biotech patents 
examiners were sent on a short-term attachment at the Australian patent 
office to be trained under experienced Australian patent examiners. ‘The 
International Exchange Programme for Patent Examiners’ is another joint 
                                                 
577 NGUI, Clarence Y.K., 2005. Continuing the biotech challenge, 	%			, Available at: 
<http://findarticles.com/p/articles/mi_qn6207/is_20051101/ai_n24909340> [Accessed 26 
February 2009] 
578 Refer <http://www.pemudah.gov.my/info> 
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MyIPO-BiotechCorp project to enhance the proficiency of Malaysian biotech 
patent examiners as well as to foster strategic ties with IP Offices identified to 
be at the leading edge of the industry. MyIPO-BiotechCorp secured 
agreements from both the European and Korean Patent Offices where each 
patent office have hosted for Malaysian patent examiners for attachment and 
training in 2007.579  
 
The drafting of MyIPO official guidelines for the examination of patent 
applications is another positive effort which is very much anticipated by the 
biotechnology industry. The Guidelines are hoped to clear the apparent 
vagueness on the interpretation of some related terms with regard to 
biotechnological inventions, in particular plant biotechnology. 
 
3 8$%,$%>$%#'"#$%
In short, while Malaysia has identified biotechnology and agriculture as key 
economic drivers, commercialization of local grown technology is in its infancy. 
Scientists are struggling to translate their bench work into dollars and cents, 
whereas the local entrepreneurs and industry are not in the forefront yet to 
invest and buy technologies from public research institutes and universities. 
Hence, there is a real need for all those involved in this industry to rise to the 
challenges and impediments in order to enhance the growth in the Malaysian 
scenario of biotechnology in general and the agricultural biotechnology in 
particular. After all, as highlighted in the preceding discussion, Malaysia has all 
the vital ingredients to succeed in the biotechnology sector, namely, proper 
policy, clear direction, sound implementation as well as infrastructure, yet it 
needs to improve on its critical mass and to ensure sufficiently trained human 
                                                 
579 , Note 489, at p.30. 
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resources to meet the requirement along the value chain of each biotech 
product, from R&D right through commercialization to prevent unwarranted 
delay. 
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The Malaysian biotech industry is dominated by small-to-medium sized 
companies with a handful of larger players, such as those running plantations, 
which have developed strong R&D arms within their corporations.580 As far as 
research activities are concerned, biotechnology research in Malaysia is mainly 
undertaken by public sector institutions such as MARDI, MPOB, MRB, FRIM, 
MCB and the like. Having said that, it is pertinent to note that the private 
sector’s involvement in agricultural biotechnology is primarily focused on plant 
tissue and cell culture. This ranges from the production of ornamental plants 
such as orchids and pitcher plants, herbal plants which have medicinal uses, to 
mass-propagated top-of-the line plants. 
 
The focus of this chapter is on the analysis of the data which has been 
collected via semi-structured interviews with a number of public sector 
research institutions. The results of the interviews are important, as the 
selected research institutions represent a large component of the views of 
plant breeders in Malaysia. The questions for the semi-structured interview 
were carefully drafted with the main aim to assess  the extent of use, 
awareness, appropriateness and effectiveness of the existing legal protection 
vis-à-vis IPRs available to those involved in agricultural biotechnology. The 
response to the interview was to some extent an indicative of the views of 
those involved in the industry and R&D of agricultural biotechnology. In 
                                                 
580
 An excellent example of a large player is Sime Darby Berhad, whose operations span across 20 
countries and is supported by a team of over 100,000 people worldwide. <http:// 
http://www.simedarby.com/Corporate_Profile.aspx> 
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addition, the interviews seek to identify those areas where further legislative 
activity might be needed.  
 
8 .'!)",1*'$%$)#!'!!',%###!%*!%,!

For the purpose of this research, the following agencies and research 
institutions were selected as the respondents for the semi-structured 
interviews: 
1) MARDI (The Malaysian Agricultural Research and Development Institute) 
2) FRIM (The Forest Research Institute Malaysia) 
3) MPOB (The Malaysian Palm Oil Board) 
4) MRB (The Malaysian Rubber Board) 
5) MCB (The Malaysian Cocoa Board) 
 
The selection of the above respondents was justified on the basis that the 
main industrial crops in Malaysia are oil palm, rubber and cocoa, of which the 
research work is undertaken by MPOB, MRB and MCB respectively, whereas 
the research activities for other types of plants such as rice, banana, coconut, 
papaya and so forth are entrusted to MARDI.  
 
On top of the above five agencies and research institutions, general interviews 
on the topic of agricultural biotechnology, patents and plant breeders rights’ 
as well as visits for the purpose of data collection581 were also carried out at 
these bodies: 
1)  BiotechCorp (Malaysian Biotechnology Corporation) 
2) MOSTI (The Ministry of Science, Technology and Innovation) 
                                                 
581 Some of the data and information obtained has been incorporated in the discussion in the 
preceding Chapter of this thesis. 
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3) Crop Quality Control Division, Department of Agriculture (DOA) 
4) Patent Division, Intellectual Property Corporation of Malaysia (MyIPO) 
In fact, these bodies and agencies play the role of regulators and facilitators to 
the matters and issues related to biotechnology and IPRs in Malaysia. 

8 . 0	+
MARDI was established in the 1970s with the main objective of generating and 
promoting new, appropriate and efficient technologies towards the 
advancement of the food, agriculture, food and agro-based industries. One of 
the MARDI’s vital functions is conducting research in the fields of science, 
technology, economics, and society with regard to production, utilization and 
processing of all crops (except rubber, oil palm and cocoa), livestock and food. 
Since agricultural biotechnology has been identified as one of the key 
technologies needed for transforming and modernizing agriculture, MARDI has 
expertise in many areas of agricultural biotechnology such as molecular 
biology, genetic engineering, diagnostics, bioreactor technology and biosafety. 
The expertise in these areas could generate state of the art technology in the 
agriculture sector.582 
 
MARDI research teams focus on various crops, which include rice and papaya. 
MARDI has been successful in producing and establishing the transformation 
system for local rice varieties. Transgenic rice containing the coat-protein gene 
for the  virus has been developed, and glasshouse screening has been 
completed. Transgenic rice with herbicide resistance has also been produced 
and is currently in glasshouse trials. Other than rice, work on gene cloning for 
papaya ringspot virus coat protein gene and the ethylene gene ACC oxidase 
                                                 
582 Refer <http://www.mardi.my> 
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for improved shelf-life started concurrently with the development of the 
transformation system for papaya. Now transgenic papaya containing the 
shelf-life gene are being produced and analyzed.583 A local variety of papaya 
resistant to ring spot virus will be a boost to local farmers as it poses a big 
problem to them especially in the southern parts of Peninsular Malaysia. This 
will increase the yield and improve the quality of their produce, while 
protecting the plants from the virus. 
 
8 . .
FRIM was founded in 1929, and is currently one of the leading institutions in 
tropical forestry research, both within Malaysia and abroad. FRIM is primarily 
responsible for the planning and implementing of research for the 
development of the forestry sector and conservation of forest resources in 
Malaysia. The biotechnology-related research activities are under the Forest 
Biotechnology Division of FRIM, which is involved in creating new planting 
material through genetic engineering. The functions of the Division include 
seed testing, seed storage facilities, DNA sequencing and so forth.584 
 
8 . 4

Malaysia currently accounts for 39% of world palm oil production and 44% of 
world exports.585 Being one of the biggest producers and exporters of palm oil 
and palm oil products, Malaysia has an important role to play in fulfilling the 
growing global need for oils and fats sustainably. In this regard, MPOB, the 
premier government agency, has been entrusted to serve the country’s oil 
                                                 
583 The project is part of the Papaya Biotechnology Network of Southeast Asia initiated by the 
International Service for the Acquisition of Agri-Biotech Applications (ISAAAA). 
584 Refer <http://www.frim.gov.my> 
585 Refer : <http://www.mpoc.org.my/Malaysian_Palm_Oil_Industry.aspx> [Accessed  31st 
August 2010] 
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palm industry. Research and development is the thrust of MPOB’s activities, 
ranging from upstream production to downstream processing which is carried 
out by the various research divisions. The research activities are aimed at 
maximizing productivity, improving production efficiency and quality, and 
increasing value creation by expanding the palm oil and palm kernel oil value 
chain to promote a globally competitive and sustainable industry. 
 
MPOB plays a significant role in applying and promoting oil palm 
biotechnology, notably research relating to crop production and management 
as well as advanced biotechnology, which include breeding and genetics and 
tissue culture.586 

8 . 3
 
The Malaysian Rubber Board (MRB) is the custodian of the rubber industry in 
Malaysia. MRB has contributed significantly to the development of the rubber 
industry for the last 78 years. The R&D excellence in natural rubber, 
accomplished by the Rubber Research Institute of Malaysia (RRIM) which is 
now under MRB, has had an impact on the Malaysian natural rubber industry 
and other natural rubber producing countries. 
 
The primary objective of MRB is to assist in the development and 
modernization of the Malaysian rubber industry in all aspects from cultivation 
of the rubber tree, the extraction and processing of its raw rubber, the 
manufacture of rubber products and the marketing of rubber and rubber 
products. 
 
                                                 
586 Refer : <http://www.mpob.gov.my> 
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Research undertaken in the Biotechnology Unit covers the areas of tissue 
culture and genetic transformation aiming at the enhancement of crop 
productivity by improving selected agronomic traits of the rubber tree, 
molecular markers and genetics, plant physiology, biochemistry and molecular 
biology, reproductive biology and latex allergy. While these areas encompass 
the basic and strategic biological research activities undertaken on  
			,587 a significant portion of the unit’s research has been structured 
to address specific needs of the rubber industry.588 

8 . 8

The Malaysian Cocoa Board (MCB) was established in 1988 with the main 
objective of developing the cocoa industry in Malaysia to be well integrated 
and competitive in the global market. Emphasis is given to increasing 
productivity and efficiency in cocoa bean production and increasing 
downstream activities.  
 
A specific centre under the MCB, that is, COCOABiotech Centre of Excellence 
was established in 2002. This centre aims to implement research and 
development cocoa biotechnology program of innovation and application. 
Some of the important achievements in agro-biotechnology include molecular 
fingerprinting of cocoa clones, molecular markers for selection of shorter cocoa 
trees, development of cocoa trees resistant to pod borer and so forth.589 



                                                 
587 Latin name for rubber tree from which the largest volumes of latex are harvested for use in the 
manufacture of natural rubber 
588 Refer : < http://www.lgm.gov.my> 
589 Refer : <http:www.koko.gov.my> 
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8 . 6$#!,$'-
BiotechCorp was established in 2005 with the aim of nurturing and 
accelerating growth of Malaysian biotechnology companies, as well as to 
create a conducive environment for biotechnology. 
 
As far as agricultural biotechnology is concerned, BiotechCorp continues to 
take pro-active steps towards developing a more vibrant agriculture sector by 
facilitating the establishment of several commercial entities involved in key 
areas of agricultural biotechnology in the country such as in agricultural 
genomics, production of planting materials through tissue culture technology 
and production of bio-pesticides and bio-fertilizers for plant protection and 
nutrition. As at 31st December 2008, 31 agricultural biotechnology companies 
under Industry Development Division (Agriculture) have been awarded 
Bionexus status,590 which is a kind of recognition awarded by the Malaysian 
government through BiotechCorp to qualified companies that participate in 
and undertake value-added biotechnology businesses. 
 
8 . :
The Ministry of Science, Technology and Innovation provides assistance to 
those with the expertise and resources to carry out biotech-driven R&D and to 
develop businesses in the sector, especially in the priority areas such as 
agriculture. National Biotechnology Division (BIOTEK) under MOSTI is a part of 
MOSTI’s biotechnology cluster to harness the full potential of biotechnology in 
the new economy. Since its establishment in 1995, BIOTEK has consistently 
                                                 
590 BiotechCorp Final 2008 Annual Report, Available at : 
<http://www.biotechcorp.com.my/pdf/Final%202008%20Annual%20Report.pdf> 
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been involved in R&D, technology development and biotechnology awareness 
programs. 
 
The pivotal role of BIOTEK is managing and facilitating funding for those with 
the expertise to carry out research on platform technologies. Besides, BIOTEK 
embarks on technology transfer, files patents, sets up good laboratory practice 
facilities and forms bio-informatics networking.591 
 
8 . 7'$-H#($%#'$+&$%+!-'#!%#$)	*',#'!
The Department of Agriculture (DOA) has been registering fruit clones since 
the early 1930's and was officially authorized as the National Registrar of 
Varieties in 1994 by the Ministry of Agriculture. The responsibility in 
implementing the PNPV Act 2004 has been entrusted to the DOA. Presently, 
there are 45 crop examiners nationwide who work for research institutes and 
government agencies, including 16 examiners who work for DOA. The New 
Plant Varieties Test Center was established in year 2008, with facilities such as 
fields and greenhouse for conducting growing tests. 
 
The 2008 Regulations592 were gazetted on 20th October 2008, hence the Crop 
Quality Control Division which acts as the Malaysian PVP office has been 
accepting applications for registration of new variety as from the 
abovementioned date. The cumulative number of applications now has 
reached 54.593 

                                                 
591 Refer : <http:www.mosti.gov.my>; MALAYSIA. Ministry of Science, Technology and 
Innovation, 2007. (%"
	O%" +. "
(.$. Putrajaya: BIOTEK Malaysia. 
592 Protection of New Plant Varieties Regulations 2008. 
593 As at September 2010, source : <http://pvpbkkt.doa.gov.my/> 
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Intellectual Property Corporation of Malaysia was established with the main 
objectives of establishing a strong and effective administration as well as 
strengthening intellectual property laws in Malaysia. The Patent Division of 
MyIPO has three subdivisions in terms of its examination functions, that is 
patent formality section, engineering and applied science. In this regard, 
patent applications of agricultural biotechnological inventions fall under the 
responsibility of the applied science division. 
 
8 4	!%*#!!2$)(%
%#'!!!'
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
Genetic modification research in Malaysia mainly involves crop improvement 
work, especially in relation to developing pest and disease tolerant crop 
varieties, high-yielding and value added crop varieties. To date, there is no 
record of a commercial variety being released for commercial planting that has 
been genetically modified using recombinant DNA technology.594 In Malaysia, 
there are several commercial crops being studied or being modified 
genetically, for example papaya, rice, and chilli by MARDI, oil-palm by MPOB, 
cocoa by MCB, rubber tree by MRB and teak by FRIM. 
 
It is of paramount importance to ascertain and identify the types of 
biotechnology research undertaken by the RIs and relevant bodies, as it would 
be indicative and reflective of the research trends in Malaysia. The relevant 
question to be answered is whether R&D in those RIs is focusing on ‘gene’ 
from its very basic stage, or whether the RIs research teams are merely 
                                                 
594 Refer : Biotechnology Information Centre (MABIC) 
<http://www.bic.org.my/?action=localscenario&do=legislation> [Accessed 01 December 2010] 
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replicating and applying the current available biotechnology in plant biotech 
worldwide. It was discovered based on the interviews595 and various online 
sources596 that generally, most research activities in those RIs focus on 
genetic engineering for crop improvement, disease and herbicide resistance 
and value added products. In this regard, some of the technologies used are 
inevitably based on existing plant biotechnology which has been proven a 
success in the industrialized countries such in the U.S. and Europe.  
 
One relevant example would be the application of %"	 		 (%) 
transgenic technology to various plants in Malaysia, such as rice, papaya, 
sweet potato and the like. The research is on-going, hence it remains to be 
proven whether %-transgenic technology would work and be effective for 
other types of crops than corn and cotton.597 On the global stage, the majority 
of commercially released transgenic plants are currently limited to plants that 
have introduced resistance to insect pests and herbicides. Insect resistance is 
achieved through incorporation of a gene from % that encodes a protein that 
is toxic to some insects. For example, if the cotton bollworm, a common 
cotton pest, feeds on %-cotton it will ingest the toxin and die. Herbicides 
usually work by binding to certain plant enzymes and inhibiting their action. 
The enzymes that the herbicide inhibits are known as the herbicides target 
site. Herbicide resistance can be engineered into crops by expressing a version 
of target site protein that is not inhibited by the herbicide. This is the method 
                                                 
595 The various semi-structured interviews with selected RIs and relevant bodies were carried out 
in June- August 2008, and in August 2009. 
596 All RIs have their own website, detailing their research focus and R&D activities. MARDI : 
<http://www.mardi.my>; MPOB: <http://www.mpob.gov.my>; MRB: 
<http://www.lgm.gov.my>; FRIM: <http://www.frim.gov.my>; MCB: 
<http://www.koko.gov.my>. 
597 Ironically, scientists from India, China and the United States have discovered that Bt crops ie 
genetically engineered with % toxin proteins from the soil bacterium %"	 		 
targeted at insect pests, often failed to protect against pest attacks, and have other problems as 
well. Refer :< http://www.i-sis.org.uk/SCFOBTC.php> [Accessed 23rd August 2010]. 
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used to produce 	 resistant crop plants. In this regard, insect-
protected plants containing a natural insecticide protein from % (for example 
%$cotton and %-corn) have successfully provided millions of farmers 
worldwide with increased yields, reduced insecticide costs and fewer health 
risks. Hence, it is not surprising for a developing country such as Malaysia to 
apply similar technology in order to enhance specific plants for the benefit of 
local farmers and consumers. At this juncture, it is worth noting public RIs in 
Malaysia are actively researching the application of %-transgenic technology 
for target plants and crops, for instance, disease and herbicide resistant 
varieties in rice and cassava as undertaken by MARDI’s research team.  
 
The research emphasis598 of respective RIs is summarized in the following 
table. 
"!8 0
The area of research emphasis of major RIs in Malaysia 
 !!',-
Malaysian Agricultural Research and 
Development Institute (MARDI) 
(i)Delayed ripening in papaya 
(ii)Disease resistance in rice, chilli,   
    papaya and sweet potato 
(iii)Floral colour in orchids 
(iv)Improved quality and nutrition in  
     rice, cassava and sweet corn 
(v)Yield improvement and herbicide   
     resistance in rice 
Malaysian Palm Oil Board (MPOB) 
(i)Yield improvement 
(ii)Improved oil quality 
(iii)Production of biodiesel 
(iv)Research on oil palm genomes 
Malaysia Rubber Board (MRB) (i)Disease resistance 
(ii)Production of high-value protein 
                                                 
598 The information is based on the data collected from the semi-structured interview sessions and 
respective RI’s websites. 
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Malaysian Cocoa Board (MCB) 
(i)Disease resistance 
(ii)Yield improvement 
(iii)Production of specialty cocoa trees 
Forest Research Institute of 
Malaysia(FRIM) 
(i)Delayed flowering and disease  
   resistance in teak 
 
The knowledge and understanding of the current nature, research focus and 
R&D activities undertaken and carried out by those RIs in Malaysia is vital to 
ascertain the suitable, best IP protection for the R&D yields and output. This is 
because plant breeders, researchers and investors in Malaysia presently have 
the option under patent laws or plant variety rights; either or both types of 
protection that best suit their needs to protect their inventions. 
 
8 4 .!*%),%,!$)*',#'"$#!,%$$*(>+,#&#!
All research institutes which play significant roles in agricultural biotechnology 
R&D in Malaysia have their own specific unit or division to run their 
biotechnology research activities. This is parallel to the Government’s 
aspiration and mission to boost the local biotechnology sector. In fact, 
effective R&D is one of the Government’s primary initiatives towards 
harvesting the potential of biotechnology as a growing source of the country’s 
wealth creation. 
 
The RIs like MARDI, MRB and MCB are backed by Government funding and 
budget allocation to maintain their operation and R&D, whereas MPOB derives 
its funding mainly from cess599 imposed on the industry for every tonne of 
palm oil and palm kernel oil produced. Nevertheless, in addition, MPOB 
receives budget allocations from the government to fund development projects 
                                                 
599 Tax imposed on palm oil producer, that is at the rate of RM9 per tonne of palm oil and palm 
kernel oil produced at the mills and crushers (as at December 2008); Refer : <http: 
//www.palmoilhq.com> 
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and for approved research projects under the Intensification of Research in 
Priority Areas (IRPA) programme.600 MRB similarly imposes cess601 on natural 
rubber production as part of its funding sources, other than the budget 
allocations from the Government. 
 
It is essential to ascertain the sources of funding of the RIs as it would affect 
and shape their R&D activities on a wider perspective. The relevant discussion 
on this matter follows in the latter part of this chapter. 
 
The following table summarizes the finding of the semi-structured interviews 
with regard to the data on biotech-related R&D of the RIs: 
"!8 .
The summary of finding collected during the semi-structured interview 
Research Institutes 
/ Organization 
(RIs) 
Years of 
involvement in 
biotechnology 
Percentage of 
employees 
involved in 
biotech R&D 
Percentage 
of financial 
resources for 
biotech R&D 
Plant 
species 
MARDI 20 > 50 NA 
All 
crops 
except 
palm 
oil, 
rubber, 
cocoa 
MPOB 40 20 NA palm oil 
MRB 20 15 >10 rubber 
MCB 9 15 >10 cocoa 
                                                 
600 , note 486. 
601 A cess at the rate of 3.85 cents shall be imposed on every kilogramme of natural rubber 
exported from Peninsular Malaysia. (Order 2(1) of Malaysian Rubber Board (Cess) Order 2000 
under Malaysian Rubber Board (Incorporation) Act 1996). 
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FRIM 10 10 10 
Forestry 
(acacia, 
teak, 
rattan, 
bamboo 
etc) 
herbs 
 
All RIs interviewed have their own specific unit or division dealing with 
research in agricultural biotechnology. Being RIs, all of them have been 
involved in biotechnology research since their establishment; this is very true 
as the term biotechnology in general encompasses both ‘conventional’ and 
‘modern’ biotechnological revolution. After all, their long research involvement 
in agricultural biotechnology is not surprising as it is one of the most 
promising developments in modern science, in addition to the fact that 
Malaysia is well endowed with natural resources in agriculture. 
 
Research in agricultural biotechnology as being undertaken by these RIs 
revolves around the genetic improvement of industrial crops and plant 
varieties, agricultural genomics, as well as tissue culture technology in 
transgenic crops and forest trees.602 There are in fact a number of ongoing 
researches on genetically modified plants but all are still at the experimental 
stage, as confirmed by MARDI. Other key research areas for the agriculture 
sector include livestock farming, animal health and nutrition, bio-pesticides 
and bio-fertilizers, extraction of metabolites and nutritionally enhanced 
agriculture products.  
 
The significance of biotechnology research is represented in the percentage of 
the employees and researchers involved in the research, as well as the 
                                                 
602 The fact is confirmed by the RIs during the semi-structured interviews as carried out in 2008. 
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funding or budget allocation for such activities as shown in Table 5.1. The 
percentage of employees committed to agricultural biotechnological research 
in the RIs ranges from 10 to 50 percent, evidencing the growing importance 
and prominence of biotechnological industry in Malaysia. In relation to this, 
the Government of Malaysia in its Ninth Malaysia Plan allocates a total of RM 
2,021.3 million funding for biotechnology sector.603 
 
8 4 4
#!%#%*	,#&#!
Biotechnology is a product of human efforts and innovation and can only 
develop in a condition with solid scientific and technological background. The 
response from the RIs and government agencies during the semi-structured 
interview sessions reveals that patenting activities have been an important 
part of their integrated role in R&D. The following table essentially summarizes 
their patenting work. 
"!8 4
Statistic of patenting activities by major RIs in Malaysia 
Research 
Institutes / 
Organization 
(RIs) 
The year in 
which first 
Malaysian 
patent 
application 
made 
Number of current 
patents 
(year 2008) 
Patents 
abroad 
Number 
of 
patents 
applied 
annually 
Average 
number 
of 
patents 
granted 
annually 
MARDI 1996 
Approved/granted: 3 
Filed/Pending: 15 
No 5-8 3 
MPOB 1980s 
Approved/granted: 60 
Filed/Pending: 150 
Yes 18-20 3 
MRB 
1934 (first 
patent applied) 
Approved/granted: 119 
Filed/pending: 16 
Yes 4 2 
MCB 2004 
Approved/granted: 5 
Filed/pending: Not 
available 
Yes 1 1 
FRIM 1990 
Approved/granted: 19  
Filed/pending: 19 
Yes 4 2 
 
                                                 
603 Source : 9th Malaysia Plan, Economic Planning Unit. 
311 
 
It is interesting to note that applying for patents seem to be an obligation 
undertaken by these RIs and agencies. After all, it has become a trend 
nowadays as patent applications provide a good indicator of technological 
innovation and capacity performance of an institution or body. It is clear from 
Table 5.2 that patenting activities in these research institutions have taken 
place as early as 1934, that is when MRB applied for its first patent.604 
However, as far R&D in local biotechnology is concerned, patenting works has 
started to gain momentum in 1980s and 1990s.  
 
MRB for instance started its work on genetic transformation of rubber cells in 
the year 1990. In fact MRB has been very active in their biotechnology 
research, focusing , on the transgenic rubber tree research with the 
aim of improving rubber tree productivity. The transgenic rubber tree stands 
to gain a wide variety of desirable agronomic traits. High latex and timber 
yield are some of the areas that the rubber industry stands to gain and to 
serve the latex based sectors and the wood based industries. 
 
Based on the figures in the Table 5.2, it is very clear that MPOB has been the 
most active institution in patenting activities. It has 60 approved patents, 
while 150 applications are still pending.605 As a matter of fact, MPOB plays a 
significant role in applying and promoting oil palm biotechnology in 
Malaysia606. It is one of the most productive agencies in producing technology 
                                                 
604
 The patent was concerning the improvements relating to the treatment of rubber latex. Source 
: <http://www.lgm.gov.my/general/NRHistory.aspx> [ Accessed 19 January 2010] 
605 The figure is correct as at Jun 2008, obtained during the semi-structured interview sessions 
with MPOB official. 
606 Privately-owned corporation which is also focusing on oil palm research in Malaysia is Sime 
Darby. It has recently reported its success on oil palm genome research which is instrumental to 
boost palm oil yields, better planting materials and generation of new variety of crops. Refer : 
<http://biz.thestar.com.my/news/story.asp?file=/2009/5/14/business/3896765&sec=business> 
[Accessed 08 September 2010] 
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and new innovations which contribute directly to the palm oil industry. The 
large number of patents held and applied by MPOB is attributed to the fact 
that it works directly for the industry players in the local palm oil industry, and 
their funding operation and revenue is mainly generated from cess collection 
of palm oil and palm kernel oil produced at the mills and crushers.  In 
addition, MPOB receives budget allocations from the government to fund 
development projects and for approved research projects. Having said that, 
MPOB is obviously very active and has shown a strong commitment in its 
research and development, and this goes parallel with their patenting 
activities. Interestingly, filing of patent had been a culture for MPOB since the 
introduction of its IP policy in 1999.607 
 
Other than MPOB, MARDI is another important RI in Malaysia, which has been 
very active it its research activities ever since its establishment in 1971. 
Nevertheless, most of its research outputs remain in the laboratory as they 
have not been patented nor commercialized. As far as patent applications are 
concerned, patenting activities in MARDI has started to gain pace in 1996. 
MARDI has since been moving gradually from a pure focus on research 
activities towards a more active approach in terms of patents and 
commercialization. In fact, MARDI has set up  certain targets in terms of 
achieving its number of patents filed and granted, which is set around 5 to 8 
patents annually.  
 
Nevertheless, MARDI has yet to file or hold any patents abroad. This is 
attributable to the fact that it sees no necessity yet to file international patents 
                                                 
607 Refer : <http://palmnews.mpob.gov.my/palmnewsdetails/palmnewsdetail.php?idnews=3072> 
[Accessed 08 September 2010] 
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to protect their research results, which revolve around new food cops varieties 
and clones. One of the underlying reasons is the financial factor, as patenting 
abroad would incur a high cost. As far as patenting is concerned, MARDI has 
put in a total of 14 patent applications over 10 years (1996-2006).608 The 
number is minimal, yet it reflects a positive development and progress in 
protecting its research via IPRs notably patents. 
 
It is worth noting in comparison to MPOB and MRB who work directly for the 
industry players and hence very efficacious in patenting their inventions, 
MARDI is much less aggressive in its patenting activities as there is a lack of 
takers or investors for its research outputs and inventions. This is further 
attributed to the fact that most local agriculture-based manufacturers are 
small and medium-sized companies, with limited financial resources and 
funding to commercialize MARDI’s inventions. 
 
FRIM equally shows an active participation in protecting its inventions via 
patents, and currently holds 29 patents.609 As one of the world reputed centres 
for tropical forestry research, FRIM has more than 100 years of experience in 
forestry and forest products research. Their patenting activities started in 
1990, with a total of 19 patents held currently,610 though its annual number of 
patents filed remains minimal. Being one of the twelve mega-diversity 
countries in the world, FRIM has a very significant role in agro-forestry and 
biotechnology, researching into plants and forest produces. Some of the plants 
                                                 
608
 The figure is based on a report in a newspaper, which is available at : <http:// 
www.bic.org.my/BICalert/0107/080107NST-0.pdf>[Accessed 19 January 2010] 
609
 As at June 2008. 
610
 Source : <http://www.frim.gov.my/commerlization2.cfm> [Accessed 19 January 2010] 
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which are being actively researched into at FRIM include rattan, bamboo, 
" herbs and teak. 
 
MCB currently owns 5 patents, targeting a minimum of one patent application 
to be filed annually. Malaysia is Asia's largest cocoa grinder in terms of 
capacity and volume hence MCB was established in 2004 to focus its research 
exclusively on the cocoa bean plant. The role played by MCB is important to 
the development of the cocoa industry in Malaysia to be well integrated and 
competitive in the global market ultimately. MCB’s current biotechnology 
research in cocoa biotechnology is inevitable to create higher yielding cocoa 
hybrids in order to assist cocoa farmers to produce more of this precious 
commodity. 
 
In short, patenting activities that have been taking place in the major RIs in 
Malaysia to some extent serve as a positive indicator, signifying the increased 
awareness of IPRs among local breeders to protect their products of research 
and development. After all, any research in agricultural biotechnology projects 
is expensive, attracting a large amount of investment and financial resources, 
as well as being hugely time-consuming. Having said that, IP protection via 
the patent regime is seen as one of the strongest, justifiable protections for 
the biotechnological inventions, which include agricultural biotechnology.  
 
At this juncture, it is worth noting that as far as Malaysian scenario is 
concerned, there remains some assertion and perception from general public 
and NGO’s that the products of research and development by research 
institutions should be freely available as a large portion of the funding comes 
from the Government. This argument could be met by the fact that even the 
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Government in the long run being the financier and investor would expect a 
return of investment and making profits or at least to cover the research cost. 
This is in addition to providing the researchers involved in the research project 
the extra monetary initiatives and driving force in their research efforts and 
endeavours. 
 
To recap, based on the data and figures obtained during the semi-structured 
interviews, it is clear that patenting activities among Malaysian local breeders 
have started to gain pace and popularity and it is not surprising that they 
would become trends in the near future, in line with the view that strong 
patent protection would stimulate further innovation. 

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As has been mentioned in the early part of this thesis, the Malaysian patent 
legislation consists of an interesting mix of provisions adopted from UK patent 
laws, with some uniquely national features. Hence, the RIs and agencies 
admitted that there are some common, typical problems inherent in the 
Malaysian patent law systems.  
 
MARDI’s officials were of the view that patent applications in Malaysia are 
quite costly. In this regard, MCB shared the same view with MARDI in 
highlighting the high cost611 for a patent application in Malaysia. This is 
                                                 
611
 On average, a lawyer's fee for drafting a patent description would be between RM5000 and 
RM10,000. To get an invention patented, a rough estimate of the cost is between RM8,000 to 
RM9,000. This is however excluding professional translation fees. The total cost however may go 
up to RM 40, 000 depending the various types of patents. Source : Shearn Delamore & Co, as 
reported in the newspaper, available at : < http:// www.bic.org.my/BICalert/0107/080107NST-
0.pdf>[Accessed 19 January 2010] 
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aggravated by the difficulties in finding a qualified and skilful patent agent 
specialized in agricultural biotechnology. MPOB on the other hand highlighted 
other problems such as time-factor, as a patent application is time-consuming, 
right from the time it is filed until the final stage when the patent is granted. 
Another problem is lack of skills on the part of local patent agents in drafting 
patent application in the areas of biotechnological patent inventions. 
Interestingly, MOPB encountered no problem in applying for patents abroad, 
provided the patent application at the national phase is successful. 
 
MRB and FRIM seem to share the same view with MPOB, stating that the time-
frames are a challenge in a patent applications. In the event that an 
application requires for further amendment, the whole process would be much 
longer in time and overall it is really time-consuming before a grant of a 
patent could take place. 
 
It is important to note at this juncture that the problems of time-frame and 
‘time-consuming’ in patent applications are in fact inherent and inevitable. In 
other words, delays in the patent granting process is a common problem faced 
by Malaysia. This is actually based on the patent legislation and system itself. 
In Malaysia, the average time to obtain a patent ranges from twelve to thirty 
months from PCT national phase entry, and from forty-two to sixty months 
from priority date for Paris Convention applications. After all, all Malaysian 
patent applications are subject to substantive examination, which is very time-
consuming. The current examination system relies extensively on the results 
of search and examination of the same invention in certain recognized 
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jurisdictions, which include patent offices of Australia, UK, Japan, Korea, the 
US and the EPO.612 
 
8 4 3 .
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As the pace of scientific discovery in agricultural biotechnology has accelerated 
over the past few decades, the use of patents and other IRRs to protect the 
inventions and techniques applicable to plant breeding and seed technology 
has increased tremendously, particularly in developed countries such as the 
US and European countries.   
 
In this regard, RIs and agencies which are directly involved in the R&D of 
agricultural biotechnology play vital roles in realizing the country’s aspiration 
and vision to become one of the global players in biotechnology. Therefore, 
Malaysia is committed to providing a strong IP protection regime under the 
Biotechnology Policy. As far as patent is concerned, MPOB is the leader in 
patenting its research outputs relating to agricultural biotechnology. MPOB has 
a total of 6 patents which directly relate to protect techniques applicable to 
plant breeding technology, namely palm oil. Interestingly, it has also applied 
for and been granted patents in countries such as Thailand, the US, Indonesia 
and the UK. MPOB plays a significant role in applying and promoting oil palm 
biotechnology. It has the whole complement of genes, promoters and 
transformation techniques for producing high oleic oil palm via genetic 
engineering. Research is on-going on oil palm specifically, and more patents 
are estimated to be filed as and when the research yields its desired objective.  
 
                                                 
612 This was confirmed by Patent Division, MyIPO during the interview session carried out in July 
2009. 
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Other RIs and agencies like MARDI, MRB, MCB and FRIM do not  however own 
any patents on techniques in plant breeding technology, although they are 
also actively involved in research of agricultural biotechnology. MCB is 
thoroughly researching on transgenic cocoa plants and it expects to succeed in 
its research efforts some time in the near future.613Some of the main area of 
research in cocoa biotechnology include research in tissue culture and plant 
regeneration for the mass propagation of superior trees and as a platform for 
genetic engineering, pest resistant cocoa via in vitro technology and genetic 
transformation as well as research to  produce high flavour Malaysian cocoa 
and specialty cocoa beans.614 The latest achievement by MCB is the success in 
creating partially transgenic cocoa somatic embryos, but transgenic plants 
have yet to be generated. MCB is anticipating another 10 years to create a 
fully disease resistant cocoa trees before releasing them to farmers.615 
 
8 4 8
%#'!#(
'$#!,#$%	%	#!'%#&!
The Protection of New Plant Varieties Regulations 2008 of Malaysia came into 
operation on October 20 2008, enabling Malaysia's Protection of New Plant 
Varieties Act 2004 to be implemented. 
 
Since agriculture is one of the major sources of Malaysia’s economy, there is a 
compelling need to protect the main crops such as palm oil trees, rubber trees 
and cocoa, not only in Malaysia, but also in other countries which are capable 
of growing such trees. The introduction of new varieties for these crops is an 
                                                 
613
 As confirmed by the MCB during the interview via email in August 2008. 
614
 Refer : <http://www.koko.gov.my/CocoaBioTech/Program.html>[Accessed 08 September 
2010] 
615 Refer : <http://www.koo.gov.my/CocoaBiotech?AcDOCTRTPB.html> [Accessed 08 September 
2010] 
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essential component to maintain and sustain good and high crop productivity 
and quality.  
 
At this juncture, it is to be noted that since the filing of applications to register 
new plant varieties and grant of breeder’s rights in Malaysia  only began at the 
end of year 2008, there is no specific data obtained from the relevant research 
institutions and agencies, as the interviews for the purpose of data collection 
were carried out some time from early towards the end of the year 2008. The 
views of the RIs and the agencies, which could be speculative, on plant variety 
rights system of protection were gathered and would be analyzed in this 
Chapter, as they represent a large component of plant breeders in Malaysia. 
Having said that, the statistics as provided by the Department of Agriculture 
(DOA) on the current status and numbers of plant varieties application serve 
as major source on the figures and data relevant for this Chapter. Currently, 
the cumulative number of applications received by the DOA is 43, and there 
has yet to be any grant of plant breeder’s right, as all applications must 
undergo processes of examination as spelt out under the 2004 Act as well as 
the 2008 Regulation. 
 
The following data is the summary of the applications with regard to MARDI, 
MPOB, MRB, MCB and FRIM. 
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Number of plant varieties application by major RIs in Malaysia 
Research 
Institutes / 
Organization 
(RIs) 
Total number of new 
varieties application 
submitted to DOA (as at 
August 2010) 
Details of application 
(types of plant 
varieties) 
MARDI 14 
2 ornamentals 1 
vegetable and 11 
cereals (rice) 
MPOB 0 - 
MRB 0 - 
MCB 3 Cocoa 
FRIM 0 - 
Source: Department of Agriculture (DOA) 
It is not surprising to note that out of the total of 54 applications received by 
DOA, 14 applications come from MARDI, 3 applications from MCB, and there 
are no applications from MPOB, MRB and FRIM.616 This could be linked to the 
stand and views taken by MARDI and other remaining RIs on the effectiveness 
and necessity of the protection via plant breeder’s rights. Their views are 
scrutinized in the following discussion. 
 
8 4 8 0!$%-#!%#%*$)%!2-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The Malaysian Patents Act 1983 expressly states that plant varieties are not 
patentable.617 Hence, it seems that there was lack of formal protection for the 
new plant varieties in Malaysia prior to the implementation of the 2004 Act, 
despite the fact that the informal registration of new fruits varieties has been 
available for certification purposes since the early 1930’s.618 MARDI which had 
                                                 
616
 Other Malaysian applicants include Sabah Forestry Development Authority, Felda Agricultural 
Sdn Bhd, Universiti Kebangsaan Malaysia, private companies (Malaysian Agrifood Corporation 
Berhad, Ligno Biotech Sdn Bhd) and foreign applicants from the US and Netherlands. Source : 
DOA at <http://pvpbkkt.doa.gov.my/> [Accessed 24 August 2010] 
617
 Section 13(2)(b) of Patents Act 1983. 
618
 Refer : <http://pvpbkkt.doa.gov.my/> 
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been involved in research of all types of crops which include fruits and 
vegetables (except oil palm, rubber and cocoa) was looking forward to the 
implementation of the 2004 Act. Thus, it is not surprising that MARDI has 
started to submit its applications for plant breeder’s rights after the Regulation 
2008 came into force. In fact, MARDI has been in the forefront in terms of 
application for plant breeder’s rights as compared to other research institutes 
like MPOB, MRB, MCB and FRIM. 
 
MARDI takes a firm stand on the ban on patenting plant varieties, holding that 
the ban should be retained, and all the new plant varieties should be legally 
protected under the 2004 Act. MARDI is of the view that the 2004 Act provides 
an effective system of protection for the development of the breeding of the 
new varieties of plant. The scope of protection offered under the Protection of 
New Plant Varieties Act 2004 is comprehensive, extending to acts carried out 
on a commercial basis including producing or reproducing, conditioning for the 
purpose of propagation, offering for sale, marketing, exporting, importing and 
stocking the material for the earlier activities. Hence, unauthorized conduct of 
such acts will constitute an infringement under the 2004 Act.  
 
In addition, MARDI is in full support of the 2004 Act as the limitation that 
serves as the exclusion to the infringing acts under the Act does facilitate the 
development of new plant varieties and related research. The 2004 Act 
specifically states that the rights do not extend to any act done privately on a 
non-commercial basis or for an experimental purpose or any act done for the 
purpose of breeding other plant varieties, propagation by small farmers using 
harvested material of the registered plant variety planted on their own 
holding, exchange of reasonable amount of propagating materials among 
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small farmers and the sale of farm-saved seeds in situations where non-usage 
is beyond the control of the farmer.619 In this regard, MARDI comes under the 
exception of ‘experimental purpose’ hence its research activities should not be 
affected.  
 
MARDI’s view on retaining the ban on patenting of new plant varieties could be 
attributed to the fact that it was primarily established to conduct research to 
benefit the local farmers’ community, by way of providing better variety of 
crops to upgrade farming activities and yield enhancements. In line with this 
objective, MARDI does not look at patents as the most suitable tool to help the 
local farming community in Malaysia, as patenting research output such as 
seeds would increase the price of a patented seed supply. Any increase in the 
price may not be in favour of the farmers’ interest, and that would not help 
the local farmers, in particular subsistence and small-scale farmers, as the 
benefits of a patented seed supply could be insufficient to compensate for its 
higher price. 
 
One practical example to show MARDI’s practice and approach in managing its 
R&D output is the commercialization of a new variety of sweet potato named 
‘Vitato’620 in 1994. This new variety is more nutritious than other types of 
existing sweet potato variety because of its high B-carotene content as well as 
the ability to produce a much higher yield. Since the new PNPVP Act 2004 was 
not available when the variety was released for commercialization, obviously it 
was neither protected under PVP nor under the Patents Act 1983 which 
                                                 
619
 Section 31(1) Protection of New Plant Varieties Act 2004. 
620 Refer MARDI Agricultural Technology Website (MAGRITECH) : 
<http://agromedia.mardi.gov.my/magritech/tech_detail_fdcrop.php?id=328> [Accessed 08 
September 2010] 
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expressly exclude plant varieties from patentability. The interesting part of this 
invention by MARDI was that it was publicly available for local farmers for 
growing purposes via arrangement with MARDI.621 At this juncture, it is crystal 
clear that MARDI Agricultural Technology research team is giving priority to 
improve the living of local farming community via free access to the new 
variety rather than going into protecting its invention by way of patents or any 
other means available. The same approach is taken by MARDI in managing 
and distributing its new rice variety622 to local farmers throughout the country 
without any licensing fees whatsoever, with the primary objective of improving 
the paddy/rice breeding and increasing the productivity level of local rice. 
 
MPOB and MRB on the other hand hold an opposite view of MARDI. Both of 
these research institutes are proponents of patent protection for their research 
invention. MPOB and MRB are of the view that the ban on patenting of new 
plant variety should be lifted in order to give new varieties of plant a strong IP 
protection via patent system. In addition, they argue that protection via 
patent regime would generate more income and profit to the country and 
better economic gain as a whole. Their stand is parallel with the fact that as 
compared to MARDI which aims to serve and protect the interests of the 
farmers’ community, MPOB and MRB work directly with and for the industry 
players in their specialized agricultural  sector, hence there is a pressing, real 
need for both of the institutions to secure the strongest protection available 
for their research efforts and outcome. Having said that, patent protection is 
perceived as generally providing stronger and better protection ac compared 
                                                 
621 The same approach was taken by MARDI when another new variety of sweet potato which is 
virus-free was released in 2005, as the 2004 Act was yet to be implemented at that time. 
622 Over the past 35 years, MARDI has released 34 high-yielding rice varieties. Source : 
<http://www.mardi.my> 
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to plant breeder’s rights, though this perception continues to be a contentious 
issue worldwide. 
 
MCB shares the same view with MPOB and MRB, holding that the ban on 
patenting of new plant varieties should not be retained, for the reason that 
their forth-coming new high value cocoa varieties deserve strong protection 
through the patent right for the country’s benefit in the long run. This is 
because as far as commercialization of research and development of any 
invention is concerned, patents could be used to recoup the investment as well 
as generating income via licensing. FRIM on the other hand holds opposite 
view, stating that the ban on patenting should remain on ethical reasons, 
, patent should never be allowed on life forms which include plant varieties. 
 
To sum up, there are basically two opposite views on the ban on patenting of 
plant varieties, some of the research institutes are in favour of lifting the ban, 
while some are of the view that the ban should be retained. As far as the 
Malaysian Patents Act 1983 is concerned, the issue and discussion remains 
hypothetical at this moment of time, as the existing law states firmly that 
plant and animal varieties are non-patentable inventions.623 In this regard, it is 
worth noting that neither the Patents Act 1983 nor the Protection of New Plant 
Varieties Act 2004 makes it clear whether an invention in the form of a 
genetically modified plant that has, for example, increased resistance to 
certain types of pests, is patentable if the genetic modification (involving 
significant human intervention) used to achieve the result can be applied to 
plants in general and is not confined to any particular variety. It would seem 
that such inventions may be patentable, provided they fulfill other 
                                                 
623
 Section 13(1)(b) Patents Act 1983. 
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requirements of the Patents Act 1983, such as novelty, inventiveness, 
industrial applicability and requirements relating to non-contravention of public 
order and morality.624 
 
As far as the Protection of New Plant Varieties Act 2004 is concerned, although 
the filing of applications to register new plant varieties and grant of breeder's 
rights in Malaysia have begun since the Regulation came into operation in 
2008, it is too early at this stage to ascertain the problems, if any, that may 
arise in the implementation of the Act. Undoubtedly, the implementation of 
the Act could be seen as another milestone for Malaysia's agricultural sector 
and the country's National Biotechnology Policy as well as its IP protection 
system as a whole. 
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Further to the preceding discussion on the unclear position of patentability of a 
plant-related invention which may include genetically modified plants in 
Malaysia, the relationship and interface between patent law and plant 
breeders' rights is essentially inevitable in light of modern developments in 
biotechnology. 
 
From the responses that have been gathered during the interviews, some of 
the RIs and agencies are apprehensive about patenting varieties of plants 
though they acknowledge that genes and gene transfer technology at a 
biotechnological level should be covered by a patent system. In general, plant 
varieties have hitherto been excluded from the grant of a patent by most 
patent systems, which include Malaysia, for reasons that seem to be 
                                                 
624
 Section 11 and Section 31 Patents Act 1983. 
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unclear.625 Given a choice between the two types protection for their 
agricultural biotechnological inventions, MARDI, being the proponent of plant 
breeders right, would obviously opt for the plant variety right system of 
protection on the reason that such a system is seen to offer the most suitable 
type of protection for all new plant varieties researched and developed by 
MARDI. Besides, it is not thought to be in the public interest at large and 
Malaysian farmer’s community in particular to permit such an extensive 
monopoly over plant varieties, given their communal importance. This view is 
also adopted by FRIM, taking into consideration the scope of protection 
covered under the Protection of New Plant Varieties Act 2004.626  
 
Surprisingly, MRB shares the same view with MARDI, holding that plant 
breeder’s right would be preferable on the basis of simpler procedure and 
lower fees, as compared to higher cost incurred in a patent application. MPOB 
being the proponent of patent protection maintains that patent is still 
preferable even if the plant invention is equally qualified to be protected under 
the plant breeder’s right system of protection.627 MCB concurs with this view, 
justifying its stand on the enormous amount of time and money spent into 
researching and developing its new high value cocoa varieties. Having 
invested a considerable amount of money and time in developing innovative 
products, a patent on the research output would enable commercialization of 
the invention to obtain returns on investments as well as to generate profits.  
                                                 
625
 INNES, N.L., #%!"#3	. Available at: < http://www.agric-
econ.uni-kiel.de/Abteilungen/II/forschung/file5.pdf> [Accessed 27 January 2010] 
626 At the time of the interview (June 2008), the Act was yet to be implemented as the 2008 
Regulation was only released in October 2008. Hence the view is to some extent based on 
estimation and expectation. 
627 It is to be noted that MPOB’s legal advisor (with whom the interview was made) admitted her 
lack of knowledge on the plant breeder’s right system and its scope of protection, on the reason 
that it was yet to be implemented in Malaysia. This is to some extent justifiable, as at the time of 
the interview (June 2008), the Act was yet to be implemented, because the 2008 Regulation was 
only released in October 2008. 
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Interestingly, despite the mixed reaction towards the patent system and plant 
breeder’s right, there is a unanimous recognition from all the research 
institutions and agencies that patents provide much stronger protection than 
plant breeder’s right for the products of biotechnological research. 
 
The gathered responses from the research institutions and agencies on their 
preferred system of protection for their invention is to some extent translated 
in the current number of application of new plant varieties, as received by the 
Department of Agriculture.628 MARDI has filed a total of three applications, 
whereas MPOB, MRB MCB and FRIM have yet to file any applications.629 
 
To recap, the exclusion from patentability under Malaysian Patents Act 1983 is 
sufficiently clear to cover plant varieties, yet an invention involving plants 
seem to be patentable. What remains unclear is whether genetically modified 
plants can be both patentable as well as registrable under the Protection of 
New Plant Varieties Act 2004.630 In this regard, it would appear that Malaysia’s 
position would be consistent to that of international practice. A genetically 
modified variety would not be patentable but a plant invention that consists of 
genetically modified cell-lines would be. A clear legal position on this area is 
vital for plant breeders in Malaysia, to assist them in selecting the best and 
most suitable IPR in protecting their agricultural biotechnological inventions. 
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628 As at January 2010. 
629 Refer : <http://pvpbkkt.doa.gov.my/> 
630
 AZMI, 	Note 423. 
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As far as research in agricultural biotechnology is concerned, as mentioned in 
the early part of this Chapter, most of the research activities in Malaysia are 
conducted by government funded RIs and agencies631. Despite having a 
vibrant research community, Malaysia has lagged behind the international 
community in terms of translating research into new patents and companies. 
Among the factors contributing to the poor commercialization rate was the 
lack of co-located inventors and effective entrepreneurial strategies. This could 
be attributed to the fact that traditionally commercialization was not the main 
focus or high priority of these government-funded institutions. In fact, there 
was to some extent a communication gap between scientists, researchers and 
academicians on one hand and the commercial sector involving entrepreneurs 
and business people from the relevant industry on the other. 
 
Realizing the issues and challenges in commercialization of biotechnological 
products, the Government has taken some pro-active strategies, inter alia, the 
establishment of the National Biotechnology Directorate (NBD) in 1995 under 
the Ministry of Science, Technology and the Environment. One of the NBD's 
goals is on commercializing government-funded biotech research, other than 
strengthening research capability and capacity in biotechnology, as well as 
facilitating the development of biotechnology-based industry.  
 
                                                 
631 Research and development in plant biotechnology is also being actively pursued by the large 
plantation companies such as Guthrie Chemara Research, Golden Hope Plantation Berhad, United 
Plantation, Eastern Plantation Agency and Sime Darby. These companies have their own research 
arms and their function is often to serve the requirements and needs of their in-house market. 
The activities of the private sector are mainly restricted to those areas that have an almost 
immediate pay-off, hence their research are only focused on oil palm, bananas and ornamentals. 
Source : FAO report, available at: < http://www.fao.org/docrep/v4845e/V4845E0b.htm> 
[Accessed 27 January 2010]  
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Other strategies which have been implemented by the Malaysian government 
are by ways of grants aimed at translating research to commercialization. The 
Intensification of Research in Priority Areas (IRPA) is one of the biggest 
research funds, and the NBD also manages a research fund dedicated to 
biotechnology. For example, under the Eighth Malaysia Plan, IRPA has an 
allocation of RM1 billion, RM310 million of which is earmarked for the 
commercialization of biotech and other projects through the Industrial Grant 
Scheme (IGS) and Commercialization of Research and Development Fund 
(CRDF).632 
 
Coming back to the research institutions and agencies, based on the 
information obtained during the interview, all the five RIs and agencies have 
been commercializing their research products via licensing. Therefore, 
licensing of patent rights is the most popular and common commercialization 
pathway among the main research institutions in Malaysia. After all, patent 
licensing is the most prudent method of generating income from an invention, 
that is via royalties. MPOB and MCB are in the forefront in terms of patent 
licensing, as they even license their patents abroad. MARDI, MRB and FRIM 
have yet to license their patent rights abroad.  
 
Another method of commercialization of MARDI research product is via 
assignment, that is by way of sale and transfer of ownership of the patent by 
the assignor to the assignee. In fact, assignment is sometimes preferable by 
MARDI researchers in commercializing their research products for the reason 
that such a permanent transfer of their patents to the assignee, would release 
                                                 
632 Tang, C.M.,  2003. 3'/	+		. [online], 
Avalaible at: <http://www.nature.com/bioent/2003/030401/full/bioent731.html> [Accessed 29 
January 2010]. 
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them from the responsibility of monitoring the patented inventions in the 
event there is any patent infringement.   
 
As for MPOB, other than patent licensing, it also generates income from their 
research inventions via lump sum sale payment or direct sale. The reason is to 
avoid the risk of uncertain royalties with a licence, hence MPOB in certain 
research inventions prefers to receive a once only lump sum payment, at the 
outset, receiving all the value of the patent on one single occasion only. MCB 
is taking the same approach with MPOB in generating income from their 
patented inventions. With regard to MRB, in order to boost commercialization 
for its R&D products, MRB has gone to the extent of setting up certain sub-
companies to handle marketing strategies and matters related to 
commercialization of its inventions. This is for the reason that its researchers 
are lacking in marketing skills and strategies, hence experts in those areas 
would do a better job in promoting and commercializing MRB’s inventions. 
 
It is interesting to note at this juncture that all the five RIs and bodies are 
unanimous in viewing that the patent regime is the the best method and most 
effective protection for their agricultural biotechnological inventions, as 
compared to other alternative methods like trade secret or contractual 
agreements. MPOB being the proponent of patent holds that patent is always 
given priority to protect their R&D products. MRB and MCB concur on this 
view, with some other additional reasoning, such as patent would enable the 
investors to recoup their investment and make profits. Ultimately, patent 
would benefit the country to generate more income in the long run. On the 
other hand, most of the research institutions and agencies are of the view that 
trade secret protection is too complicated, risky and unreliable to protect their 
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research products, whereas contractual agreements are not favourable for the 
reason that such agreements are limited and only enforceable between the 
contracting parties.  
 
It is worth noting that the commercialization which has taken place in these 
institutions, present challenges, , as highlighted by MARDI during the 
interview. It was revealed that as far as MARDI is concerned, the move to 
commercialization has not resulted in any significant licensing revenue for 
MARDI, although it has licensed certain patents to some local companies. One 
reason cited is that the products which are produced by local companies under 
MARDI patent licensing are having a difficult time to penetrate the market and 
to compete with existing products. The problem could be attributed to the fact 
that local companies generally lack capabilities and competitiveness in 
marketing due to limited funds to be allocated for aggressive marketing 
strategies. 
 
Essentially, public sector research and development activities have contributed 
to technical improvements. Nevertheless, progress on the commercialization of 
such output was limited.  This was largely due to problems related to the lack 
of industry-relevant research and development projects and finance to fund 
the various stages of commercialization from the laboratory to the market 
place.  A survey633 of 5,232 projects implemented by the public research 
institutions and universities during the Sixth and Seventh Malaysian Plans 
(year 1990-2000) revealed that 14.1 per cent of these projects were identified 
as potential candidates for commercialization while only 5.1 per cent were 
                                                 
633 The survey is based on an online article by Aziz, Dato’Mohd Rosli Abdul. ,	+%
!	 Available at: <http://banktani.tripod.com/bio.htm> [Accessed 01 February 2010] 
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commercialized.  However, an assessment of research and development 
undertaken in the primary commodity sub-sector indicated that the 
percentage of commercialization of research and development in industrial 
agricultural commodities was 8.9 per cent.  In this regard, the palm oil sector 
contributed the highest commercialization rate of 12.1 per cent. 
 
In short, one of the major causes underlying this unfortunate state of affairs is 
the lack of a strong entrepreneurial environment and mechanisms for 
commercialization. In this regard, the Government’s continuous support and 
commitment for strong R&D programs at various RIs and universities in 
agricultural biotechnology should exploit the potential from biotechnology 
towards accelerating the development of agricultural biotechnology industry in 
Malaysia. In addition, RIs are obliged to place more emphasis on research 
related to product and process development for industry in order to generate 
more research and development projects that can be commercialized. 
 
 
8 6$%,$%>$%#'"#$%
The future looks promising for agricultural biotechnology in Malaysia, 
especially with strong endorsement by the Government which recognizes it as 
a high-end technology to be fully exploited in the twenty-first century, 
supported with full commitment from various RIs, public universities as well as 
a number of private companies. Being a country with strong agrarian roots 
and with the push into agricultural biotech, it is natural for Malaysia to 
leverage its traditional strengths in the agricultural sector. This Chapter has 
analyzed the viewpoint of plant breeders in Malaysia on patent protection for 
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agricultural biotechnology R&D outputs as well as their views on plant 
breeders’ right system which has just been implemented.  
 
It is found that patenting activities of R&D inventions in the major RIs and 
agencies have already taken place for quite some time, but they started to 
gain popularity and become a trend from the year 2000s onwards. The 
findings could be seen as positive indicator of the awareness on the 
importance of protecting their inventions via IPRs notably patents. Besides, 
patents are useful indicators for identifying the fields where technological 
advances are being made, and this includes agricultural biotechnology. 
 
The patent regime seems to be preferred by the majority of the RIs and 
agencies for the reason that it offers strong and reliable protection over 
inventions, as well as the opportunity to recoup the investment and make 
profits. Nevertheless, as far as the legal framework is concerned, there is a 
need to further clarify the scope of patentable and non-patentable inventions 
under Patents Act 1983, to the effect that an invention in the form of a 
genetically modified plant would be patentable provided the invention is not 
confined to any particular variety.  
 
The effectiveness of protection offered under the Protection of New Plant 
Varieties Act 2004 is yet to be seen, but this pan-Malaysian, 		 form 
of protection is specifically tailored for breeders of new plant varieties in 
Malaysia. The protection offered under the 2004 Act, in comparison to the 
patent system, may be preferable among plant breeders for some reasons, 
 , the lesser cost incurred in registering for a plant variety right. 
Nevertheless, the time factor to fulfill the requirements of uniformity and 
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stability of a plant variety is a concern which is relevant to be taken into 
account in ascertaining the best method of protection for such a variety or 
transgenic plant. 
 
With regard to commercialization of R&D inventions, public sector RIs have 
produced significant amounts of research on resource-based industries.  
However, the initiative to commercialize such findings remains limited due to 
the high costs and risks involved.  The Government’s role and initiatives are 
inevitable to provide assistance and support to Malaysian-owned companies to 
enable them to step forward to spearhead and stimulate the commercialization 
of findings of local R&D.   
 
All in all, the Malaysian biotechnology industry is on track to accelerate 
commercialization in biotechnology by the year 2011 with the full support of 
the National Biotechnology Policy and BiotechCorp. 
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Innovation and creativity are one of fundamental drivers of progress in most 
societies. All countries, which include developed and developing countries, 
have the potential to develop their intellectual property assets, and to reap 
benefits from them for their people. The ability to manage and exploit 
innovation and resultant intellectual property rights is a key to success in 
today’s world in which intellectual, rather than physical, assets are one of the 
primary sources of wealth and competitive advantage. Recognition and 
protection of intellectual property assets are therefore necessary preconditions 
for development today. The World Economic Forum Global Competitiveness 
Report, for example, indicates that a correlation between the protection of 
intellectual property rights and national competitiveness exists. The 20 
countries which were perceived as having the most stringent intellectual 
property protection were classed among the top 27 in the WEF’s growth 
competitiveness index. Conversely, the 20 countries perceived as having the 
weakest intellectual property regimes were ranked among the bottom 36 for 
growth and competitiveness.634 
 
Interestingly, many developing countries apparently recognize the importance 
of a strong IP regime and are increasingly using the protection of IPto grow 
and expand local innovation-based industries. This Chapter seeks to answer 
the main research question of this thesis, namely to propose the best way to 
                                                 
634 World Economic Forum, Global Competitiveness Report 2004-5, available at : < 
http://www.weforum.org/pdf/Gcr/GCR_05_06_Executive_Summary.pdf> [Accessed 30 
September 2010] 
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protect agricultural biotechnological inventions in Malaysia. The discussion 
includes an overview of the current IPR legislation in Malaysia, as well as the 
recent developments for the protection of the agricultural biotechnological 
inventions in Malaysia. The proposed model which is presented in this Chapter 
would take into consideration relevant factors, in particular the pace of 
development of Malaysia as a developing country. The model is also drafted by 
taking into account all the things learnt and benefited from the existing IPR 
jurisdictions in Europe and the U.S. as covered in previous Chapters of this 
thesis. 

6 .,1*'$%
6 . 0''!%#
!*#$%%(
Malaysia has a strong IPR regime and ranks high among East Asian countries 
in IPR protection. Hence, it is not surprising that Malaysia is committed to 
providing a strong IP protection regime under its National Biotechnology 
Policy. There are two main streams of protection for agricultural 
biotechnological inventions namely under the patent regime (Patents Act 
1983) and under PVP (Protection of New Plant Varieties Act 2004).  
 
6 . . 	*',#' $#!,%$$*( !!', % ( 
!'#%*
!%*!
 
Some of the impediments and challenges635 which are oft-cited; the lack of 
skilled, experienced manpower in the field of biotechnology, a lack of linkages 
between industry and R&D, the issue of commercialization and the low 
                                                 
635 The impediments have been discussed in detail in Chapter 4 (under item 4.3). 
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percentage of global players are also part of the challenges that contribute to 
the slow growth of biotechnology R&D.  
 
6 . 4?(#!'!%!!)$'%!%%,!
'!*!%(
While intellectual property protection is a necessary pre-condition of 
development in today’s world, such protection has to be supported by other 
appropriate policies and a deep commitment by governments to establish an 
effective infrastructure to process and make use of intellectual property rights. 
Without positive action by individual governments, the intellectual property 
system will not fulfill its potential as a tool for development, growth and 
progress. 
 
Government is fully aware of the persisting challenges as mentioned in the 
preceding discussion, hence it is acknowledged that the country needs to 
improve and enhance its IPR regime in order to speed up and optimize the 
growth of its biotechnology industry. This is strengthened by the fact that 
Malaysia aspires to become one of Asia's top biotechnologydestinations, with 
lucrative biotechnology industry. Hence, it is inevitable that the country needs 
to strengthen its legislation vis-à-vis IPR protection in order to assure a 
conducive environment for the development of the biotechnology industry. 
Being a developing country with such a high aspiration, the question is 
whether Malaysia needs to adopt the IPR regimes as practised in developed 
nations, or whether it is viable for the country to formulate and focus solely on 
a unique 		 IPR model to cater for the needs and protection of those 
involved in the agricultural biotechnology industry. 

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In terms of patents statistics, the number of patents applied for in the 
agricultural biotechnology sector is relatively low if compared to healthcare 
and industrial biotechnology. For example, from the year 2004-2008, 
agricultural biotechnology recorded 14.3% patents applied for and 11.9% 
patents granted, while the substantial percentage of patents applied for and 
granted comes from healthcare and industrial biotechnology.636 It is 
noteworthy that the statistics could serve as indicator of companies’ concern 
about the exclusion of patentability of plants and animal varieties. In addition, 
some companies may prefer to keep their inventions as trade secrets rather 
than going through the lengthy, time-consuming process of patenting. 
However, the number of patents applied for and granted is not the only 
indicator, yet to some extent they are an important tool to measure the 
successful commercialization of ideas and IP. Hence, there is obviously a need 
to enhance the existing IP legislation, in particular in relation to patent laws 
and PVP laws, in order to stimulate more patent applications with the aim of 
stimulating more R&D and boost commercialization of the R&D outputs in 
agricultural biotechnology. 
 
6 4$!'!,!%#!&!$-!%#
Malaysia’s ranking in terms of IP rights enforcement has improved to number 
27 in 2009, compared to number 33 in 2008. Awareness in terms of patent 
protection and recognition of its value and importance has risen in Malaysia 
and the number of patents in force per 100,000 of the population improved in 
2009.637 Thrust seven of the National Biotechnology Policy638 highlighted the 
                                                 
636
 BIOTECH CORP., 2009. 	%"37;;A<7;E;,  Available at : < 
http://www.biotechcorp.com.my/Documents/AboutBiotechCorp/country%20report%20double.pdf
> [Accessed 04 October 2010]. 
637 ! 
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need to improve the country's innovation system by reviewing the legal and 
regulatory framework. In the context of IP protection for agricultural 
biotechnological inventions, there have been recent developments. These 
developments are part of the continuous enhancement of Malaysia’s legislative 
and regulatory framework to create an environment that is conducive to 
innovation and investment in biotechnology in Malaysia. 
 
Part of this effort involves making regulatory changes to give researchers a 
share in the ownership of the IP and in the monetary rewards derived from 
their work. As far as the IPR laws are concerned, the government is 
undertaking several studies and is reviewing its institutional, legal and 
regulatory and financial framework. 
 
6 4 0 +')# % $) !B%#$% *!%! )$' "$#!,%$$*(
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
The government is aware that an efficient and effective IP protection system is 
necessary to ensure that attainment of protection and rights are rapid and 
straightforward. In order to achieve this, the administration of the Intellectual 
Property Corporation of Malaysia (MyIPO) must be improved and strengthen to 
meet the yearly increase in registration applications and also to ensure that 
the needs of applicants are met. Other than simple application procedures and 
speedy registration, availability of quality public search facilities and efficient 
information dissemination systems639, clear registration and examination 
guidelines are essential elements which contribute to a high standard of IP 
                                                                                                                                      
638 The National Biotechnology Policy (NBP) was launched in 2005 to provide a development 
framework for the biotechnology industry in Malaysia. 
639 , note 518. MyIPO’s online filing system is under PANTAS, which is also an online patents 
and trademark database. 
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protection. As far as biotechnology is concerned, there is a real need for 
patent examiners at MyIPO to have a clear examination guideline in dealing 
with biotechnology patents, hence a manual of such guidelines has been 
drafted in last few years. The manual is still in draft form and yet to be 
finalized, pending various meetings and discussions with stakeholders and 
representatives from biotechnology industry players.640 
 
6 4 .!&!2$)!B#%*
###!"(-!,,$##!!
The Government, via MyIPO, has recently set up a special committee for the 
purpose of reviewing and proposing any amendment to the current IPR 
statutes namely Patents Act 1983, Trade Marks Act 1976, Copyright Act 1987, 
Industrial Designs Act 1996. 
 
According to MyIPO,641 the Patents Act 1983 will be undergoing some 
amendment. There are not going to be any major changes or amendment in 
terms of patentability criteria, although there is some discussion on whether 
the industrial application requirement needs to be tightened up in relation to 
biotechnological inventions. One of the areas of amendment would be defining 
the term ‘microorganism’ for clarification purposes. Currently, under Section 
13(1)(b) of the Patents Act, ‘man-made living micro-organisms’, ‘micro-
biological processes’ and ‘the products of such micro-organism processes’ is 
not excluded from patentability. However, the Act has no clear definition of 
such terms. With the definition in place, inventors need no longer be 
apprehensive on the patentability of their biotech inventions and are 
encouraged to file patents to protect their innovation.  
                                                 
640 Latest update as confirmed by MyIPO via email communication on 6th September 2010. 
641 The Director General of MyIPO has indicated that they are targeting for the Patent Act 
amendments to be tabled to parliament by early 2011; Source : 	  note 9. 
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Other than reviewing the provisions of the statutes, the committee had also 
been in meetings with the stakeholders to discuss and obtain feedback in 
relation to issues relating biotech inventions, transgenic plant and animal 
inventions, stem cells, genes and so forth. The outcome of the review by the 
special committee is yet to be made available to the public as the discussions 
are still ongoing.642 
 
6 4 4	,,!$%#$

To-date, Malaysia has yet to become a Member of UPOV. Although the current 
Malaysian Act, namely Protection of New Plant Varieties Act 2004 can be said 
to be 90 percent UPOV-compliant and was created with entry into UPOV in 
mind, some provisions would have to be revised and amended if Malaysia 
were to ratify UPOV 1991 pursuant to UPOV Council’s recommendation.643 
Apparently there is no easy way to comply with the UPOV Council’s 
recommendation in some of the major parts, for example to separate the 
provision on the lower threshold of registrability for traditional varieties from 
the current 2004 Act, due to the reason that the Act itself was enacted 
 to provide for the protection of the rights of informal breeders which 
include farmers, local communities and indigenous people. 
 
Joining UPOV would be a big step forward for Malaysia, as the agricultural 
sector is dependant on two main crops, namely palm oil trees and rubber trees 
which need to be protected not only in Malaysia, but also in other countries 
which are capable of growing such trees. The country's rapidly growing 
                                                 
642 The information is given by one of the committee members in the special committee, solely for 
the thesis purpose, as the minute and details of the meeting is confidential. 
643 , note 540. 
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agricultural and horticultural sectors would also benefit from UPOV 
membership, but the Government is currently giving priority to the 
implementation of the domestic law over the UPOV accession. Hence, the 
Government is keen to see the response from the breeders as the 2004 Act 
has just been implemented in October 2008. The agenda of accession to UPOV 
is not totally abandoned yet it is held in abeyance. After all, it has been proven 
that breeders only introduce foreign bred varieties in large numbers in a 
country after it has gained UPOV membership, which provides a seal of 
approval that the plant varieties laws in a particular country are up to 
standard.644 
 
6 3!-'$-$!
$!)$'(
The Government, via the National Biotechnology Policy, rightfully identifies the 
effectiveness  of the regulatory framework as a key factor for the development 
of the biotechnology sector in Malaysia. It is important for a country which has 
a clearly stated objective in relation to developing biotechnology as an engine 
for national growth to then reflect such policies in its legal and regulatory 
framework, especially those directly impacting the area of biotechnology. 
 
6 3 0!$%)'$!B#%*$!
This thesis has carefully and purposely selected  important models from two 
main jurisdictions, namely the European model and U.S. model for the 
purpose of comparison and learning from the their experiences in managing 
their IP laws vis-à-vis protection of agricultural biotechnological inventions. 
                                                 
644 For example, South Korea had only national applications for plant protection before joining 
UPOV in 2002, but in its first year of membership it received 350 foreign applications. Refer : 
OLLIER, PETER. 2008. 	 	 + +   -	  available at : 
<http://www.managingip.com/Article/1941365/Channel/194878/Asia-reaps-benefit-of-plant-
variety-laws.html?ArticleId=1941365&p=2> [Accessed 07 October 2010] 
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Understandably, both models are from developed nations, whereas Malaysia is 
currently under the status of a developing country. The selection of the models 
is premised on the fact that Malaysia aspires to become a developed nation in 
year 2020. In this regard, it is logical and justifiable for the country to steer its 
legal and regulatory framework based on the IP laws of developed countries, 
provided it suits local circumstances and the affected industry. 
 
6 3 0 0'#$!'$-!>I
Chapter Two discussed in detailed the two important systems of legal 
protection for agricultural biotechnological inventions as currently practised in 
Europe and UK via patent regime and plant breeder’s rights. As far as the 
scenario in Europe is concerned, the European patent regime is governed 
under two main sources of patent law, namely the EPC and the Biotechnology 
Directive (EU Directive 98/44). Under the EPC, plant varieties are considered 
non-patentable subject-matter and protected only under a specialized plant 
breeders’ rights form of protection. The EU Directive 98/44 which was adopted 
by the European Parliament and the Council of the EU in harmonizing the 
national laws of EU Member States is seen as a real need to clear any 
uncertainty relating to the protection of biotechnological inventions. 
 
<=!$%!'%#)'$'$-!%$!
Plant breeder’s rights under the UPOV Convention were initially introduced to 
provide for a much more appropriate, specifically designed sui generis right 
and protection for European breeders. It was also felt that plant material could 
not meet the patent law notion of novelty, and plant breeding programs could 
rarely be shown to be inventive. In addition, it was thought that it would not 
be in the public interest to allow plant breeders to have an over-extensive 
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monopoly and it would be difficult for plant material to meet the disclosure 
requirement. Nevertheless, it has been proven nowadays that with the 
progress and development in plant bioscience, all the perceived challenges are 
no longer fully justified. The 1961 and 1978 UPOV Acts which contained a 
prohibition on protection of the grant of patent right over a plant variety was 
removed from the text of the 1991 Act of UPOV. The evolution of UPOV 
indicates that the breeders and inventors in agricultural biotechnology industry 
in Europe currently have the option to select the best method of protection for 
their R&D output, either via plant breeder’s right or via patent law.  
 
On the issue of patentability of agricultural biotechnological inventions, 
specifically plant varieties and transgenic plants, the current position in Europe 
is that a plant variety 	 remains non-patentable under patent laws645, but 
an invention is patentable if it concerns plants or animals provided the 
technical feasibility of the invention is not confined to a particular plant or 
animal variety.646 In other words, provided that a patent application that is 
directed to a plant-related invention satisfies the patentability requirement of 
novelty, inventiveness, sufficiency of disclosure, and capability for industrial 
application, such patents over plants are now permitted under the EPC as 
patents can be granted for inventions that cover more than a single variety. 
This observation is made on the basis of the amended EPC, the European 
Directive and recent European case law as discussed in Chapter Two of this 
thesis. 
 
                                                 
645 For example, Section 76A(1) UK Patents Act 1977 (under Schedule A2). 
646 Rule 23c(b) EPC. 
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In one aspect, European law appears to give priority to the PVR system as 
plant varieties may be protected by national PVRs or by a uniform Community-
wide PVR; European patents are excluded for plant varieties and for essentially 
biological processes for the production of plants. Nevertheless in reality, the 
European legal framework does not really reduce the area of possible overlap 
between the two systems, since the patent system remains capable of 
covering plant-related innovations notwithstanding the exclusivity of 
protection of plant varieties under the PVR system. In this regard, it is 
submitted that the European legal framework is far from drawing a clear 
demarcation line between the two systems of protection. Instead, the overlap 
area remains rather broad so that, on the issue of availability of protection, 
European law is, in its practical consequences, not so different from national 
systems such as the US systems which expressly accept the patentability of 
plant varieties. 
 
Turning back to the issue on the European model of IP legal framework in 
protecting to agricultural biotechnological inventions, it is submitted the 
current legal position in Europe seems to work quite well for the industry. For 
example, in UK, until the early 1960s, plant breeding in was largely confined to 
publicly funded research. This situation changed dramatically in the mid-1960s 
when Plant Breeders’ Rights were introduced in the UK through the 1964 Plant 
Varieties and Seeds Act. This triggered a rapid expansion of plant breeding as 
a commercial enterprise in its own right, and paved the way for major 
advances in the performance, quality and diversity of crop production in UK.647 
It is clear that plant breeders have delivered major advances in the yield, 
                                                 
647 BRITISH SOCIETY OF PLANT BREEDERS, # %/ 0 %			  	"" + "
, Available at : <www.bspb.co.uk> [Accessed 12 October 2010]. 
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quality and performance of agricultural and horticultural crops in UK. In the 
year 2009, 98% of winter wheat varieties and 97% of spring barley varieties 
sold as certified seed came from UK breeders.648 Today, much of the basic 
research into crop science is still conducted by public sector organizations, but 
the majority of commercial plant breeding takes place within the private 
sector. The situation is similar to Malaysia, in the sense that most of the R&D 
activities of agricultural biotechnology is carried out by government funded 
bodies and institutions, and some commercial plant breeding take place within 
the private sector, which includes big corporations like Sime Darby.649 
 
Nevertheless, the issue of farm-saved seeds650 has been one of the major 
concerns in Europe as some local farmers651 are dependant on their saved-
seed for replanting. The issue might not be that relevant to Malaysia’s scenario 
of farming community, as farmers in Malaysia, for example paddy planters are 
in practice of obtaining fresh seeds for every season, supplied by relevant 
government authorities. Nevertheless, the relevant part of the issue is the fact 
that the concept of the farmers’ exemption which has been introduced in UK, 
exempting ‘small farmers’652 from paying royalties for their farm-saved seed. 
Under the exemption, small farmers are only authorized to re-use their own 
seed for planting. The similar approach is adopted by Malaysian’s government 
under the Protection of New Plant Varieties Act 2004, which gives recognition 
and protection of contribution made by farmers, local communities and 
                                                 
648 Refer <http://www.fairplay.org.uk > [Accessed 12 October 2010] 
649 Refer <http://www.simedarbyplantation.com/Plantations_Overview-;_Malaysia.aspx> 
[Accessed 13 October 2010] 
650 For certain crop species – particularly small-grain cereals, growers used to save their own seed 
for sowing the following year. 
651 For example, in UK, in year 2001, 30% of farmers were dependant on farm-saved cereal seed 
for replanting their farm, hence a number of them have objected to the principle of paying 
royalties on farm-saved seed. Refer : 
<http://5d.5a.5746.static.theplanet.com/article.php?artid=91> [Accessed 12 October 2010] 
652 Those who produce less than 92 tons of cereal, P Refer Section 9 of UK Plant Varieties Act 
1997. 
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indigenous people653 towards the creation of new plant varieties under specific 
provision of the 2004 Act.654 
 
Plant breeding remains a vital industry to keep Britain and other European 
countries competitive in world markets. The introduction and implementation 
of PVR in UK in particular and in Europe at large has to some extent 
successfully been used as a legal way to facilitate the development of new 
plant varieties, seeds and the seed market thus assuring seed quality for 
farmers. The patent regime on the other hand continues to offer a better, 
stronger protection for plant related inventions as administered under the 
EPO. This is particularly the case where technologies can be applied to several 
different varieties of the same crop, or across a range of different species. 
Patent protection is inevitable in such a situation as developments cannot be 
protected under the variety-specific system of PVR. 
 
6 3 0 .!,$%$!#!  
Chapter Three explored the three types of legal protection currently available 
for plant-related invention in the US, that is via plant patent, the plant variety 
protection certificate and the utility patent. Legal protection for plant varieties 
was introduced in the US long before the development of genetically 
engineered plants. Such a unique, open system of legal protection in the US 
could be traced back to historical reasons and local circumstances at that 
particular point of time. When it comes to contemporary patent protection for 
new plants and other living things, it helps to know the context that two 
                                                 
653 In order to give better protection to the rights of indigenous people, the Malaysian Government 
had been considering a draft Access and Benefit Sharing Law since year 2002, but as at to-date, 
the efforts have not materialized into any Act. Refer : <http://www.grain.org/briefings/?id=97> 
[Accessed : 01 December 2010]. 
654 For example, Section 31(1) (d), (e) and (f). 
348 
 
important statutory changes provide. One took place in 1930 (the Plant Patent 
Act),655 and the other in 1970 (the Plant Variety Protection Act). In both 
instances, Congress responded to what industry players said was an inability 
to get utility patent protection for their inventions on an equal footing with 
other industries. Congress expanded the scope of patentable subject matter 
on both occasions. 
 
Such a legal system in the US for the protection of agricultural 
biotechnological inventions is based on the fundamental role of intellectual 
property in the promotion of agricultural research and innovation. With an 
average time to market for each new product exceeding 10 years in most 
cases, due to stringent regulatory approval timelines, the crop protection 
industry could not contribute to future investment without patent protection. 
Since the first commercial biotech crops were grown in 1996, plant 
biotechnology has been rapidly adopted by farmers in the U.S. Increasingly, 
farmers are now planting biotech seeds because of the clear benefits they 
bring. Crops commercialized to date have been modified to improve agronomic 
traits like insect resistance and herbicide tolerance or a combination of the 
two. 
 
<=!$%!'%#)'$#!	!',%$!
The present system of legislation and legal framework in the U.S. is very much 
shaped and influenced by the industry players. Congress responded to 
breeders’ requests in 1930 by enacting PPA, and in 1970, a patent-like system 
for seed-reproduced plants was enacted, namely the PVPA. The enactment of 
                                                 
655 The PPA ‘was the first legislation anywhere in the world to grant patent rights to plant 
breeders.’ !'(	 !"
		  69 F.3d 1560, 1563 (Fed. Cir. 1995), 	 
note 438. 
349 
 
the PVPA was   in response to the exertion by crop seed companies 
which sought for an IP protection for their sexually reproduced plants. 
Nevertheless, the significant exceptions inherent in the PVPA proved                      
unsatisfactory among commercial seed companies. As a result, utility patent 
protection remained desirable to the seed companies. The system evolved in 
the 1980s when IP protection for crop breeding innovations in the U.S. was 
expanded, and its enforcement has been strengthened. This has encouraged 
the development, introduction, and rapid adoption of highly successful 
transgenic varieties of soybeans, cotton, corn, and canola. 
 
Such an open tri-partite system of protection for plant innovation may not be 
useful to Malaysia for historical reasons, which are very different to the U.S. 
As far as the Malaysian situation is concerned, laws and statutes are drafted 
and enacted by Parliament. In the U.S., as mentioned above, it was obvious 
that breeders and industry players played an important influence in shaping 
the legal framework and laws relating to plant inventions, and history has 
swhon that Congress responded via enactment of new law to assure the 
relevant legal protection. For example, in the U.S., before 1930, plant 
breeders who created new types of plants had no claim to the marketing rights 
or sales of their plants, even though it might have taken them a great amount 
of time and effort to breed a new plant. Hence the PPA was enacted to help 
plant breeders make up for the costs of developing new types of plants. Since 
breeding and researching new plants can take a lot of time, money and effort, 
having exclusive marketing rights helps make it worthwhile for breeders to 
keep creating new plants.  
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Such a scenario is uncommon in Malaysia, taking into account the fact that 
modern agricultural biotechnology is a new field and the awareness of the 
importance of legal protection for the R&D output and biotechnology invention 
is still lacking. In most of public research institutions for instance, obtaining IP 
protection for an invention was not a culture, until the trend changed in the 
last few years, in response to the Government efforts to raise the awareness 
of the importance of IP legislation. Conventional breeders and farmers who 
have been involved in traditional plant breeding in Malaysia did not encounter 
the similar problems in the U.S. prior to 1930, as the farming and agricultural 
industry was not a big industry that required specific legal protection via 
patent or the like. Besides, Malaysia was a under foreign occupation, until it 
gained independence in 1957, and the Patents Act of Malaysia was only 
enacted in 1983. 
 
Malaysia instituted a range of IP laws in the 1980s, including the Patents Act 
of 1983. The Patents Act has been amended several times, both before and 
after Malaysia joined the WTO and signed TRIPS in 1995. The Patents Act 
excludes from patentability the same life-science subject matter excluded in 
TRIPS, including plant and animal varieties and essentially biological 
processes. Hence the issue of legal protection of agricultural biotechnological 
inventions emerged only in late 1990s, after the signing of the TRIPS 
Agreement, in parallel to the increased concern and active R&D in agricultural 
biotechnology by public funded institutions like MARDI, MPOB, MRB and the 
like.656 The Protection of New Plant Varieties Act of 2004 is a much newer 
piece of legislation, which has only recently been implemented in year 2008. 
 
                                                 
656 The discussion on the role of these RIs was made in Chapter Four and Five of this thesis. 
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Another issue which would be a major concern is the interest of small farmers 
and local companies that may be jeopardized if Malaysia were to adopt the 
three-tier protection for plant innovation as currently in practice in the U.S. 
The implementation of such an open system of protection (via plant patent, 
PVP and utility patent) would undoubtedly attract foreign companies in 
particular multi-national corporations to file and apply for patent grants over 
their invention in the country. The statistics and analysis in Chapter Three 
have shown that for some types of protection, foreign companies would 
dominate as the majority percentage of patent ownership657 and the allocation 
of rights lacking balance is always an issue in such a situation. Based on the 
U.S. experience, there is a very high probability that if Malaysia were to 
strengthen its current patent laws, for example by lifting the ban on patenting 
plant varieties so that they would come under patentable subject-matter, 
multi-national corporations and big international players would be in the front 
row to file their patent applications, rather than the small farmers of local RIs. 
 
Those against the patent system in the U.S. argue that it does not recognize 
or reward the contribution of communities of farmers who have developed, 
over long periods of time, the landraces that form the basis of the pedigrees of 
modern crop varieties. In a developing country like Malaysia wherein the small 
and medium size farming community constitutes an important segment of the 
industry, it is submitted that the alternative, simpler system as available 
under the new statute (PNPVA) would gradually gain popularity among local 
                                                 
657 For example, statistics in Chapter Three (Chart 3.5) show that majority of total ownership of 
granted plant patents is held by foreign residents. 
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breeders, though the effectiveness of the protection remains to be seen,658 
vis-à-vis its exceptions and relatively generous exemptions. 
 
6 3 .!$!)$'(#2$2(--'$, 
Based on the two current model laws as discussed above, it is the finding of 
this thesis that there is unlikely to be a single IP protection framework that will 
stimulate innovative plant breeding and work best for the development of 
agricultural biotechnology industry. Both existing systems of protection via 
patent regime and PVR are important as they play their own, unique role in 
providing the suitable methods of protection and a wider option for plant 
breeders and inventors in agricultural biotechnology. 

6 3 . 0!#'!$)$!$)
(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)$'(  
Assessing the optimal level of IP protection for Malaysia is not an easy task. 
The obligation becomes much more difficult in balancing the rights between 
the interests of the small farmers, indigenous people and local breeders and 
those private companies, multi-national corporations in agricultural 
biotechnology industry. A weak IP right might be more appropriate for local 
seed systems, for example, in allowing free access of patented seeds to local 
farmers, but inevitably stronger rights are necessary to protect the 
commercial and export crops which are part of important commodity for 
Malaysia such palm oil and rubber trees. 

<=!!%%,!!%#$)!B#%*
#!%#	,#0974
                                                 
658 As at October 2010, the PVP Office has received a total of 54 applications since October 2008, 
and there is yet any grant of PBR certificate to the applicants. 
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It is submitted that stronger IP protection would be much more attractive for 
inventors and investors in plant breeding and those involved in R&D of 
agricultural biotechnology. The current scope of patent protection under the 
1983 Act is generally at a par with the international standard from various 
jurisdictions of IP laws, but some enhancement would be plausible as a 
dynamic move towards strengthening the existing framework. 
 
<=!'!'-'$&$%%%#!'-'!##$%
The first enhancement that would be of paramount importance is to provide 
for a clear, express provision to allow patentability of transgenic plants. The 
current position on the issue of patentability of transgenic plants is only by 
way of implication. The presumption of patentability of transgenic plants is 
made on the basis that the Patents Act 1983 does not expressly prohibit their 
patenting, as they do not fall under any provisions of Section 13 of the 1983 
Act which spells out the list of non-patentable inventions.659 An express 
provision on this matter would eliminate any uncertainty or potential debate 
on the patentability of transgenic plants which do not amount to or do not fall 
under plant variety exceptions. 
 
The second enhancement which is equally essential is to provide for a clearer 
interpretation for the terms that relate to patent requirements, namely 
‘inventive step’ and ‘industrial application’ vis-à-vis plant related innovations. 
                                                 
659 13.—(1) Notwithstanding the fact that they may be inventions within the meaning of section 
12, the following shall not be patentable: 
(a) discoveries, scientific theories and mathematical methods; 
(b) plant or animal varieties or essentially biological processes for the production of plants or 
animals, other than man-made living micro-organisms, micro-biological processes and the 
products of such micro-organism processes; 
(c) schemes, rules or methods for doing business, performing purely mental acts or playing 
games; 
(d) methods for the treatment of the human or animal body by surgery or therapy, and diagnostic 
methods practised on the human or animal body: 
Provided that this paragraph shall not apply to products used in any such methods. 
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The draft manual of examination of biotechnological patent is a timely effort 
that is thought would address these issues of uncertainty in determining the 
requirement of inventive step and industrial application for agricultural 
biotechnological inventions. MyIPO is currently finalizing the works on 
revamping and reviewing the IP statutes of Malaysia, and the tasks include 
reviewing the Patents Act 1983. With regard to the draft manual of 
examination of biotechnological patent, it is the pipeline, and the draft would 
be dealt with and eventually would be finalized after the completion of the 
review of the related IP Acts. 
 
A clearer provision and interpretation of patent law would make the application 
for patent and the filing process easier for the patent applicants and 
eventually facilitate a quicker process of patent examination.660 Such a matter 
would eventually contribute towards a better, improved patent system in 
Malaysia. 
 
<"= ! ##( %%$&#$%  #$ "! ! &"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A unique feature of Malaysian patent law as compared to UK is on the part of 
utility innovation. Section 17 of Malaysia Patents Act 1983 provides for the 
definition, application and conversion from an application for a patent into an 
application for a certificate for a utility innovation and vice versa. Utility 
innovation means ‘any innovation which creates a new product or process, or 
any improvement of a known product or process, which can be made or used 
in any kind of industry, and includes an invention.’ Utility innovation has lesser 
                                                 
660 The formulation of an amended, clearer interpretation would entail a deeper discussion as such 
a task could only be done  by referring to various existing manual on patent examination 
guidelines from various jurisdictions such as the Europe, the U.S., Japan, Australia and so forth. 
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requirements compared to a patent which needs to involve an inventive step. 
Hence, the certificate of utility innovation is actually meant for a less 
innovative invention. As the term ‘any kind of industry’ is general and wide 
and would cover agricultural biotechnology industry, it is submitted that the 
protection afforded via the certificate should be made equally available to 
transgenic plants and new plant varieties that are not limited to a single 
variety. 
 
A utility innovation can be applied for as long as it is new and industrially 
applicable. Even though the utility innovation is subjected to a substantive 
examination as a patent application, the omission of the ‘inventive step’ 
requirement would enable the applicant to enforce his right more quickly than 
a typical patent application routine. Any plant related invention that fulfils the 
criteria of novelty and industrial applicability is submitted to qualify for 
protection under utility innovation. In this regard, it is noteworthy that the 
R&D agricultural biotechnological research in Malaysia is largely focusing on 
the application of existing technology. For example, some RIs in Malaysia have 
been focusing on two input traits (Bt and herbicide tolerance) and this 
suggests that part of the nature of R&D agricultural research in Malaysia is 
only making use of the ‘old’ technology rather than initiating and venturing 
into totally new technology. The approach is justified on the premise that it is 
much more economical and practical to produce certain target crops with Bt 
and herbicide tolerance, for example, MCB is solely focusing on cocoa plant 
and all kinds of research activities relating to cocoa biotechnology. 
 
The availability of protection under utility innovation for plant innovation would 
provide a better option for plant breeders, as there are only two criteria to be 
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fulfilled instead of three. This means that transgenic plants, at any stage of 
research, that do not fulfill, or have problems in satisfying, the requirement of 
inventive step, may be protected by way of certificate if utility innovation. 
After all, much plant breeding is sequential, utilizing the best existing varieties 
to enhance future ones. While the requirement of ‘novelty’ is always to be 
met, that of ‘inventive step’ may be much lower or in case of Malaysian patent 
laws, absent altogether. This means that the utility innovation examination 
process would be faster, because of the omission of one patentability 
requirement, as compared to patent application. 
 
In one aspect, the proposed approach in allowing utility innovation for 
transgenic plants and new plants varieties which are not limited to single 
variety, to some extent parallels to the approach in the U.S. system of plant 
patent, which allows transgenic plant and plant varieties that propagate 
asexually to be patented without an enablement requirement. In other words, 
utility innovation in Malaysia does not require the invention to be ‘inventive’, 
while application for plant patents in the U.S. exempts the detailed description 
associated with utility patents. Such an approach is practical and feasible to 
facilitate protection for plant-related innovation in Malaysia. 
 
<,=!"%$%-#!%#%*$)-%#&'!#!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An important enhancement is in relation to the issue of non-patentability of 
plant varieties. The 1983 Act is parallel to UK Patents Act 1977, hence lifting 
the ban on patentability of plant varieties would amount to a drastic diversion 
from the UK patent laws as well as the European patent laws. It is submitted 
that the liberal approach adopted by American patent law framework is not 
suitable for Malaysia, as the R&D in the agricultural sector is still in the hands 
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of public research institutes. This is in contrast to the situation in the U.S, in 
which multi-national corporations and the private sector are the main players 
in the industry. After all, the American patent law regime is largely based on 
historical reasons, which are not applicable or relevant to Malaysia. It is 
therefore submitted that the Malaysian patent regime should adopt the current 
European approach in retaining the ban on patenting of new plant varieties, 
but the scope is restricted in the sense that if the plant invention in is not 
limited to a particular variety, then patent should be allowed. 
 
Allowing patentability for such plant varieties which are not limited to a single 
variety is important and would provide assurance and security for inventors, 
plant breeders and researchers in protecting their inventions. As discussed in 
Chapter Two, it is reiterated and submitted that in comparison to PVP, the 
patent system provides for a stronger protection for agricultural 
biotechnological inventions. The submission is premised on the patentability 
requirements that the invention must be new, involve an inventive step and 
applicable for industrial application are relatively easier and quicker to be 
satisfied, as compared to the DUS requirements to be fulfilled under PVP. The 
uniformity and stability requirements eventually consume a long period of 
time, and protection via PVP would only be obtained once a plant variety could 
be shown as uniform and stable.  
 
On the other hand, under the patent system, an inventor of a transgenic plant 
(which may embrace a plant variety) has the option to apply for patent 
protection right from the very early stage of research, for instance patent on 
genes or plant cells or process. This is because patent rules permit the 
inventor to apply early to the patent office at a time when many details of the 
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invention have still to be clarified. Further work and investment may be 
necessary before the invention becomes a marketable product. Allowing 
patentability of plant varieties (that is not limited to single variety) would be 
feasible and workable in relation to recent developments in plant bioscience 
and biotechnology. Some of the latest advancement in plant biotechnology 
have proven that there would not be much problem in satisfying those 
patentability requirements under patent laws. In this regard, patent 
applications could now be filed and granted in most jurisdictions for the 
invention in the form of transgenic plants provided the patentability 
requirements are met. 
 
<=!##$%$) '!!',!B!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There is reasonable overlap between patent and PVP, and some of the 
revisions to UPOV strengthen the IP protection and bring it closer to patent-
like protection. Both regimes contain provisions for the research exemption, 
nevertheless, there are fundamental differences between the research 
exemption under the patent and PVR system. The research exemption is an 
exception from the infringement of a patent for the purposes of conducting 
research activities. This allows a person to make use of the patented invention 
without the permission of the patent owner of the use if meant for ‘research’ 
as defined by the patent law. Under the Malaysian Patents Act 1983, the 
research exemption is incorporated in Section 37(1) which states that: ‘the 
rights under the patent shall extend only to acts done for industrial or 
commercial purposes and in particular not to acts done only for scientific 
research.’ 
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Most jurists are of the view that patents are able to restrict research on plant 
varieties to a greater degree than PVRs. This is due to the very narrow scope 
of research exemptions under patent laws, for example, in the U.S., such 
exemptions are confined to philosophical use and idle curiosity. In contrast, in 
Europe, member States have adopted research exemptions, inspired by Art. 
27(b) of the Community Patent Convention (1989 version), and whose scope 
is generally broader than that of the American provision. Interestingly, in the 
U.K., other than the experimental research activities and private acts which 
have no commercial purposes, the exemptions are much more expansive as 
compared to Malaysian patent law. Section 60(5)(g) of the U.K. Patents Act 
1977 grants a farmers’ exemption, similar to the field of plant varieties 
protection.661 Hence, farmers and plant breeders in the U.K. stand in a better 
position, as they are entitled for exemption both under the PVP as well as the 
patent law regime. 
 
As far as research activities are concerned, especially those carried out by 
public RIs, they would receive a huge set back without free access to the 
existing, fundamental technology. In order to ensure optimum progress of 
biotechnology without obstructions, a policy that would balance the rights of 
the patentee and that of the public has to be made. Narrow research 
exemptions would hinder the public from the opportunity to freely use the 
patented subject matter for their research during the patent term, which 
would result in stifling research. As far as Malaysian patent law is concerned, it 
is submitted that the term ‘scientific research’ which is the activity allowed by 
                                                 
661 Section 60(5)(g) An act which, apart from this subsection, would constitute an infringement of 
a patent for an invention shall not do so if - it consists of the use by a farmer of the product of his 
harvest for propagation or multiplication by him on his own holding, where there has been a sale 
of plant propagating material to the farmer by the proprietor of the patent or with his consent or 
agricultural use. 
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virtue of research exemption under Section 37 of the 1983 Act is sufficiently 
broad so as to permit the use of the patented invention for research in 
particular those carried out by public RIs. To date, there is yet to be any 
litigation or court decision in Malaysia pertaining to the extent of research 
exemption under the Patents Act 1983, in spite of the probability that there 
might be litigation due to the increased use of patented inventions for 
research without permission from the patentee, in particular if the patent is 
owned by a private company or multi-national corporation. 
 
In short, research exemption provision under patent law in Malaysia is 
reasonably broad and proportional to facilitate scientific research activities and 
this would provide a balanced framework to encourage the progress of 
agricultural biotechnology. Hence, it is of paramount importance that public 
RIs should make use of the exemption under the Patents Act 1983 to access 
patented inventions so that they would be able to boost their research 
activities and development without undue difficulty. Eventually, it is hoped 
that the IP holding firms would be unable to block off an area of research and 
ultimately it would help to strengthen the position of local researchers who are 
working to develop new technologies using tools that have been patented by 
others. 

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Identifying the appropriate balance between breeders’ needs and farmers and 
consumers of plant varieties is a matter that has perplexed policy makers 
worldwide as there are no readily identifiable alternatives. As far as PVP is 
concerned, the related legislation, namely the Protection of New Plant 
Varieties Act (PNPVA) 2004 and the Protection of New Plant Varieties 
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Regulations 2008 are relatively new, as the implementation of the former has 
only commenced on 20th October 2008 after the gazetting of the 2008 
Regulations. Having said that, it remains to be seen whether the PVP regime 
would actually work in terms of giving the best protection for interested and 
targeted parties from the agricultural biotechnology industry which include 
farmers, local communities and indigenous people, other than RIs and private 
companies. 
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Protection via PVP has become possible in Malaysia with the establishment of 
the 2004 Act. The Act was very much welcomed by breeders in Malaysia as 
prior to the 2004 Act, there was no specific Act protecting the exclusive rights 
of the breeders of new plant varieties. The Malaysian government realized the 
importance of PVP for the development of the country. Malaysia, is a member 
of the World Trade Organization (WTO) and a signatory to the TRIPS 
Agreement, which under Article 27.3 (b), stipulates that member countries 
shall provide for the protection of plant varieties by a patent or by an effective 
		 system or by any combination thereof. As such, Malaysia is able to 
fulfill its obligation of Article 27.3 (b) for the TRIPS Agreement with the 
introduction of the PVP legislation. 
 
The PNPVA is significant in the sense that it is aimed at providing for the 
protection of the rights of breeders of new plant varieties, the recognition and 
protection of contribution made by farmers, local communities and indigenous 
people towards the creation of new plant varieties, as well as encouraging 
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investment in and development of the breeding of new plant varieties in both 
public and private sectors.662 
 
By virtue of the 2004 Act, breeders of new plant varieties in Malaysia are now 
in a better position to have access to new and improved varieties for 
commercial growing.663 PVP under UPOV has been shown to stimulate foreign 
breeders in making available their modern varieties. It can create an incentive 
for breeders from industrialized countries to export their best and most recent 
varieties to countries in which an effective PVP system has been implemented. 
As far as the Malaysian domestic scenario is concerned, RIs which represent a 
substantial component of the agricultural biotechnology industry players, for 
example MARDI, have the option of filing applications to Plant Variety Office 
under the Department of Agriculture for the protection of their R&D output. 
The effectiveness of the protection via the PVP in Malaysia is yet to be proven 
as the Plant Variety Office at this stage is still examining the applications 
received, and there is yet any certificate of plant variety rights which have 
been successfully issued to the applicant or breeders.664 
 
Since the Malaysian Patents 1983 excludes plant varieties from being made 
patentable, the PNPVA in one aspect is an exclusive piece of legislation that 
caters for the protection of new plant varieties. Nevertheless, the situation and 
latest development in Europe could be taken as a useful guide for Malaysia to 
develop its PVP system. In this regard, it is submitted, as mentioned in 
preceding discussion, that the PNPVA is the most suitable, exclusive method 
                                                 
662 The Preamble of the PNPVA 2004. 
663 Temperate flower growers in Malaysia, for example, are facing problem in getting new varieties 
from Netherlands and other countries which bred these varieties.  Refer : 
<http://pvpbkkt.doa.gov.my/> [Accessed 25 October 2010] 
664 As at October 2010, a total of 54 applications have been received by the Plant Variety Office, 
Department of Agriculture. Refer<http://pvpbkkt.doa.gov.my/> [Accessed 25 October 2010] 
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for the protection of new plant varieties. However, if the plant innovations in 
the form of new plant varieties embrace more than a single variety, it is 
proposed that protection for such an invention is to be made available under 
patent regime. In other words, plant varieties, for example transgenic plants, 
which may embrace plant varieties but are not limited to single variety, or 
which do not fulfill the DUS criteria665 under the PNPVA 2004, should be made 
protectable under the Patents Act 1983. 
 
Protection by way of PVP in Malaysia should be encouraged as it provides for a 
cheaper method of protection in terms of fees, and the application process is 
equally simpler, as compared to patent application process.666 Nevertheless, 
contrary to some beliefs and contention, it is submitted that in terms of time 
factor, protection by way of PVP may in some circumstances, consume a 
longer period of time, depending on the types of plants. This is due to the 
uniformity and stability requirements that may consume a long period of time, 
and protection via PVP would only be obtained once a plant variety could be 
shown as uniform and stable.667 In such a situation, patent would provide a 
faster means of protection, as compared to PVP.  
 
Protection via PVP is necessary in Malaysia as the rights of breeders, local 
farmers and indigenous people would properly and legally be recognized. The 
                                                 
665 Section 14(1) of the PNPVA 2004; Section 14(2) of the Act provides that: ‘where a plant 
variety is bred, or discovered and developed by a farmer, local community or indigenous people, 
the plant variety may be registered as a new plant variety and granted a breeder’s right if the 
plant variety is new, distinct and identifiable. 
666 Patent application filing is normally handled by a specialized patent agent, whereas under the 
PVP, the breeders themselves can file the application without the need of an agent. 
667 For example, short term crops or plants, the examination process range from twelve to twenty-
four months, for an intermediate term plant such as rubber tree, it ranges from twenty-four to 
sixty months, whereas for a long-term crop like oil palm, it ranges up to hundred and twenty 
months (approximately 10 years). The information is provided by PVP Official during the interview 
session, 	  note 536. 
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plant breeders’ rights certificate holder may exclude others from selling the 
protected variety, producing it for sale and making repeated use of the 
protected variety as a step to commercially produce another variety. 
Obviously, PVP is specifically designed to protect the propagating material 
(including seed, cuttings, divisions, tissue culture) and harvested material (cut 
flowers, fruit, foliage) of a new variety. The pro-active effort on the part of 
Department of Agriculture in raising the awareness and promoting the newly 
introduced system of protection for plant variety to the local breeders and 
public at large is a vital, commendable effort to contribute to the success of 
the PVP regime in Malaysia. 
 
Although the current Malaysian Act can be said to be 90 percent UPOV-
compliant, some provisions would have to be amended if Malaysia were to 
ratify UPOV 1991. Hence, Malaysia has yet to join UPOV and in fact, the effort 
and steps towards acceding to UPOV Convention are currently put on hold, as 
the Government has prioritized the implementation of the Act over the UPOV 
accession. Nevertheless, the agenda to accede to UPOV would definitely revive 
when the need for the accession reemerge in the near future. 
 
6 3 4!
$!)$'(%%#!
To recap, it is reiterated that the American IPR model which is based on three-
tiered level of protection is unlikely to fit into Malaysian’s circumstances due to 
historical reasons of such a system, as well as the different level of economic 
development and slower agricultural biotechnological R&D and the industry 
growth in Malaysia.  
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The European IPR model in some aspects, in particular the one in practice and 
is being implemented in the UK, is submitted to be of very useful guidance for 
Malaysia. The approach in defining the ‘controversial’ term and scope of 
patentability of plant varieties could be adopted by Malaysian legislature in 
enhancing and amending the Patents Act 1983. Essentially, patentability of the 
new plant varieties should be allowed, if the plant innovation is not limited to a 
single variety of plant, provided that all the patenting requirements are made.  
 
In view of providing a conducive regulatory framework via a strong patent 
regime, and to extend the protection of plant innovation via certificate of 
utility model, the effort of accession to UPOV is obviously not a matter of 
priority, at least for five to ten years to come. This is premised on the fact that 
the Government is obliged to protect the interest of domestic plant breeders, 
small farmers and indigenous people, on top of developing national capability 
in agro-biotechnology. The PNPVA 2004 which is a 		 and very much 
pan-Malaysian by nature, though is inconsistent with a few provision of UPOV, 
has been carefully drafted, hence it is well justified for the Government to see 
whether such a system will work for the benefit of the domestic R&D 
researchers and industry players. Interestingly, although the PNPVA 2004 is 
not fully UPOV-compliant, it has managed to attract quite a number of 
applications from foreign companies668. All in all, the issue of accession to 
UPOV would definitely revive when the agricultural biotechnology industry in 
Malaysia is fully developed, say in ten years to come, parallel to the National 
Biotechnology Policy and the BiotechCorp’s vision and mission.669 
                                                 
668 To-date, applications from abroad come from the U.S., Netherlands and New Zealand. Refer: 
<http://pvpbkkt.doa.gov.my/> [Accessed 11 November 2010] 
669 Refer : 
<http://www.biotechcorp.com.my/Documents/AboutBiotechCorp/BiotechCorp%20Annual%20Rep
ort%202009.pdf> [Accessed 11 November 2010] 
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In conclusion, it is the finding of this thesis that the exclusion from 
patentability for plant varieties has to be seen in relation to the aim of the 
UPOV Convention: plant varieties could and should be protected under this 
regime and this should remain as an option in the hands of breeders or 
inventors, whereas other plant-related inventions, which may also encompass 
plant varieties, not protectable under PVP, should be patentable as any other 
invention under the Patents Act 1983. 
 
It also the finding of this thesis that the patent system provides a better 
protection for agricultural biotechnology inventions in most circumstances. 
Hence, as far as the Malaysian scenario is concerned, for economically 
important crops like palm oil and rubber trees, RIs such MOPB and MRB are 
making a right choice by choosing patent protection for their R&D output 
wherever applicable. Under the patent system, an inventor of a transgenic 
plant (which may embrace a plant variety) has the option to apply for patent 
protection right from the very early of research stage, for instance patent on 
genes or plant cells or process. This is because patent rules permit the 
inventor to apply early to the patent office at a time when many details of the 
invention have still to be clarified. Further work and investment may be 
necessary before the invention becomes a marketable product. This aspect of 
the patent system provides some security for the inventor, an aspect that is 
missing under PVP hence may appeal to plant breeders. The recent 
developments in plant bioscience and biotechnology have proven that there 
would not be much problem in satisfying those patentability requirements 
under patent laws.  
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The exemptions under the PVP are aimed to balance the interests of breeders 
as the inventors of new plant varieties and farmers as the users of the 
protected varieties. Interestingly, patent system also provides for research 
exemptions in order to balance the rights and interests of inventors and 
society. The experimental use exception is one such aspect of patent law 
which may be further explored as means of facilitating change. As the current 
scope and boundaries of the exemptions under patent law are uncertain and 
has been confined to a very narrow sphere of use in some jurisdictions such as 
the U.S., this is by no mean an international standard. In this regard, there is 
a need to explore and benefit from the research exemptions under the Patents 
Act 1983. In this way, RIs, including plant breeders, and the whole industry 
players would be able to make full use of the exemptions under the 1983 Act 
to facilitate the access to patented inventions for their research activities. 
Legislators and the judiciary would do well to heed calls for clarification. 
However, any reformulation of the experimental use exception for plant 
biotechnology should always take into account the legitimate interest of the 
patent owner. 
 
The patent system in Malaysia can further be enhanced by tackling the issues 
of uncertainty in some of the terms in the Patents Act 1983. Clarification of 
the terms such as ‘inventiveness’ and ‘industrial application’ would assist both 
patent applicant and patent examiner in patent filing and patent examination 
respectively that would eventually contribute towards more efficient patent 
system in Malaysia. The manual for examination of biotechnology patent which 
is still at the drafting stage is essential and very much anticipated by the 
industry players in particular to improve the biotechnology patent application 
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and examination system. The expansion of the utility innovations for plant 
innovations would provide a wider option for inventors, researchers and plant 
breeders to make the preferred selection of IPR protection that best suits and 
safeguards their inventions. In the absence of an effective IPR system, 
research firms would keep a considerable amount of information about plant 
genomes and the function of genes for example, secret, thus restricting its use 
in further knowledge creation and technology innovation. 
 
All in all, the challenge for Malaysia as a developing country is to have an IPR 
system comprehensive and effective enough to cover technologies of modern 
agricultural biotechnology, yet ensuring a fair competition so that one or a few 
corporations do not control the vital inputs of agriculture. The above IP model 
with the proposed features as discussed above is submitted with the objective 
of stimulating the transfer of technology and scientific co-operation with 
industrialized countries, on top of boosting the development of agricultural 
biotechnology industry as well as protecting and safeguarding innovative 
activities within Malaysia itself. 
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This chapter brings together the results and conclusions from previous 
chapters. It shall discuss the strength and weakness of this research. Besides, 
some directions for future research and recommendations are also presented 
in this chapter. In essence, this research has answered all its research 
questions and has achieved all its initial objectives. 
 
: .J$'%!('!&#!
It has been a subject of debate and a matter of dispute whether plants and 
agricultural biotechnological inventions can be the subject of patent protection, 
in addition to or as an alternative to the protection afforded by plant variety 
rights. Biotechnological patents have been criticized for granting an excessive 
scope of protection to proprietors, whereas plant variety rights have been 
slighted for not providing enough protection. Hence, this research has been 
built on few main themes, namely; the discussion on IP protection for 
agricultural biotechnological inventions as currently in practice in Europe and 
the U.S., as well as the deliberation on the current system as practised in 
Malaysia. 
 
The work is aimed at the prospect of Malaysia as developing country to 
enhance its current IP framework and legislation in order to develop its 
agricultural biotechnology industry. The research focused on whether there is 
a single system as a model of IP regime to be adopted for Malaysia in order to 
provide the best IP protection for its agricultural biotechnological inventions. 
In answering this question, all the relevant factors and consideration were 
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taken into account, such as the status of Malaysia as a developing country, the 
pace of biotechnological inventions R&D relating to plants which is much 
slower in comparison to the development in the Europe and in the U.S., the 
different nature of farming activities, economic strength, main players in the 
industry and so forth.  Explanatory in nature, this research employed a 
pragmatic, critical and multi-literature approach to optimize the investigation 
and exploration of the research questions. The research is unique in the sense 
that, on top of black-letter law approach, it also employs a qualitative 
approach in the form semi-structured interview which has been successfully 
carried out, targeting a number of selected bodies and RIs. Such agencies, 
bodies and RIs which are mainly public funded RIs represent a substantial 
component of agricultural biotechnology industry in Malaysia hence would be 
directly affected by whatever laws which are enacted and implemented in 
Malaysia. This empirical aspect of the research is vital because it would 
demonstrate the views as to the appropriateness and effectiveness of the 
systems available to the researchers and plant breeders in agricultural 
biotechnology. 
 
: 4!!',##$%
The present research has notable strength and limitations. The first strength is 
the fact that the recommendations and proposal from this research contributes 
to the pool of literature in the area of IPR related issues in Malaysia. As 
modern agricultural biotechnology in Malaysia a is relatively new industry as 
compared the development in the industrialized nations, literature work and 
legal writing by Malaysian jurists from the IPR perspective  is very much 
limited as compared to the works and legal references available other 
jurisdictions notably from the Europe and the U.S.  
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The other strength of this research is from the empirical part of it. The 
information gathered from the semi-structured interviews with the targeted 
RIs and bodies are valuable as it was the first hand, reliable data and inputs 
that came direct from the legal section of those RIs and bodies. 
 
Nevertheless, there are some inevitable limitations in the research. The 
information and evidence used in this analysis have been partly furnished by 
way of referring to patent law and policies of European countries, in particular 
the U.K. as well as the U.S., judicial cases and secondary resources, based on 
the works of other writers. The researcher did not have the opportunity to 
organize field work to gather empirical data in those selected countries 
personally, hence no direct information or interaction with the local experts 
from those countries. Nevertheless, the researcher is of the opinion that the 
information gathered from the official websites of relevant bodies are highly 
credible and reliable. The data has been of paramount importance in 
formulating the proposal in the form of IP model for Malaysia as incorporated 
in Chapter 6. 
 
The other limitation is concerning the targeted RIs and bodies as the 
interviewees for the semi-structured interviews. The selection of the targeted 
interviewees was made on the basis that they are the substantial component 
of those involved in R&D for agricultural biotechnology in Malaysia. Therefore, 
they are, to some extent, representing the important players of the 
agricultural biotechnology industry in Malaysia. The researcher did not have 
the opportunity to extend the interview to the legal department or unit private 
companies that are involved in agricultural biotechnology due to time 
372 
 
constraints as well as due to the fact that most of the private companies and 
corporations were reluctant to be interviewed on the reason of data 
confidential policy of their respective companies. 

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The researcher has given her best effort in this research in order to fulfil its 
objectives. Broadly, the conclusions of this thesis are; 
First, both existing systems of protection in Malaysia via patent regime and 
PVR are important as they play their own, unique role in providing the suitable 
methods of protection and a wider option for plant breeders and inventors in 
agricultural biotechnology. 
Second, there is a need to enhance the Patents Act 1983 via some 
amendments to certain provisions,  to clear any ambiguities inherent 
with certain terms relating to patentability requirements , as well as to provide 
for express provisions allowing for patenting of transgenic plants. 
Third, the certificate of utility innovation is to be extended and to be made 
applicable for agricultural biotechnological inventions, which include new plant 
variety which is not limited to a single variety of plant. 
Fourth, to adopt European approach in allowing patentability for new plant 
varieties which are not limited to a single or a particular variety, if all 
patentability requirements are met. 
Fifth, to optimize the use if research exemptions under the Patents Act 1983 
for the benefits of R&D research, in cases where such research activities 
require access to patented inventions. 
Sixth, to encourage the utilization of PVP system to interested plant breeders 
and inventors, as the system has its own merits and benefits in particular to 
protect new plant varieties. 
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There are questions and concerns whether the IP models (namely the 
European and the American670) which are based on the system of 
industrialized nations would fit into the current context of Malaysia, a 
developing country. The answer seems to be affirmative as Malaysia aspires to 
be a developed country by year 2020 and the Government’s policy and efforts 
are all geared towards boosting the growth of the country’s agricultural 
biotechnology industry. Nevertheless, there is certainly no single model which 
would work best for Malaysia, but the effort to strengthen and tighten up the 
IP legislation is submitted as one of the best option to provide a conducive 
environment for patenting activities in the country. At the same time, the 
interest of small farmers’ community, indigenous people and small-medium 
sized local biotechnology companies must not also be neglected. 

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The issues of the effectiveness of PVP system in Malaysia could be investigated 
further. It would be essential for future research to assess and improve the 
analysis on the benefit of the system to the plant breeders in Malaysia, based 
its implementation. At this point of time, the PVP has just been implemented 
and there is yet any certificate of plant breeder’s rights granted to any 
applicant.671 The study on the positive impact and benefit of the PVP system 
would be beneficial to promote the system to the industry players in 
agricultural biotechnology. 
                                                 
670 As far as the US laws are concerned, the FTA negotiations between the US and Malaysia, once 
concluded, will definitely affect the current legal framework of Malaysia. Both countries launched 
negotiations on 8 March 2006 in Washington D.C.  To date, eight rounds of negotiations have 
been held. IPRs were one of the issues discussed during the negotiations. Negotiations were put 
on hold as both countries reviewed their respective positions. Malaysia is now negotiating with the 
US within the Trans-Pacific Partnership (TPP) arrangement. Refer Malaysian Ministry of Trade and 
Industry official website : < 
http://www.miti.gov.my/cms/content.jsp?id=com.tms.cms.section.Section_55af1514-c0a8156f-
2af82af8-1bbb377f> [Accessed 30 November 2010]. 
671 As at November 2010. Refer <http://pvpbkkt.doa.gov.my/> 
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Directive 98/44/EC of the European Parliament and the Council of 6 July 1998 
on the legal protection of biotechnological inventions. 
EC Regulation on Community Plant Variety Rights of July 27, 1994 
European Directive on Biotechnology Invention 1998 
European Patent Convention 1973 
International Union for the Protection of New Varieties of Plants (UPOV) 1961, 
1978 and 1991 
Paris Convention for the Protection of Industrial Property1883
Patent Act 1790 (US) 
Patent Act 1952 (US) 
Patent Act 1977 (UK) 
Patents Act 1983 (Malaysia) 
Patent Cooperation Treaty 1970 
Plant Protection Act 1930 (US) 
Plant Varieties Act 1997 (UK) 
Plant Variety Protection Act 1970 (as amended in 1994) (US) 
Protection of New Plant Varieties Act 2004 (Malaysia) 
Strasbourg Patent Convention 1963 
Trade-Related aspects of Intellectual Property rights (TRIPS) 1991 
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These questions are aimed to solicit information to assess the appropriateness 
and effectiveness of the existing legal protection vis-à-vis intellectual property 
rights (namely patents and plant variety rights protection) available to those 
involved in agricultural biotechnology and industry players. The interview also 
seeks to identify those areas where further legislative activity might be 
needed. The information and data received is solely for my PhD research 
purpose. 





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[1.1]  (a)Name of  Organization: 
 
  (b)Address: 
 
  (c)Name and Position of the Respondent/Interviewee: 
 
 
[1.2] State the nature of your Organization’s business. Where your business 
involves several activities, please list them and indicate the main one(s). 
 
 
 
[1.3] Is your organization business confined to Malaysia? 
Yes / No 
 
[1.4] If ‘no’ to 1.4, please list the foreign countries where your organization 
operates and state its business activity or activities in each such foreign 
country. 
 
 
 
[1.5] Does your organization collaborate with foreign organizations in the area 
of agricultural biotechnology? 
Yes / No 
 
[1.6] If ‘yes’ to 1.4, please list the foreign organizations and the countries 
where they are based. 
 
 
 
[1.7] How many fulltime employees does your organization currently employ? 
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[2.1] If agricultural biotechnology is only a part of its business, how many 
years has your organization been involved in this activity? 
 
       
      [2.2] Please list the  plant species your organization is working. 
 
 
 
[2.3] Does your organization have a department or an employee solely 
engaged in managing the organization’s patent, trademark and other 
intellectual property rights? 
Yes / No 
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[2.4] If ‘no’ to 2.3, does your organization rely for that expertise primarily on 
  
(a) Patent Agents?     Yes / No 
(b) Legal advisors?     Yes / No 
(c) Legal divisions of associated firms?  Yes / No 
(d) Plant Variety Rights Office?   Yes / No 
 
[2.5]  
(a) What percentage of your organization’s employees are engaged on 
research relating to agricultural biotechnology? 
 
 
(b) How many of your employees are fulltime research staffs? 
 
 
[2.6] What percentage of its financial resources does your organization 
commit to agricultural biotechnology and related R & D? 
  
(i) 1-5% 
(ii) 6-10% 
(iii) above 10% (please specify) 
 
[2.7]  
(a) Is your organization party to a joint R & D venture relating to agricultural 
biotechnology? 
Yes / No 
 
(b) If ‘yes’ to (a), what were the main reasons for your organization entering 
the joint venture(s)? 
 
 
 
[2.8] Does your organization carry out subcontract research relating to 
agricultural biotechnology for other organizations? 
Yes / No 
 


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[3.1] Has your organization ever applied for a patent for any purpose in 
Malaysia? 
Yes / No 
 
[3.2]  
(a) In what year was your first Malaysian patent application made? 
 
 
(b) Was this application successful?   
Yes / No 
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(c) What was the invention concerned with? 
 
 
[3.3]  
(a) What percentage of your organization’s patent applications (foreign and 
Malaysian) are rejected? 
 
 
(b) How many Malaysian patents does your organization currently hold? 
 
 
[3.4]  
(a) Does your organization hold patents abroad? 
Yes / No 
 
(b) If ‘yes’ to (a), how many foreign patents does it hold? 
 
 
(c) If ‘yes’ to (a), in which foreign countries does your organization hold 
patents? 
 
 
[3.5] How many patents does your organization apply for each year 
(a) in Malaysia, and 
 
      
(b) abroad? 
 
 
[3.6] How many patents are granted to your organization each year 
(a) in Malaysia, and 
  
   
(b) abroad? 
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[4.1] How many of your organization’s current patents relate directly to, or 
specifically protect techniques applicable to plant breeding and seed 
technology 
  
(a) in Malaysia? 
 
(b) abroad (give countries)? 
 
 
[4.2] Is your organization’s current number of patents relating directly to, or 
specifically protecting techniques applicable to, plant breeding and seed 
technology more or less than it was 
 
(a) 1 year ago?    More / Less 
(b) 5 years ago?    More / Less 
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(c) 10 years ago?    More / Less 
(d) 20 years ago?    More / Less 
 
[4.3] What typical problems does your organization encounter when it applies 
for a patent 
 
(a) in Malaysia, and 
 
(b) abroad? 
 
 
[4.4] At present, a patent cannot be granted under Malaysian patent law for a 
new plant variety. 
 
(a) Would your organization like to see this ban on patenting deleted from 
Malaysian patent law?  
Yes / No 
 
(b)If ‘yes’ to (a), why would you like to see the ban deleted? 
 
 
 
(c) If ‘no’ to (a), why would you like to see the ban retained? 
 
 
 
[4.5]  
(a) If the ban on patenting a plant variety were deleted from Malaysian patent 
law, would your organization patent its new varieties rather than seek plant 
variety rights for them? 
Yes / No 
 
(b)If  yes’ to (a), why would your organization choose a patent over plant 
variety rights? 
 
 
(c)If ‘no’ to (a), why would your organization choose plant variety rights over 
a patent? 
 
 
[4.6] It is possible in some countries (eg the USA) to patent a new plant 
variety. 
 
(a) Has your organization applied for a patent on a variety in any such 
country? 
Yes / No 
 
(b) If ‘yes’ to (a), was the patent application successful? 
Yes / No 
 
(c) If ‘yes’ to (a), what kind of variety was involved in the application? 
 
(d) If ‘no’ to (b), why was the patent application not successful? 
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(e) Do you have a patent application pending in any such country in respect of 
a new plant variety? 
Yes / No 
 
[4.7] If Malaysian law were to be amended to allow the patenting of plants, 
should patent protection be available for 
 
(a) families or species,   Yes / No 
(b) varieties,      Yes / No 
(c) whole plants    Yes / No 
(d) parts of plants?    Yes / No 
 
[4.8] It appears possible both in Malaysia and abroad to patent a gene. 
 
(a) Has your organization ever applied for a patent on a gene 
  (i) in Malaysia?   Yes / No 
  (ii) abroad?    Yes / No 
 
(b) If ‘yes’ to (a), was the patent application granted, or is it still pending? 
      Granted:  Yes / No  Pending:  Yes / No 
 
(c) How many applications by your organization to patent specific genes are 
currently pending? 
 
 
[4.9]  
(a)Does your organization agree that patent protection should be available for 
genes? 
Yes / No 
 
(b) If ‘no’ to (a), why does your organization believe that this protection 
should not be available? 
 
(c) If ‘yes’ to (a), why does your organization believe that this protection 
should be available? 
 
[4.10] What does your organization think are likely to be the long-term 
economic effects of allowing genes to be patented 
 
(a) on your plant breeding programmes? 
 
(b) on investments in agricultural biotechnology? 
 
[4.11] Given a choice, which of the following forms of intellectual property 
would your organization prefer for new plants that your organization breeds or 
discovers, 
 
(a) patent protection only?                                          Yes / No  
      
(b) existing plant variety rights only?   Yes / No 
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(c) A new form of plant variety rights which affords greater protection than the 
existing form of plant variety rights?   Yes / No 
 
(d) both patents and plant variety rights?   Yes / No 
 
(e) a choice between plant variety rights and patents? Yes / No 
 
(f) a new form of protection covering plants and agricultural biotechnology, 
based on the general idea of plant variety rights but affording greater 
protection than the existing form of plant variety rights, but not patents? 
Yes / No 
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[5.1] Has your organization ever applied for plant variety rights (PVR) in 
Malaysia? 
Yes / No 
 
[5.2]  
(a)In what year was your first Malaysian application to the Plant Variety Rights 
Office at Kuala Lumpur (PVRO) made? 
 
 
(b) Was the application successful?  
Yes / No 
 
[5.3]  
(a) What percentage of your organization’s applications to the PVRO for PVR 
are successful? 
 
 
(b) On what ground(s) or for what reason(s) does the PVRO typically reject 
your organization’s applications? 
 
    (i) Lack of distinctness    Yes / No 
    (ii) Insufficiently uniform   Yes / No 
    (iii) Insufficiently stable   Yes / No 
    (iv) Other (please specify) 
 
(c) Has your organization ever applied against rejection of an application for 
PVR? 
Yes / No 
 
(d) How many Malaysian PVR certificate does your organization currently hold? 
 
 
[5.4]  
(a) Does your organization hold plant variety rights certificates abroad? 
Yes / No 
 
(b) If ‘yes’ to (a), how many foreign certificates does your organization hold? 
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(c) If ‘yes’ to (a), in which foreign countries does tour organization hold such 
certificates? 
 
 
[5.5] Is your organization’s current number of plant variety rights certificates 
issued by the PVRO more or less than it was 
 
(a) 1 year ago?  More / Less 
(b) 5 years ago?  More / Less 
(c) 10 years ago?  More / Less 
(d) 20 years ago?  More / Less 
 
[5.6] (a) Having regard to your response to 5.5, is the number restricted by 
the capacity of the system? 
Yes / No 
 
(b) Having regard to your response to part (a) of this question, which crops 
are most affected? 
 
 
[5.7] Having regard to your response to 5.6, would you submit more varieties 
to PVRO if you could do so? 
Yes / No 
 
[5.8] How many plant varieties does your organization submit for plant 
varieties rights each year 
(a) in Malaysia, and 
 
(b) abroad? 
 
[5.9] How many plant variety rights certificates are granted to your 
organization each year 
(a) in Malaysia, and 
 
(b) abroad? 
 
[5.10] What typical problems does your organization encounter when it 
applies for a grant of plant varieties rights 
(a) in Malaysia, and 
 
(b) abroad? 
 
 
[5.11] Does your organization apply for plant variety rights on its new 
varieties 
(a) because there is no alternative intellectual property protection currently 
available? 
Yes / No 
 
(b) where alternative protection is available, because plant variety rights 
afford the better legal protection for plant varieties? 
Yes / No 
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(c) where alternative protection is available, because the alternative costs 
more to obtain than does plant variety rights protection? 
Yes / No 
 
[5.13] What reforms, if any, would your organization like to see made to the 
present plant variety rights system in Malaysia? 
 
(a) System of examining applied for varieties: 
 
 
 
(b) Extent of the protection given by PVR: 
 
 
(c) Use of protected varieties in commercial breeding programmes: 
 
 
(d) Other desirable or necessary reforms 
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[6.1] How does your organization commercialize its R&D plant-related 
innovations / patented agricultural biotechnology inventions / protected 
varieties 
 
(a) in Malaysia: 
 (i) direct sales?     Yes / No 
 (ii) licensing?     Yes / No 
 (iii) wholesale?     Yes / No 
 (iv) retail      Yes / No 
 (v) Other method (please specify if any) 
 
 
(b) abroad: 
 (i) direct sales?     Yes / No 
 (ii) licensing?     Yes / No 
 (iii) wholesale?     Yes / No 
 (iv) retail      Yes / No 
 (v) Other method (please specify if any) 
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[7.1] If your organization is in favour of deleting the current ban on patenting 
plant varieties in Malaysian patent law, what benefits can you see arising from 
this? 
 
 
 
[7.2] (Alternative to 6.1) If your organization is in favour of retaining the 
current ban on patenting plant varieties in Malaysian patent law, what benefits 
can you see as arising from this? 
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[7.3] Do you think alternative method of protection (for example trade secret, 
contractual agreement etc) is more effective/better  in protecting the 
agricultural biotechnological inventions? 
Yes / No 
 
Please state your reason: 
 
 
 
[7.4] Are there any questions not in this questionnaire that you feel should 
have been included? 
 
 
 
 
 
 
 
 
 
 
 



B/1B

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